R1 RCM
Annual Report 2014

Plain-text annual report

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 Form 10-K ýANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended December 31, 2014OR ¨TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934For the transition period from to Commission file number 001-34746 Accretive Health, Inc.(Exact name of registrant as specified in its charter) Delaware 02-0698101(State or other jurisdiction ofincorporation or organization) (I.R.S. EmployerIdentification No.)401 North Michigan AvenueSuite 2700Chicago, Illinois 60611(Address of principal executive offices) (Zip Code)(312) 324-7820Registrant’s telephone number, including area codeSecurities registered pursuant to Section 12(b) of the Act:Title of each class: Name of each exchange on which registered:None NoneSecurities registered pursuant to Section 12(g) of the Act:Common Stock, $0.01 par valueIndicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ¨ No ýIndicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ¨ No ýIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past90 days. Yes ¨ No ýIndicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted andposted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit andpost such files). Yes ¨ No ýIndicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’sknowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ýIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of“large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one): Large accelerated filer ý Accelerated fileroNon-accelerated filer¨Smaller reporting companyo (Do not check if a smaller reporting company) Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No ýAggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant, based on the last sale price for such stock on June 30, 2014:$454,304,464.As of June 1, 2015, the registrant had 97,948,301 shares of common stock, par value $0.01 per share, outstanding.ACCRETIVE HEALTH, INC.TABLE OF CONTENTS PagePART I Item 1.Business1 Item 1A.Risk Factors17 Item 1B.Unresolved Staff Comments36 Item 2.Properties37 Item 3.Legal Proceedings37 50 Item 4.Mine Safety Disclosures39 PART II Item 5.Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities40 Item 6.Selected Consolidated Financial Data46 Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations50 Item 7A.Quantitative and Qualitative Disclosures About Market Risk63 Item 8.Consolidated Financial Statements and Supplementary Data63 Item 9.Changes in and Disagreements with Accountants on Accounting and Financial Disclosure63 Item 9A.Controls and Procedures64 Item 9B.Other Information69 PART III Item 10.Directors, Executive Officers and Corporate Governance70 Item 11.Executive Compensation76 Item 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters108 Item 13.Certain Relationships and Related Transactions, and Director Independence111 Item 14.Principal Accountant Fees and Services114 PART IV Item 15.Exhibits and Financial Statement Schedules115 SIGNATURES116 FORWARD-LOOKING STATEMENTSThis Annual Report on Form 10-K contains forward-looking statements, within the meaning of the federal securities laws, that involve substantial risksand uncertainties. You should not place undue reliance on these statements. All statements, other than statements of historical facts, included in this AnnualReport on Form 10-K regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives ofmanagement and expected market growth are forward-looking statements. The words “anticipate”, “believe”, “estimate”, “expect”, “intend”, “may”, “plan”,“predict”, “project”, “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statementscontain these identifying words. These forward-looking statements include, among other things, statements about: •our ability to regain a listing on a national securities exchange;•our ability to attract and retain customers;•our financial performance;•the advantages of our solutions as compared to those of others;•our plans to incorporate our value based reimbursement capabilities within our revenue cycle management service offering;•our ability to establish and maintain intellectual property rights;•our ability to retain and hire necessary employees and appropriately staff our operations; and•our estimates regarding capital requirements and needs for additional financing.We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place unduereliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in theforward-looking statements we make. We have included important factors in the cautionary statements included in this Annual Report, particularly in “Part I -Item 1A - Risk Factors,” that could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-lookingstatements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make.You should read this Annual Report and the documents that we have filed as exhibits to the Annual Report completely and with the understanding thatour actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements,whether as a result of new information, future events or otherwise, except as required by law.PART IUnless the context indicates otherwise, references in this Annual Report to "Accretive Health," "Accretive," the "company," "we," "our," and "us"mean Accretive Health, Inc. and its subsidiaries.Item 1.BusinessOverviewAccretive Health is a leading provider of revenue cycle services that help healthcare providers generate sustainable improvements in their operatingmargins and cash flows while also enhancing patient, physician and staff satisfaction for our customers.We achieve these results for our customers through an integrated approach encompassing our end-to-end revenue cycle management service offeringand physician advisory services. We do so by deploying a unique operating model that leverages our extensive healthcare site experience, innovativetechnology and process excellence. We also offer modular services, allowing clients to engage us for only specific components of our end-to-end revenuecycle management service offering.Our primary service offering consists of revenue cycle management, or RCM, which helps healthcare providers to more efficiently manage their revenuecycles. This encompasses patient registration, insurance and benefit verification, medical treatment documentation and coding, bill preparation andcollections from patients and payers. We assist our RCM customers in increasing the portion of the maximum potential services revenue they receive whilesimultaneously reducing their revenue cycle operating costs. Together, these benefits can generate significant and sustainable improvements in operatingmargins and cash flows for our customers. Our management and staff supplement each customer’s existing RCM process and staff, and help operate ourcustomers’ processes. We educate and empower our customers’ employees so that over time we can jointly deliver improved results using the proprietarytechnology included in our applications. Once implemented, our technology applications, processes and services are deeply embedded in our customer’sday-to-day operations. We believe this service offering is adaptable to meet an evolving healthcare regulatory environment, technology standards and markettrends. Importantly, our RCM agreements typically provide that we and our customers share in the benefits that are derived on behalf of our customers,particularly revenue increases and, in most cases, cost savings resulting from the application of our solutions. We believe that this sharing of benefits alignsour objectives and interests with those of our customers (including patient satisfaction).Our physician advisory services, or PAS, offering, which we incorporated into our RCM offering in the third quarter 2014, assists hospitals incomplying with payer requirements regarding whether to classify a hospital visit as an in-patient or an out-patient observation case for billing purposes. Thisoffering consists of both concurrent review and retrospective chart audits to help our customers achieve compliant and accurate billing. We also providecustomers with retrospective appeal management service support for both governmental and commercial payers. Our physicians conduct detailedretrospective reviews of medical records to identify medical necessity for hospital services and the required documentation to appropriately support anappeal. We employ trained physicians to deliver these services.We offered our population health solutions, or PHS, services on a standalone basis until the third quarter of 2014. This offering was designed to enablehealthcare providers to more effectively manage the health of a defined patient population by identifying those individuals who are most likely toexperience an adverse health event and, as a result, incur high healthcare costs in the coming years. In the fourth quarter of 2014, we began integratingcapabilities from this offering into our core RCM offering in order to enhance our value-based reimbursement capabilities for our RCM customers and toprepare our customers for future changes in healthcare. We currently do not serve any customers for PHS. 1We develop and refine our offerings based in part on information, processes and management experience garnered through working with some of thelargest and most prestigious hospitals and healthcare systems in the United States, as well as in anticipation of regulatory and market changes that impact ourcustomers. Our customers typically are single or multi-hospital healthcare systems, including faith-based healthcare systems, community healthcare systems,academic medical centers and their respective affiliated ambulatory clinics and physician practice groups, certain of which have common affiliations to largerumbrella healthcare organizations that are also parties to our customer contracts with their respective affiliates. We have developed strategic, long-termrelationships with our customers and focus on providers that we believe understand the value of our operating model and have demonstrated success in bothclinical and operational outcomes.Our StrategyWe strive to be the partner of choice for U.S. healthcare providers in RCM, a strategically important service that aligns clinical, financial andadministrative functions, allowing providers to focus on delivering quality care with ever-increasing efficiency. Key elements of our strategy include: •Delivering tangible, long-term results through an integrated offering. Our solutions are designed to help our customers achieve sustainableeconomic value through improvements in their operating margins and cash flows, which provides us with performance-based revenues. Ourintegrated offerings address the financial impact on our clients arising from the quality of clinical documentation and the efficient administration ofcertain clinical or quasi-clinical functions. Our integrated offerings also alleviate the need for our customers to purchase services from multiplesources, saving them time, money and integration challenges in their efforts to improve their revenue cycle activities.•Developing, utilizing and enhancing effective and proprietary operational processes to improve our customers’ revenue yield. We have developedand continue to design proprietary processes intended to help our customers to increase net revenue yields on amounts owed to them. To helpimprove revenue collection from payers and patients, we have developed proprietary algorithms to assess risk for all of our customers’ receivables.Our methodology is designed to enable nearly 100% of outstanding claims to be reviewed, prioritized and appropriately pursued. We believe thatour focus on collecting revenue from a broader range of outstanding claims and reducing the average time to collect differentiates our RCM services.•Seeking to expand the scope of services to existing customers and diversify our customer base. We benefit from long-term relationships with someof the nation’s largest health networks such as Ascension Health, which was our founding customer and remains our largest customer, as well asIntermountain Healthcare and Trinity Health. We seek to expand the scope of our services to healthcare providers within the network of our existingcustomers’ hospital systems. We also focus on marketing to other healthcare providers and seek to leverage our relationships with existing customersas references to continue to attract business from new customers.•Developing enhanced service offerings that are designed to enable our customers and prospects to improve their operations and to effectivelyparticipate in new payment models. We plan to introduce new services that we believe will be attractive to both existing and prospective customers.These include offerings to support the movement toward value-based reimbursement, or VBR, that is being driven through a confluence ofgovernment regulation, payer programs and benefit plan designs advanced by large employers and payers. These new payment models are intendedto shift the utilization of healthcare resources away from volume-based episodic care of patients who are sick or have chronic conditions to the pro-active management of patient populations to promote wellness and provision of care in lower acuity settings. We believe that the impact onproviders, including our customers, will be that they will increasingly bear financial risk in clinical outcomes. Our VBR services within our RCMoffering are designed to provide operational support to help providers assess their risk as they engage in value-based-reimbursement arrangements.We also may selectively pursue acquisitions and/or strategic relationships that will enable us to broaden our service offerings.2Our ServicesDrawing on our combination of our extensive healthcare-site expertise, innovative technology and process excellence, we seek to deliver measurableeconomic value to our customers across our revenue cycle management and physician advisory solutions.Revenue Cycle Management OfferingOur primary RCM service offering consists of comprehensive, integrated technology and RCM services, which address the full spectrum of revenuecycle operational issues faced by healthcare providers.To implement our integrated solution, we supplement each customer’s existing RCM process and staff with our qualified experienced RCM specialists,leaders and staff and connect our proprietary technology and analytical applications to each customer’s existing technology systems. Our employees havesignificant experience in healthcare management, revenue cycle operations, technology, quality control and other management disciplines. Our solution isadapted to the hospital’s organizational structure to minimize disruption to existing operation and staff. We seek to integrate our technology, personnel, ouraccumulated body of knowledge and our culture within each customer’s revenue cycle activities, with the expectation that we will enjoy a long-termcollaborative relationship with each customer. We deliver technology and operational support in the form of both on-site management and centralizedstaffing to deliver improved efficiency and quality across all RCM functions.Our RCM agreements generally provide us with the opportunity to earn two types of performance-based fees associated with achieved efficiencies andimprovements in our customer’s revenue cycle processes: net operating fees and incentive fees.Net operating fees represent the gross base fees we charge our customers for operating the revenue cycle processes included in our agreements lesscorresponding costs of customers’ revenue cycle operations which we undertake to pay pursuant to our RCM agreements. For some customers, the amount ofour net operating fees is reduced by an agreed upon percentage of such difference, representing the customer’s share of cost reductions resulting from ourservices. We help our customers reduce their revenue cycle costs by implementing new operational practices, optimizing their technology suite anddeploying more efficient processes. In certain cases, we work with our customers to transfer aspects of their revenue cycle operations to our shared servicescenters, which typically results in lower operating costs than operating those aspects of the revenue cycle at the customers’ site.We have modified a portion of our RCM agreements to eliminate the gross base fees along with our financial obligation to pay our customers' revenuecycle operation expenses.Incentive fees represent our negotiated share of the increases in our customers’ operating revenues and are earned by improving their net revenue yield.We help many of our customers improve their collection of amounts owed by payers and patients for healthcare services. We refer to this as net revenue yield.We use our proprietary technology or other financial metrics to calculate their improvement in net revenue yield. When using the method of calculating thisimprovement that employs our proprietary technology, we compare the customer’s actual cash collections for a given instance of care to the maximumpotential cash receipts that the customer should have received from the instance of care. We then aggregate these calculations for all instances of care andcompare the result to the aggregate calculation for a defined period before we began to provide our services to the customer. When using other financialmetrics to calculate this improvement, we typically employ metrics that are already being tracked by, or easily calculated from, our customers’ respectiveaccounting systems and compare the results of those metrics against the results for the same metrics for a defined period before we began to provide ourservices to the customer.We seek to improve our customers’ processes using a variety of techniques including:•Gathering Complete Patient and Payer Information. We focus on gathering complete patient information and validating insurance eligibility andbenefits so patient care services can be recorded and billed to the3appropriate parties. For scheduled healthcare services, we educate patients as to their potential financial responsibilities before receiving care.Through our systems we maintain an automated electronic scorecard which measures the efficiency of up-front data capture, authorization, billingand collections throughout the life cycle of any given patient account. These scorecards are analyzed in the aggregate, and the results are used tohelp improve work flow processes and operational decisions for our customers.•Improving Claims Filing and Payer Collections. Through our proprietary technology and process expertise, we identify, for each patient encounter,the amount our customer should receive from a payer if terms of the applicable contract with the payer and patient policies are followed. Over time,we compare these amounts with the actual payments collected to help identify which payers, types of medical treatments and patients representvarious levels of payment risk for a customer. Using proprietary algorithms and analytics, we consider actual reimbursement patterns to predict thepayment risk associated with a customer’s claims to its payers, and we then direct increased attention and time to the riskiest accounts.•Identifying Alternative Payment Sources. We use various methods to find payment sources for uninsured patients and reimbursement for servicesnot covered by payers. Our patient financial screening technology and methodologies often identify federal, state or private grant sources to helppay for healthcare services. These techniques are designed to ease the financial burden on uninsured or underinsured patients, increase thepercentage of patient bills that are actually paid, and improve the total amount of reimbursement received by our customers.•Employing Proprietary Technology and Algorithms. We employ a variety of proprietary data analytics and algorithms. For example, we identifypatient accounts with financial risk by applying proprietary analysis techniques to the data we have collected. Our systems are designed tostreamline work processes through the use of proprietary algorithms that focus revenue cycle staff effort on those accounts deemed to have thegreatest potential for improving net revenue yield or charge capture. We adjust our proprietary predictive algorithms to reflect changes in payer andpatient behavior based upon the knowledge we obtain from our entire customer base. As new customers are added and payer and patient behaviorchanges, the information we use to create our algorithms expands, increasing the accuracy, reliability and value of those algorithms.•Using Analytical Capabilities and Operational Excellence. We draw on the experience that we have gained from working with some of the besthealthcare provider systems in the United States to train our customers’ staff about new and innovative RCM practices. We use sophisticatedanalytical procedures to identify specific opportunities to improve business processes.•Increasing Charge Capture. We are able to help our customers increase their charge capture by implementing optimization techniques and relatedprocesses. We use sophisticated analytics software to help improve the accuracy of claims filings and the resolution of disputed claims from payers.We also overlay a range of capabilities designed to reduce missed charges, improve the clinical/reimbursement interface and produce bills thatcomply with payer requirements and applicable healthcare regulations.•Leveraging our Shared Services Centers. We help our customers increase their revenue cycle efficiency by implementing improved practices,streamlining work flow processes and outsourcing aspects of their revenue cycle operations to our shared services centers. Examples of services thatcan be completed at our shared services centers in the United States and India include pre-registration, medical transcription, cash posting,reconciliation of payments to billing records, and patient and payer follow-up. By leveraging the economies of scale and experience of our sharedservices centers, we believe that we offer our customers better quality services at a lower cost.We believe that these techniques are enhanced by our proprietary and integrated technology, management experience and well-developed processes.Our proprietary technology applications include workflow automation and direct payer connection capabilities that enable revenue cycle staff to focus onproblem accounts rather than on manual tasks, such as searching payer websites for insurance and benefits verification for all patients. We employtechnology that identifies and isolates specific cases requiring review or action, using the same interface for all4users, to automate a host of tasks that otherwise can consume a significant amount of staff time. Our proprietary technology enhances the ability of ourcustomers' revenue cycle staff to improve their interaction with patients.We use real-time feedback from our customers to improve the functionality andperformance of our technology and processes and incorporate these improvements into our service offerings on a regular basis. We strive to apply operationalexcellence throughout our customers' entire revenue cycle.Physician Advisory Services OfferingOur PAS offering provides concurrent level of care billing classification reviews, as well as retrospective chart audits to assist hospitals in properlybilling payers for selected services. These services complement our RCM offering and our ability to provide our customers end-to-end management services,and, accordingly, some of our RCM customers are also customers of our physician advisory services offering. According to the policies of the Centers forMedicare & Medicaid Services, or CMS, the decision to classify a patient as an in-patient or out-patient observation case for billing purposes is based oncomplex medical judgment that can only be made after the physician has considered a number of factors, including the patient’s medical history and currentmedical needs, the severity of signs and symptoms, the medical predictability of adverse events and the patient’s anticipated length of stay. Using our secureweb portal, hospital customers transmit pertinent data about the case at hand to our trained physicians, who then leverage our proprietary diagnosisguidelines and the extensive information within our knowledge database to reach an informed billing classification judgment, which we then provide to ourcustomers as a recommendation.We also provide customers with retrospective appeal management service support for both governmental and commercial payers. Our physiciansconduct detailed retrospective reviews of medical records to identify medical necessity for hospital services and the required documentation to appropriatelysupport an appeal.We believe that our PAS offering provides our customers with a number of operational benefits, such as•direct physician to physician contact,•improved service levels, and•real-time reporting and analytics.Population Health Solutions OfferingOur PHS services were designed to enable healthcare providers to partner with payers for the creation and implementation of payment structures basedon clinical success, measured at either the individual level or among a defined population of patients, and to assist providers in maximizing their financialperformance under such compensation structures. These services were designed to help healthcare providers enhance the patient and physician experienceand to assist healthcare providers in capturing a share of any reduction in healthcare costs they are able to achieve under revised compensation structures byhelping them negotiate contracts with payers that provide an equitable sharing of the savings in total medical costs among the payers and healthcareproviders, and manage their revenue cycle process under such contracts. In the fourth quarter of 2014, we began integrating capabilities from this offeringinto our core RCM offering in order to enhance our value-based reimbursement capabilities for our RCM customers and to prepare our customers for futurechanges in healthcare payment systems. We currently do not serve any customers for our PHS and no longer offer these services on a stand-alone basis.Market OpportunityThe market for our service offerings consists primarily of multi-hospital systems and other healthcare providers in the United States. We believe thatmacroeconomic, regulatory and healthcare industry conditions will continue to impose financial pressures on healthcare providers and will increase theimportance of managing their revenue cycle operations effectively and efficiently. New reimbursement models in the healthcare industry measure bothfinancial and clinical performance metrics, and increasingly shift economic risk of clinical outcomes to5providers. We believe our integrated revenue cycle offering can help providers adapt to, and improve reimbursement levels under, such risk-basedcompensation structures.SegmentsAll of our significant operations are organized around the single business of providing end-to-end management services of revenue cycle operations forU.S.-based hospitals and other medical services providers.We view our operations and manage our business as one operating and reporting segment. All of our net services revenue and trade accountsreceivable are derived from healthcare providers domiciled in the United States. The information about our business should be read together with ourconsolidated financial statements and related notes included elsewhere in this Annual Report on Form 10-K. See Note 11, Segments and CustomerConcentrations, to our consolidated financial statements for information regarding our segment and customer concentrations.CustomersOur customers typically are single or multi-hospital healthcare systems, including faith-based healthcare systems, community healthcare systems,academic medical centers and their respective affiliated ambulatory clinics and physician practice groups, certain of which have common affiliations to largerumbrella healthcare organizations that are also parties to our customer contracts with their respective affiliates. We seek to develop strategic, long-termrelationships with our customers and focus on providers that we believe understand the value of our operating model and have demonstrated success in boththe provision of healthcare services and the ability to achieve financial and operational results.Customer AgreementsWe generally provide our RCM offering pursuant to managed services agreements with our customers. In rendering our services, we must comply withcustomer policies and procedures regarding charity care, personnel, data security, compliance and risk management, as well as applicable federal, state andlocal laws and regulations.Our managed services agreements with our RCM customers typically span three to five years. After the initial term of the agreement, many of ourmanaged services agreements automatically renew unless terminated by either party upon prior written notice.In general, our RCM agreements provide that:•we are required to staff a sufficient number of our own employees on each customer’s premises and provide the technology necessary to implementand manage our services;•our management and staff work cooperatively with our customers’ management and staff to achieve mutually specified objectives;•we earn performance-based fees that are tied to the achievement of financial benchmarks related to increases in customer revenues and/or reductionsin operating costs;•the parties provide representations and indemnities to each other; and•the agreements are subject to termination by either party in the event of a material breach which is not cured by the breaching party.Our agreements for physician advisory services generally vary in length between one and three years. Generally, the agreements automatically renewafter their initial term unless terminated by either party upon prior written notice. Customers pay a contractually negotiated fee for this service on a per-usebasis.6Sales and MarketingOur new business opportunities are generated through a combination of high-level industry contacts of members of our senior management team andsystematic relationship building by a team of senior sales executives. Our sales and marketing process generally begins by engaging senior executives of theprospective hospital or healthcare system, typically followed by our assessment of the prospect’s existing operations, and a review of the findings. We beginnegotiations with a standardized contract that is customized as necessary after collaborative discussions of operational and management issues and ourproposed working relationship. Our sales process for RCM managed services agreements typically lasts six to 18 months from the introductory meeting to theagreement’s execution, while our sales process for our physician advisory services offering typically lasts three to four months.TechnologyTechnology DevelopmentOur technology development organization operates out of various facilities in the United States and India. We are increasing the amount of resourcesthat we invest in the improvement of our technology in order to enhance the services that we provide our customers. All customer sites run the same base setof code. We use a beta-testing environment to develop and test new technology offerings at one or more customers, while keeping the rest of our customerson production-level code.Our applications are deployed on a highly-scalable architecture based upon Microsoft and other industry leading platforms. We offer a commonexperience for end-users and believe the consistent look and feel of our applications allows our customers and staff to use our software suite quickly andeasily.We devote substantial resources to our development efforts and plan at an annual, bi-annual and quarterly release level. We employ a structured systemto assess the impact that potential new technologies or enhancements will have on net service revenue, costs, efficiency and customer satisfaction. The resultsof this analysis are evaluated in conjunction with our overall corporate goals when making development decisions. In addition to our technologydevelopment team, our operations personnel play an integral role in setting technology priorities in support of their objective of keeping our softwareoperating 24 hours a day, 7 days a week.Technology Operations and SecurityOur applications are hosted in data centers located in Alpharetta, Georgia; Philadelphia, Pennsylvania; and Salt Lake City, Utah; and our internalfinancial application suite is hosted in a data center in Minneapolis, Minnesota. These data centers are operated for us by third parties and are compliant withthe Statement on Standards for Attestation Engagements, or SSAE, No. 16, Reporting on Controls at a Service Organization (formerly referred to as Statementon Auditing Standards, or SAS, 70). Our development, testing and quality assurance environments are operated from the third-party data centers inAlpharetta, Georgia and Philadelphia, Pennsylvania; with a separate server room in our Chicago, Illinois office. We have agreements with our hardware andsystem software suppliers for support 24 hours a day, 7 days a week. Our operations personnel also use our resources located in our other U.S. facilities, aswell as our India facilities.Customers use high-speed internet connections or private network connections to access our business applications. We utilize commercially availablehardware and a combination of custom-developed and commercially available software. We designed our primary application in this manner to permitscalable growth. For example, database servers can be added without adding web servers, and vice versa.Databases are backed-up frequently by automatically shipping log files with accumulated changes to separate sets of back-up servers. In addition toserving as a back-up, these log files update the data in our online analytical processing engine, enabling the data to be more current than if only refreshedovernight. Data and information7regarding our customers’ patients is encrypted when transmitted over the internet or traveling off-site on portable media such as laptops or backup tapes.Customer system access requests are load-balanced across multiple application servers, allowing us to handle additional users on a per-customer basiswithout application changes. System utilization is monitored for capacity planning purposes.We believe that this architecture enables us to scale ouroperations effectively and efficiently.Our software interacts with our customers’ software through a series of real-time and batch interfaces. We do not require changes to the customer’s corepatient care delivery or financial systems. Instead of installing hardware or software in customer locations or data centers, we specify the information that acustomer needs to extract from its existing systems in order to interface with our systems. This methodology enables our systems to operate with manycombinations of customer systems, including custom and industry-standard implementations. We have successfully integrated our systems with older andnewer systems, with package and custom systems and with major industry-standard products and solutions.When these interfaces are in place, we provide an application suite across the hospital revenue cycle. For our purposes, the revenue cycle starts when apatient registers for future service or arrives at a hospital or clinic for unscheduled service, and ends when the hospital has collected all the appropriaterevenue from all possible sources. Thus, we provide eligibility, address validation, skip tracing, charge capture, patient and payer follow-up, analytics andtracking, charge master management, contract modeling, contract “what if” analysis, collections and other functions throughout the customer’s revenuecycle. Since our databases run on generally available hardware and software, we are able to use standard applications to develop, maintain and monitor oursolutions. Databases for one or more customers can run on a single database server with disk storage being provided from a shared storage area network, orSAN, with physical separation maintained between customers. In the event of a server failure, we have maintenance contracts in place that require the serviceprovider to have the server back on-line in four hours or less, or we move the customer processing to alternate servers. Our databases and servers are backed-up in full on a weekly basis and undergo incremental back-ups nightly. The SAN is configured as a redundant array of inexpensive disks, or RAID, and thisRAID configuration protects against disk failures having an impact on our operations. Database log files are stored separately from database files to reduceincidents of data loss. Data and information regarding our customers' patients is encrypted when at rest, when transmitted over the internet, and whentraveling off-site on portable media such as laptops or backup tapes.In the event that a combination of events causes a system failure, we typically can isolate the failure to one or a small number of customers. We believethat no combination of failures by our systems can impact a customer’s ability to deliver patient care.Our third-party data centers are designed to withstand many catastrophic events, such as blizzards and hurricanes. To protect against a catastrophicevent in which our primary data center is completely destroyed and service cannot be restored within a few days, we store backups of our systems anddatabases off-site. In the event that we are required to move operations to a different data center, we would re-establish operations by provisioning newservers, restoring data from the off-site backups and re-establishing connectivity with our customers’ host systems. Because our systems are web-based, nochanges would need to be made on customer workstations, and customers would be able to reconnect as our systems became available again.We monitor the response time of our application in a number of ways. We monitor the response time of individual transactions by customer and placemonitors inside our operations and at key customer sites to run synthetic transactions that demonstrate our systems’ end-to-end responsiveness. Our hostingprovider reports on responsiveness server-by-server and identifies potential future capacity issues. In addition, we survey key customers regarding systemresponse time to make sure customer-specific conditions are not impacting performance of our applications.We dedicate significant resources to protecting our customers’ confidential and protected health information, or PHI. Our security strategy employsvarious practices and technologies to control, audit and protect access to sensitive information. We received and have maintained since January 2013, acertification status from the Health8Information Trust Alliance, or HITRUST. HITRUST is a healthcare industry group focused on identifying a prescriptive set of information technologycontrols that are based on standards and regulations relevant to the healthcare industry. HITRUST certification is aligned with ISO 27001 and ISO 27002. OurHITRUST certification validates our continued commitment to compliance with the Health Insurance Portability and Accountability Act of 1996, asamended, and the regulations that have been issued under it, such as the HITECH and OMNIBUS regulations, which we collectively refer to as HIPAA, and tovarious states’ security and privacy laws regarding the creation, access, storage or exchange of personal health and financial information. Our HITRUSTcertification status also signifies that we exhibit and are able to maintain high security standards for the management and protection of electronic PHI.Proprietary Software SuitesRevenue Cycle Management. Our integrated suite of RCM technology provides a layer of analytics, rules processing and workflow capabilities thatinterface with provider systems to optimize process efficiency and effectiveness. These technologies power the detection of defects on patient accounts andenable staff workflow at point of service areas, customer sites and our shared service centers.•“AHtoAccess” powers workflow in customer central business offices and at our scaled shared service centers for pre-registration, financial clearance,and financial counseling. The platform processes patient accounts through proprietary rules engines tuned to identify defects in demographic data,authorization processes, insurance benefits and eligibility, and medical necessity. Our rules engines in AHtoAccess are also used to calculate patientbalance estimations and prior balance accounts receivables. For the uninsured, the platform helps staff triage patients to find coverage for their visit.Our technology enables staff to work on an exception basis eliminating the need for manual intervention on accounts with no exceptions identified.•“AHtoLink” delivers all of the insight and defect detection capabilities of our proprietary rules engines in real-time to point of service emergencydepartment and registration areas within the hospitals and clinics. When defects or inconsistent data are detected in the data entry or registrationprocess, users receive targeted messages alerting them to resolve the issue while the patient is still in front of them.•“AHtoContact,” our patient contact application, provides the workflow and data for patient contact center representatives. It enables effective financialdiscussions with patients on outstanding balances. The platform is integrated in to our call center, call-routing, auto-dialer capabilities and facilitatesimproved outcomes through propriety process and technology approaches.•“AHtoContract,” our proprietary contract modeling platform, is used to accurately calculate the maximum allowed reimbursement for each claim basedupon models of the hospital’s contract with each payer. This platform is used to provide insight into the health of payer contracts and to power portionsof the workflow tools described above.•“AHtoAnalytics”, our web-based reporting and analytics platform, produces over 300 proprietary reports derived from the financial, process andproductivity data that we accumulate as a result of our services, which enable us to monitor and identify areas for improvement in the efficacy of ourrevenue cycle management services.•“Integrated Defect Prevention” application, which we are currently in the process of deploying through a pilot program, aims to classify defects in aproprietary nomenclature and distribute data to back end teams for follow up and resolution. Defects will be identified and noted on accounts as theyoccur. Along with our “Yield-Based Follow Up” application, this platform is designed to power customer patient financial services departments and ourshared services.These propriety technology applications run on an integrated platform built on a modern event driven architecture and rules engines that allow real-time integration of systems and operational workflows.9Physician Advisory Services. Our proprietary PAS tools are designed to assist our customers in the initiation of a service request by our physicianadvisory team. Our platform allows for the electronic submission, tracking, reviewing and auditing of patient cases referred to us. The PAS portal environmentis established as a secure site that enables us to receive patient records from case managers and route them to our physicians for review. This workflow issupported by an analytics engine within the web portal that provides our customers the ability to improve their compliance and workflow with our real timereporting, dashboards and worklists.Value-Based Reimbursement, or VBR. Our proprietary technology within our VBR capability includes a secure web-based workflow application thatis designed to enable patient engagement staff, revenue cycle analysts, and physician/hospital care teams to monitor and manage gaps identified by ourproprietary rules engines. Our Quality, Revenue, and Measurement Coding rules engines represent a foundational framework which leverages a central datawarehouse of aggregated data from disparate sources. Gaps stemming from these rules engines are presented in a prioritized and user-friendly manner throughworkflow applications that drive operational follow up and management. Our web-based application is divided across Patient Outreach, Point of Care andReconciliation interfaces to allow for targeted resolution within operational support models across the revenue cycle. Patient Outreach leverages an autodialer and prioritized work list to enable both proactive and reactive engagement with patients who are unscheduled, scheduled, or discharged. The Point ofCare interface and report capabilities will provide actionable insights to help physicians achieve outcomes defined in value-based contracts. TheReconcile & Analyze tool allows for reporting, analysis and resolution of revenue gaps across the revenue cycle continuum. All three interfaces are supportedby dashboards and analytics which enable integrated reporting and root cause analysis.CompetitionThe market for our solutions is highly competitive and we expect competition to intensify in the future. We believe that competition for the services weprovide is based primarily on the following factors: •knowledge and understanding of the complex healthcare payment and reimbursement system in the United States;•a track record of delivering revenue improvements and efficiency gains for hospitals and healthcare systems;•predictable and measurable results;•the ability to deliver a solution that is fully-integrated along each step of a hospital’s revenue cycle operations;•cost-effectiveness, including the breakdown between up-front costs and pay-for-performance incentive compensation;•reliability, simplicity and flexibility of our technology platform;•understanding of the healthcare industry’s regulatory environment; and•sufficient and scalable infrastructure and financial stability.We also believe that several aspects of our business model differentiate us from our competitors:•we focus on performance-based compensation as a way to share in the economic value that we help create for our customers;•we focus on optimizing our customers’ entire, end-to-end revenue cycle process, which we believe is more advantageous than models that merelyfocus on certain aspects or individual sub-processes within the revenue cycle;10•our offering integrates talented personnel with our proven business methods augmented by our proprietary technology; and•we have extensive knowledge and service offerings that are specialized to help faith-based and other non-profit organizations deliver on their coremission of providing healthcare to their patients.We believe that we compete effectively based upon all of these criteria, although our ability to acquire new customers has been and may continue to beadversely effected by unfavorable publicity arising from the lawsuit filed in January 2012 by the Minnesota Attorney General and our Restatement that areeach described in "Part I - Item 1A - Risk Factors – If we are unable to retain our existing customers, our financial conditions will suffer."While we do not believe any single competitor delivers services in the same integrated manner as our revenue cycle management offering provides, weface competition from various sources. The internal RCM staffs of hospitals, which historically have performed the functions addressed by our services, ineffect compete with us. Hospitals that previously have made investments in internally developed solutions sometimes choose to continue to rely on their owninternal RCM staff.We also compete with several categories of external market participants, most of which focus on specific components of hospital revenue cycle.External market participants include: •software vendors and other technology-supported RCM business process outsourcing companies;•traditional consultants; and•information technology outsourcers.These types of external participants also compete with us in the field of physician advisory services. In addition, the commercial payer community canprovide information or services that are intended to assist providers in transitioning to a value-based reimbursement environment, and thus we indirectlycompete with those commercial payers.Although we believe that there are barriers to replicating our end-to-end RCM solution, we expect competition to intensify in the future. Othercompanies may develop superior or more economical service offerings that healthcare providers could find more attractive than our offerings. Moreover, theregulatory landscape may shift in a direction that is more strategically advantageous to existing and future competitors.Government RegulationThe customers we serve are subject to a complex array of federal and state laws and regulations. These laws and regulations may change rapidly andunpredictably, and it is frequently unclear how they apply to our business. We devote significant efforts, through training of personnel and monitoring, toestablish and maintain compliance with all regulatory requirements that we believe are applicable to our business and the services we offer.Government Regulation of Health InformationPrivacy and Security Regulations. HIPAA contains substantial restrictions and requirements with respect to the use and disclosure of individuals’ PHI.HIPAA prohibits a covered entity from using or disclosing an individual’s PHI unless the use or disclosure is authorized by the individual or is specificallyrequired or permitted under HIPAA. Under HIPAA, covered entities must establish administrative, physical and technical safeguards to protect theconfidentiality, integrity and availability of electronic PHI maintained or transmitted by them or by others on their behalf.HIPAA applies to covered entities, such as healthcare providers that engage in HIPAA-defined standard electronic transactions, health plans andhealthcare clearinghouses. In February 2009, HIPAA was amended by the11Health Information Technology for Economic and Clinical Health, or HITECH, Act to impose certain of the HIPAA privacy and security requirementsdirectly upon “business associates” that perform functions on behalf of, or provide services to, certain covered entities. Most of our customers are coveredentities and we are a business associate to many of those customers under HIPAA as a result of our contractual obligations to perform certain functions onbehalf of, and provide certain services to, those customers. As a business associate, we sometimes also act as a clearinghouse in performing certain functionsfor our customers. In order to provide customers with services that involve the use or disclosure of PHI, HIPAA requires our customers to enter into businessassociate agreements with us.Such agreements must, among other things, provide adequate written assurances: •as to how we will use and disclose the PHI;•that we will implement reasonable administrative, physical and technical safeguards to protect such information from misuse:•that we will enter into similar agreements with our agents and subcontractors that have access to the information;•that we will report security incidents and other inappropriate uses or disclosures of the information; and•that we will assist the customer with certain of its duties under HIPAA.Transaction Requirements. In addition to privacy and security requirements, HIPAA also requires that certain electronic transactions related tohealthcare billing be conducted using prescribed electronic formats. For example, claims for reimbursement that are transmitted electronically to payers mustcomply with specific formatting standards, and these standards apply whether the payer is a government or a private entity. We are contractually required tostructure and provide our services in a way that supports our customers’ HIPAA compliance obligations. On October 1, 2015, the International Classificationof Diseases 9, or ICD-9, used to report medical diagnoses and in-patient procedures will be replaced by ICD-10. This change will affect coding for all coveredentities and will require system and business changes throughout the healthcare industry. We are working collaboratively with our customers to prepare forthe transition to the new code sets.Data Security and Breaches. In recent years, there have been well-publicized data breach incidents involving the improper dissemination of personalhealth and other information of individuals, both within and outside of the healthcare industry. Many states have responded to these incidents by enactinglaws requiring holders of personal information to maintain safeguards and to take certain actions in response to data breach incidents, such as providingprompt notification of the breach to affected individuals and government authorities. In many cases, these laws are limited to electronic data, but states areincreasingly enacting or considering stricter and broader requirements. Under the HITECH Act and its implementing regulations, business associates are alsorequired to notify covered entities, which in turn are required to notify affected individuals and government authorities of data security breaches involvingunsecured PHI. In addition, the U.S. Federal Trade Commission, or FTC, has prosecuted some data breach cases as unfair and deceptive acts or practices underthe Federal Trade Commission Act, or FTC Act. We have implemented and maintain physical, technical and administrative safeguards intended to protect allpersonal data, and have processes in place to assist us in complying with applicable laws and regulations regarding the protection of this data and properlyresponding to any security incidents.State Laws. In addition to HIPAA, most states have enacted patient confidentiality laws that protect against the unauthorized disclosure of confidentialmedical information, and many states have adopted or are considering further legislation in this area, including privacy safeguards, security standards anddata security breach notification requirements. Such state laws, if more stringent than HIPAA requirements, are not preempted by the federal requirements,and we must comply with them even though they may be subject to different interpretations by various courts and other governmental authorities.12Other Requirements. In addition to HIPAA, numerous other state and federal laws govern the collection, dissemination, use, access to andconfidentiality of individually identifiable health and other information and healthcare provider information. The FTC has issued and several states haveissued or are considering new regulations to require holders of certain types of personally identifiable information to implement formal policies and programsto prevent, detect and mitigate the risk of identity theft and other unauthorized access to or use of such information. Further, the U.S. Congress and a numberof states have considered or are considering prohibitions or limitations on the disclosure of medical or other information to individuals or entities locatedoutside of the United States.Government Regulation of ReimbursementOur customers are subject to regulation by a number of governmental agencies, including those that administer the Medicare and Medicaid programs.Accordingly, our customers are sensitive to legislative and regulatory changes in, and limitations on, the government healthcare programs and changes inreimbursement policies, processes and payment rates. During recent years, there have been numerous federal legislative and administrative actions that haveaffected government programs, including adjustments that have reduced or increased payments to physicians and other healthcare providers and adjustmentsthat have affected the complexity of our work. For example, the Patient Protection and Affordable Care Act of 2010, or ACA, may reduce reimbursement forsome healthcare providers while increasing reimbursement for others including primary care physicians. In addition, the ACA mandates the implementationof various programs and value and quality-based reimbursement incentives that may impact the amount of reimbursement for our customers. For example, theadjustment related to the Medicare Value-Based Purchasing Program will increase from 1.5% in 2015 to 2.0% in 2017 and the adjustment related to theHospital Readmission Reduction Program increased from 1.0% in 2013 to 3.0% in 2015 and applies to an increased number of conditions. It is possible thatthe federal or state governments will implement additional reductions, increases or changes in reimbursement in the future under government programs thatadversely affect our customer base or increase the cost of providing our services. Any such changes could adversely affect our own financial condition byreducing the reimbursement rates of our customers.Fraud and Abuse LawsA number of federal and state laws, generally referred to as fraud and abuse laws, apply to healthcare providers, physicians and others that make, offer,seek or receive referrals or payments for products or services that may be paid for through any federal or state healthcare program and in some instances anyprivate program. Given the breadth of these laws and regulations, they may affect our business, either directly or because they apply to our customers. Theselaws and regulations include:Anti-Kickback Laws. There are numerous federal and state laws that govern patient referrals, physician financial relationships, and inducements tohealthcare providers and patients. The federal healthcare anti-kickback law prohibits any person or entity from offering, paying, soliciting or receivinganything of value, directly or indirectly, for the referral of patients covered by Medicare, Medicaid and certain other federal healthcare programs or theleasing, purchasing, ordering or arranging for or recommending the lease, purchase or order of any item, good, facility or service covered by these programs.Courts have construed this anti-kickback law to mean that a financial arrangement may violate this law if any one of the purposes of an arrangement is toinduce referrals of federal healthcare programs, patients or business, regardless of whether there are other legitimate purposes for the arrangement. There areseveral limited exclusions known as safe harbors that may protect certain arrangements from enforcement penalties although these safe harbors tend to bequite narrow. Penalties for federal anti-kickback violations can be severe, and include imprisonment, criminal fines, civil money penalties with tripledamages and exclusion from participation in federal healthcare programs. Anti-kickback law violations also may give rise to a civil False Claims Act, or FCA,action, as described below. Many states have adopted similar prohibitions against kickbacks and other practices that are intended to induce referrals, andsome of these state laws are applicable to all patients regardless of whether the patient is covered under a governmental health program or private health plan.False or Fraudulent Claim Laws. There are numerous federal and state laws that forbid submission of false information or the failure to discloseinformation in connection with the submission and payment of provider claims13for reimbursement. In some cases, these laws also forbid abuse of existing systems for such submission and payment, for example, by systematic overtreatment or duplicate billing of the same services to collect increased or duplicate payments.In particular, the federal FCA prohibits a person from knowingly presenting or causing to be presented a civil false or fraudulent claim for payment orapproval by an officer, employee or agent of the United States. The FCA also prohibits a person from knowingly making, using, or causing to be made or useda false record or statement material to such a claim. The FCA was amended on May 20, 2009 by the Fraud Enforcement and Recovery Act of 2009, or FERA.Following the FERA amendments, the FCA’s “reverse false claim” provision also creates liability for persons who knowingly conceal an overpayment ofgovernment money or knowingly and improperly retain an overpayment of government funds. In addition, ACA requires providers to report and returnoverpayments and to explain the reason for the overpayment in writing within 60 days of the date on which the overpayment is identified, and the failure todo so is punishable under the FCA. Violations of the FCA may result in treble damages, significant monetary penalties, and other collateral consequencesincluding, potentially, exclusion from participation in federally funded healthcare programs. The scope and implications of the FCA amendments have yet tobe fully determined or adjudicated and as a result it is difficult to predict how future enforcement initiatives may impact our business.In addition, under the Civil Monetary Penalty Act of 1981, the Department of Health and Human Services Office of Inspector General has the authorityto impose administrative penalties and assessments against any person, including an organization or other entity, who knowingly presents, or causes to bepresented, to a state or federal government employee or agent certain false or otherwise improper claims.Stark Law and Similar State Laws. The Ethics in Patient Referrals Act, known as the Stark Law, prohibits certain types of referral arrangementsbetween physicians and healthcare entities and thus potentially applies to our customers. Specifically, under the Stark Law, absent an applicable exception, aphysician may not make a referral to an entity for the furnishing of designated health service, or DHS, for which payment may be made by the Medicareprogram if the physician or any immediate family member has a financial relationship with that entity. Further, an entity that furnishes DHS pursuant to aprohibited referral may not present or cause to be presented a claim or bill for such services to the Medicare program or to any other individual or entity.Violations of the statute can result in civil monetary penalties and/or exclusion from federal healthcare programs. Stark Law violations also may give rise to acivil FCA action. Any such violations by, and penalties and exclusions imposed upon, our customers could adversely affect their financial condition and, inturn, could adversely affect our own financial condition.Laws in many states similarly forbid billing based on referrals between individuals and/or entities that have various financial, ownership or otherbusiness relationships. These laws vary widely from state to state.Laws Limiting Assignment of Reimbursement ClaimsVarious federal and state laws, including Medicare and Medicaid, forbid or limit assignments of claims for reimbursement from government fundedprograms. Some of these laws limit the manner in which business service companies may handle payments for such claims and prevent such companies fromcharging their provider customers on the basis of a percentage of collections or charges. We do not believe that the services we provide our customers resultin an assignment of claims for the Medicare or Medicaid reimbursements for purposes of federal healthcare programs. Any determination to the contrary,however, could adversely affect our ability to be paid for the services we provide to our customers, require us to restructure the manner in which we are paid,or have further regulatory consequences.Emergency Medical Treatment and Active Labor ActThe federal Emergency Medical Treatment and Active Labor Act, or EMTALA, was adopted by the U.S. Congress in response to reports of a widespreadhospital emergency room practice of “patient dumping.” At the time of EMTALA’s enactment, patient dumping was considered to have occurred when ahospital capable of providing the needed care sent a patient to another facility or simply turned the patient away based on such patient’s14inability to pay for his or her care. EMTALA imposes requirements as to the care that must be provided to anyone who seeks care at facilities providingemergency medical services. In addition, CMS of the U.S. Department of Health and Human Services has issued final regulations clarifying those areas withina hospital system that must provide emergency treatment, procedures to meet on-call requirements, as well as other requirements under EMTALA. Sanctionsfor failing to fulfill these requirements include exclusion from participation in the Medicare and Medicaid programs and civil monetary penalties. Inaddition, the law creates private civil remedies that enable an individual who suffers personal harm as a direct result of a violation of the law to sue theoffending hospital for damages and equitable relief. A hospital that suffers a financial loss as a direct result of another participating hospital’s violation of thelaw also has a similar right.EMTALA generally applies to our customers, and we assist our customers with the intake of their patients. Although we believe that our customers’medical screening, stabilization and transfer practices are in compliance with the law and applicable regulations, we cannot be certain that governmentalofficials responsible for enforcing the law or others will not assert that we or our customers are in violation of these laws nor what obligations may be imposedby regulations to be issued in the future.Regulation of Debt Collection ActivitiesThe federal Fair Debt Collection Practices Act, or FDCPA, regulates persons who regularly collect or attempt to collect, directly or indirectly, consumerdebts owed or asserted to be owed to another person. Certain of our accounts receivable activities may be deemed to be subject to the FDCPA. The FDCPAestablishes specific guidelines and procedures that debt collectors must follow in communicating with consumer debtors, including the time, place andmanner of such communications. Further, it prohibits harassment or abuse by debt collectors, including the threat of violence or criminal prosecution,obscene language or repeated telephone calls made with the intent to abuse or harass. The FDCPA also places restrictions on communications withindividuals other than consumer debtors in connection with the collection of any consumer debt and sets forth specific procedures to be followed whencommunicating with such third parties for purposes of obtaining location information about the consumer. In addition, the FDCPA contains various noticeand disclosure requirements and prohibits unfair or misleading representations by debt collectors. Finally, the FDCPA imposes certain limitations on lawsuitsto collect debts against consumers.Debt collection activities are also regulated at the state level. Most states have laws regulating debt collection activities in ways that are similar to, andin some cases more stringent than, the FDCPA. In addition, some states require companies engaged in the collection of consumer debt to be licensed. In allstates where we operate, we believe that we currently hold all required state licenses or are exempt from licensing.We are also subject to the Telephone Consumer Protection Act, or TCPA. In the process of communicating with our customers’ patients, we use avariety of communications methods. The TCPA places certain restrictions on companies that place telephone calls to consumers.The FTC has the authority to investigate consumer complaints relating to the FDCPA and the TCPA, and to initiate or recommend enforcement actions,including actions to seek monetary penalties. State officials typically have authority to enforce corresponding state laws. In addition, affected consumers maybring suits, including class action suits, to seek monetary remedies (including statutory damages) for violations of the federal and state provisions discussedabove.Regulation of Credit Card ActivitiesWe process, on behalf of our customers, credit card payments from their patients. Various federal and state laws impose privacy and information securitylaws and regulations with respect to the use of credit cards. If we fail to comply with these laws and regulations or experience a credit card security breach, ourreputation could be damaged, possibly resulting in lost future business, and we could be subjected to additional legal or financial risk as a result of non-compliance.15Foreign RegulationsOur operations in India are subject to additional regulations that govern the creation, continuation and winding up of companies, as well as therelationships between the shareholders, the company, the public and the government.Intellectual PropertyWe rely upon a combination of patent, trademark, copyright and trade secret laws and contractual terms and conditions to protect our intellectualproperty rights, and have sought patent protection for aspects of our key innovations.We have been issued three U.S. patents, which expire in 2028, 2030 and 2031, and have filed seven additional U.S. patent applications aimed atprotecting the four domains of our AHtoAccess software suite: patient access, improving maximum potential reimbursement, follow-up and measurement. SeeTechnology – Proprietary Software Suites section of "Part 1 - Item 1 - Business" for more information. Legal standards relating to the validity, enforceabilityand scope of protection of patents can be uncertain. We do not know whether any of our pending patent applications will result in the issuance of patents orwhether the examination process will require us to narrow our claims. Our patent applications may not result in the grant of patents with the scope of theclaims that we seek, if at all, or the scope of the granted claims may not be sufficiently broad to protect our products and technology. Our three grantedpatents or any patents that may be granted in the future from pending or future applications may be opposed, contested, circumvented, designed around by athird party or found to be invalid or unenforceable. Third parties may develop technologies that are similar or superior to our proprietary technologies,duplicate or otherwise obtain and use our proprietary technologies or design around patents owned or licensed by us. If our technology is found to infringeany patent or other intellectual property right held by a third party, we could be prevented from providing our service offerings and/or subjected tosignificant damage awards.We also rely, in some circumstances, on trade secrets to protect our technology. We control access to and the use of our application capabilities througha combination of internal and external controls, including contractual protections with employees, customers, contractors and business partners. We licensesome of our software through agreements that impose specific restrictions on our customers’ ability to use the software, such as prohibiting reverseengineering and limiting the use of copies. We also require employees and contractors to sign non-disclosure agreements and invention assignmentagreements to give us ownership of intellectual property developed in the course of working for us.Consistent with common industry practices, we sometimes utilize open source software or third party software products to meet our clients needs.Financial Information About Geographic AreasAll of our customers are entities organized and located within the United States. We do not derive any customer revenue from countries outside theUnited States.16EmployeesAs of June 1, 2015, we had approximately 2,960 full-time employees, as well as approximately 70 part-time employees. Of these employees,approximately 1,490 full-time and all part-time employees were located in the U.S., and approximately 1,540 full-time employees were located in India. Ouremployees are not represented by a labor union and we consider our current employee relations to be good.As a services business, our employees’ skills and experience are significant assets. We expend significant effort searching for individuals with extensiveexperience in healthcare or revenue process management issues in complex industries. Our less experienced employees attend training sessions. In addition,all of our employees are required to undergo mandatory compliance training, including HIPAA compliance training.Corporate InformationWe were incorporated in Delaware under the name Healthcare Services, Inc. in July 2003 and changed our name to Accretive Health, Inc. in August2009. Our principal executive offices are located at 401 North Michigan Avenue, Suite 2700, Chicago, Illinois 60611, and our telephone number is(312) 324-7820.Information AvailabilityOur Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and all amendments to those reports are availablefree of charge on our website at www.accretivehealth.com under the “Investor Relations” page as soon as reasonably practicable after such material iselectronically filed with, or furnished to, the Securities and Exchange Commission, or the SEC. The content on any website referred to in this Annual Reporton Form 10-K is not incorporated by reference into this report, unless expressly noted otherwise.Item 1A.Risk FactorsRisks Related to Our Financial Reporting ProcessesThe Restatement of our consolidated financial statements has had, and could continue to have, a material adverse impact on us.In the first quarter of 2013, we determined to restate our previously issued consolidated financial statements, or the Restatement. The Restatementcorrected accounting errors relating to timing of recognition of net services revenue, as well as the presentation of net services revenue and cost of services,and also certain capitalized costs for internal use software, goodwill, income taxes and other miscellaneous items. We completed the Restatement inDecember 2014. In connection with the Restatement, we incurred substantial unanticipated costs (primarily accounting related) of approximately $57.3million in the year ended December 31, 2014. In addition, we have incurred and will continue to incur in 2015 additional costs related to the Restatementthat was completed in 2014, including related internal control remediation. We have been required to expend significant time and resources in connectionwith the Restatement, and the attention of our management team has been diverted by these efforts. Because of the Restatement, and the delay in completingour financial statements for the years ended December 31, 2013 and December 31, 2012, we have been unable to timely file with the SEC the requiredperiodic reports associated with these years and the required periodic reports for 2014 and the first quarter of 2015. As a result of these events, we havebecome subject to significant risks and occurrences relating to the following matters, which are described in more detail below: •possible adverse consequences of failure to file past SEC reports;•limitations on access to public debt and equity capital markets;•impacts of material weaknesses in internal control over financial reporting;17•potential changes in tax liabilities; and•civil litigation.We have identified material weaknesses in our internal control over financial reporting which, if not corrected, could affect the reliability of ourconsolidated financial statements and have other adverse consequences.Section 404 of the Sarbanes-Oxley Act and the related SEC rules require management of certain public companies to assess the effectiveness of theirinternal control over financial reporting annually and to include in Annual Reports on Form 10-K a management report on that assessment, together with anattestation report by an independent registered public accounting firm. Under Section 404 and the SEC rules, a company cannot conclude that its internalcontrol over financial reporting is effective if there exist any material weaknesses in its financial controls. A material weakness is a deficiency, orcombination of control deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of ourannual or interim financial statements will not be prevented or detected on a timely basis.We have identified material weaknesses in our internal control over financial reporting as of December 31, 2014. These material weaknesses aredescribed in “Part II - Item 9A - Controls and Procedures” of this Annual Report on Form 10-K. We have taken and will continue to take actions to remediatethe material weaknesses and improve the effectiveness of our internal control over financial reporting. We cannot, however, assure you that we will be able tocorrect these material weaknesses in a timely manner. Any failure in the effectiveness of internal control over financial reporting, particularly if it results inmisstatements in our financial statements, could cause us to fail to meet our reporting obligations and could adversely affect investor perceptions of ourcompany.As a result of our Restatement, we face limitations in registering securities for a public offering, acquisitions or equity incentive plans, which couldadversely affect our business.As a result of the Restatement and our delayed filings, we are ineligible to use “short-form” registration statements that would allow us to incorporateby reference our SEC reports into our registration statements, or to use “shelf” registration statements until we have filed all of our periodic reports in a timelymanner for a period of 12 months. This could increase the costs of selling securities publicly and could significantly delay such sales and adversely affect ourbusiness. This also has resulted in our inability to permit use of our registration statement on Form S-8, which we filed to register the issuance and sales ofsecurities under our equity incentive plans, which could adversely affect our ability to grant awards to adequately incentivize and retain employees.Risks Relating to our Business and IndustryWe may not be able to achieve or maintain profitability.We incurred net losses in 2014, 2012, 2011 and 2010. We expect to report additional quarterly and annual losses in future periods, in accordance withGAAP. We incurred significant expenses during 2013 and 2012 related to, among other things, legal defense, crisis management costs, and strandedpersonnel costs arising from the lawsuit filed in January 2012 by the Minnesota Attorney General that is described in “Part I – Item 3 – Legal Proceedings”and that we settled in 2012. We incurred significant costs for the Restatement, restructuring activities and legal proceedings during 2014 and 2013 and arelikely to continue to incur additional costs in connection with those matters in 2015. Further, we anticipate continuing to incur significant additional costsfor technology to improve the quality and reliability of the processes used to secure patient health information. We intend to continue to increase ouroperating expenses associated with sales and marketing in future years in an effort to expand our business. If our revenue does not increase to offset theseincreases in costs, our operating results would be adversely affected. You should not consider our historical operating results as indicative of future operatingresults, and we cannot assure you that we will be able to achieve or maintain profitability in the future. Each of the risks described in this “Risk Factors”section, as well as other factors, may adversely affect our future operating results.18Litigation has materially adversely affected our business, financial condition, operating results and cash flows and caused unfavorable publicity andis likely to continue to do so.We were named as a defendant in a lawsuit filed in January 2012 by the Minnesota Attorney General alleging violations of federal and Minnesota statehealth privacy laws and regulations, Minnesota debt collection laws and Minnesota consumer protection laws resulting from, among other things, the theft inMinnesota in 2011 of an employee’s laptop that contained PHI. In addition, in April 2012, the Attorney General released to the public a “ComplianceReview” alleging, or raising questions about, our non-compliance with federal and Minnesota health privacy laws, the federal Fair Credit Reporting Act,EMTALA, federal and Minnesota debt collections laws and Minnesota consumer protection laws. All disputes with the Minnesota Attorney General (andrelated investigations by the Minnesota Department of Commerce and Minnesota Department of Human Services) were fully and finally resolved in aSettlement Agreement, Release, and Consent Order dated July 30, 2012, without any admission of liability or wrongdoing by us. There have been otherinquiries related to these matters, including one by the FTC. On December 31, 2013, without any admission of liability or wrongdoing and without paymentof any monetary penalty or fine, we entered into a Consent Order agreement with the FTC to resolve the FTC’s investigation. Pursuant to the Consent Order,we agreed, among other things, to maintain a comprehensive information security program reasonably designed to protect the security, confidentiality andintegrity of personal information collected from or about consumers. If we fail to maintain a comprehensive information security program, we may be subjectto future inquiries or litigation.The Minnesota-related legal matters and related inquiries led to several securities-related class action and derivative lawsuits. The securities-relatedclass actions were settled within the limits of our insurance coverage and a preliminary approval for a settlement of the derivative suits, also within the limitsof our insurance coverage, was granted by the U.S. District Court on March 19, 2015 and hearing for final approval has been scheduled for July 23, 2015.The Restatement has also led to litigation. A securities-related class action lawsuit has been filed and amended against us, a current director, and certainof our former officers in connection with the Restatement. The SEC’s Division of Enforcement in the Chicago Regional Office is also conducting aninvestigation regarding the circumstances surrounding the Restatement. In addition, one of the Minnesota-related derivative suits was amended to includeclaims regarding the Restatement. These lawsuits and investigation are described in “Part I – Item 3 – Legal Proceedings.” The lawsuit and investigation haveresulted in, and may lead to additional, unfavorable publicity for us and may have a disruptive effect upon the operation of our business and consume thetime and attention of our senior management.In addition, we incurred substantial expenses in connection with these litigation matters, including substantial fees for attorneys. Although we maintaininsurance that may provide coverage for some or all of these expenses, and we have given notice to our insurers of the claims, our insurers have responded byreserving their rights under the policies, including the rights to deny coverage under various policy exclusions. There is risk that the insurers will rescind thepolicies, that some or all of the claims will not be covered by such policies, or that, even if covered, our ultimate liability will exceed the available insurance.We are unable to predict the outcome of pending legal actions. The ultimate resolution of the securities class action lawsuit related to the Restatementand the pending derivative suits related to the Minnesota-related matters and the Restatement could have a material adverse effect on our financial results,financial condition or liquidity, and on the trading price of our common stock.The above matters and attendant publicity have resulted in widespread, unfavorable publicity for us and have materially adversely affected, and maycontinue to materially adversely affect, our business, financial condition, operating results and cash flows in various ways, including as follows: •in 2012, we and Fairview Health Services, or Fairview, decided to amend the RCM agreement between us to transition the management of therevenue cycle operations to Fairview leadership, and we received a19notice of termination from Fairview of the PHS agreement between us. In December 2013, following mediation, we reached a confidential agreementto resolve all of our differences with Fairview;•in 2012, in connection with the settlement of the Minnesota Attorney General lawsuit, as disclosed in “Part I – Item 3 – Legal Proceedings,” wevoluntarily agreed to cease all remaining operations in Minnesota and have wound down our operations with our Minnesota customers;•other customers have terminated or may seek to terminate or modify their service agreements with us;•we believe that potential new customers have been deterred from entering into service agreements with us, and the terms on which we are able toenter into new service agreements, or renew agreements with existing customers, in the future may be less favorable to us;•the time and attention of management has been diverted from our business;•we have encountered increased difficulty in attracting and retaining employees;•we have incurred, and will continue to incur, substantial legal and other expenses in defending the pending and settled lawsuits; and•the remaining pending lawsuits could subject us to significant liability or result in significant settlement payments.In addition, other governmental authorities could initiate inquiries into our business practices, and additional lawsuits may be filed against us.Additional litigation could result in the incurrence of substantial additional expense, subject us to significant liability or result in significant settlementpayments, further divert management’s attention from our business, and thereby materially adversely affect our business, financial condition, operatingresults and cash flows.Hospital systems affiliated with Ascension Health currently account for a significant portion of our net services revenue as well as our gross cashgenerated from contracting activities, and we have several other customers that have each accounted for 10% or more of our gross cash generated fromcontracting activities in past periods. The termination or expiration of our new master professional services agreement with Ascension Health, or anysignificant loss of business from our large customers, would have a material adverse effect on our business, results of operations and financial condition.In August 2012 we entered into a new five-year master professional services agreement, or MPSA, with Ascension Health. As a result of the fact thatsubstantially all of the hospital systems affiliated with Ascension Health for which we previously conducted RCM operations have opted in to the MPSA byexecuting a new supplement agreement with us, on February 27, 2015, Ascension Health provided us notice of termination of our prior master servicesagreement with Ascension Health dated December 31, 2007 (which we refer to as the Legacy Agreement), with such termination to be effective as ofDecember 31, 2015. We continue to provide services to one physician group affiliated with Ascension Health pursuant to the Legacy Agreement that did notexecute a new supplement agreement with us. We ceased providing services under the Legacy Agreement to one customer in the second quarter of 2014,which customer did not execute a supplement agreement with us and to one additional customer that was acquired by a third party in the first quarter of 2015.Hospital systems affiliated with Ascension Health have accounted for a significant portion of our net services revenue each year since our formation. In2014, 2013 and 2012, net services revenue from hospitals affiliated with Ascension Health represented 12%, 73% and 5% of our total net services revenue,respectively, in such periods. Additionally, in 2014, 2013 and 2012, gross cash generated from customer contracting activities, as defined in "Part II - Item 6 –Selected Consolidated Financial Data", with hospital systems affiliated with Ascension Health represented 53%, 42% and 47%, respectively, of our totalgross cash generated from contracting activities in such periods. St. John Health (an affiliate of Ascension Health ) individually accounted for 12%, 28% and1% of our total20net services revenue and 12%, 7% and 10% of our gross cash generated from contracting activities in 2014, 2013 and 2012, respectively. Additionally, in2014, Columbia St. Mary's and Sacred Heart (also affiliates of Ascension Health) individually accounted for 0% and 12% of our total net services revenueand 10% and 1% of our gross cash generated from contracting activities, respectively.In light of the fact that we only recognize revenues for our RCM services upon the expiration or termination of the underlying RCM customer contract,or upon other defined events in accordance with our revenue recognition policies, we believe that gross cash generated from contracting activities is a moremeaningful measure of our significant customers in any given period than their respective contributions to consolidated revenue during such period. Ourrevenue recognition policies can result in cash flow accumulations from RCM activities over three to five years prior to a revenue recognition event, andconsolidated net revenues that are inconsistent with the cash flows from the same underlying operations. We do not believe that the loss of any of our othercustomers that accounted for greater than ten percent of our consolidated revenues in 2014, 2013 and 2012 would have a material adverse effect on ouroperations or financial results. Any of our other customers, including hospital systems affiliated with Ascension Health, can elect not to renew their managedservices agreements with us upon expiration. We intend to seek renewal of all managed service agreements with our customers, but cannot assure you thatany of them will be renewed or that the terms upon which they may be renewed will be as favorable to us as the terms of the initial managed servicesagreements. The termination of the MPSA, the loss of any of our other large customers or their failure to renew their managed services agreements with usupon expiration, or a reduction in the fees for our services for these customers could have a material adverse effect on our business, results of operations andfinancial condition.The early termination of certain customer agreements, including certain customer agreement terminations in connection with the Minnesota-relatedlegal matters described above, has adversely affected our financial results.In 2012, we amended the revenue cycle operations agreement with Fairview to transition the management of those operations to Fairview leadershipand we received from Fairview a notice of termination of the population health solutions agreement. Fairview accounted for 8% and 5% of our net servicesrevenue in 2013 and 2012, respectively, and for 8% and 2% of our gross cash received from contracting activities in 2013 and 2012, respectively. Inconnection with the settlement of the Minnesota Attorney General lawsuit as described in “Part I – Item 3 – Legal Proceedings,” we agreed to voluntarilycease all remaining operations in Minnesota and wound down our operations with one of our Minnesota based physician advisory services customers and ourtwo Minnesota based revenue cycle customers, one of which, Fairview, was also a PHS customer. In addition, during 2013 and 2012, we reached settlementagreements with two other customers which provided for early terminations of those customers’ agreements. In 2015, another customer terminated its revenuecycle services agreement with us.The loss of the customer agreements noted above adversely affected our operating results in 2014, 2013 and 2012 and will negatively impact ourrevenues and/or operating results through 2018 when the initial term under the last of these customer agreements would have reached its normal expiration.If we are unable to retain our existing customers or acquire new customers, our financial condition will suffer.Our success depends in part upon the retention of our customers, particularly Ascension Health and its affiliated hospitals, and our ability to acquirenew customers. We derive our net services revenue primarily from managed services agreements pursuant to which we receive performance-based fees.Customers can elect not to renew their managed services agreements with us upon expiration. If a managed services agreement is not renewed for any reason,we would not derive the financial benefits that we would expect to derive by serving that customer beyond the initial term of our managed servicesagreement. If a managed services agreement is terminated for any reason, including for example, if we are found to be in violation of certain federal or statelaws or excluded from participating in federal and state healthcare programs such as Medicare and Medicaid, we will not receive the payments we would haveotherwise anticipated receiving over the life of the agreement.21Some of our managed services agreements require us to adhere to extensive, complex data security, network access and other institutional proceduresand requirements of our customers, and we cannot guaranty that some of our customers will not allege that we have not complied with all such proceduresand requirements. If we breach a managed services agreement or, for certain of our managed services agreements, fail to perform in accordance withcontractual service levels, we may be liable to the customer for damages, and either we or the customer may generally terminate an agreement for a materialuncured breach by the other. Any of these events could adversely affect our business, financial condition, operating results and cash flows. Ascension Healthand another healthcare organization with multiple affiliates that contract with us individually under a master services agreement can also terminate theiragreements with us if the receipt of services under the agreement causes or will cause a material negative impact to the customer’s brand, reputation oroperations, in such customer’s good faith estimation, because of the manner in which we provided services for it or any other customer. In addition, financialissues or other changes in customer circumstances, such as a customer change in control (including as a result of increasing consolidation within thehealthcare provider industry), may cause us or the customer to seek to modify or terminate a managed services agreement. Increasing consolidation within thehealthcare provider industry may also make it more difficult for us to acquire new customers, as consolidated healthcare systems may be more likely to haveincumbent revenue cycle management providers or significant internal revenue cycle capabilities. For example, certain of our smaller customers have beenacquired by larger healthcare systems and ceased to be customers.In 2014, two of our customers provided us with notices of termination of their respective RCM agreements with us, in accordance with the terms ofthose agreements. As a result of those notices, one such agreement terminated in the second quarter of 2014 and the other terminated in the third quarter of2014. However, one of those customers entered into a new managed services agreement with us to provide revenue cycle services under new terms followingthe termination of its existing agreement.Also in 2014, our RCM agreement with another customer expired, although we currently continue to provide certain services to that customer under theRCM agreement in connection with the resolution of specified payer accounts receivable in exchange for a fixed fee. We also entered into a new masterservices agreement with that customer pursuant to which we are providing certain specified RCM services.Our agreements with certain customers require us to offer to such customer service fees that are at least as low as the fees we charge any othercustomer receiving comparable services at comparable or lower volumes.Our MPSA with Ascension Health requires us to offer to Ascension Health’s affiliated hospital systems fees for our services that are at least as low as thefees we charge any other customer receiving comparable services at lower volumes. If we were to charge lower service fees to any other customer receivingcomparable services at lower volumes, we would be obligated to charge such lower fees to the hospital systems affiliated with Ascension Health effective asof the date such lower charges were first implemented for such other customer. Additionally, our RCM agreement with another customer requires us toprovide that customer with a gain sharing incentive rate that is as low as the rate provided to any new customer. If we offer customers lower rates than asdiscussed above, it could have a material adverse effect on our results of operations and financial condition.Our agreements with hospital systems affiliated with Ascension Health and with some other customers include provisions that could impede or delayour ability to enter into managed services agreements with new customers.Under the terms of our agreement with Ascension Health, we cannot begin to negotiate the provision of services to certain designated competitors thatare in close proximity to a hospital affiliated with Ascension Health that has executed a supplement agreement with us until we have informed and discussedthe situation with such Ascension Health affiliate. In addition, our managed services agreement with one customer not affiliated with Ascension Healthrequires us to consult with such customer before providing services to competitors specified by such customer. The obligations described above couldimpede or delay our ability to enter into managed services agreements with new customers.22The markets for our RCM service offering may develop more slowly than we expect and some potential customers for our services have been and mayin the future be deterred by the lawsuit initiated against us by the Minnesota Attorney General, the Restatement, and legal proceedings resulting from thesechallenges, and because they previously have made or in the future will make investments in internally developed solutions and choose to continue to relyon their own internal resources, which could adversely affect our revenue and our ability to achieve or maintain our profitability.Our success depends, in part, on the willingness of hospitals, physicians and other healthcare providers to implement integrated solutions for the areasin which we provide services. Some hospitals may be reluctant or unwilling to implement our solutions for a number of reasons, including failure to perceivethe need for improved revenue cycle operations or lack of knowledge about the potential benefits our solutions provide. In addition, some potentialcustomers for our services may be deterred by the lawsuit initiated against us by the Minnesota Attorney General that we settled in 2012, or the Restatement,and the resulting related legal proceedings.Even if potential customers recognize the need to improve revenue cycle operations, they may not select solutions such as ours because theypreviously have made or in the future will make investments in internally developed solutions and choose to continue to rely on their own internal resources.As a result, the markets for integrated, end-to-end revenue cycle management services may develop more slowly than we expect, which could adversely affectour revenue and operating results.Our business operations currently include the collection, on behalf of our customers, of medical co-pays and other payments that are due to ourcustomers from their patients. This business practice has been perceived negatively by the public and this negative perception has adversely affected (andmay continue to adversely affect) our business, results of operations and financial condition.We currently collect, on behalf of our customers, medical co-pays and other non-defaulted payments that are due to our customers from their patients,pursuant to managed services agreements with our customers. Collection of these payments from patients may become a more significant part of our RCMservices as industry trends continue to increase patient responsibility as a percentage of total compensation to healthcare providers. This business practice,which has received widespread, unfavorable publicity as a result of the lawsuit initiated against us by the Minnesota Attorney General that we settled in 2012and resulting related legal proceedings, has been negatively perceived by the public and has led us to change aspects of our business practices, made it moredifficult to retain existing customers and attract new customers, extended the time it takes to enter into service agreements with new customers, and resultedin a material adverse effect on our business, results of operations and financial condition, and it may continue to do so.We operate in a highly competitive industry, and our current or future competitors may be able to compete more effectively than we do, which couldhave a material adverse effect on our business, revenue, growth rates and market share.The market for our solutions is highly competitive and we expect competition to intensify in the future. The rapid changes in the U.S. healthcare marketdue to financial pressures to reduce the growth in healthcare costs and from regulatory and legislative initiatives such as the ACA are increasing the level ofcompetition. We face competition from a steady stream of new entrants, including the internal RCM staff of hospitals, as described above, and externalparticipants. External participants that are our competitors in the revenue cycle market include software vendors and other technology-supported RCMbusiness process outsourcing companies; traditional consultants; and information technology outsourcers. These types of external participants also competewith us in the field of population health solutions and physician advisory services (which services and capabilities have been or are being integrated into ourRCM service offering). Our competitors may be able to respond more quickly and effectively than we can to new or changing opportunities, technologies,standards, regulations or customer requirements. We may not be able to compete successfully with these companies, and these or other competitors mayintroduce technologies or services that render our technologies or services obsolete or less marketable. Even if our technologies and services are moreeffective than the offerings of our competitors, current or potential customers23might prefer competitive technologies or services to our technologies and services. Increased competition is likely to result in pricing pressures, which couldadversely affect our margins, growth rate or market share.We face a selling cycle of variable length to secure new RCM agreements, making it difficult to predict the timing of specific new customerrelationships.We face a selling cycle of variable length, typically spanning six to 18 months or longer, to secure a new managed services agreement. Even if wesucceed in developing a relationship with a potential new customer, we may not be successful in entering into a managed services agreement with thatcustomer. In addition, we cannot accurately predict the timing of entering into managed services agreements with new customers due to the complexprocurement decision processes of most healthcare providers, which often involves high-level management or board committee approvals. Consequently, wehave only a limited ability to predict the timing of specific new customer relationships. Moreover, we believe that the unfavorable publicity we received as aresult of the lawsuit initiated against us by the Minnesota Attorney General that we settled in 2012, the Restatement, and the resulting related legalproceedings have reduced our attractiveness to some potential healthcare providers and consequently, have resulted in the lengthening of the selling cyclewith potential new customers.Delayed or unsuccessful implementation of our technologies or services with our customers or implementation costs that exceed our expectationsmay harm our financial results.To implement our solutions, we work with our customer’s existing vendors, management and staff and layer our proprietary technology applications ontop of the customer’s existing patient accounting and clinical systems. Each customer’s situation is different, and unanticipated difficulties and delays mayarise such as delays in, or the inability to, obtain approvals or access rights from our customers’ vendors. If the implementation process is not executedsuccessfully or is delayed, our relationship with the customer may be adversely affected and our results of operations could suffer. Implementation of oursolutions also requires us to integrate our own employees into the customer’s operations. The customer’s circumstances may require us to devote a largernumber of our employees than anticipated, which could increase our costs and harm our financial results.Our quarterly results of operations and cash flows fluctuate as a result of many factors, some of which may be outside of our control.Our revenues fluctuate and will continue to fluctuate widely from quarter to quarter based on revenue recognition criteria under GAAP.In addition, the timing of any new customer additions is not likely to be uniform throughout the year, which can also cause fluctuations in our quarterlyresults. Operating costs are typically higher in quarters in which we add new customers because we incur expenses to implement our operating model at thosecustomers. Further, fees billable to customers under many of our managed services agreements experience fluctuations as they are tied contractually to thelevel of our customers’ cash receipts. Fees have a significant effect on our cash flows, and changes in the amount of fees can cause significant fluctuations inour quarter-to-quarter operating cash flows. Our cash flows can also be impacted by the timing of operating costs.Our restructuring activities may negatively impact our operations.In the second quarter of 2013, we commenced a series of measures designed to better align our operational structure and to improve efficiency. As partof these measures, we recorded approximately $5.2 million of restructuring costs in 2013, consisting primarily of employee separation costs. In the firstquarter of 2014, we commenced additional restructuring actions in order to allow us to more effectively and efficiently allocate necessary resources forinnovation, invest in growth and enhance customer service, which included reductions in our workforce in certain corporate, administrative and managementfunctions and the relocation of certain corporate functions from our headquarters in Chicago, Illinois. Additionally, in the fourth quarter of 2014, wecommenced further restructuring actions in order to align our organizational structure and resources to better support our primary business of revenue cyclemanagement and adjust staffing levels for volume reductions in our PAS business24resulting from the implementation of the 2014 Medicare hospital inpatient prospective payment system final rule, or the Two-Midnight Rule. As part of theseactions, we recorded approximately $22.1 million, consisting primarily of employee separation and facilities-related expenses. Reductions in personnel mayadversely affect or delay various sales, marketing and product development programs and activities and could have negative effects on our internal controlover financial reporting. These restructuring activities could be disruptive to our business and have a material adverse effect on our financial results.If we lose key personnel or if we are unable to attract, hire, integrate and retain our key personnel and other necessary employees, our business couldbe harmed.Our future success depends in part on our ability to attract, hire, integrate and retain key personnel. Our future success also depends in part on thecontinued contributions of our executive officers and other key personnel, each of whom may be difficult to replace. The loss of services of any of ourexecutive officers or key personnel, or the inability to continue to attract qualified personnel could have a material adverse effect on our business,particularly as a result of our recent and ongoing restructuring activities. Competition for the caliber and number of employees we require is intense. We mayface difficulty identifying and hiring qualified personnel at compensation levels consistent with our existing compensation and salary structure. In addition,we invest significant time and expense in training each of our employees, which increases their value to competitors who may seek to recruit them. If we failto retain our employees, we could incur significant expenses in hiring, integrating and training their replacements, and the quality of our services and ourability to serve our customers could diminish, resulting in a material adverse effect on our business.The imposition of legal responsibility for obligations related to our employees or our customers’ employees could adversely affect our business andsubject us to liability.Under our agreements with customers, we work with our customers’ employees engaged in the activities included in the scope of our services. Ourmanaged services agreements establish the division of responsibilities between us and our customers for various personnel management matters, includingcompliance with and liability under various employment laws and regulations. We could, nevertheless, be found to have liability with our customers foractions against or by employees of our customers, including under various employment laws and regulations, such as those relating to discrimination,retaliation, wage and hour matters, occupational safety and health, family and medical leave, notice of facility closings and layoffs and labor relations, aswell as similar liability with respect to our own employees, and any such liability could result in a material adverse effect on our business.If we fail to manage our operations effectively, our business would be harmed.We have not always been fully successful in managing the expansion of our operations which has led, at times to some customer dissatisfaction andweaknesses in our operating, internal and financial controls. To manage potential future growth, we will need to hire, integrate and retain highly skilled andmotivated employees, and will need to work effectively with a growing number of customer employees engaged in revenue cycle operations. We will alsoneed to continue to improve our financial, internal and management controls, reporting systems and procedures. If we do not effectively manage ouroperations, we may not be able to execute on our business plan, respond to competitive pressures, take advantage of market opportunities, satisfy customerrequirements or maintain high-quality service offerings.Disruptions in service or damage to our shared services centers and third-party operated data centers could adversely affect our business.Our shared services centers and third-party operated data centers are essential to our business. Our operations depend on our ability to operate ourshared services centers, and to maintain and protect our applications, which are located in data centers that are operated for us by third parties. We cannotcontrol or assure the continued or uninterrupted availability of these third-party data centers. In addition, our information technologies and systems, as wellas our data centers and shared services centers, are vulnerable to damage or interruption from various causes,25including (1) acts of God and other natural disasters, war and acts of terrorism and (2) power losses, computer systems failures, internet andtelecommunications or data network failures, operator error, losses of and corruption of data and similar events. We have a business continuity plan andmaintain insurance against fires, floods, other natural disasters and general business interruptions to mitigate the adverse effects of a disruption, relocation orchange in operating environment at one of our data centers or shared services centers, but the situations we plan for and the amount of insurance coverage wemaintain may not be adequate in every particular case. In addition, the occurrence of any of these events could result in interruptions, delays or cessations inservice to our customers, or in interruptions, delays or cessations in the direct connections we establish between our customers and payers. Any of theseevents could impair or inhibit our ability to provide our services, reduce the attractiveness of our services to current or potential customers and adverselyaffect our financial condition and results of operations.In addition, despite the implementation of security measures, our infrastructure, data centers, shared services centers or systems that we interface with,including the internet and related systems, may be vulnerable to physical break-ins, hackers, improper employee or contractor access, computer viruses,programming errors, denial-of-service attacks or other attacks by third parties seeking to disrupt operations or misappropriate information or similar physicalor electronic breaches of security. Any of these can cause system failure, including network, software or hardware failure, which can result in servicedisruptions. As a result, we may be required to expend significant capital and other resources to protect against security breaches and hackers or to alleviateproblems caused by such breaches.If our security measures are breached or fail and unauthorized access is obtained to a customer’s data, our service may be perceived as not beingsecure, the attractiveness of our services to current or potential customers may be reduced, and we may incur significant liabilities.Our services involve the storage and transmission of customers’ proprietary information and protected health, financial, payment and other personalinformation of patients. We rely on proprietary and commercially available systems, software, tools and monitoring, as well as other processes, to providesecurity for processing, transmission and storage of such information, and because of the sensitivity of this information, the effectiveness of such securityefforts is very important. The systems currently used for transmission and approval of credit card transactions, and the technology utilized in credit cardsthemselves, all of which can put credit card data at risk, are determined and controlled by the payment card industry, not by us. If our security measures arebreached or fail as a result of third-party action, employee error, malfeasance or otherwise, someone may be able to obtain unauthorized access to customer orpatient data. Improper activities by third parties, advances in computer and software capabilities and encryption technology, new tools and discoveries andother events or developments may facilitate or result in a compromise or breach of our computer systems. Techniques used to obtain unauthorized access orto sabotage systems change frequently and generally are not recognized until launched against a target, and we may be unable to anticipate these techniquesor to implement adequate preventive measures. Our security measures may not be effective in preventing these types of activities, and the security measuresof our third-party data centers and service providers may not be adequate. If a breach of our security occurs, we could face damages for contract breach,penalties for violation of applicable laws or regulations, possible lawsuits by individuals affected by the breach and significant remediation costs and effortsto prevent future occurrences. In addition, whether there is an actual or a perceived breach of our security, the market perception of the effectiveness of oursecurity measures could be harmed and we could lose current or potential customers.We may be liable to our customers or third parties if we make errors in providing our services, and our anticipated net services revenue may be lowerif we provide poor service.The services we offer are complex, and we make errors from time to time. Errors can result from the interface of our proprietary technology applicationsand a customer’s existing technologies or we may make human errors in any aspect of our service offerings. The costs incurred in correcting any materialerrors may be substantial and could adversely affect our operating results. Our customers, or third parties such as our customers’ patients, may assert claimsagainst us alleging that they suffered damages due to our errors, and such claims could subject us to significant legal defense costs in excess of our existinginsurance coverage and adverse publicity regardless of the merits or eventual outcome of such claims. In addition, if we provide poor service to a customerand the customer26therefore realizes less improvement in revenue yield, the incentive fee payments to us from that customer will be lower than anticipated.We offer our services in many jurisdictions and, therefore, may be subject to federal, state and local taxes that could harm our business or that wemay have inadvertently failed to pay.We may lose sales or incur significant costs should various tax jurisdictions be successful in imposing taxes on a broader range of services. Impositionof such taxes on our services could result in substantial unplanned costs, would effectively increase the cost of such services to our customers and mayadversely affect our ability to retain existing customers or to gain new customers in the areas in which such taxes are imposed.Our growing operations in India expose us to risks that could have a material adverse effect on our costs of operations.We employ a significant number of persons in India and expect to continue to add personnel in India. While there are cost and service advantages tooperating in India, significant growth in the technology sector in India has increased competition to attract and retain skilled employees and has led to acommensurate increase in compensation expense. In the future, we may not be able to hire and retain such personnel at compensation levels consistent withour existing compensation and salary structure in India. In addition, our reliance on a workforce in India exposes us to disruptions in the business, politicaland economic environment in that region. Maintenance of a stable political environment is important to our operations, and terrorist attacks and acts ofviolence or war may directly affect our physical facilities and workforce or contribute to general instability. Our operations in India require us to comply withlocal laws and regulatory requirements, which are complex and of which we may not always be aware, and expose us to foreign currency exchange rate risk.Our Indian operations may also subject us to trade restrictions, reduced or inadequate protection for intellectual property rights, security breaches and otherfactors that may adversely affect our business. Negative developments in any of these areas could increase our costs of operations or otherwise harm ourbusiness.Negative public perception in the United States regarding offshore outsourcing and proposed legislation may increase the cost of delivering ourservices.Offshore outsourcing is a politically sensitive topic in the United States. For example, various organizations and public figures in the United Stateshave expressed concern about a perceived association between offshore outsourcing providers and the loss of jobs in the United States. In addition, there hasbeen publicity about the negative experience of certain companies that use offshore outsourcing, particularly in India. Current or prospective customers mayelect to perform such services themselves or may be discouraged from transferring these services from onshore to offshore providers to avoid negativeperceptions that may be associated with using an offshore provider. Any slowdown or reversal of existing industry trends towards offshore outsourcing wouldincrease the cost of delivering our services if we had to relocate aspects of our services from India to the United States where operating costs are higher.Legislation in the United States may be enacted that is intended to discourage or restrict offshore outsourcing. In the United States, federal and statelegislation has been proposed, and enacted in several states to restrict or discourage U.S. companies from outsourcing their services to companies outside theUnited States. Some states also have issued guidance that prohibits offshore outsourcing of services for the Medicaid program. It is possible that additionallegislation could be adopted or regulatory guidance issued that would restrict U.S. private sector companies that have federal or state government contracts,or that receive government funding or reimbursement, such as Medicare or Medicaid payments, from outsourcing their services to offshore service providers.Any changes to existing laws or the enactment of new legislation restricting offshore outsourcing in the United States may adversely affect our ability to dobusiness, particularly if these changes are widespread, and could have a material adverse effect on our business, results of operations, financial condition andcash flows.27Regulatory RisksThe healthcare industry is heavily regulated. Our failure to comply with regulatory requirements could create liability for us, result in adversepublicity and adversely affect our business.The healthcare industry is heavily regulated and is subject to changing political, legislative, regulatory and other influences. Many healthcare laws arecomplex, and their application to specific services and relationships may not be clear. In particular, many existing healthcare laws and regulations, whenenacted, did not anticipate the services that we provide. There can be no assurance that our operations will not be challenged or adversely affected byenforcement initiatives. Enforcement activity is growing and is an identified priority of federal and state governments. Our failure to accurately anticipate theapplication of these laws and regulations to our business, or any other failure to comply with regulatory requirements, could create liability for us, result inadverse publicity and adversely affect our business. Federal and state legislatures and agencies frequently consider proposals to revise laws that impact thehealthcare industry or to revise or create additional statutory and regulatory requirements. Such proposals, if implemented, could adversely affect ouroperations, the attractiveness of our services to existing customers and our ability to market new services, or could create unexpected liabilities for us. We areunable to predict what changes to laws or regulations might be made in the future or how those changes could affect our business or our operating costs.Developments in the healthcare industry, including national healthcare reform, could adversely affect our business.The healthcare industry has changed significantly in recent years and we expect that significant changes will continue to occur. The timing and impactof developments in the healthcare industry are difficult to predict. We cannot be sure that the markets for our services will continue to exist at current levelsor that we will have adequate technical, financial and marketing resources to react to changes in those markets. Many of the provisions of the ACA, whichwas enacted in 2010, first became effective in 2014. Therefore, it is not yet possible for us to accurately predict if, or how, these changes will impact ourability to develop increases in revenue yield for our customers, encourage more companies to enter our market, provide advantages to our competitors andresult in the development of solutions that compete with ours. Moreover, healthcare reform remains a major policy issue at the federal level, and amendmentsto or the repeal of the existing legislation and additional healthcare legislation in the future could have adverse consequences for us or the customers weserve. Other material changes, such as the required transition by October 1, 2015 to ICD-10 will impose significant system and business changes throughoutthe healthcare industry, and could be disruptive to our customers and our business. Such disruption could result in, among other things, the imposition ofsignificant new challenges to our ability to achieve performance targets specified under our customer contracts, as well as a need for us to redeploy resourcesor to obtain new resources in an effort to meet such challenges, all of which could adversely affect our business or our results of operations. Additionally,several reductions or changes to Medicare reimbursement have been enacted recently or will be implemented (such as the federal government sequestrationreductions), which reductions and changes could reduce the amounts received by our customers and may have an adverse indirect effect on our business.In addition, one aspect of the 2014 Medicare hospital inpatient prospective payment system final rule, or the Two- Midnight Rule, generally permitshospitals to classify Medicare patients as inpatients for billing purposes only if a physician documents a reasonable expectation that the patient will requireinpatient hospital care for a continuous duration that covers two midnights. Congress has also extended a moratorium on Recovery Auditor Contractor, orRAC, audits of these billing classification decisions until October 1, 2015. Many of our current and potential PAS customers believe that the combination ofthe Two-Midnight Rule and the congressional moratorium on RAC audits significantly simplifies many billing classification decisions and reduces riskassociated with those decisions. As a result, the demand for our PAS offerings has declined substantially. Further, with CMS’ one time offer to pay out 68%on certain categories of pending appeals by providers, demand for PAS appeals services may continue to decline significantly.Healthcare reform also is causing the transition of some payment methods and provider reimbursement from volume-based reimbursement to value-based reimbursement models, which can include risk-sharing, accountable28care organizations, capitation, bundled payment and other innovative approaches. While such new reimbursement models may provide us with opportunitiesto provide new or additional services to our customers (e.g., our value based reimbursement capabilities within our RCM services offering) and to participatein incentive based payment arrangements for our services, there can be no assurance that such new models and approaches will prove to be profitable to ourcustomers or to us. Further, such new models and approaches may require investment by us to develop technology or expertise to offer necessary andappropriate services or support to our customers, and the amount of such investment and the timing for return of such investment are not fully known at thistime due to the uncertainties of healthcare reform and payment and reimbursement model transitions that are occurring. Certain new care delivery andreimbursement models are being offered as pilot programs or as limited or transitional programs, and there is no assurance that such programs will continue orbe renewed. Any of these models and approaches, and changes generally in the healthcare industry, can impact the relationships between our customers andpayers, from which our customers derive revenue and with which revenue our customers pay for our services. Adoption of such new models and approachesmay require compliance with a range of federal and state laws relating to fraud and abuse, insurance, reinsurance and managed care regulation, billing andcollection, corporate practice of medicine restrictions and licensing, among others. Many states in which these new value-based structures are beingdeveloped lack regulatory guidance or a well-developed body of law for these new models and approaches, or may not have updated their laws or enactedlegislation yet to reflect the new healthcare reform models. As a result, although we have structured, and will attempt to structure and conduct, our operationsin accordance with our interpretation of current laws and regulations, new laws, regulations or guidance could have a material adverse effect on our currentand future operations and could subject us to the risk of restructuring or terminating our customer agreements and arrangements, as well as the risk ofregulatory enforcement, penalties and sanctions, if state enforcement agencies disagree with our interpretation of state laws.If we violate HIPAA, the HITECH Act or state health information privacy laws, we may incur significant liabilities, and any such violations couldmake it more difficult to retain existing customers or attract new customers, extend the time it takes to enter into service agreements with new customers,and result in a material adverse effect on our business, results of operations and financial condition.HIPAA contains substantial restrictions and requirements with respect to the use and disclosure of individuals’ PHI. Under HIPAA, covered entities,including health plans, healthcare providers, and healthcare clearinghouses that conduct HIPAA-defined standard electronic transactions, are restricted inhow they use and disclose PHI and must establish administrative, physical and technical safeguards to protect the confidentiality, integrity and availabilityof electronic PHI maintained or transmitted by them or by others on their behalf. Most of our customers are covered entities and we are a business associate tomany of those customers under HIPAA as a result of our contractual obligations to perform certain functions on behalf of, and to provide certain services to,those customers. As a business associate, we sometimes also act as a clearinghouse in performing certain functions for our customers. In addition, theMinnesota Attorney General’s lawsuit, which we settled in 2012, alleged that we are a “healthcare provider” as defined in HIPAA. Although we believe thatwe are not a healthcare provider, if we were found to be a healthcare provider, we could have liability under the provisions of HIPAA that apply to providersas well as under state health information privacy and licensing laws. Our use and disclosure of PHI is restricted by HIPAA and the business associateagreements we are required to enter into with our covered entity customers. In 2009, HIPAA was amended by the HITECH Act to impose certain of the HIPAAprivacy and security requirements directly upon business associates of covered entities and increase significantly the monetary penalties for violations ofHIPAA. The HITECH Act also requires business associates to notify covered entities, who in turn must notify affected individuals and governmentauthorities, of data security breaches involving unsecured PHI. Since the passage of the HITECH Act, enforcement of HIPAA violations has increased, asindicated by the announcement of a number of significant settlement agreements and/or sanctions by federal authorities, the pursuit of HIPAA violations bystate attorneys general, and the roll-out of a new federal audit program for covered entities (which will in the future be extended to business associates).In addition to HIPAA, most states have enacted patient confidentiality laws that protect against the unauthorized disclosure of confidential medicalinformation, and many states have adopted or are considering further legislation in this area, including privacy safeguards, security standards and datasecurity breach notification requirements. Such state laws, if more stringent than HIPAA, are not preempted by the federal requirements, and we29must comply with them even though such state laws may be subject to different interpretations by various courts and other governmental authorities.We have implemented and maintain physical, technical and administrative safeguards intended to protect all personal data and have processes in placeto assist us in complying with applicable laws and regulations regarding the protection of this data and properly responding to any security incidents orbreaches. We voluntarily sought, and received, HITRUST certification to help ensure compliance. A knowing breach of HIPAA’s requirements could exposeus to criminal liability. A breach of our safeguards and processes that is not due to reasonable cause or involves willful neglect could expose us to significantcivil penalties and the possibility of civil litigation under HIPAA and applicable state law. In 2011, a laptop computer used by one of our employees thatcontained PHI for patients of two customers was stolen. The laptop was password-protected but was not encrypted, in violation of company policy. Wenotified both customers of the 2011 theft, which customers in turn notified the affected individuals as well as the appropriate regulators. The MinnesotaAttorney General subsequently initiated a lawsuit against us, which we settled in 2012, for, among other things, alleged violations of federal and Minnesotastate health privacy laws and regulations arising from the laptop theft. Laptop computers used by our employees that contained PHI have also been stolen onother occasions. We do not believe that any patient data has been compromised as a result of any of these thefts. Nonetheless, these incidents have made itmore difficult to retain existing customers and attract new customers. They have also extended the time it takes to enter into service agreements with newcustomers, and could result in a material adverse effect on our business, results of operations and financial condition.If we fail to comply with federal and state laws governing submission of false or fraudulent claims to government healthcare programs and financialrelationships among healthcare providers, we may be subject to civil and criminal penalties or loss of eligibility to participate in government healthcareprograms.A number of federal and state laws, including anti-kickback restrictions and laws prohibiting the submission of false or fraudulent claims, apply tohealthcare providers, physicians and others that make, offer, seek or receive payments or split fees for referrals of products or services that may be paid forthrough any federal or state healthcare program and, in some instances, any private program. These laws are complex and their application to our specificservices and relationships may not be clear and may be applied to our business in ways that we do not anticipate. Federal and state regulatory and lawenforcement authorities have recently increased enforcement activities with respect to Medicare and Medicaid fraud and abuse regulations and otherhealthcare reimbursement laws and rules. From time to time, participants in the healthcare industry receive inquiries or subpoenas to produce documents inconnection with government investigations. We could be required to expend significant time and resources to comply with these requests, and the attentionof our management team could be diverted by these efforts. Furthermore, if we are found to be in violation of any federal or state fraud and abuse laws, wecould be subject to civil and criminal penalties, forced to restructure our business and excluded from participating in federal and state healthcare programssuch as Medicare and Medicaid which would result in significant harm to our business and financial condition.The federal healthcare anti-kickback law prohibits any person or entity from offering, paying, soliciting or receiving anything of value, directly orindirectly, for the referral of patients covered by Medicare, Medicaid and other federal healthcare programs or the leasing, purchasing, ordering or arrangingfor or recommending the lease, purchase or order of any item, good, facility or service covered by these programs. Many states have adopted similarprohibitions against kickbacks and other practices that are intended to induce referrals, and some of these state laws are applicable to all patients regardless ofwhether the patient is covered under a governmental health program or private health plan. New payment structures, such as accountable care organizationsand other arrangements involving combinations of hospitals, physicians and other providers who share payment savings, potentially implicate anti-kickbackand other fraud and abuse laws. We seek to structure our business relationships and activities to avoid any activity that could be construed to implicate thefederal healthcare anti-kickback law and similar laws. We cannot assure you, however, that our arrangements and activities will be deemed outside the scopeof these laws or that increased enforcement activities will not directly or indirectly have a material adverse effect on our business, financial condition orresults of operations. Any determination by a federal or state agency or court that we have violated any of these laws could subject us to civil or criminalpenalties, could require us to change or30terminate some portions of our operations or business, could disqualify us from providing services to healthcare providers doing business with governmentprograms, could give our customers the right to terminate our managed services agreements with them and, thus, could have a material adverse effect on ourbusiness and results of operations. Moreover, any violations by, and resulting penalties or exclusions imposed upon, our customers could adversely affecttheir financial condition and, in turn, have a material adverse effect on our business and results of operations.There are also numerous federal and state laws that forbid submission of false information or the failure to disclose information in connection with thesubmission and payment of healthcare provider claims for reimbursement. In particular, the federal FCA, prohibits a person from knowingly presenting orcausing to be presented a false or fraudulent claim for payment or approval by an officer, employee or agent of the United States. In addition, the FCAprohibits a person from knowingly making, using, or causing to be made or used a false record or statement material to such a claim. The FCA may beenforced by the government or by private whistleblowers under the “qui tam” provisions of the statute. Whistleblowers are entitled to a share of any recoveryin a FCA case. Changes to the FCA enacted as part of the ACA make it easier for whistleblowers to bring FCA claims. Violations of the FCA may result intreble damages, significant monetary penalties, and other collateral consequences including, potentially, exclusion from participation in federally fundedhealthcare programs. The scope and implications of the amendments to the FCA pursuant to the FERA have yet to be fully determined or adjudicated and as aresult it is difficult to predict how future enforcement initiatives may affect our business.These laws and regulations may change rapidly, and it is frequently unclear how they apply to our business. Errors created by our proprietaryapplications or services that relate to entry, formatting, preparation or transmission of claim or cost report information may be determined or alleged to causethe submission of false claims or otherwise be in violation of these laws and regulations. Any failure of our proprietary applications or services to complywith these laws and regulations could result in substantial civil or criminal liability and could, among other things, adversely affect demand for our services,invalidate all or portions of some of our managed services agreements with our customers, require us to change or terminate some portions of our business,require us to refund portions of our base fee revenues and incentive payment revenues, cause us to be disqualified from serving customers doing businesswith government payers, and give our customers the right to terminate our managed services agreements with them, any one of which could have a materialadverse effect on our business.We cannot be certain that governmental officials responsible for enforcing EMTALA, or other parties, will not assert that our customers are inviolation of EMTALA, and defending and settling allegations of EMTALA violations could have a material adverse effect on our business even if we areultimately not found to have contributed to such violations.EMTALA requires Medicare-participating hospitals that have emergency departments to provide a medical screening examination and stabilizingtreatment to all individuals who come to the hospital seeking treatment of an emergency medical condition, regardless of the patient’s ability to pay for thecare. Sanctions for failing to fulfill these requirements include exclusion from participation in the Medicare and Medicaid programs and civil monetarypenalties. In addition, the law creates private civil remedies that enable an individual who suffers personal harm as a direct result of a violation of the law tosue the offending hospital for damages and equitable relief.In 2012, the Minnesota Attorney General’s “Compliance Review” described circumstances raising potential EMTALA concerns at Fairview and raisedquestions as to whether our practices contributed to any such violations. An investigation by the Minnesota Department of Health on behalf of the federalgovernment concluded in September 2012 that Fairview had violated EMTALA and required Fairview to implement a corrective action plan. Since we arenot a healthcare provider, EMTALA is not applicable to us, but we cannot be certain that governmental officials responsible for enforcing EMTALA, or otherparties, will not assert that our other customers are in violation of EMTALA. If our customers are found to have violated EMTALA, they may assert claimsthat our management practices contributed to the violation. Defending and settling allegations of EMTALA violations could have a material adverse effecton our business even if we are ultimately not found guilty of a violation.31Our failure to comply with debt collection and other consumer protection laws and regulations could subject us to fines and other liabilities, whichcould harm our reputation and business, and could make it more difficult to retain existing customers or attract new customers, extend the time it takes toenter into service agreements with new customers, and result in a material adverse effect on our business, results of operations and financial condition.The FDCPA regulates persons who regularly collect or attempt to collect, directly or indirectly, consumer debts in default that are owed or asserted tobe owed to another person. However, our business practices that involve collecting, or assisting our customers in collecting, non-defaulted amounts owed bypatients for current and prior services activities may be determined to be subject to the FDCPA. Many states impose additional requirements on debtcollection communications, and some of those requirements may be more stringent than the federal requirements. Moreover, regulations governing debtcollection are subject to changing interpretations that may be inconsistent among different jurisdictions. Further, we are subject to the TCPA, which imposescertain restrictions on companies that place telephone calls to consumers.We could incur costs or could be subject to fines or other penalties under the TCPA, the FDCPA and the FTC Act if we are determined to have violatedthe provisions of those regulations during the course of conducting our operations. We, or our customers, could be required to report such breaches toaffected consumers or regulatory authorities, leading to disclosures that could damage our reputation or harm our business, financial position and operatingresults. As a result of the 2011 laptop theft giving rise to the Minnesota Attorney General’s lawsuit and the related FTC inquiry of our data security practices,in December 2013, we entered into a consent order with the FTC pursuant to which no fine or penalty was paid but in which we agreed, among other things,to maintain a comprehensive information security program reasonably designed to protect the security, confidentiality, and integrity of personal informationcollected from or about consumers. Future allegations of this type could require us to change aspects of our business practices, make it more difficult to retainexisting customers or attract new customers, extend the time it takes to enter into service agreements with new customers, and result in a material adverseeffect on our business, results of operations and financial condition.Potential additional regulation of the disclosure of health information outside the United States may increase our costs.Federal or state governmental authorities may impose additional data security standards or additional privacy or other restrictions on the collection,use, transmission and other disclosures of health information. Legislation has been proposed at various times at both the federal and the state levels thatwould limit, forbid or regulate the use or transmission of medical information pertaining to U.S. patients outside of the United States. Some states have alsoimposed limitations through rule making or executive action. If additional states or the federal government were to adopt additional limitations, that mayrender our operations in India impracticable or substantially more expensive. Moving such operations to the United States may involve substantial delay inimplementation and increased costs.Risks Related to Intellectual PropertyWe may be unable to adequately protect our intellectual property.Our success depends, in part, upon our ability to establish, protect and enforce our intellectual property and other proprietary rights. If we fail toestablish or protect our intellectual property rights, we may lose an important advantage in the market in which we compete. We rely upon a combination ofpatent, trademark, copyright and trade secret law and contractual terms and conditions to protect our intellectual property rights, all of which provide onlylimited protection. We cannot assure you that our intellectual property rights are sufficient to protect our competitive advantages. Although we have filedseven U.S. patent applications, we cannot assure you that any patents that will be issued from these applications will provide us with the protection that weseek or that any future patents issued to us will not be challenged, invalidated or circumvented. We have also been issued three U.S. patents, but we cannotassure you that they will provide us with the protection that we seek or that they will not be challenged, invalidated or circumvented. Legal standardsrelating to the validity, enforceability and scope of protection of patents are uncertain. Any patents that may be issued in the future from pending or futurepatent applications or our three issued32patents may not provide sufficiently broad protection or they may not prove to be enforceable in actions against alleged infringers. Also, we cannot assureyou that any trademark registrations will be issued for pending or future applications or that any of our trademarks will be enforceable or provide adequateprotection of our proprietary rights.We also rely in some circumstances on trade secrets to protect our technology. Trade secrets may lose their value if not properly protected. We endeavorto enter into non-disclosure agreements with our employees, customers, contractors and business partners to limit access to and disclosure of our proprietaryinformation. The steps we have taken, however, may not prevent unauthorized use of our technology, and adequate remedies may not be available in theevent of unauthorized use or disclosure of our trade secrets and proprietary technology. Moreover, others may reverse engineer or independently developtechnologies that are competitive to ours or infringe our intellectual property.Accordingly, despite our efforts, we may be unable to prevent third parties from infringing or misappropriating our intellectual property and using ourtechnology for their competitive advantage. Any such infringement or misappropriation could have a material adverse effect on our business, results ofoperations and financial condition. Monitoring infringement of our intellectual property rights can be difficult and costly, and enforcement of ourintellectual property rights may require us to bring legal actions against infringers. Infringement actions are inherently uncertain and therefore may not besuccessful, even when our rights have been infringed, and even if successful may require a substantial amount of resources and divert our management’sattention.Claims by others that we infringe their intellectual property could force us to incur significant costs or revise the way we conduct our business.Our competitors protect their intellectual property rights by means such as patents, trade secrets, copyrights and trademarks. We have not conducted anindependent review of patents issued to third parties. Additionally, because patent applications in the United States and many other jurisdictions are keptconfidential for 18 months before they are published, we may be unaware of pending patent applications that relate to our proprietary technology. Any partyasserting that we infringe its proprietary rights would force us to defend ourselves, and possibly our customers, against the alleged infringement. These claimsand any resulting lawsuit, if successful, could subject us to significant liability for damages and invalidation of our proprietary rights or interruption orcessation of our operations. The software and technology industries are characterized by the existence of a large number of patents, copyrights, trademarksand trade secrets and by frequent litigation based on allegations of infringement or other violations of intellectual property rights. Moreover, the risk of sucha lawsuit will likely increase as our size and scope of our services and technology platforms increase, as our geographic presence and market share expandand as the number of competitors in our market increases.Any such claims or litigation could:•be time-consuming and expensive to defend, whether meritorious or not;•require us to stop providing the services that use the technology that infringes the other party’s intellectual property;•divert the attention of our technical and managerial resources;•require us to enter into royalty or licensing agreements with third parties, which may not be available on terms that we deem acceptable, if at all;•prevent us from operating all or a portion of our business or force us to redesign our services and technology platforms, which could be difficult andexpensive and may make the performance or value of our service offerings less attractive;•subject us to significant liability for damages or result in significant settlement payments; or33•require us to indemnify our customers, as we are required by contract to indemnify some of our customers for certain claims based upon theinfringement or alleged infringement of any third party’s intellectual property rights resulting from our customers’ use of our intellectual property.Intellectual property litigation can be costly. Even if we prevail, the cost of such litigation could deplete our financial resources. Litigation is also time-consuming and could divert management’s attention and resources away from our business. Furthermore, during the course of litigation, confidentialinformation may be disclosed in the form of documents or testimony in connection with discovery requests, depositions or trial testimony. Disclosure of ourconfidential information and our involvement in intellectual property litigation could materially adversely affect our business. Some of our competitors maybe able to sustain the costs of complex intellectual property litigation more effectively than we can because they have substantially greater resources. Inaddition, any uncertainties resulting from the initiation and continuation of any litigation could significantly limit our ability to continue our operations andcould harm our relationships with current and prospective customers. Any of the foregoing could disrupt our business and have a material adverse effect onour operating results and financial condition.Risks Related to the Ownership of Shares of Our Common StockOur common stock has been delisted from the New York Stock Exchange, or NYSE, and is not listed on any other national securities exchange, whichmay negatively impact the trading price of our common stock and the levels of liquidity available to our stockholders.Our common stock was suspended from trading on the NYSE prior to the opening of the market on March 17, 2014 (and subsequently delisted) andbegan trading under the symbol “ACHI” through the facilities of the OTC Markets Group, Inc. on that date.We can provide no assurance that we will be able to relist our common stock on a national securities exchange or that the stock will continue beingtraded on the over-the-counter, or OTC, marketplace. The trading of our common stock on the OTC marketplace rather than the NYSE may negatively impactthe trading price of our common stock and the levels of liquidity available to our stockholders.Securities traded in the OTC market generally have significantly less liquidity than securities traded on a national securities exchange due to factorssuch as the reduced number of investors that will consider investing in the securities, the reduced number of market makers in the securities, and the reducednumber of securities analysts that follow such securities. As a result, holders of our common stock may find it difficult to resell their shares at prices quoted inthe market or at all. Furthermore, because of the limited market and low volume of trading in our common stock that could occur, the share price of ourcommon stock could more likely be affected by broad market fluctuations, general market conditions, fluctuations in our operating results, changes in themarket’s perception of our business, and announcements made by us, our competitors, parties with whom we have business relationships or third parties. Thelack of liquidity in our common stock may also make it difficult for us to issue additional securities for financing or other purposes, or to otherwise arrangefor any financing we may need in the future.The trading price of our common stock has been volatile and may continue to be volatile.Since December 31, 2010, our common stock has traded at a price per share as high as $32.82 and as low as $5.20. The trading price of our commonstock is likely to continue to be highly volatile and could be subject to wide fluctuations in response to various factors. In addition to the risks described inthis section, factors that may cause the market price of our common stock to fluctuate include:•our failure to timely file our SEC periodic reports;•the SEC investigation relating to the Restatement;•fluctuations in our quarterly financial results or the quarterly financial results of companies perceived to be similar to us;34•changes in estimates of our financial results;•failure to meet expectations of securities analysts;•the loss of service agreements with customers;•lawsuits filed against us by governmental authorities or stockholders;•unfavorable publicity concerning our operations or business practices;•our common stock’s eligibility for stock exchange listing;•investors’ general perception of us; and•changes in general economic, industry, regulatory and market conditions.In addition, if the stock market in general experiences a loss of investor confidence, the trading price of our common stock could decline for reasonsunrelated to our business, financial condition or results of operations.Anti-takeover provisions in our charter documents and Delaware law could discourage, delay or prevent a change in control of our company andmay affect the trading price of our common stock.We are a Delaware corporation and the anti-takeover provisions of the Delaware General Corporation Law may discourage, delay or prevent a change incontrol by prohibiting us from engaging in a business combination with an interested stockholder for a period of three years after the person becomes aninterested stockholder, even if a change in control would be beneficial to our existing stockholders. In addition, our restated certificate of incorporation andamended and restated bylaws may discourage, delay or prevent a change in our management or control over us that stockholders may consider favorable. Ourrestated certificate of incorporation and amended and restated bylaws:•authorize the issuance of "blank check" preferred stock that could be issued by our board of directors to thwart a takeover attempt;•provide for a classified board of directors, as a result of which the successors to the directors whose terms have expired will be elected to serve fromthe time of election and qualification until the third annual meeting following their election;•require that directors only be removed from office for cause and only upon a supermajority stockholder vote;•provide that vacancies on the board of directors, including newly created directorships, may be filled only by a majority vote of directors then inoffice;•limit who may call special meetings of stockholders; prohibit stockholder action by written consent, requiring all actions to be taken at a meeting ofthe stockholders; and•require supermajority stockholder voting to effect certain amendments to our restated certificate of incorporation and amended and restated bylaws.At our 2015 Annual Meeting of Stockholders scheduled to be held on August 14, 2015, our board has recommended that stockholders vote to approvean amendment to our current restated certificate of incorporation that would provide for the phased-in declassification of our board of directors and theannual election of all directors. If our stockholders approve this amendment, our board of directors would make conforming changes to our amended andrestated bylaws. If the amendment is approved by stockholders, our restated certificate of35incorporation would provide that directors may be removed with or without cause, with the same supermajority vote that currently applies (the affirmativevote of the holders of at least two-thirds of the shares entitled to vote at an election of directors).We may not pay any cash dividends on our capital stock in the foreseeable future.Although we paid cash dividends on our capital stock prior to our May 2010 initial public offering, or IPO, there is no assurance that we will pay cashdividends on our common stock in the foreseeable future. Any future dividend payments will be within the discretion of our board of directors and willdepend on, among other things, our financial condition, results of operations, capital requirements, capital expenditure requirements, contractual restrictions,provisions of applicable law and other factors that our board of directors may deem relevant. We may not generate sufficient cash from operations in thefuture to pay dividends on our common stock.Item 1B.Unresolved Staff CommentsNone.36Item 2.PropertiesWe lease our existing facilities and do not own any real estate property.Our corporate headquarters occupy approximately 43,000 square feet in Chicago, Illinois under a lease expiring on August 31, 2020. In addition, wehave a right of first offer to lease an additional 11,100 square feet of space on another floor in the same building. We also lease office space and otherfacilities in Chicago, Illinois; Kalamazoo, Michigan; Warren, Michigan; Southfield, Michigan; Birmingham, Alabama; Jupiter, Florida; Cape Girardeau,Missouri; and three facilities near New Delhi, India. Pursuant to our managed services agreements with customers, we occupy space on-site at all hospitalswhere we provide our RCM services. We generally do not pay customers for our use of space provided by them for our use in the provision of RCM servicesto that customer.We believe that our facilities are sufficient for our current needs. We intend to add new facilities or expand existing facilities as we add employees orexpand or change our geographic markets and office locations, and we believe that suitable additional or substitute space will be available as needed toaccommodate any such expansion of our operations. Item 3.Legal ProceedingsOn January 19, 2012, the State of Minnesota, by its Attorney General, filed a complaint against us in the United States District Court for the District ofMinnesota, alleging violations of federal and Minnesota state health privacy laws and regulations, Minnesota debt collection laws, and Minnesota consumerprotection laws resulting from, among other things, the theft in Minnesota in July 2011 of an employee’s laptop that contained PHI. On January 25, 2012, theCommissioner of the Minnesota Department of Commerce served us an administrative subpoena seeking information and documents about our debtcollection practices and the privacy of personal and health data within our possession or control. On February 3, 2012, we entered into a Consent Cease andDesist Order with the Commissioner, voluntarily agreeing to cease all debt collection activity in the State of Minnesota. As previously disclosed, on July 30,2012, without any admission of liability or wrongdoing, we entered into a Settlement Agreement, Release and Order with the Minnesota Attorney General tosettle the lawsuit filed by the Minnesota Attorney General and the investigation commenced by the Minnesota Department of Commerce and to resolve fullyall disputes which in any way related to, arose out of, emanated from, or otherwise involved such lawsuit or investigation and all investigations by theMinnesota Attorney General, the Minnesota Department of Commerce, and the Minnesota Department of Human Services relating to us. As part of thesettlement, we paid a settlement sum of $2.5 million and voluntarily agreed to cease all remaining operations in Minnesota.On April 26, 2012 and May 1, 2012, we, along with certain of our former officers, were named as a defendant in two putative securities class actionlawsuits filed in the U.S. District Court for the Northern District of Illinois, which were consolidated as Wong v. Accretive Health et al. The primaryallegations are that our public statements, including filings with the SEC, were false and/or misleading about our violations of certain federal and Minnesotaprivacy and debt collection laws. On September 26, 2013, without any admission of liability or wrongdoing, we entered into a Settlement Agreement toresolve these suits for $14 million, which has been funded into escrow by our insurance carriers. On April 30, 2014, the U.S. District Court for the NorthernDistrict of Illinois granted final approval of the Settlement Agreement. A single objector to the Settlement Agreement appealed to the U.S. Court of Appealsfor the Seventh Circuit, and, on December 9, 2014, the court of appeals affirmed the district court’s approval of the settlement. On December 23, 2014, thatobjector submitted a petition for en banc rehearing, which was denied on January 26, 2015.In addition, we, along with certain of our directors and former officers, have been named in several putative shareholder derivative lawsuits filed in theU.S. District Court for the Northern District of Illinois on May 3, 2012 and July 31, 2012 (consolidated as Maurras Trust v. Accretive Health et al.), in theCircuit Court of Cook County, Illinois on June 23, 2012 and June 27, 2012 (consolidated as In re Accretive Health, Inc. Derivative Litigation) and in theCourt of Chancery of the State of Delaware on November 5, 2012 (Doyle v. Tolan et al.). The primary37allegations are that our directors and officers breached their fiduciary duties in connection with the alleged violations of certain federal and Minnesotaprivacy and debt collection laws.On July 11, 2013, the Court of Chancery of the State of Delaware granted our motion to stay Doyle v. Tolan et al., in favor of the action pending in theU.S. District Court for the Northern District of Illinois. On September 24, 2013, the U.S. District Court for the Northern District of Illinois granted our motionto dismiss without prejudice, giving plaintiffs in that case leave to file an amended consolidated complaint, which plaintiffs filed on October 22, 2013,amending their complaint to also include allegations with respect to the Restatement. On February 25, 2015, we entered a settlement agreement withplaintiffs in all of these suits that would resolve all of the derivative actions, subject to court approval. On February 26, 2015, plaintiffs in the action pendingin the U.S. District Court for the Northern District of Illinois filed a motion seeking preliminary approval of the settlement, which was granted on March 19,2015. A final fairness hearing is scheduled for July 23, 2015.On May 17, 2013, we, along with certain of our directors, former directors and former officers, were named as a defendant in a putative securities classaction lawsuit filed in the U.S. District Court for the Northern District of Illinois (Hughes v. Accretive Health, Inc. et al.). The primary allegations, relating toour March 8, 2013 announcement that we would be restating our prior period financial statements, are that our public statements, including filings with theSEC, were false and/or misleading with respect to our revenue recognition and earnings prospects. On November 27, 2013, plaintiffs voluntarily dismissedour directors and former directors (other than Mary Tolan). On January 31, 2014, we filed a motion to dismiss the complaint. On September 25, 2014, theCourt granted our motion to dismiss without prejudice, however the plaintiffs filed a Second Amended Complaint on October 23, 2014. On November 10,2014, we filed a motion to dismiss the Second Amended Complaint. While that motion was still pending, on January 8, 2015, plaintiffs filed a motion toamend the Second Amended Complaint, seeking to add allegations regarding the recently issued Restatement. On April 22, 2015, the court granted plaintiffs’motion to amend, and a Third Amended Complaint was filed on May 13, 2015. We moved to dismiss the Third Amended Complaint on June 3, 2015. Wecontinue to believe we have meritorious defenses and intend to vigorously defend ourselves, Mary Tolan, and our former officers against these claims. Theoutcome is not presently determinable.The SEC’s Division of Enforcement in the Chicago Regional Office is also conducting an investigation regarding the circumstances surrounding theRestatement. We are fully cooperating with the investigation.On February 11, 2014, we were named as a defendant in a putative class action lawsuit filed in the U.S. District Court for the Southern District ofAlabama (Church v. Accretive Health, Inc.). The primary allegations are that we attempted to collect debts without providing the notice required by theFDCPA and attempted to collect debts after they were discharged in bankruptcy. We believe that we have meritorious defenses and intend to vigorouslydefend ourselves against these claims. The outcome is not presently determinable.On July 22, 2014, we were named as a defendant in a putative class action lawsuit filed in the U.S. District Court for the Eastern District of Michigan(Anger v. Accretive Health, Inc.). The primary allegations are that we attempted to collect debts without providing the notice required by the FDCPA. Webelieve that we have meritorious defenses and intend to vigorously defend ourselves against these claims. The outcome is not presently determinable.On February 6, 2015, we were named as a defendant in a putative class action lawsuit filed in the U.S. District Court for the Eastern District of Michigan(Cassale v. Accretive Health, Inc.). The primary allegations are that we attempted to collect debts without complying with the provisions of the FDCPA. Thecase was settled in April 2015.On February 24, 2015 (amended Feb. 25, 2015), the Plaintiff in the Church action (above) filed a motion with the Joint Panel for Multidistrict Litigationto transfer and consolidate the Church, Anger and Cassale actions for pretrial purposes in the Southern District of Alabama where the Church case iscurrently pending. That motion was withdrawn in May 2015.In April 2015, we were named among other defendants in an employment action brought by a former employee before the Maine Human RightsCommission alleging that she was improperly terminated in retaliation38for uncovering alleged Medicare fraud. We filed our response with the MHRC on May 19, 2015 seeking that we be dismissed entirely from the action. Theplaintiff has filed a parallel qui tam action in the District of Maine (Worthy v. Eastern Maine Healthcare Systems) in which she makes the same allegations. The U.S. Department of Justice declined to intervene in the federal court action, and the case was unsealed in April 2015 but has not been served on anydefendant. We believe that we have meritorious defenses to both the MHRC action and the federal court case and intend to vigorously defend ourselvesagainst these claims. The outcomes are not presently determinable.From time to time we may become subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinarycourse of our business. While the outcome of these other claims cannot be predicted with certainty, we do not believe that the outcome of any of these otherlegal matters will have a material adverse effect on our results of operations, financial condition or cash flows.Item 4.Mine Safety DisclosuresNot applicable.39PART IIItem 5.Market for Registrant’s Common Equity, Related Stockholder Matters and Issuers Purchases of Equity SecuritiesOur common stock has traded on the OTC market under the symbol “ACHI” since March 17, 2014 and is quoted through the facilities of the OTCMarkets Group, Inc. Our common stock traded on the NYSE under the symbol “AH” from May 20, 2010 through March 14, 2014. Our common stock wassuspended from trading on the NYSE prior to the opening of the market on March 17, 2014 (and subsequently delisted) and began trading under the symbol“ACHI” through the facilities of the OTC Markets Group, Inc. on that date. Prior to May 20, 2010, there was no public market for our common stock.The following table sets forth the high and low intraday sales prices per share of our common stock, as reported by the NYSE and the OTC MarketsGroup, Inc., as applicable, for the periods indicated: Price Range High Low2013 Quarter ended March 31, 2013 $13.54 $8.55Quarter ended June 30, 2013 $11.58 $8.91Quarter ended September 30, 2013 $11.15 $8.86Quarter ended December 31, 2013 $9.55 $7.982014 Quarter ended March 31, 2014 $9.73 $7.90Quarter ended June 30, 2014 $9.45 $7.15Quarter ended September 30, 2014 $9.27 $7.76Quarter ended December 31, 2014 $9.10 $6.86The closing sale price per share of our common stock, as reported by the OTC Markets Group, Inc., on June 15, 2015 was $5.63. As of June 15, 2015,there were approximately 70 stockholders of record of our common stock and approximately 2,800 beneficial holders.DividendsWe did not pay any dividends during the years ended December 31, 2014 and 2013. We currently intend to retain earnings, if any, to finance thegrowth and development of our business, and we do not expect to pay any cash dividends on our common stock in the foreseeable future. Payment of futuredividends, if any, will be at the discretion of our board of directors and will depend on, among other things, our financial condition, results of operations,capital expenditure requirements, contractual restrictions, provisions of applicable law, and other factors the board deems relevant.Equity Compensation Plan InformationWe maintain a 2006 Second Amended and Restated Stock Option Plan, which we refer to as the 2006 Plan. In April 2010 in connection with our IPO,we adopted a new 2010 Stock Incentive Plan, or the 2010 Plan, and, together with the 2006 Plan, the Plans. Under the 2010 Plan we may issue up to amaximum of 24,374,756 shares, including any shares that remained available for issuance under the 2006 Plan as of the date of the IPO and any sharessubject to awards that were outstanding under the 2006 Plan as of the date of the IPO that expire, terminate or are otherwise surrendered, canceled, forfeited orrepurchased by us without the issuance of shares thereunder. We will not make any further grants under the 2006 Plan. The 2010 Plan provides for the grantof incentive stock options, non-statutory stock options, restricted stock awards, or RSAs, and other share-based awards. As of December 31, 2014, anaggregate of 13,548,081 shares were subject to outstanding options and RSAs under the Plans, 10,109,036 shares40had been issued pursuant to the exercise of options issued under the Plans, and 5,262,904 shares were available for future grants of awards under the 2010Plan. However, to the extent that previously granted awards under the 2006 Plan or 2010 Plan expire, terminate or are otherwise surrendered, canceled,forfeited or repurchased by us, the number of shares available for future awards under the 2010 Plan will increase. At our 2015 Annual Meeting ofStockholders, our board of directors has recommended that stockholders vote to approve our Amended and Restated 2010 Stock Incentive Plan, whichamong things, provides for an increase in the number of shares authorized for issuance under the 2010 Plan by 5,000,000 shares.The following table summarizes information about the securities authorized for issuance under our equity compensation plans as of December 31,2014: (a) (b) (c)Plan Category Number ofSecuritiesto be Issued UponExercise ofOutstandingOptions Weighted-AverageExercise Priceof OutstandingOptions Number of Securities RemainingAvailable for Future IssuanceUnder EquityCompensation Plans(Excluding Securities reflectedin Column (a))Equity compensation plans approved by stockholders (1)(2) 12,820,604 $11.73 5,262,904Equity compensation plans not approved by stockholders (3)(4) 7,103,801 $9.42 —Total 19,924,405 $10.91 5,262,904 (1)Includes all outstanding stock options awarded under our 2006 Plan and 2010 Plan.(2)Excludes 727,477 shares of restricted stock that were unvested and not forfeited as of December 31, 2014.(3)Represents stock option inducement grants made pursuant to the NYSE inducement grant rules.(4)Excludes 1,749,988 shares of restricted stock that were unvested and not forfeited as of December 31, 2014.We entered into a Stock Option Agreement with Stephen Schuckenbrock on April 3, 2013, as an inducement award pursuant to an exemption from theNYSE’s stockholder approval requirements in connection with Mr. Schuckenbrock’s appointment as our then-chief executive officer. Pursuant to thisagreement, we granted Mr. Schuckenbrock a non-statutory stock option for the purchase of up to 2,903,801 shares of our common stock with an exerciseprice of $9.56 per share, which option vests in substantially equal monthly installments over 48 months. Pursuant to an amendment to that Stock OptionAgreement entered into in May 2015, such vesting continues irrespective of the termination of Mr. Schuckenbrock's service as an employee and director. SeeCompensation Discussion and Analysis - Employment Agreements - Agreement with Mr. Stephen Schuckenbrock in "Part III - Item 11 - ExecutiveCompensation” for more details.We entered into a Non-Statutory Stock Option Agreement and a Restricted Stock Award Agreement with Joseph Flanagan on June 3, 2013, each as aninducement award pursuant to an exemption from the NYSE’s stockholder approval requirements in connection with Mr. Flanagan’s appointment as our chiefoperating officer. Pursuant to the Non-Statutory Stock Option Agreement, we granted Mr. Flanagan a non-statutory stock option for the purchase of up to800,000 shares of our common stock with an exercise price of $11.47 per share and pursuant to the Restricted Stock Award Agreement, we granted Mr.Flanagan 400,000 shares of our common stock. These equity awards to Mr. Flanagan vest in substantially equal monthly installments over 48 months subjectto continued service with us. See Agreement for Mr. Joseph Flanagan in "Part III - Item 11 - Executive Compensation” for more details.We entered into a Non-Statutory Stock Option Agreement and a Restricted Stock Award Agreement with Dr. Emad Rizk in July 2014, each as aninducement award pursuant to an exemption from the NYSE’s stockholder approval requirements in connection with Dr. Rizk's appointment as our ChiefExecutive Officer. Pursuant to the Non-Statutory Stock Option Agreement, we granted Dr. Rizk a non-statutory stock option for the purchase of up to2,700,000 shares of our common stock with an exercise price of $8.98 per share and pursuant to the Restricted Stock41Award Agreement, we granted Dr. Rizk a restricted stock award for 1,000,000 shares of our common stock. The stock option and one-half of the restrictedstock award to Dr. Rizk vest in substantially equal annual installments over four years following the grant date, subject to continued service with us. Theremaining one-half of the restricted stock award generally will vest based on a stock price performance goal of two times the closing price of a share of ourcommon stock on the grant date, which much be equaled or exceeded for at least 20 consecutive trading days based on the average closing price for such 20-consecutive trading day period. See Agreement for Dr. Emad Rizk in "Part III - Item 11 - Executive Compensation” for more details.We also entered into a Non-Statutory Stock Option Agreement and a Restricted Stock Award Agreement with Peter P. Csapo on August 12, 2014, as aninducement award pursuant to an exemption from the NYSE’s stockholder approval requirements in connection with Mr. Csapo’s appointment as our ChiefFinancial Officer and treasurer. Pursuant to the Non-Statutory Stock Option Agreement, we granted Mr. Csapo a non-statutory stock option for the purchase ofup to 300,000 shares of our common stock with an exercise price of $8.15 per share and pursuant to the Restricted Stock Award Agreement, we granted Mr.Csapo a restricted stock award for 200,000 shares of our common stock, both of which vest in substantially equal annual installments over four yearsfollowing the grant date, subject to continued service with us. See Agreement for Mr. Peter P. Csapo in "Part III - Item 11 - Executive Compensation” for moredetails.We also entered into a Non-Statutory Stock Option Agreement and a Restricted Stock Award Agreement with David Mason on November 11, 2014, asan inducement award pursuant to an exemption from the NYSE’s stockholder approval requirements in connection with Mr. Mason's appointment as ourChief Strategy Officer. Pursuant to the Non-Statutory Stock Option Agreement, we granted Mr. Mason a non-statutory stock option for the purchase of up to400,000 shares of our common stock with an exercise price of $8.30 per share and pursuant to the Restricted Stock Award Agreement, we granted Mr. Masona restricted stock award for 300,000 shares of our common stock, both of which vest in substantially equal annual installments over four years following thegrant date, subject to continued service with us.Sales of Unregistered Securities and Use of ProceedsUse of Proceeds from Initial Public OfferingUse of IPO Proceeds. The SEC declared the Registration Statement on Form S-1 (File No. 333-162186) related to our IPO effective on May 19,2010. From the effective date of the registration statement through December 31, 2013, we used all the net proceeds from our IPO in funding our operations.Please refer to “Part II - Item 7 – Management’s Discussion and Analysis of Financial Condition” and “Part II - Item 8 – Consolidated Financial Statementsand Supplementary Data” for a discussion of our operating expenses.Unregistered Sales of Equity SecuritiesWe granted options to purchase an aggregate of (i) 4,406,856 shares of common stock during the year ended December 31, 2014 with exercise pricesranging from $7.38 to $9.45 per share and (ii) 2,365,000 shares of restricted stock during the year ended December 31, 2014, to employees and directorspursuant to the 2010 Plan and/or in reliance upon the exemption from the registration requirements of the Securities Act of 1933, or Securities Act, providedby Section 4(a)(2) of the Securities Act as sales by an issuer not involving any public offering, as set forth in the tables below. No underwriters were involvedin the foregoing transactions. All of such unregistered shares of common stock are deemed restricted securities for purposes of the Securities Act. No suchoptions have been exercised.42The following table sets forth the dates on which such options were granted and the number of shares of common stock subject to such options, theexercise price and the number of employees and directors granted options on each date for the year ended December 31, 2014:Date of Grant Common Stock Subject to Options Granted Exercise Price Number of Employees and Directors Granted Options1/2/2014 17,376 $9.14 51/3/2014 28,275 $9.09 41/7/2014 218,946 $9.45 22/4/2014 154,000 $8.83 63/4/2014 160,000 $8.61 24/1/2014 22,540 $8.38 64/2/2014 13,488 $8.53 24/29/2014 200,000 $8.05 15/2/2014 6,526 $7.70 26/3/2014 10,000 $7.38 27/1/2014 23,706 $8.00 67/2/2014 93,731 $8.00 37/21/2014 2,700,000 $8.98 18/4/2014 10,000 $8.35 18/12/2014 300,000 $8.15 19/3/2014 20,370 $8.10 110/1/2014 24,022 $7.90 610/2/2014 3,876 $7.72 112/2/2014 400,000 $8.30 1 4,406,856 The following table sets forth the dates on which such shares of restricted stock were granted, the number of shares of restricted stock and the number ofemployees and directors granted restricted stock on each date for the year ended December 31, 2014: Date of Grant Number of Shares of Restricted Common Stock Granted Number of Employees and Directors Granted Restricted Stock1/24/2014 750,000 194/29/2014 75,000 17/9/2014 40,000 17/21/2014 1,000,000 18/12/2014 200,000 111/11/2014 300,000 1 2,365,000 43Issuer Purchases of Equity SecuritiesThe following table provides information about our repurchases of common stock during the periods indicated (in thousands, except share and per sharedata):PeriodNumber of Shares Purchased (1) Average PricePaid per ShareTotal Number of Shares Purchased as Part of Publicly Announced Plans or Programs(2) Maximum Dollar Value of Shares that May Yet be Purchased Under Publicly Announced Plans or Programs (2)October 1, 2014 through October 31, 2014 3,913 $7.74 — $50,000November 1, 2014 through November 30, 2014 3,913 $7.19 — $50,000December 1, 2014 through December 31, 2014 3,913 $8.15 — $50,000(1)Repurchases of our stock related to employees’ tax withholding upon vesting of RSAs. See Note 5, Share-Based Compensation, to our consolidated financial statementsincluded in this Annual Report on Form 10-K.(2)On November 13, 2013, our board of directors authorized, subject to the completion of the Restatement, the repurchase of up to $50.0 million of our common stock fromtime to time in the open market or in privately negotiated transactions, or the 2013 Repurchase Program. The timing and amount of any shares repurchased under the2013 Repurchase Program will be determined by our management based on its evaluation of market conditions and other factors. The 2013 Repurchase Program may besuspended or discontinued at any time. We currently intend to fund any repurchases from cash on hand. The 2013 Repurchase Program was not in effect during 2014and accordingly we did not repurchase any shares of common stock under the 2013 Repurchase Program during 2014.44Stock Price Performance GraphThe following graph compares the change in the cumulative total return (including the reinvestment of dividends) on our common stock to thechange in the cumulative total return on the stocks included in the NYSE Composite Index and Morningstar Healthcare Information Services Index over theperiod from May 20, 2010, the date our shares of common stock began trading on the NYSE, through December 31, 2014. The graph assumes an investmentof $100 made in our common stock at a price of $12.00 per share, which was the per share price to the public in our IPO and an investment in each of theother indices on May 20, 2010, the first day of trading of our shares of common stock on the NYSE. We did not pay any dividends during the period reflectedin the graph.COMPARISON OF CUMULATIVE TOTAL RETURN 5/20/201012/31/201012/31/201112/31/201212/31/201312/31/2014Accretive Health, Inc.Return % 41.4741.42(49.61)(20.90)(25.12) Cum $100.00141.47200.06100.8279.7559.72 NYSE Composite IndexReturn % 21.58(3.56)16.2526.406.86 Cum $100.00121.58117.25136.30172.29184.11 Morningstar Health Information ServicesReturn % 17.6711.831.6044.647.66 Cum $100.00117.67131.59133.69193.37208.19The comparisons shown in the graph above are based on historical data and we caution that the stock price performance shown in the graph above is notindicative of, and is not intended to forecast, the potential future performance of our common stock. The information in this “Stock Price Performance Graph”section shall not be deemed to be “soliciting material” or to be “filed” with the SEC, nor shall such information be incorporated by reference into any futurefiling under the Securities Act of 1933, or the Securities Act, or the Securities Exchange Act of 1934, or the Exchange Act, except to the extent that wespecifically incorporate it by reference into such filing.45Item 6.Selected Consolidated Financial DataThe selected consolidated financial data presented below should be read in conjunction with “Part II - Item 7- Management’s Discussion and Analysisof Financial Condition and Results of Operations,” and “Part II - Item 8 - Consolidated Financial Statements and Supplementary Data,” includedelsewhere in this Form 10-K.We derived the consolidated statements of operations and comprehensive income (loss) data for the years ended December 31, 2014, 2013, and 2012,and the consolidated balance sheet data as of December 31, 2014 and 2013 from our audited consolidated financial statements, which are included in thisAnnual Report on Form 10-K. We derived the consolidated statement of operations and comprehensive income (loss) data for the year ended December 31,2011 and the consolidated balance sheet data as of December 31, 2011 from our audited restated consolidated financial statements, which are not included inthis Annual Report on Form 10-K. Lastly, we derived the consolidated statement of operations and comprehensive income (loss) data for the year endedDecember 31, 2010 and the consolidated balance sheet data as of December 31, 2010 from our unaudited restated consolidated financial statements, whichare not included in this Annual Report on Form 10-K.Selected Financial Data Year Ended December 31, 2014 2013 2012 2011 2010 (1) (unaudited) (In thousands, except per share data)Consolidated Statement of Operations Data: Net services revenue $210,140 $504,768 $72,254 $101,966 $26,945Operating expenses: Cost of services 182,144 186,752 188,666 158,715 113,607Selling, general and administrative 69,883 79,951 67,750 63,268 39,870Restatement and other 86,766 33,963 3,714 — —Total operating expenses 338,793 300,666 260,130 221,983 153,477Income (loss) from operations (128,653) 204,102 (187,876) (120,017) (126,532)Net interest income (expense) 302 330 141 26 29Net income (loss) before income tax provision (128,351) 204,432 (187,735) (119,991) (126,503)Income tax provision (benefit) (48,731) 74,349 (67,995) (48,246) (46,586)Net income (loss) $(79,620) $130,083 $(119,740) $(71,745) $(79,917)Net income (loss) per common share Basic $(0.83) $1.36 $(1.21) $(0.74) $(1.13)Diluted $(0.83) $1.34 $(1.21) $(0.74) $(1.13) As of December 31, 2014 2013 2012 2011 2010 (1) (unaudited) (In thousands)Consolidated Balance Sheet Data: Cash and cash equivalents 145,167 $228,891 $176,956 $196,725 $156,067Working capital (2) 41,593 $124,045 $139,852 $161,539 $93,995Total assets 446,373 $509,991 $557,377 $476,280 $344,602Non-current liabilities 325,470 $202,799 $85,848 $65,074 $337,551Total stockholders’ equity (deficit) (142,246) $(85,612) $(236,200) $(101,431) $(95,755) (1)Consolidated financial data related to the year ended December 31, 2010 has not been audited by our independent registered public accounting firm and, accordingly, hasbeen marked as unaudited.(2)We define working capital as total current assets excluding the current portion of deferred tax assets pertaining to the current portion of deferred customer billings, less totalcurrent liabilities excluding the current portion of deferred46customer billings. We exclude the current portion of deferred customer billings and related deferred tax assets from the definition of working capital due to the nature ofthese balances.Non-GAAP MeasuresIn order to provide a more comprehensive understanding of the information used by our management team in financial and operational decision-making, we supplement our consolidated financial statements that have been prepared in accordance with GAAP with the following non-GAAP financialmeasures: gross and net cash generated from customer contracting activities, and adjusted EBITDA. Our Board and management team use these non-GAAPmeasures as (i) one of the primary methods for planning and forecasting overall expectations and for evaluating actual results against such expectations; and(ii) as a performance evaluation metric in determining achievement of certain executive incentive compensation programs, as well as for incentivecompensation plans for employees.Use of Non-GAAP Financial InformationWe typically invoice customers for base fees and incentive fees on a quarterly or monthly basis, and typically receive cash from customers on a similarbasis. For GAAP reporting purposes, we only recognize these net operating fees and incentive fees as net services revenue to the extent that all the criteria forrevenue recognition are met, which is generally upon contract renewal, termination or "other contractual agreement event", as defined in Note 2, Summary ofSignificant Accounting Policies to the consolidated financial statements included in this Annual Report on Form 10-K. As such, net operating and incentivefees are typically recognized for GAAP purposes in periods subsequent to the periods in which the services are provided. Therefore, our net services revenueand other items in our GAAP consolidated financial statements and adjusted EBITDA will typically include the effects of billings and collections fromperiods prior to the period in which revenue is recognized. See Note 2, Summary of Significant Accounting Policies to the consolidated financial statementsfor additional information.Selected Non-GAAP MeasuresThe following table presents selected non-GAAP measures for each of the periods indicated. See below for an explanation of how we calculate and usethese non-GAAP measures, and for a reconciliation of these non-GAAP measures to the most comparable GAAP measures. Year End December 31, 2014 2013 2012 2011 2010 (In thousands)Non-GAAP Measures: Adjusted EBITDA $(15,668) $268,689 $(152,509) $(89,969) $(106,535)Net cash generated from customer contracting activities $7,759 $15,562 $47,605 $55,828 $19,243Gross cash generated from customer contracting activities $233,567 $251,641 $272,368 $247,763 $152,723Gross and Net Cash Generated from Customer Contracting ActivitiesGross and net cash generated from customer contracting activities reflect the change in the deferred customer billings, relative to GAAP net servicesrevenue, and adjusted EBITDA (defined below), respectively. Deferred customer billings include the portion of both (i) invoiced or accrued net operating feesand (ii) cash collections of incentive fees, in each case, that have not met our revenue recognition criteria. Deferred customer billings are included in thedetail of our customer liabilities balance in the consolidated balance sheet. Deferred customer billings are reduced by the amounts of revenue recognizedwhen a revenue recognition event occurs. Gross cash generated from customer contracting activities is defined as GAAP net services revenue, plus the changein deferred customer billings. Accordingly, gross cash generated from customer contracting activities is the sum of (i) invoiced or accrued net operating fees,(ii) cash collections on incentive fees and (iii) other services fees.47Net cash generated from customer contracting activities is defined as adjusted EBITDA, plus the change in deferred customer billings.These non-GAAP measures are used throughout this Form 10-K including "Part II - Item 7 - Management’s Discussion and Analysis of FinancialCondition and Results of Operations.”Gross and net cash generated from customer contracting activities include invoices issued to customers that may remain uncollected or may be subjectto credits, and cash collected may be returned to our customers in the form of concessions or other adjustments. Customer concessions and other adjustmentshave occurred in the past and we cannot determine the likelihood that they will again occur in the future.Adjusted EBITDAWe define adjusted EBITDA as net income before net interest income (expense), income tax provision, depreciation and amortization expense, share-based compensation, Restatement-related expense, reorganization-related expense and certain non-recurring items. The use of adjusted EBITDA to measureoperating and financial performance is limited by our revenue recognition criteria, pursuant to which GAAP net services revenue is recognized at the end of acontract or "other contractual agreement event", as defined in Note 2, Summary of Significant Accounting Policies to the consolidated financial statementsincluded in this Annual Report on Form 10-K. Adjusted EBITDA does not adequately match corresponding cash flows resulting from customer contractingactivities. Accordingly, as described above, in order to better compare our cash flows from customer contracting activities to our operating performance, weuse additional non-GAAP measures: gross and net cash generated from customer contracting activities. We use adjusted EBITDA in our reconciliation of netcash generated from customer contracting activities to our GAAP consolidated financial statements.We understand that although non-GAAP measures are frequently used by investors, securities analysts, and others in their evaluation of companies,these measures have limitations as analytical tools, and you should not consider them in isolation or as a substitute for analysis of our results of operations asreported under GAAP. Some of these limitations are:• Gross and net cash generated from customer contracting activities include invoiced or accrued net operating fees, and invoiced as well as collectedincentive fees which may be subject to adjustment or concession prior to the end of a contract or "other contractual agreement event", as defined inNote 2, Summary of Significant Accounting Policies to the consolidated financial statements included in this Annual Report on Form 10-K;•Gross and net cash generated from customer contracting activities include progress billings on incentive fees that have been collected for a numberof our RCM contracts. These progress billings have, from time-to-time been subject to adjustments, and the fees included in these non-GAAPmeasures may be subject to adjustments in the future;•Net cash generated from customer contracting activities and adjusted EBITDA do not reflect changes in, or cash requirements for, our workingcapital needs;•Net cash generated from customer contracting activities and adjusted EBITDA do not reflect share-based compensation expense;•Net cash generated from customer contracting activities and adjusted EBITDA do not reflect income tax expenses or cash requirements to pay taxes;•Although depreciation and amortization charges are non-cash charges, the assets being depreciated and amortized will often have to be replaced inthe future, and net cash generated from customer contracting activities and adjusted EBITDA do not reflect cash requirements for such replacementsor other purchase commitments, including lease commitments; and48•Other companies in our industry may calculate gross or net cash generated from customer contracting activities or adjusted EBITDA differently thanwe do, limiting its usefulness as a comparative measure.Reconciliation of GAAP and Non-GAAP Measures: The following table presents a reconciliation of adjusted EBITDA and net cash generated fromcustomer contracting activities to net income (loss), and gross cash generated from customer contracting activities to net services revenue the mostcomparable GAAP measures, for each of the periods indicated. Year End December 31, 2014 2013 2012 2011 2010 ( in thousands)Net income (loss) $(79,620) $130,083 $(119,740) $(71,745) $(79,917)Net interest (income) expense (302) (330) (141) (26) (29)Income tax provision (benefit) (48,731) 74,349 (67,995) (48,246) (46,586)Depreciation and amortization expense 6,047 6,823 6,355 4,862 3,448Share-based compensation expense (1) 20,172 23,801 25,298 25,186 16,549Restatement and other (2) 86,766 33,963 3,714 — —Adjusted EBITDA (15,668) 268,689 (152,509) (89,969) (106,535)Change in deferred customer billings (3) 23,427 (253,127) 200,114 145,797 125,778Net cash generated from customer contracting activities 7,759 15,562 47,605 $55,828 $19,243Net services revenue (GAAP basis) $210,140 $504,768 $72,254 101,966 26,945Change in deferred customer billings (3) 23,427 (253,127) 200,114 145,797 125,778Gross cash generated from customer contractingactivities $233,567 $251,641 $272,368 $247,763 $152,723(1)Share-based compensation expense represents the non-cash expense associated with stock options and restricted shares granted, as reflected in our Consolidated Statementsof Operations. See Note 5, Share-Based Compensation, to the consolidated financial statements included in this Annual Report on Form 10-K for the detail of the amountsof share-based compensation expense.(2)For the years ended December 31, 2014 and 2013, we incurred $57.3 and $23.1 million in Restatement-related costs, respectively. These costs were incurred to completeour Annual Report on Form 10-K and restate historical consolidated financial statements. In addition, we incurred $22.1 million and $5.2 million for the years endedDecember 31, 2014 and 2013, respectively, in reorganization-related costs as part of the effort to reduce our workforce in certain corporate, administrative and managementfunctions. These costs include severance payments, healthcare benefits, and outplacement job training. Lastly, for the year ended December 31, 2014, we incurred $7.4million in other non-recurring costs consisting of $6.5 million in costs associated with our transformation office, which was created to provide continuity and crossfunctional accountability associated with the continued execution of our turnaround plan during the period subsequent to Stephen Schuckenbrock's resignation as our ChiefExecutive Officer and prior to the appointment of Dr. Emad Rizk as our Chief Executive Officer ("Transformation Office"), and $0.9 million in additional employment taxexpense relating to prior years. In 2015, we continued to incur costs related to remediation of internal control weaknesses and higher than normal audit fees.(3)Deferred customer billings include the portion of both (i) invoiced or accrued net operating fees and (ii) cash collections on incentive fees, in each case, that have not metour revenue recognition criteria. Deferred customer billings are included in the detail of our customer liabilities balance in the consolidated balance sheets. Deferredcustomer billings are reduced by revenue recognized when revenue recognition occurs. Change in deferred customer billings represents the net change in the cumulative netoperating fees and incentive fees that have not met revenue recognition criteria.49Item 7.Management’s Discussion and Analysis of Financial Condition and Results of OperationsManagement’s Discussion and Analysis of Financial Condition and Results of Operations, or MD&A, should be read in conjunction with ourconsolidated financial statements and the related notes and other financial information included elsewhere in this Annual Report on Form 10-K. Some ofthe information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect toour plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. Please review “PartI - Item 1A - Risk Factors” of this Annual Report on Form 10-K for a discussion of important factors that could cause actual results to differ materially fromthe results described in or implied by the forward-looking statements contained in the following discussion and analysis.OverviewWe are a leading provider of services that help healthcare providers generate sustainable improvements in their operating margins and cash flows whilealso improving patient, physician and staff satisfaction for our customers. Our goal is to help our healthcare provider customers deliver high-quality care andserve their communities, and do so in a financially sustainable way. We help our customers more efficiently manage their revenue cycle process and strive tohelp prepare them for the evolving dynamics of the healthcare industry, particularly the challenges and opportunities presented by the shift to value-basedreimbursement which is designed to reward the value, rather than the volume, of healthcare services provided.While we cannot control the changes in the regulatory environment imposed on our customers, we believe that our role becomes increasingly moreimportant to our customers as macroeconomic, regulatory and healthcare industry conditions continue to impose financial pressure on healthcare providers tomanage their operations effectively and efficiently.Revenue Cycle Management, or RCM, continues to be our primary service offering. Our RCM offering helps our customers more efficiently managetheir revenue cycle process. This encompasses patient registration, insurance and benefit verification, medical treatment documentation and coding, billpreparation and collections. We focus on optimizing our customers’ entire, end-to-end revenue cycle process, which we believe is more advantageous thanalternative approaches that merely focus on certain aspects or sub-processes within the revenue cycle. Our physician advisory services, or PAS, complementsour RCM offering by strengthening our customer’s compliance with certain third-party payer requirements and limiting denials of claims. For example, ourPAS offering helps customers determine whether to classify a hospital visit as an in-patient or an out-patient observation case for billing purposes. We believethat the population health capabilities we are integrating into our RCM offering will enhance our value-based reimbursement capabilities to help providersenter into risk-bearing arrangements with payers.We operate our business as a single segment configured with our significant operations and offerings organized around the business of providing end-to-end RCM services to U.S.-based hospitals and other healthcare providers.Summary of OperationsDuring 2014, we continued to focus our efforts on several key strategic and operational imperatives aimed at delivering on our critical customerobligations and continued to expand the depth and breadth of our services. During the year, we took steps to position ourselves to capture growthopportunities in the U.S. healthcare market. These steps included meetings with and solicitation of feedback from our customers, aimed at improving ourservice execution. In addition, we continue to pursue the following initiatives intended to create value for our customers:•Increasing investment in IT: Developing new proprietary technology and investing in capabilities that enable more seamless integration with ourcustomers’ existing technology.50•Strengthening front-line teams: Improving the capabilities and quality of our workforce in the field through better training and improvements in ourhiring and retention processes.•Simplifying our measurement model: Developing and implementing a less complex measurement model to improve customer satisfaction.•Expanding our shared service center capabilities and infrastructure: Increasing opportunities for our customers to realize operating efficiencies andachieve margin improvements by utilizing our shared service centers.We also commenced a series of restructuring measures designed to allow us to more effectively and efficiently allocate necessary resources forinnovation, growth and enhanced customer service. Specific changes included optimizing our geographic facilities footprint by transitioning certainfunctions housed at our headquarters to locations close to our customers or our shared service centers. Additionally, in 2014, we hired Emad Rizk, M.D. asPresident and Chief Executive Officer, Peter Csapo as Chief Financial Officer and Treasurer and David Mason as Chief Strategy Officer.We believe these initiatives will position us to help our healthcare provider customers deliver high-quality care and serve their communities, and do soin a financially sustainable way. We expect to be able to grow gross cash generated from contracting activities in the RCM business in 2015 and beyond.Net Services RevenueRevenues from our RCM agreements consist primarily of net operating fees and incentive fees that are primarily performance based and/or contingentfees. The vast majority of our operations relate to our RCM offering, however, the criteria for recognition of revenue for RCM services results in substantialvariability in the net services revenue recognized between periods.Other services revenue is primarily derived from our physician advisory services.The following table summarizes the composition of our net services revenue for the years ended December 31, 2014, 2013 and 2012: Year ended December 31, 2014 2013 2012RCM services: net operating fees $77,456 36.9% $224,937 44.6% $9,888 13.7%RCM services: incentive fees 99,934 47.6% 210,303 41.7% 928 1.3%Other services 32,750 15.5% 69,528 13.7% 61,438 85.0%Total net services revenue $210,140 100.0% $504,768 100.0% $72,254 100.0%Cost of ServicesOur cost of services includes:•Infused management and technology expenses. We incur costs related to our management and staff employees who are devoted to customeroperations. These expenses consist primarily of the wages, bonuses, benefits, share-based compensation, travel and other costs associated withdeploying our employees to customer sites to guide and manage our customers’ revenue cycle or population health management operations. Theemployees we deploy to customer sites typically have significant experience in revenue cycle operations, care coordination, technology, qualitycontrol or other management disciplines. Included in these expenses is an allocation of the costs associated with maintaining, improving anddeploying our integrated proprietary technology suite.51•Shared services center costs. We incur expenses related to salaries and benefits of employees in our shared services centers, as well as non-payrollcosts associated with operating our shared services centers.•Other expenses. We incur expenses related to our employees who manage physician advisory services and other services. These expenses consistprimarily of wages, bonuses, benefits, share-based compensation and other costs.Selling, General and Administrative ExpensesSelling, general and administrative expenses consist primarily of expenses for executives, sales, corporate IT, legal, regulatory compliance, finance andhuman resources personnel, professional service fees related to external legal, tax, audit and advisory services, insurance premiums, facility charges, and othercorporate expenses.Restatement and Other CostsRestatement and other costs include Restatement and reorganization-related expenses and certain other non-recurring costs. Restatement-related costswere incurred starting in early 2013, following our determination to restate financial results. We also reduced our workforce in certain corporate,administrative, operations and management functions as part of a reorganization effort beginning in June 2013 and continuing into 2015. Reorganizationcosts consist of severance payments, healthcare benefits, and outplacement job training. In 2015, we continued to incur costs related to remediation ofinternal control weaknesses and higher than normal audit fees. We also incurred non-recurring costs related to additional employment tax expense in 2014relating to prior years regarding reclassification of contractors to employee status. In addition, we also incurred other non-recurring costs in 2014 related toour Transformation Office.Interest IncomeInterest income is derived from the return achieved from our cash and cash equivalents.Income TaxesIncome tax expense consists of federal and state income taxes in the United States and other local taxes in India.Application of Critical Accounting Policies and Use of EstimatesOur consolidated financial statements reflect the assets, liabilities and results of operations of Accretive Health, Inc. and our wholly-owned subsidiaries.All material intercompany transactions and balances have been eliminated in consolidation. Our consolidated financial statements have been prepared inaccordance with United States generally accepted accounting principles, or GAAP.The preparation of financial statements in conformity with GAAP requires us to make estimates and judgments that affect the amounts reported in ourconsolidated financial statements and the accompanying notes. We regularly evaluate the accounting policies and estimates we use. In general, we baseestimates on historical experience and on assumptions that we believe to be reasonable given our operating environment. Estimates are based on our bestknowledge of current events and the actions we may undertake in the future. Although we believe all adjustments considered necessary for fair presentationhave been included, our actual results may differ materially from our estimates.We believe that the accounting policies described below involve our more significant judgments, assumptions and estimates, and therefore, could havethe greatest potential impact on our consolidated financial statements. In addition, we believe that a discussion of these policies is necessary to understandand evaluate the consolidated financial statements contained in this Annual Report on Form 10-K. For further information on our critical and other52significant accounting policies, see Note 2, Summary of Significant Accounting Policies, to the consolidated financial statements included in this AnnualReport on Form 10-K.Revenue RecognitionRevenue is generally recognized when all of the following criteria are met; (i) persuasive evidence of an arrangement exists, (ii) services have beenrendered, (iii) the fee is fixed or determinable, and (iv) collectability is reasonably assured. Our primary source of revenue is RCM service fees. We alsogenerate revenue from other fixed fee consulting or transactional fee engagements. Net service fees, as reported in the consolidated statement of operationsand comprehensive income (loss), consist of: (a) RCM service fees, and (b) professional service fees earned on a fixed fee, transactional fee, or time andmaterials basis. RCM service fees are primarily contingent, but along with fixed fees are generally viewed as one deliverable. To the extent that certain RCMservice fees are fixed and not subject to refund, adjustment or concession, these fees are generally recognized into revenue on a straight-line basis over theterm of the contract.RCM service fees that are contingent in nature are recognized as revenue once all the criteria for revenue recognition are met, which is generally at theend of a contract or other contractual agreement events. Revenue is recognized for RCM service fees upon the contract reaching the end of its stated term(such that the contract relationship will not continue in its current form) to the extent that cash has been received for invoiced fees and there are no disputesat the conclusion of the term of the contract.If fees or services are disputed by a customer at the end of a contract, a settlement agreement entered into with the customer triggers revenuerecognition. An “other contractual agreement event” occurs when a renewal or amendment to an existing contract is executed in which the parties reachagreement on prior fees. We recognize revenue up to the amount covered by such agreements.RCM service fees generally consist of two types of contingent fees: (i) net operating fees and (ii) incentive fees.Net Operating FeesWe generate net operating fees to the extent we are able to assist customers in reducing the cost of their revenue cycle operations. Our delivery modelleverages the customers’ RCM personnel. Our net operating fees consist of (i) gross base fees invoiced to customers; less (ii) corresponding costs ofcustomers’ revenue cycle operations which we to pay pursuant to our RCM agreements, including salaries and benefits for the customers' RCM personnel,and related third-party vendor costs; less (iii) any cost savings we share with customers.Net operating fees are recorded in deferred customer billings until we recognize revenue on a customer contract at the end of a contract or uponreaching an "other contractual agreement event." The amount of unpaid costs of customers’ revenue cycle operations and shared cost savings are reported asaccrued service costs within customer liabilities on our consolidated balance sheet.Incentive FeesWe also generate revenue in the form of performance-based fees when we improve our customers’ revenue yield. These performance metrics vary bycustomer contract. However, certain contracts contain a contract-to-date performance metric that is not resolved until the end of the term of the contract. Insome cases, when a customer agreement is extended under an evergreen provision or other amendment, fees may not be considered finalized until the end ofthe customer relationship. Incentive fees associated with performance metrics which are not resolved until the end of the term of the contract or an “othercontractual agreement event” are recorded in deferred customer billings until we recognize revenue. Incentive fees are considered contingent fees.53Estimates of Cost of Customers’ Revenue Cycle OperationsCost of customers’ revenue cycle operations consist of invoiced costs from customers and estimated costs not yet invoiced. These costs consist ofpayroll and third-party non-payroll costs. Customers’ payroll costs are reasonably estimable; however we are significantly dependent upon informationgenerated from our customers’ records to determine the amount of third-party non-payroll costs. Furthermore, because our customers report information on acash basis, rather than on an accrual basis, we estimate the amount of non-payroll costs incurred but not invoiced in order to properly calculate the deferredcustomer billings balance of the end of each reporting period. These estimated costs are based on contractually allowable expenses, historical reimbursedcosts, and estimated lag in the timing of receipt of information for third-party non-payroll costs. The timing difference includes the lag between the servicesrendered by third-party vendors and their billings to our customers. The accruals for such costs are included in accrued service costs and are part of the netoperating fees included in deferred customer billings within the customer liabilities balance in the consolidated balance sheet. These estimates are based onthe best available information and are subject to future adjustments based on additional information received from our customers. Due to the variable natureof these estimates, the adjustments can have a significant impact on the deferred customer billings balance for any reporting period in the futureIncome TaxesWe account for income taxes under the asset and liability method. We record deferred tax assets and liabilities for future income tax consequences thatare attributable to differences between the carrying amount of assets and liabilities for financial statement purposes and the income tax bases of such assetsand liabilities. We base the measurement of deferred tax assets and liabilities on enacted tax rates that we expect will apply to taxable income in the year weexpect to settle or recover those temporary differences. We recognize the effect on deferred income tax assets and liabilities of any change in income tax ratesin the period that includes the enactment date.The carrying values of deferred income tax assets and liabilities reflect the application of our income tax accounting policies, and are based onmanagement’s assumptions and estimates about future operating results and levels of taxable income, and judgments regarding the interpretation of theprovisions of current accounting principles. We provide a valuation allowance for deferred tax assets if, based upon the weight of all available evidence, bothpositive and negative, it is more likely than not that some or all of the deferred tax assets will not be realized. We have established a partial valuationallowance with respect to certain separate state income net operating loss carryforward deferred tax assets.The estimated effective tax rate for the year is applied to our quarterly operating results. In the event that there is a significant unusual or discrete itemrecognized, or expected to be recognized, in our quarterly operating results, the tax attributable to that item would be separately calculated and recorded atthe same time as the unusual or discrete item, such as the resolution of prior-year tax matters.We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the position will be sustained on examination bytaxing authorities, based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such a position aremeasured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement.Interest and penalties related to income taxes are recognized in our tax provision in the consolidated statement of operations and comprehensiveincome (loss). See Note 8, Income Taxes, to our consolidated financial statements incorporated into this Annual Report on Form 10-K for additionalinformation on income taxes.Share-Based Compensation ExpenseWe determine the expense for all employee share-based compensation awards by estimating their fair value and recognizing that value as an expense,on a ratable basis, in our consolidated financial statements over the requisite service period in which our employees earn the awards. The fair value ofperformance and service54condition stock options is calculated using the Black-Scholes option pricing model and, for market condition stock options, the fair value is estimated usingMonte Carlo simulations.To determine the fair value of a share-based award using the Black-Scholes option pricing model, we make assumptions regarding the risk-free interestrate, expected future volatility, expected life of the award, and expected forfeitures of the awards. These inputs are subjective and generally requiresignificant analysis and judgment to develop. We aggregate all employees into one pool for valuation purposes. The risk-free rate is based on the U.S.treasury yield curve in effect at the time of grant. We estimate the expected volatility of our share price by reviewing the historical volatility levels of ourcommon stock in conjunction with that of public companies that operate in similar industries or are similar in terms of stage of development or size and thenprojecting this information toward its future expected volatility. We exercise judgment in selecting these companies, as well as in evaluating the availablehistorical and implied volatility for these companies. We calculate the expected term in years for each stock option using a simplified method based on theaverage of each option’s vesting term and original contractual term. We apply an estimated forfeiture rate derived from our historical data and our estimatesof the likely future actions of option holders when recognizing the share-based compensation expense of the options.To determine the fair value of a share-based award using Monte Carlo simulations, we make assumptions regarding the risk-free interest rate, expectedfuture volatility, expected dividend yield and performance period. The risk-free rate is based on the U.S. treasury yield curve in effect at the time of grant. Weestimate the expected volatility of the share price by reviewing the historical volatility levels of our common stock in conjunction with that of publiccompanies that operate in similar industries or are similar in terms of stage of development or size and then projecting this information toward our futureexpected volatility. Dividend yield is determined based on our future plans to pay dividends. We calculate the performance period based on the specificmarket condition to be achieved and derived from historical data and estimates of future performance.We recognize compensation expense, net of forfeitures, using a straight-line method over the applicable vesting period. Quarterly, the share-basedcompensation expense is adjusted to reflect all expense for options that vested during the period.We account for stock options issued to non-employees based on their estimated fair value determined using the Black-Scholes option pricing model.However, the fair value of the equity awards granted to non-employees is remeasured on each balance sheet date until the awards vest, and the relatedexpense is adjusted based on the resulting change in value, if any. The non-employee share-based compensation expense is recognized over the performanceperiod, which is the vesting period. Upon vesting, the performance of the non-employee is deemed complete and the vested awards are not remeasuredsubsequently.The fair value of modifications to share-based awards is generally estimated using the Black-Scholes option pricing model. If a share-basedcompensation award is modified after the grant date, incremental compensation expense is recognized in an amount equal to the excess of the fair value ofthe modified award over the fair value of the original award immediately before the modification. Incremental compensation expense for vested awards isrecognized immediately. For unvested awards, the sum of the incremental compensation expense and the remaining unrecognized compensation expense forthe original award on the modification date is recognized over the modified service period.New Accounting StandardsFor additional information regarding new accounting guidance, see Note 2, Summary of Significant Accounting Policies, to our consolidated financialstatements included in this Annual Report on Form 10-K, which provides a summary of our significant accounting policies and recently adopted accountingstandards and disclosures.55Results of OperationsYear Ended December 31, 2014 Compared to Year Ended December 31, 2013The following table provides consolidated operating results and other operating data for the periods indicated: Year Ended December 31, 2014 vs. 2013Change 2014 2013 Amount % (In thousands)Consolidated Statement of Operations Data: RCM service: net operating fees $77,456 $224,937 $(147,481) (65.6)%RCM service: incentive fees 99,934 210,303 (110,369) (52.5)%Other service fees 32,750 69,528 (36,778) (52.9)%Total net services revenue 210,140 504,768 (294,628) (58.4)%Operating expenses: Cost of services 182,144 186,752 (4,608) (2.5)%Selling, general and administrative 69,883 79,951 (10,068) (12.6)%Restatement and other 86,766 33,963 52,803 n.m.Total operating expenses 338,793 300,666 38,127 12.7 %Income (loss) from operations (128,653) 204,102 (332,755) n.m.Net interest income 302 330 (28) (8.5)%Net income (loss) before income tax provision (128,351) 204,432 (332,783) n.m.Income tax provision (benefit) (48,731) 74,349 (123,080) n.m.Net income (loss) (79,620) 130,083 (209,703) n.m.Net interest income (302) (330) 28 (8.5)%Income tax provision (benefit) (48,731) 74,349 (123,080) n.m.Depreciation and amortization expense 6,047 6,823 (776) (11.4)%Share-based compensation expense 20,172 23,801 (3,629) (15.2)%Restatement and other 86,766 33,963 52,803 n.mAdjusted EBITDA (15,668) 268,689 (284,357) n.m.Change in deferred customer billings 23,427 (253,127) 276,554 n.m.Net cash generated from customer contracting activities $7,759 $15,562 $(7,803) (50.1)%Net services revenue $210,140 $504,768 (294,628) (58.4)%Change in deferred customer billings 23,427 (253,127) 276,554 n.m.Gross cash generated from customer contracting activities $233,567 $251,641 $(18,074) (7.2)%Components of Gross Cash Generated from Customer Contracting Activities: RCM service: net operating fee $121,730 $106,453 $15,277 14.4 %RCM service: incentive fee 77,239 75,660 1,579 2.1 %Total RCM service fees 198,969 182,113 16,856 9.3 %Other service fees 34,598 69,528 (34,930) (50.2)%Gross cash generated from customer contracting activities $233,567 $251,641 $(18,074) (7.2)%n.m.—Not meaningfulNet Services RevenueNet services revenue decreased by $294.6 million, or 58.4%, from $504.8 million for the year ended December 31, 2013 to $210.1 million for the yearended December 31, 2014. The decrease was primarily driven by RCM contractual agreement events in the year ended December 31, 2013, which resulted inrevenue recognition of $435.2 million. This decrease was partially offset by other contractual agreement events amounting to $177.4 million in revenuerecognition for the year ended December 31, 2014.56In addition, other service fees decreased by $36.8 million in 2014 as compared to 2013, primarily driven by a decrease in PAS revenue ofapproximately $32.6 million. The decrease is the result of the two-midnight rule, a regulatory change in the healthcare industry related to billingclassifications for certain hospital patients. PAS revenue and profitability continues to be negatively impacted in 2015 by the two-midnight rule.Gross Cash Generated from Customer Contracting Activities (Non-GAAP)Gross cash generated from customer contracting activities decreased by $18.1 million, or 7.2%, from $251.6 million for the year ended December 31,2013, to $233.6 million for the year ended December 31, 2014. The decrease was primarily the result of a $32.6 million decrease in PAS revenue.Additionally, 2013 also included $8.2 million in other service fees from the settlement of a former population health contract. This decrease was offset by anincrease in gross cash generated with customers affiliated with Ascension Health, as approximately $20.1 million in credits were issued to these customersduring 2013 in accordance with the terms of the new agreements entered into during the year.Gross cash generated from customer contracting activities is a non-GAAP measure. Please see “Selected Non-GAAP Measures” in “Part II – Item 6 –Selected Consolidated Financial Statements” for an explanation of how we calculate and use gross cash generated from customer contracting activities andfor its reconciliation to net services revenue, the most comparable GAAP measure.Cost of ServicesTotal cost of services decreased by $4.6 million, or 2.5%, from $186.8 million for the year ended December 31, 2013, to $182.1 million for the yearended December 31, 2014. The decrease in cost of services was primarily a result of decreased costs in our PAS business, offset by an increased investment inIT and the shared service centers' capabilities and infrastructure related to RCM.Selling, General and Administrative ExpensesSelling, general and administrative expenses decreased by $10.1 million, or 12.6%, from $80.0 million for the year ended December 31, 2013 to $69.9million for the year ended December 31, 2014. The $10.1 million decrease was primarily due to cost reduction initiatives started in the prior year.Net Cash Generated from Customer Contracting Activities (Non-GAAP)Net cash generated from customer contracting activities decreased by $7.8 million from $15.6 million in 2013 to $7.8 million in 2014. This decreasewas primarily due to lower gross cash generated of $18.1 million, offset by a decrease of $10.1 million in selling, general and administrative expenses asdescribed above. Net cash generated from customer contracting activities is a non-GAAP measure. Please see “Selected Non-GAAP Measures” in “Part II –Item 6 – Selected Consolidated Financial Statements” for an explanation of how we calculate and use net cash generated from customer contracting activitiesand for its reconciliation to net income (loss), the most comparable GAAP measure.Restatement and Other CostsRestatement and other costs increased $52.8 million from $34.0 million for the year ended December 31, 2013 to $86.8 million for the year endedDecember 31, 2014. The increase was primarily driven by an increase in Restatement-related costs of $34.2 million, reorganization-related costs of $16.9million and $6.5 million in costs incurred through our Transformation Office. This increase was offset by a decrease of $4.8 million of litigation-related andother costs. These costs are considered unusual in nature by management and are reported separately under the caption “Restatement and other” in theaccompanying consolidated statement of operations and comprehensive income (loss).57Income TaxesTax expense decreased by $123.0 million, from $74.3 million in tax expense for the year ended December 31, 2013 to a tax benefit of $ 48.7 millionfor the year ended December 31, 2014. Our effective tax rate for the years ended December 31, 2014 and 2013 were approximately 38.0% and 36.4%,respectively. Our tax rate is affected by recurring items, permanent differences and state income taxes. It is also affected by discrete items that may occur inany given year, but are not consistent from year to year.Year Ended December 31, 2013 Compared to Year Ended December 31, 2012The following table sets forth consolidated operating results and other operating data for the periods indicated: Year Ended December 31, 2013 vs. 2012 Change 2013 2012 Amount % (In thousands)Consolidated Statement of Operations Data: RCM service: net operating fees $224,937 $9,888 $215,049 n.m.RCM service: incentive fees 210,303 928 209,375 n.m.Other service fees 69,528 61,438 8,090 13.2 %Total net services revenue 504,768 72,254 432,514 n.m.Operating expenses: Cost of services 186,752 188,666 (1,914) (1.0)%Selling, general and administrative 79,951 67,750 12,201 18.0 %Restatement and other costs 33,963 3,714 30,249 n.m.Total operating expenses 300,666 260,130 40,536 15.6 %Income (loss) from operations 204,102 (187,876) 391,978 n.m.Net interest income 330 141 189 n.m.Net income (loss) before income tax provision 204,432 (187,735) 392,167 n.m.Income tax provision (benefit) 74,349 (67,995) (142,344) n.m.Net income (loss) 130,083 (119,740) 249,823 n.m.Net interest income (330) (141) (189) n.m.Income tax provision (benefit) 74,349 (67,995) 142,344 n.m.Depreciation and amortization expense 6,823 6,355 468 7.4 %Share-based compensation expense 23,801 25,298 (1,497) (5.9)%Restatement and other costs 33,963 3,714 30,249 n.m.Adjusted EBITDA 268,689 (152,509) 421,198 n.m.Change in deferred customer billings (253,127) 200,114 (453,241) n.m.Net cash generated from customer contracting activities $15,562 $47,605 $(32,043) (67.3)%Net services revenue $504,768 $72,254 432,514 n.m.Change in deferred customer billings (253,127) 200,114 (453,241) n.m.Gross cash generated from customer contracting activities $251,641 $272,368 $(20,727) (7.6)%Components of Gross Cash Generated from Customer Contracting Activities: RCM service: net operating fee 106,453 118,030 $(11,577) (9.8)%RCM service: incentive fee 75,660 92,900 (17,240) (18.6)%Total RCM service fees 182,113 210,930 (28,817) (13.7)%Other service fees 69,528 61,438 8,090 13.2 %Gross cash generated from customer contracting activities $251,641 $272,368 $(20,727) (7.6)% n.m.—Not meaningful58Net Services RevenueNet services revenue increased to $504.8 million for the year ended December 31, 2013, from $72.3 million for the year ended December 31, 2012. The$432.5 million increase was primarily driven by our Ascension Health RCM contractual agreement event in the quarter ended June 30, 2013, resulting inrevenue recognition of $360.5 million, and $35.0 million in net services revenue attributable to other customer contractual agreement events. RCM servicefees increased by $28.9 million as a result of revenue recognized in the quarter ended December 31, 2013, after reaching a settlement agreement with a formerMinnesota customer. Other service fees increased by $8.1 million in 2013 as compared to 2012, driven by an $11 million increase which included an $8.2million contribution from the settlement of a population health contract in the quarter ended December 31, 2013. This increase was partially offset by adecrease in physician advisory services revenue of approximately $2.9 million in the year ended December 31, 2013, as compared to the year endedDecember 31, 2012, resulting from the impact of the two-midnight rule, a regulatory change in the healthcare industry related to billing classifications forcertain hospital patients. Physician advisory services revenue and profitability continued to be negatively impacted in 2014 by the two-midnight rule.Gross Cash Generated from Customer Contracting Activities (Non-GAAP)Gross cash generated from customer contracting activities totaled $251.6 million for 2013 compared to $272.4 million for 2012, a decrease of $20.7million. The decrease in gross cash generated from customer contracting activities was primarily a result of credits of $20.1 million given to customersaffiliated with Ascension Health during 2013 in accordance with the terms of the new agreements entered into with such customers. Gross cash generatedfrom customer contracting activities is a non-GAAP measure. Please see “Selected Non-GAAP Measures” in “Part II – Item 6 – Selected ConsolidatedFinancial Statements” for an explanation of how we calculate and use gross cash generated from customer contracting activities and for its reconciliation tonet services revenue, the most comparable GAAP measure.Cost of ServicesTotal cost of services decreased by $1.9 million, or 1.0%, from $188.7 million for the year ended December 31, 2012, to $186.8 million for the yearended December 31, 2013. The decrease in cost of services was primarily a result of lower cost of services in the population health business.Selling, General and Administrative ExpensesSelling, general and administrative expenses increased by $12.2 million, or 18.0%, to $80.0 million for the year ended December 31, 2013, from $67.8million for the year ended December 31, 2012. The $12.2 million increase was primarily due to our senior management transition costs, increased investmentspending in IT, internal audit and compliance areas and short term incentive compensation costs.Net Cash Generated from Customer Contracting Activities (Non-GAAP)The net cash generated from customer contracting activities totaled $15.6 million in 2013 compared to a generation of $47.6 million in cash for 2012.This change of $32.0 million was primarily due to lower gross cash generated by $20.7 million and increased selling, general and administrative expenses by$12.2 million, as described above. Net cash generated from customer contracting activities is a non-GAAP measure. Please see “Selected Non-GAAPMeasures” in “Part II – Item 6 – Selected Consolidated Financial Statements” for an explanation of how we calculate and use net cash generated fromcustomer contracting activities and for its reconciliation to net income (loss), the most comparable GAAP measure.Restatement and other CostsRestatement and other costs amounted to $34.0 million for the year ended December 31, 2013, compared to $3.7 million for the year ended December31, 2012. The increase was primarily driven by Restatement-related costs59of $23.1 million, reorganization-related costs of $5.2 million and $3.3 million of litigation-related costs . These costs are considered unusual in nature bymanagement and are reported separately under the caption “Restatement and other” in the accompanying consolidated statement of operations andcomprehensive income (loss). We continued to experience substantial costs in 2014 related to Restatement and reorganizing activities.Income TaxesTax expense increased by $142.3 million, to $74.3 million for the year ended December 31, 2013, from a $68.0 million tax benefit for the year endedDecember 31, 2012. The increase was attributable to our revenue recognition event for affiliates of Ascension Health (see above). Our effective tax rate for theyears ended December 31, 2013 and 2012 was approximately 36% of our pre-tax income (loss).Liquidity and Capital ResourcesCash flows from operating, investing and financing activities, as reflected in our Consolidated Statements of Cash Flows, are summarized in thefollowing table: Year Ended December 31, 2014 2013 2012 (In thousands)Net cash provided by (used in) operating activities $(77,236) $54,423 $29,166Net cash used in investing activities (6,034) (1,877) (10,544)Net cash used in financing activities (194) (100) (38,361)Effect of exchange rate changes on cash (260) (511) (30)Net increase (decrease) in cash and cash equivalents $(83,724) $51,935 $(19,769)As of December 31, 2014, 2013, and 2012, we had cash and cash equivalents of $145.2 million, $228.9 million, and $177.0 million, respectively.These balances consist primarily of highly liquid money market funds. Our cash and cash equivalents, at any time, include amounts paid to us in advance bycustomers for the purpose of reimbursing their revenue cycle operations costs. See Note 2, Summary of Significant Accounting Policies, to our consolidatedfinancial statements included in this Annual Report on Form 10-K for additional information. We expect that the combination of our current liquidity andexpected additional cash generated from operations will be sufficient to satisfy our anticipated cash requirement through at least the next twelve months.Year Ended December 31, 2014 Compared to Year Ended December 31, 2013Operating ActivitiesCash from operating activities decreased by $131.7 million from cash provided of $54.4 million for the year ended December 31, 2013 to cash used of$77.2 million for the year ended December 31, 2014. The decrease was primarily attributable to timing of customer reimbursements and the transition of aportion of our RCM agreements to eliminate our gross base fees together with our financial obligation to pay our customers' revenue cycle operationsexpenses. The additional decrease is also due to an increase in Restatement and other expenditures of $52.8 million from $34.0 million for the year endedDecember 31, 2013 to $86.3 million for the year ended December 31, 2014.60Investing ActivitiesCash used in investing activities increased by $4.1 million from $1.9 million for the year ended December 31, 2013 to $6.0 million for the year endedDecember 31, 2014. This increase was due to an increase in investment in IT and the shared service centers' capabilities and infrastructure.Financing ActivitiesCash used in financing activities increased by $0.1 million from $0.1 million for the year ended December 31, 2013 to $0.2 million for the year endedDecember 31, 2014. The decrease is a result of an increase in treasury stock purchases of $0.2 million from $0.2 million the year ended December 31, 2013 to$0.4 million for the year ended December 31, 2014, offset by an increase in excess tax benefit from share-based awards of $0.1 million.Year Ended December 31, 2013 Compared to Year Ended December 31, 2012Operating ActivitiesCash provided by operating activities increased by $25.2 million from $29.2 million for the year ended December 31, 2012 to $54.4 million for theyear ended December 31, 2013. The increase in cash provided by operations in 2013 as compared to 2012 was primarily attributable to higher cash receiptsfrom customers and lower legal payments (net of insurance proceeds) related to the Minnesota litigation. The increase in cash provided by cash receipts fromcustomers was largely attributed to execution of new supplemental agreements between us and hospital systems affiliated with Ascension Health, whichoccurred in the second quarter of 2013. The execution of these agreements resulted in the collection of certain fees which were finalized in conjunction withthe agreements and that pertained to services provided in 2012. These increases were partially offset by increased expenditures of $23.1 million related to theRestatement and $6.0 million related to other expenses in 2013 when compared to 2012.Investing ActivitiesCash used in investing activities decreased by $8.6 million from $10.5 million for the year ended December 31, 2012 to $1.9 million for the year endedDecember 31, 2013. This decrease was primarily attributed to fewer capital expenditures being made in 2013 compared to 2012. Use of cash for investingactivities in 2012 was primarily related to purchases of hardware and software related to the build-out of our technology infrastructure and to support ourcustomers, as well as leasehold improvements to align our office space with the growth in headcount required to support our physician advisory servicesoffering, and related to the build-out of our shared services centers. These investments were substantially complete by 2013.Financing ActivitiesCash used in financing activities decreased by $38.3 million from $38.4 million for the year ended December 31, 2012 to $0.1 million for the yearended December 31, 2013. The cash used in 2012 related to our $50.0 million stock buyback plan which was completed in the third and fourth quarters of2012, offset by the receipt of $7.4 million in proceeds and $2.5 million in associated tax benefits from our employees’ stock option exercises.Revolving Credit FacilityIn September 2011, we reduced our outstanding line of credit with the Bank of Montreal from $15.0 million to $3.0 million. Our line of credit expiredon February 15, 2015 and was not renewed. The $3.0 million line of credit could only be utilized in the form of letters of credit and was secured by a $5.0million demand deposit with the Bank of Montreal. The line of credit had an initial term of three years and was renewable annually thereafter. As ofDecember 31, 2014, 2013 and 2012, we had outstanding letters of credit of approximately $0.7 million, $0.9 million, and $1.8 million, respectively, whichreduced the available line of credit to $2.3 million, $2.1 million and $1.2 million, respectively.61Future Capital NeedsOn November 13, 2013, our board of directors authorized a repurchase of up to $50.0 million of our common stock from time to time in the open marketor in privately negotiated transactions following the completion of the Restatement. We will determine the timing and amount of any shares repurchasedbased on our evaluation of market conditions and other factors, and we intend to fund any such repurchases from cash on hand. No shares of common stockhad been repurchased under this plan as of the date of this Annual Report on Form 10-K. Any repurchased shares will be available for use in connection withour stock plans and for other corporate purposes. The repurchase program may be suspended or discontinued at any time.In connection with our strategic initiatives, we plan to continue to enhance customer service by increasing our investment in technology to enable oursystems to more effectively integrate with our customers’ existing technologies. We plan to continue to deploy resources to strengthen our informationtechnology infrastructure in order to drive additional value for our customers. We also continue to invest in our shared services capabilities. We also plan onexpanding our capabilities in India which will require investments. We may also selectively pursue acquisitions and/or strategic relationships that willenable us to broaden or further enhance our offerings.Additionally, new business development remains a priority as we plan to continue to boost our sales and marketing efforts. We plan to continue to addexperienced personnel to our sales organization, develop more disciplined sales processes, and create an integrated marketing capability.Contractual ObligationsLeasesThe following table presents our obligations and commitments to make future minimum rental payments under all non-cancelable operating leaseshaving remaining terms in excess of one year as of December 31, 2014 (in thousands): Year Ended December 31, 2015 2016 2017 2018 2019 Thereafter TotalFuture minimum rental payments $6,208 $5,067 $5,837 $5,697 $4,965 $13,624 $41,398We rent office space and equipment under a series of operating leases, primarily for our Chicago corporate office, shared services centers and Indiaoperations. Our leases contain various rent holidays and rent escalation clauses and entitlements for tenant improvement allowances. Lease payments areamortized to expense on a straight-line basis over the lease term.Uncertain Tax PositionsWe have a $1.1 million liability for uncertain tax positions as of December 31, 2014. These have been excluded from the “Contractual Obligations”table as we cannot reasonably estimate the period of cash settlement for the tax positions presented in our financial statements as a reduction of our deferredtax asset.Off-Balance Sheet ArrangementsOther than operating leases for office space and the revolving credit facility as noted above, there were no off-balance sheet transactions, arrangementsor other relationships with other persons in 2014, 2013, and 2012 that would have affected our liquidity or the availability of, or requirements for, capitalresources.62Item 7A.Qualitative and Quantitative Disclosures about Market RiskInterest Rate Sensitivity. Our interest income is primarily generated from interest earned on operating cash accounts. Our exposure to market risksrelated to interest expense as of December 31, 2014 was limited to outstanding letters of credit under the revolving line of credit, which bore interest at thegreater of the bank-established prime commercial rate, a LIBOR plus 1% rate, or a rate that combines the characteristics of both. We do not enter into interestrate swaps, caps or collars or other hedging instruments. As a result, we believe that the risk of a significant impact on our operating income from interest ratefluctuations is not substantial.Foreign Currency Exchange Risk. Our results of operations and cash flows are subject to fluctuations due to changes in the Indian rupee because aportion of our operating expenses are incurred by our subsidiary in India and are denominated in Indian rupees. However, we do not generate any revenuesoutside of the United States. For the years ended December 31, 2014, 2013, and 2012, 5%, 4% and 5%, respectively, of our expenses were denominated inIndian rupees. As a result, we believe that the risk of a significant impact on our operating income from foreign currency fluctuations is not substantial.Item 8.Consolidated Financial Statements and Supplementary DataThe financial statements required by this Item are located beginning on page F-1 of this report.Item 9.Changes in and Disagreements with Accountants on Accounting and Financial DisclosureNone63Item 9A.Controls and ProceduresThis Item 9A includes information concerning the controls and controls evaluation referred to in the certifications of our Chief Executive Officer andChief Financial Officer required by Rule 13a-14 of the Exchange Act included in this Annual Report as Exhibits 31.1 and 31.2.OverviewAs previously disclosed under “Item 9A - Controls and Procedures” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013, orthe 2013 10-K, we concluded that our internal control over financial reporting was not effective as a result of the material weaknesses identified in the 201310-K.During 2014, we spent considerable time and deployed considerable resources performing extensive analytics and substantive procedures andsupporting the audit process to complete the restated financial statements for 2011, as well as the financial statements for the years ended December 31, 2012and 2013, or collectively, the Restatement. In light of these efforts, we were unable to remediate our material weaknesses; however, we continue to investsignificant time and resources and take actions to remediate material weaknesses in our internal control over financial reporting.While our remediation efforts continue, we have relied on and will continue to rely on extensive, temporary manual procedures and other measures asneeded to assist us with meeting the objectives otherwise fulfilled by an effective internal control environment. These procedures include, but are not limitedto:•Significant extension of the timeline for the 2014 financial statement close process, thereby allowing us to conduct additional analysis andsubstantive procedures, including preparation of account reconciliations and making additional adjustments as necessary to verify theaccuracy and completeness of our financial reporting; and•Hiring additional resources and retaining outside consultants with relevant accounting experience, skills and knowledge, working under oursupervision and direction to assist with account closing and the financial statement preparation process for 2014.Notwithstanding the existence of the material weaknesses as described below, we believe that the consolidated financial statements in this AnnualReport fairly present, in all material respects, our financial position, results of operations and cash flows as of the dates, and for the periods, presented, inconformity with GAAP.Management’s Report on Internal Control Over Financial ReportingManagement, under the supervision of our Chief Executive Officer and Chief Financial Officer, is responsible for establishing and maintainingadequate internal control over financial reporting (as defined in Rules 13a-15(f) under the Exchange Act). Internal control over financial reporting isdesigned to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reportingpurposes in accordance with GAAP, and includes those policies and procedures that:•pertain to the maintenance of records that in reasonable detail accurately and fairly reflect our transactions and dispositions of our assets;•provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance withgenerally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations ofour management and directors; and•provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition,64use or disposition of our assets that could have a material effect on our financial statements.Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of anyevaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degreeof compliance with the policies or procedures may deteriorate. A material weakness is a deficiency, or a combination of deficiencies, in internal control overfinancial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be preventedor detected on a timely basis.Our management conducted a process to assess the effectiveness of our internal control over financial reporting as of December 31, 2014, based on thecriteria established in Internal Control - Integrated Framework (1992) issued by the Committee of Sponsoring Organizations of the Treadway Commission, orCOSO. This framework highlights that the control environment sets the tone of the organization, influences the control consciousness of its people, and is thefoundation for all other components of internal control over financial reporting.During the assessment process, we identified material weaknesses in our control environment related to establishing and maintaining accountingpolicies and procedures, process-level controls and accountability for recording complex transactions. The material weaknesses in our control environmentcontributed to material weaknesses at the control-activity level as we did not:•design and maintain adequate procedures or controls over the accurate recording of revenue and related costs of our complex customercontracts and agreements;•maintain adequate review and approval procedures over the recording of certain tangible and intangible assets; or•maintain a sufficient complement of personnel with appropriate levels of accounting knowledge, experience, and training commensurate withthe nature and complexity of our business and contract activity.Because of the pervasive nature of the material weakness related to the control environment, we cannot be sure that all material weaknesses that mayhave existed at December 31, 2014 have been identified.As a result of the material weaknesses described above, management has concluded that, as of December 31, 2014, our internal control over financialreporting was not effective. The “Report of Independent Registered Public Accounting Firm” relating to internal control over financial reporting as ofDecember 31, 2014, is presented on page 68.Evaluation of Disclosure Controls and ProceduresDisclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) are designed to ensure that information requiredto be disclosed by us in reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specifiedin SEC rules and forms and that such information is accumulated and communicated to management including its principal executive officer and principalfinancial officer to allow timely decisions regarding required disclosures.In connection with the preparation of this report, our management, under the supervision and with the participation of the Chief Executive Officer andChief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2014. Based on our identification ofmaterial weaknesses in internal control over financial reporting described above (which we view as an integral part of our disclosure controls), our inability tofile our Annual Reports on Form 10-K for the fiscal year ended December 31, 2014, and our Quarterly Report on Form 10-Q for the quarterly periods in 2014within the statutory time periods, and the evaluation that we have performed, our Chief Executive Officer and Chief Financial Officer concluded that, as of65December 31, 2014, our disclosure controls and procedures were not effective.Remediation of Material Weakness in Internal Control Over Financial ReportingOur management is committed to the planning and implementation of remediation efforts to address all material weaknesses as well as other identifiedareas of risk. These remediation efforts, summarized below, which are implemented, in the process of being implemented or are planned for implementation,are intended to address the identified material weaknesses and to enhance our overall financial control environment.During 2013, 2014 and 2015, numerous changes were made throughout our organization and significant actions have been taken to reinforce theimportance of a strong control environment, including training and other steps designed to strengthen and enhance our control culture.To remediate the control environment deficiencies identified herein, our leadership team, including the Chief Executive Officer, and the ChiefFinancial Officer, has reaffirmed and reemphasized the importance of internal control, control consciousness and a strong control environment. To date we have:•adopted new accounting policies for revenue recognition and software capitalization;•established a contract governance committee to oversee all contracting activity;•appointed experienced professionals to key leadership positions;•established a new reporting structure with more clearly defined accountabilities;•implemented a new internal reporting model and performance metrics based on cash flow performance;•centralized certain accounting functions and revised organizational structures to enhance accurate reporting and ensure appropriateaccountability;•hired additional accounting personnel with appropriate backgrounds and skill sets, including professionals with certified public accountantqualifications, master’s degrees and public accounting experience and creating new positions for a Director of Revenue and a Director ofTaxes;•completed the implementation of a more robust contract governance structure to assure appropriate administration, compliance andaccounting treatment for new or amended contract terms;•established a contracting boundaries protocol to clarify the delegation of contracting authority to personnel involved in establishingcustomer contract terms;•established a formal delegation of authority from the Board of Directors to management with further delegation to accountable personnel;•expanded the use of our financial reporting systems to facilitate more robust analysis of operating performance, budgeting and forecasting;and66•strengthening our current disclosure committee with formalized processes to enhance the transparency of our external financial reporting.Our management believes that meaningful progress has been made against remaining remediation efforts; although timetables vary, managementregards successful completion as an important priority. Remaining remediation activities include:•restructuring key revenue, cost and related reimbursement accounting policies and processes;•establishing additional programs to provide appropriate accounting and controls training to financial, operations and sales staff and corporateexecutives on an ongoing basis;•enhancing our Sarbanes-Oxley compliance procedures; and•executing our financial account closing and the financial statement preparation process in a timely and accurate manner.When fully implemented and operational, our management believes the measures described above will remediate the control deficiencies we haveidentified and strengthen our internal control over financial reporting. We are committed to improving our internal control processes and intend to continueto review and improve our financial reporting controls and procedures. As we continue to evaluate and work to improve our internal control over financialreporting, we may take additional measures to address control deficiencies or determine to modify, or in appropriate circumstances not to complete, certain ofthe remediation measures described above.Changes in Internal Control Over Financial ReportingOther than matters discussed in this Item 9A, there have been no changes in our internal control over financial reporting since our last Annual Reportfiled on Form 10-K for the year ended December 31, 2013 that have materially affected, or are reasonably likely to materially affect, our internal control overfinancial reporting.67Report of Independent Registered Public Accounting FirmThe Board of Directors and Stockholdersof Accretive Health, Inc.We have audited Accretive Health, Inc.’s internal control over financial reporting as of December 31, 2014, based on criteria established in InternalControl-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (1992 framework) (the COSO criteria).Accretive Health, Inc.’s management is responsible for maintaining effective internal control over financial reporting, and for its assessment of theeffectiveness of internal control over financial reporting included in the accompanying Management’s Report on Internal Control over Financial Reporting.Our responsibility is to express an opinion on the company’s internal control over financial reporting based on our audit.We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards requirethat we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in allmaterial respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weaknessexists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures aswe considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financialreporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’sinternal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail,accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded asnecessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of thecompany are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assuranceregarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on thefinancial statements.Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of anyevaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degreeof compliance with the policies or procedures may deteriorate.A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonablepossibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis. Thefollowing material weaknesses have been identified and included in management’s assessment. Management has identified material weaknesses in its controlenvironment related to establishing and maintaining accounting policies and procedures, process-level controls and accountability for recording complextransactions. Management has also identified material weaknesses at the control-activity level as it did not design and maintain adequate procedures orcontrols over the accurate recording of revenue and related costs of its complex customer contracts and agreements, maintain adequate review and approvalprocedures over the recording of certain tangible and intangible assets, and did not maintain a sufficient complement of personnel with appropriate levels ofaccounting knowledge, experience, and training commensurate with the nature and complexity of its business and contract activity. We have audited inaccordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheets of Accretive Health, Inc.as of December 31, 2014 and 2013, and the related consolidated statements of operations and comprehensive income (loss), stockholders’ equity (deficit),and cash flows for each of the three years in the period ended December 31, 2014. These material weaknesses were considered in determining the nature,timing and extent of audit tests applied in our audits of the Company’s68financial statements for the year ended December 31, 2014, and this report does not affect our report dated June 23, 2015, which expressed an unqualifiedopinion on those financial statements.In our opinion, because of the effect of the material weaknesses described above on the achievement of the objectives of the control criteria AccretiveHealth, Inc. has not maintained effective internal control over financial reporting as of December 31, 2014, based on the COSO criteria./s/ Ernst & Young LLPChicago, IllinoisJune 23, 2015Item 9B.Other InformationNone69PART IIIItem 10.Directors, Executive Officers and Corporate GovernanceOur Board of DirectorsSet forth below is information about each member of our board of directors. Messrs. Kaplan, Logan and Wolfson have informed us that they havedecided not to stand for re-election at our 2015 Annual Meeting of Stockholders, or Annual Meeting. Messrs. Kaplan, Logan and Wolfson will continue toserve as directors until the Annual Meeting. The information below includes each director's age, length of service as a director of our company, his or herprincipal occupation and business experience for at least the past five years and the names of other publicly held companies of which he or she serves as adirector. There are no family relationships among any of our directors, nominees for director or executive officers.Class I DirectorsMichael B. Hammond. Age 65. Mr. Hammond has been a member of our board of directors since May 2015. Mr. Hammond is a co-founder of HammondHanlon Camp, a healthcare investment banking and financial advisory firm, and has served as a principal of Hammond Hanlon Camp since September 2011. From 2001 to 2007, Mr. Hammond served as president and chief executive officer of Shattuck Hammond Partners, a health care investment banking firm thathe co-founded in 1993 (now Morgan Keegan Healthcare Investment Banking). From 2007 to September 2011, Mr. Hammond served as managing director ofShattuck Hammond Partners and as a member of the management committee of the Morgan Keegan Investment Banking Division. From 1999 to 2001, Mr.Hammond served as president and chief executive officer of PricewaterhouseCoopers Securities LLC. Prior to co-founding Shattuck Hammond Partners, Mr.Hammond managed the healthcare investment banking businesses at Salomon Brothers and Morgan Stanley, and was a principal at Cain Brothers, Shattuck& Company. Mr. Hammond currently serves as a board member of Precyse Solutions, LLC, a provider of health information management services andtechnologies, and as a member of the Vanderbilt Law School Board of Advisors. Mr. Hammond served for 17 years on the boards of Danbury Health Systemand Hospital. We believe Mr. Hammond’s experience as president and chief executive officer of a large financial advisory firm and a healthcare investmentfirm, together with his experience managing the healthcare investment banking business at a major national investment bank qualifies him to serve on ourboard.Denis J. Nayden. Age 61. Mr. Nayden has been a member of our board of directors since October 2003 and served as co-chairman of our board until July2009. Mr. Nayden has served as a managing partner of Oak Hill Capital Management, LLC, a private equity firm, since 2003. From 2000 to 2002, he waschairman and chief executive officer of GE Capital Corporation, the financing unit of General Electric Company, and prior to that had a 25-year tenure atGeneral Electric. Mr. Nayden was a director of Genpact Limited, a publicly-held global provider of business process services, from January 2005 to October2012, and RSC Holdings Inc., a publicly-held equipment rental provider, from November 2006 to May 2012. He is currently a director of Avolon HoldingsLimited, a publicly held global aircraft leasing company, as well as several privately-held companies. He also serves on the board of trustees of the Universityof Connecticut. We believe Mr. Nayden’s experience as chief executive of several large organizations, his experience in private equity investing and hisexperience as a director of public and private companies qualify him to serve on our board.Emad Rizk, M.D., Age 52. Dr. Rizk has served as our president and chief executive officer and as a member of our board of directors since July 2014.From 2003 to June 2014, Dr. Rizk served as the president of McKesson Health Solutions, a division of McKesson Corporation, a healthcare servicescompany. Prior to joining McKesson Health Solutions, Dr. Rizk served as the lead partner and global director, medical management/pharmacy for DeloitteConsulting from 1994 to 2003. Dr. Rizk currently serves on the boards of directors of Accuray Incorporated, a publicly-held corporation, IntarciaTherapeutics Inc., a bio-pharmaceutical company and the National Alliance for Hispanic Health, a nonprofit organization, and served as vice-chairman of theNational70Clinical Advisory Board, a healthcare organization focused on providing insight into the future direction of healthcare, management and delivery of patientcare, from 1994 to 2000. We believe that Dr. Rizk’s experience as president of a division of a large, publicly-held corporation in the healthcare industry,together with his experience as a director of a publicly-held corporation, qualify him to serve on our board.Steven J. Shulman. Age 64. Mr. Shulman has been a member of our board of directors since April 2013, and was appointed Chairman of the Board ofDirectors effective April 2, 2014. Since 2008, Mr. Shulman has served as business executive at Shulman Family Ventures, a private equity firm. Mr. Shulmanhas served as an operating partner at Water Street Health Partners, a healthcare-focused private equity firm, from 2008 until March 2015. From 2008 untilDecember 2013, Mr. Shulman served as operating partner at Tower Three Partners LLC, a private equity firm. From December 2002 to February 2008, Mr.Shulman served as chairman and chief executive officer of Magellan Health Services, a specialty healthcare management organization. From 2000 to 2002,he served as chairman and chief executive officer of Internet Healthcare Group (IHCG), an early-stage healthcare services and technology venture fund that hefounded. From 1997 to 1999, Mr. Shulman served as chairman, president and chief executive officer of Prudential Healthcare, Inc. Mr. Shulman serves on theboards of several privately-held companies. He also serves on the Dean’s Council at the State University of New York at Stony Brook. We believe that Mr.Shulman’s experience in private equity investment, his experience as an operating partner for a healthcare private equity firm and his experience as chiefexecutive of several large organizations in the healthcare industry, as well as his experience as a director of several privately held companies, qualifies him toserve on our board.Class II DirectorsEdgar Bronfman, Jr. Age 60. Mr. Bronfman has been a member of our board of directors since October 2006. Mr. Bronfman is a Managing Partner ofAccretive LLC, a private equity firm, which he joined in 2002. From early 2004 until January 2012, Mr. Bronfman served as chairman and chief executiveofficer of Warner Music Group, a publicly-held record company. Before joining Warner Music Group in March 2004, Mr. Bronfman served as chairman andchief executive officer of Lexa Partners LLC, a management venture capital group which he founded in April 2002. Mr. Bronfman was vice chairman of theboard of directors of Vivendi Universal, S.A. from December 2000 until December 2003 and also served as an executive officer of Vivendi Universal fromDecember 2000 until December 2001. Prior to the formation of Vivendi, Mr. Bronfman served as president and chief executive officer of The SeagramCompany Ltd. from June 1994 until December 2000 and as president and chief operating officer of Seagram from 1989 until June 1994. Mr. Bronfman is adirector of Warner Music Group and IAC/InterActiveCorp, a publicly-held operator of Internet businesses. Mr. Bronfman is also a member of the board oftrustees of the New York University Medical Center, and a member of the Council on Foreign Relations. We believe Mr. Bronfman’s experience as chiefexecutive of several large organizations, his experience in venture capital and private equity investing and his experience as a director of public and privatecompanies qualify him to serve on our board.APPAC, a minority shareholder group of Vivendi Universal, initiated an inquiry in the Paris Court of Appeal into various issues relating to Vivendi,including Vivendi’s financial disclosures, the appropriateness of executive compensation, and trading in Vivendi stock by certain individuals previouslyassociated with Vivendi. The inquiry has encompassed certain trading by Mr. Bronfman in Vivendi stock. Several individuals, including Mr. Bronfman andthe former CEO, CFO and COO of Vivendi, had been given the status of “mis en examen” in connection with the inquiry. Although there is no equivalent to“mis en examen” in the U.S. system of jurisprudence, it is a preliminary stage of proceedings that does not entail any filing of charges. In January 2009, theParis public prosecutor formally recommended that no charges be filed and that Mr. Bronfman not be referred for trial. On October 22, 2009, the investigatingmagistrate rejected the prosecutor’s recommendation and released an order referring for trial Mr. Bronfman and six other individuals, including the formerCEO, CFO and COO of Vivendi. While the inquiry encompassed various issues, Mr. Bronfman was referred for trial solely with respect to certain trading inVivendi stock. In June 2010, Mr. Bronfman was part of a trial in the Trial Court in Paris at which the public prosecutor and the lead civil claimant both tookthe position that Mr. Bronfman should be acquitted. On January 21, 2011, the court found Mr. Bronfman guilty of the charge relating to his trading inVivendi stock, found him not liable to the civil claimants, and imposed a fine of 5 million euros and a suspended sentence of 15 months. Mr. Bronfmanappealed the Trial Court decision to the Paris Court of Appeal. In November 2013, Mr. Bronfman participated in a re-trial before a new judicial panel as partof his appeal of the Paris Trial Court’s 2011 ruling. In71May 2014, the new judicial panel rendered its decision. The new judicial panel affirmed the Paris Trial Court’s finding that Mr. Bronfman was guilty of thecharge, but stated that its finding would appear only in French judicial records and not Mr. Bronfman’s public record, removed the suspended sentenceimposed by the Paris Trial Court and suspended 2.5 million Euros of the original fine of 5 million Euros. The new judicial panel affirmed the Paris TrialCourt’s finding that Mr. Bronfman was not liable to the civil claimants. Mr. Bronfman has appealed the verdict and believes that his trading in Vivendi stockwas proper. Under French law, the penalty is suspended pending the final outcome of the case.Steven N. Kaplan. Age 55. Mr. Kaplan has been a member of our board of directors since July 2004. Since 1988, Mr. Kaplan has served as a professor atthe University of Chicago Booth School of Business, where he currently is the Neubauer Family Professor of Entrepreneurship and Finance and serves as thefaculty director of the Polsky Center for Entrepreneurship. Mr. Kaplan also serves as a director of Morningstar, Inc., a publicly-held provider of independentinvestment research, and on the boards of trustees of the Columbia Acorn Trust and Wanger Asset Trust. We believe Mr. Kaplan’s experience as a public andprivate company director and his experience in the field of entrepreneurship and management qualifies him to serve on our board.Arthur A. Klein, M.D. Age 67. Dr. Klein has been a member of our board of directors since May 2015. Dr. Klein has served as president of The MountSinai Health Network, executive vice president of Mount Sinai Health System and executive vice president of Icahn School of Medicine since March 2013.From November 2011 to March 2013, Dr. Klein served as western regional executive director of North Shore-LIJ Health System. Dr. Klein joined North-ShoreLIJ in 2009 as senior vice president of Children’s Services and served as executive director of North Shore-LIJ’s Steve and Alexander Cohen Children’sMedical Center of New York from March 2009 to November 2011. Prior to his tenure at North-Shore LIJ, Dr. Klein was senior vice president and chiefphysician officer at Lifespan Corporation, a hospital system in Rhode Island. He was also associate dean for strategy and special projects at the Warren AlpertMedical School of Brown University and also served as executive vice president and chief operating officer at The New York Presbyterian Hospital - WeillMedical College of Cornell University. Dr. Klein is currently a member of the board of trustees of Sackler School of Medicine in Tel Aviv, Israel and theboard of directors of Stamford Hospital in Stamford, Connecticut, and Committee for Hispanic Children and Families, Inc. Dr. Klein also currently serves onthe healthcare executive advisory council of United Healthcare Services, Inc. Dr. Klein has also served for 6 years on the national board of the VoluntaryHospital Association of America, and as the chair of the committee on the health professions of the American Hospital Association. We believe Dr. Klein’sexperience as president of a large healthcare delivery network and as an executive for several other hospital systems qualifies him to serve on our board.Amir Dan Rubin. Age 45. Mr. Rubin has been a member of our board of directors since May 2015. Mr. Rubin has served since January 2011 as presidentand chief executive officer of Stanford Health Care, the academic health system affiliated with Stanford University. From October 2005 to January 2011, Mr.Rubin served as chief operating officer of the UCLA Hospital System, responsible for the operations of the Ronald Reagan UCLA Medical Center, MattelChildren's Hospital at UCLA, the Resnick Neuropsychiatric Hospital at UCLA, Santa Monica-UCLA Medical Center and Orthopedic Hospital, and an array ofoutpatient centers across the west side of Los Angeles. Prior to UCLA, Mr. Rubin served as chief operating officer for Stony Brook University Hospital inLong Island, New York and as assistant vice president of operations for Memorial Hermann Hospital in Houston, Texas. Mr. Rubin currently serves on theboards of Stanford Health Care, Lucile Packard Children’s Hospital and the National Center for Healthcare Leadership. We believe Mr. Rubin’s experience aspresident and chief executive officer and as chief operating officer of large, academic health systems qualifies him to serve on our board.Robert V. Stanek. Age 62. Mr. Stanek has been a member of our board of directors since November 2013. Mr. Stanek has served as an advisor toSafeguard Scientifics, Inc., a publicly traded venture capital firm, since May 2015. Mr. Stanek served as the chief executive officer and a member of the boardof directors of Dabo Health Inc., a healthcare data services company, from December 2014 to April 2015. Mr. Stanek joined the senior management team ofCatholic Health East, a national healthcare system, in 1997 and served as its president and chief executive officer from 2003 until 2010. From 1992 to 1997,Mr. Stanek served in a variety of roles with the Mercy Health System of Western New York, including as its president and chief executive officer. Mr. Stanekwas elected to the board of trustees of the Catholic Health Association of the United States in 2006, served as its chairman from June722011 through June 2012 and served as Speaker of the Assembly from June 2012 through June 2013. Mr. Stanek is currently a member of the board ofdirectors of Accumen, Inc. We believe that Mr. Stanek’s experience as president and chief executive officer and as a member of the board of trustees of a large,national hospital system qualifies him to serve on our board.Class III DirectorsCharles J. Ditkoff. Age 53. Mr. Ditkoff has been a member of our board of directors since May 2015. Mr. Ditkoff has been counsel at the law firm ofMcDermott Will & Emery since July 2012 and has served as chairman of the Healthcare Advisory Board of The Vistria Group, a private equity firm focusingon healthcare, education and financial services, since January 2014, a member of the advisory board of Opera Solutions, a data analytics company, sinceSeptember 2013, a senior advisor to Alvarez & Marsal, a global turnaround management and professional services firm, since July 2012, and a senior advisorto the Marwood Group, a healthcare focused advisory and consulting firm, since July 2012. Mr. Ditkoff served as vice chairman of Healthcare Corporate andInvestment Banking from May 2010 to July 2012, group head of Global Healthcare Group from 2005 to 2009 and managing director, head of healthcareservices from 1999 to 2004 at Bank of America Merrill Lynch. Previously, he was principal/vice president of the corporate finance group at Morgan Stanley.Mr. Ditkoff is currently a member of the board of directors of Quantia Inc., and Cumberland Consulting Group. We believe Mr. Ditkoff’s experience leadingthe healthcare division of a large investment bank, as well as his experience as an advisor or director to several healthcare and financial organizations qualifyhim to serve on our board.Lawrence B. Leisure. Age 64. Mr. Leisure has been a member of our board of directors since May 2015. Mr. Leisure has served as a managing director ofChicago Pacific Founders, a private equity firm focusing on senior living and healthcare delivery services, since April, 2014, chairman of ADVI Health, LLC,a healthcare advisory firm, since June 2013, a senior advisor for Kleiner Perkins Caufield & Byers, a venture capital firm, since January, 2014 and chairman ofHealthspottr Media, LLC, a health innovation and collaboration organization, since 2009. Mr. Leisure previously served as an operating partner with KleinerPerkins Caufield & Byers from January 2011 to January 2014 and founded and served as managing partner of AccelusHealth Partners, LLC, (a healthcareadvisory firm) from January 2010 to June 2013. From 2009 to January 2010, Mr. Leisure served as senior vice president, Ingenix Consulting of UnitedHealthGroup, a health information technology and services company. Mr. Leisure is currently a member of the board of directors of Recovery Ways, LLC andLumiata, Inc. We believe Mr. Leisure’s experience as senior adviser or managing partner of various private equity firms and healthcare advisory firmsqualifies him to serve on our board.Stanley N. Logan. Age 60. Mr. Logan has been a member of our board of directors since April 2011. Mr. Logan has served as president and chiefoperating officer of XSell Technologies Inc., a technology managed services company, since January 2015. From November 2013 to December 2014,Mr. Logan was an independent advisor who consulted with businesses on financial and operational matters. Mr. Logan was a partner and chief operatingofficer of Sikich LLP, a management consulting firm, from February 2012 to October 2013. Previously, Mr. Logan served as a managing director in theforensic accounting practice of LECG Corporation, a global business advisory services consulting firm, from February 2010 until March 2011. From 2006until 2009, Mr. Logan served as a vice president of Huron Consulting Group, a consulting firm. From 2003 to 2006, Mr. Logan was managing partner ofKPMG LLP’s Chicago office and he was national sector leader for consumer products at KPMG in 2002. From 1980 to 2002, Mr. Logan held variouspositions at Arthur Andersen LLP, including audit partner, manager and senior accountant. Mr. Logan was a certified public accountant. From 2007 to July2014, he served on the board of directors of Schawk, Inc. and was also a member of Schawk’s audit committee. From 2003 until 2007, Mr. Logan served onthe boards of directors of The Field Museum, where he served as a member of its finance committee, and Ravinia Festival Association, where he served as amember of its audit committee. We believe that Mr. Logan’s extensive financial and accounting experience qualifies him to serve on our board.Alex J. Mandl. Age 71. Mr. Mandl has been a member of our board of directors since November 2013. Mr. Mandl is currently the non-executivechairman of Gemalto N.V., a digital security company resulting from the merger of Axalto Holding N.V. and Gemplus International S.A. From June 2006 untilDecember 2007, Mr. Mandl served as executive chairman of Gemalto. From 2002 to June 2006, Mr. Mandl was president, chief executive officer73and a member of the board of directors of Gemplus. He has served as principal of ASM Investments, a company focusing on early stage funding in thetechnology sector, since 2001. From 1996 to 2001, Mr. Mandl was chairman and CEO of Teligent, Inc., a telecommunications company. Mr. Mandl wasAT&T’s president and chief operating officer from 1994 to 1996, and its executive vice president and chief financial officer from 1991 to 1993. From 1988 to1991, Mr. Mandl was chairman and chief executive officer of Sea-Land Services Inc. Mr. Mandl served as a director of Dell Inc. from 1997 to October 2013.Mr. Mandl served from 2007 to 2010 as a director of Hewitt Associates, Inc. and from March 2008 to October 2010 as a director of Visteon Corporation.Mr. Mandl was a member of the board of directors of Horizon Lines, Inc. from January 2007 and became the Chairman in February 2011, retiring in April2012. Mr. Mandl is currently a member of the board of directors of Gemalto N.V., Arise Virtual Solutions Inc., Levant Power Corp. and Genpact Limited. Webelieve that Mr. Mandl’s experience as chief executive officer of several large organizations, as well as his experience as a director of private and publicly-held corporations qualify him to serve on our board.Mark A. Wolfson. Age 62. Mr. Wolfson has been a member of our board of directors since October 2003. Mr. Wolfson is a senior advisor of Oak HillCapital Management, LLC, a private equity firm, and is a founder and managing partner of Jasper Ridge Partners, L.P. (formerly known as Oak HillInvestment Management, L.P.). Mr. Wolfson has been on the faculty of the Stanford University Graduate School of Business since 1977, has served as itsassociate dean, and has held the title of consulting professor since 2001. He has been a research associate of the National Bureau of Economic Research since1988 and serves on the executive committee of the Stanford Institute for Economic Policy Research. From 1999 to 2013, Mr. Wolfson served as a director ofeGain Communications Corporation, a publicly-held provider of multi-channel customer service and knowledge management software and from 1999 to2012, Mr. Wolfson served as a director of Financial Engines, Inc., a publicly-held provider of portfolio management and retirement services and investmentadvice; and several privately-held companies. He is also an advisor to the investment committee of the William and Flora Hewlett Foundation. We believeMr. Wolfson’s experience as a public and private company director and his experience in the fields of economics and management qualifies him to serve onour board.Our Executive OfficersOur executive officers and their respective ages and positions, are described below. Our officers serve until they resign or the board terminates theirposition. There are no family relationships among any of our directors, nominees for director and executive officers.Emad Rizk, M.D., Age 52. President and Chief Executive Officer. For more information, see “Our Board of Directors” above.Peter Csapo. Age 44. Chief Financial Officer and Treasurer. Mr. Csapo has served as our chief financial officer since August 2014. From August 2011through September 2013, Mr. Csapo served as the chief financial officer and area senior vice president of VHA Inc., a national network of not-for-profithealthcare organizations that work together to improve performance and efficiency in clinical, financial and operational management. From October 2004through January 2011, Mr. Csapo was chief financial officer at McKesson Health Solutions, a division of McKesson Corporation, a healthcare servicescompany. In addition to his role as Chief Financial Officer, Mr. Csapo also held various operating roles at McKesson Health Solutions from 2004 through2011, including vice president of healthcare informatics from February 2007 through January 2010, and vice president of customer operations from February2010 through January 2011. McKesson Health Solutions focuses on aligning providers and payers through cost and quality initiatives such as caremanagement services and medical management and payment solutions software. From February 2011 through July 2011, and from October 2013 throughJuly 2014, Mr. Csapo focused on personal investments and various community activities.Joseph G. Flanagan, Age 44, Chief Operating Officer. Mr. Flanagan has served as our chief operating officer since April 2013. From February 2010 toApril 2013, Mr. Flanagan served as senior vice president of Worldwide Operations at Applied Materials, Inc., which provides manufacturing solutions for thesemiconductor, flat panel display and solar photovoltaic industries. From April 2006 to February 2010, Mr. Flanagan served in various capacities at NortelNetworks, a telecommunication company, including, from March 2009 to February 2010, as74president of Nortel Business Services and senior vice president of Global Operations. Mr. Flanagan served most of his career at General Electric where he mostrecently was general manager of the organization’s Power Controls Division from February 2005 to April 2006. Prior to that, from June 1993 to February2005, Mr. Flanagan held a number of positions including general manager, operations, GE Consumer and Industrial EMEA; general manager, mergers andacquisitions, GE Digital Energy; and general manager, Industrial Controls.Section 16(a) Beneficial Ownership Reporting ComplianceSection 16(a) of the Exchange Act requires our directors, executive officers and the holders of more than 10% of our common stock to file with the SECinitial reports of ownership of our common stock and other equity securities on a Form 3 and reports of changes in such ownership on a Form 4 or Form 5.Officers, directors and 10% stockholders are required by SEC regulations to furnish us with copies of all Section 16(a) forms they file. To our knowledge,based solely on a review of our records and written representations by the persons required to file these reports, during the year ended December 31, 2014, thereporting persons complied with all Section 16(a) filing requirements.Code of Business Conduct and EthicsOur board of directors has adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including ourprincipal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A copy of the codeof business conduct and ethics is posted on the Investor Relations section of our website. In addition, we intend to post on our website all disclosures that arerequired by law or NYSE listing standards concerning any amendments to, or waivers of, our code.Audit CommitteeOur board of directors has established a standing audit committee. Our audit committee assists our board of directors in its oversight of our accountingand financial reporting process and the audits of our financial statements. The current members of our audit committee are Messrs. Logan (chair), Mandl,Kaplan and Wolfson. Our board of directors has determined that each of the members of our audit committee satisfies the requirements for financial literacyunder the current requirements of NYSE rules and regulations. Our board of directors has further determined that each of Mr. Logan and Mr. Mandl is an“audit committee financial expert” as such term is defined in Item 407(d)(5) of Regulation S-K. Messrs. Logan, Kaplan and Wolfson have notified theCompany that they have decided not to stand for re-election at the Annual Meeting. If re-elected as a Class III director at the Annual Meeting, Mr. Mandl willassume the role of chairman of the audit committee immediately following the Annual Meeting. Our board of directors intends to appoint additional membersto the audit committee so that the audit committee consists of at least three members, each of whom satisfies the independence requirements contemplated byRule 10A-3 under the Exchange Act and one of whom is an “audit committee financial expert” as such term is defined in Item 407(d)(5) of Regulation S-K.75Item 11.Executive CompensationCOMPENSATION DISCUSSION AND ANALYSISThis Compensation Discussion and Analysis, or CD&A, provides information about our executive compensation philosophy and the components ofour compensation programs, including information about how we align the compensation for our named executive officers, or NEOs, with our goals andperformance. The CD&A is intended to help readers better understand the information found in the tables and narrative that follow.Compensation Objectives and PhilosophyOur executive compensation program aims to attract and retain highly talented executives by providing competitive pay and benefits and to reward ourexecutives for performance that aligns with our operating and strategic goals, with the ultimate objective of increasing stockholder value. The structure of ourexecutive compensation program enables us to provide a competitive total compensation package that ties a portion of each executive’s overallcompensation to key corporate financial goals and significant accomplishments.At least 85% of target total direct executive compensation is in the form of short-term and long-term financial incentives. Both the short-term and long-term incentives are intended to align executives with stockholder interests and the successful execution of long-term strategic plans.We attract and retain executives by providing a market competitive compensation program consisting of base salary, annual bonus and long-termincentives, coupled with benefits to support health, wellness and other life events. The box below highlights the key considerations behind the development,review and approval of our named executive officers’ compensation.ObjectivesOur named executive officer compensation program is designed to:Ÿ Align the interests of our executives with those of our stockholdersŸ Pay for performance by rewarding the achievement of our annual and long-term operating and strategic goalsŸ Recognize individual contributionsŸ Attract, retain and motivate highly talented individuals who have the breadth and depth of experience to successfully execute our business strategyIn 2014, we continued our focus on restructuring and enhancing our leadership team in an effort to more effectively and efficiently allocate our resources forinnovation, growth and improved customer service. This CD&A focuses on the current and former executive officers who served during all or part of 2014:Dr. Emad Rizk, President and Chief Executive Officer - Dr. Rizk joined Accretive Health as President and Chief Executive Officer in July 2014.Peter Csapo, Chief Financial Officer and Treasurer - Mr. Csapo joined Accretive Health as Chief Financial Officer and Treasurer in August 2014.Joseph Flanagan, Chief Operating Officer - Mr. Flanagan joined Accretive Health as Chief Operating Officer in April 2013.Stephen Schuckenbrock, former President and Chief Executive Officer - Mr. Schuckenbrock joined Accretive Health as President and Chief ExecutiveOfficer in April 2013 and resigned from this role in July 2014, when he became an advisor to the new Chief Executive Officer, Dr. Rizk. In October 2014,Mr. Schuckenbrock resigned as an employee of Accretive Health and in May 2015, resigned as a director of Accretive Health.Sean Orr, former Senior Vice President, Finance and former Chief Financial Officer and Treasurer - Mr. Orr joined Accretive Health in August 2013 asChief Financial Officer and Treasurer and left this position in August 2014, assuming the position of Senior Vice President, Finance. In December 2014,Mr. Orr resigned as an employee of Accretive Health.76 2014 PerformanceCompany AchievementsThroughout 2014, we used various elements of our executive compensation program to help focus our named executive officers on restructuring,profitability and current and future growth. During this period, our executives have achieved important goals, including:•Implementing various actions to strengthen our foundation, which has improved organizational effectiveness, reduced costs and created a structure to drivecustomer focus and field engagement.•Completing our financial restatement.•Making meaningful progress towards remediating our control environment deficiencies by:◦Adopting new accounting policies for revenue recognition and software capitalization;◦Appointing experienced professionals to key leadership positions;◦Establishing a new reporting structure with more clearly defined accountabilities; and◦Implementing a new internal reporting model and performance metrics based on cash flow performance.•Developing a comprehensive plan to complete the remaining control environment deficiency remediation activities.•Stabilizing and upgrading technology infrastructure to prepare for scalable growth.•Taking steps to position us to capture growth opportunities within the U.S. healthcare marketplace, including:◦Increasing investment in IT - We have invested over one-third of our 2014 information technology budget in technologies to enable us to moreseamlessly integrate with customers’ existing technologies.◦Simplifying the measurement model - We have made progress in simplifying our model to measure results for customers.◦Improving the consistency of results for customers - We have developed a more rigorous and systematic approach to gather and apply the insightswe gain from daily operations across the entire customer base.Linking Pay with PerformanceWhile we have made significant progress in strengthening our foundation, 2014 continued to be a challenging period during which we have fallen short ofour financial targets.Therefore, as a result of our performance in 2014, neither Mr. Schuckenbrock nor Mr. Orr received long-term incentive grants for 2014; however, newly-hirednamed executive officers received long-term incentives as part of their initial compensation package, and Mr. Flanagan received long-term incentives toencourage retention.Executive compensation for 2014 was consistent with our compensation objectives and reflects our operating performance, demonstrating our commitmentto pay our executives for the performance they deliver.Overview of 2014 Compensation Decisions and ActionsFactors Guiding Our DecisionsThe following factors guided the executive compensation decisions for 2014:•Executive compensation program objectives•Operating performance•Recommendations of the Chief Executive Officer for other named executive officers•Advice of an independent compensation consultant•Competitive market practices77•The need to attract critical, top tier talent at a challenging time for our companyKey 2014 Executive Compensation DecisionsWe have faced significant business challenges since 2012, which have informed our executive compensation decision making. The compensationdecisions made during 2014, as outlined below, demonstrate our commitment to recruit and retain the high caliber executives required to address ourcompany’s challenges, and provide incentives tied to improved financial and stock performance.2014 was a year of transition as new, highly experienced leadership members were recruited and hired to replace certain key executives, including ourChief Executive Officer. Therefore, the decisions below reflect the compensation decisions made for both the outgoing named executive officers as well asthose newly hired.Base SalaryNo increases were made to the base salary of any named executive officers in 2014. Salaries for the newly-hired named executive officers weredetermined based on competitive compensation data for similar positions and the need to attract leaders with the experience to meet our current businesschallenges. Starting base salaries for Dr. Rizk and Mr. Csapo are $750,000 and $470,000, respectively.Annual Cash Incentive BonusBased on our performance during 2014, including significant accomplishments critical to the continued viability of the company, the CompensationCommittee determined that bonus payouts would be 112% of target for Dr. Rizk, 100% of target for Messrs. Csapo and Flanagan and 65% of target for Mr.Orr and that Mr. Schuckenbrock, who resigned as our Chief Executive Officer in July 2014, would not receive a bonus. Bonus targets for Dr. Rizk and Mr.Csapo were prorated based on their dates of hire in 2014.Dr. Rizk received a bonus higher than target because of his significant accomplishments in the first six months in his role, including addingexperienced healthcare executives to the leadership team, overseeing the completion of key operational changes to support our strategic growth, and leadingthe completion of our financial restatement.Note: For 2014, the Annual Cash Incentive Bonus will be paid out to our current named executive officers and all other direct reports of the ChiefExecutive Officer in restricted stock that vests 1/12 per month over a one-year period, commencing on April 10, 2015, rather than in cash. The number ofshares of restricted stock that will be awarded to each individual will equal the amount of the cash incentive bonus to be paid in restricted stock to suchindividual, divided by the closing trading price of a share of our common stock on the date of grant, which we expect to be in mid-year 2015. This decisionwas reached primarily to promote retention, and we believe that delivering the 2014 annual bonus through equity adds an additional level of pay-for-performance since its actual value is based on the stock price at the time the executive sells vested shares.Vice presidents and senior vice presidents (other than the Chief Executive Officer’s direct reports) received half of their award in cash and will receivehalf in restricted stock, while similar to other years, bonus-eligible employees below the vice president level received their award in cash.Executives who will receive all or a portion of their 2014 annual bonus in restricted stock will also be awarded additional restricted stock, equal to20% of the non-cash portion of the annual bonus amount, which will also vest 1/12 per month over a one-year period, commencing on April 10, 2015, tooffset the fact that the restricted stock will be provided in lieu of cash, will not be granted until mid-year 2015 and has vesting restrictions as noted above.78Long-Term IncentivesAs part of their offers of employment to join Accretive Health, Dr. Rizk and Mr. Csapo each received long-term incentive grants in the form of stockoptions and restricted shares to provide a significant amount of their total compensation packages as variable pay. These grants are intended to create animmediate alignment between their interests and those of our stockholders, and to provide a powerful incentive to increase the value of our organization andthus our stock price. Dr. Rizk received a stock option grant with a grant date fair value of $12,150,000, a time-based restricted stock award grant with a grantdate fair value of $4,490,000 and a performance-based restricted stock grant with a grant date fair value of $3,620,000; Mr. Csapo received a stock optiongrant with a grant date fair value of $1,221,000 and a restricted stock award with a grant date fair value of $1,630,000.Flanagan Retention AgreementAs an important incentive for Mr. Flanagan to remain with us during a critical juncture in our Chief Executive Officer transition process, we enteredinto an amendment to our employment agreement with Mr. Flanagan in April 2014. This arrangement provided for cash and equity compensation elements.The material terms of this agreement are described under "Employment Agreements - Agreement with Mr. Joseph Flanagan" in this Compensation Discussionand Analysis.Pay-for-Performance FocusAligning Pay with PerformancePay-for-performance is one of the objectives of our executive compensation philosophy. Named executive officers can earn target compensation onlyto the extent we achieve our corporate goals. Additionally, their actual annual incentive award takes into account their individual performance in supportingseveral key business objectives. Our incentive compensation program for named executive officers is designed to link total compensation with theachievement of our business goals, some of which are short-term, while others may take several years to achieve. Annual Cash Incentive BonusStock OptionsRestricted Stock Awards Short-Term (Cash)Note: For 2014, the Annual Cash Incentive Bonusfor our current named executive officers will bepaid out in restricted stock that vests 1/12 permonth over a one-year period, commencing onApril 10, 2015, rather than in cash. The restrictedstock will not be granted until mid-year 2015.Long-Term (Equity)Long-Term (Equity)ObjectiveShort-term business performanceStockholder value creationStockholder value creationTime Horizon1 YearGenerally vest over 4 yearsSubject to continued employment with thecompany, exercisable for up to 10 yearsGenerally vest over 4 yearsMetricsSpecific tactical, strategic and financialbusiness objectivesand Individual performanceStock priceStock price¹1As part of Dr. Rizk’s offer of employment, he received half of his restricted stock with performance-based vesting.Our executive compensation decisions in recent years have been affected by our efforts to build a leadership team that will help ensure our companyperforms at its highest level. This focus, however, has not changed our strong emphasis on pay-for-performance. While we require competitive compensationpackages to attract new79leaders who will help Accretive Health perform well both internally and externally, we follow a compensation strategy that heavily emphasizes performance.For our Chief Executive Officer, this means that a majority of his compensation is in the form of incentive compensation, and the majority of this isfocused on delivering long-term performance.During the leadership transitions we have experienced in recent years, we have made decisions to ensure that the majority of long-term incentives arefocused on increasing value to our stockholders as well as our company’s future, leveraging our plans to build stockholder value. By making the greatestportion of our Chief Executive Officer’s compensation package in the form of performance-based pay, with value directly tied to the increase in value of ourorganization and thus our stock price, we aim to ensure that our executive compensation packages are strongly focused on pay-for-performance, not merelyattraction and retention.The chart below shows the breakdown of Dr. Rizk’s 2014 compensation package, highlighting the emphasis on long-term incentives.Consideration of “Say-on-Pay” VoteOur stockholders approved the non-binding advisory proposal on the compensation of our named executive officers with a 99.8% favorable vote at ourannual meeting of stockholders held in 2011, our most recent annual meeting at which such a vote was taken. Based on this approval from stockholders, andin light of the financial restatement activity, the Compensation Committee determined that no changes to our executive compensation program werewarranted as a result of the stockholder advisory vote.Also, at our 2011 annual meeting of stockholders, our stockholders voted to adopt the recommendation of our Board of Directors to conduct futureadvisory votes on the compensation of our named executive officers every three years. Accordingly, the next stockholder advisory vote on the compensationof our named executive officers is being held at the Annual Meeting.80Determining Executive CompensationIn determining compensation changes for named executive officers from year to year, the Compensation Committee generally focuses on total directexecutive compensation, which consists of base salary, annual cash incentive bonus and long-term equity incentive awards.Factors Guiding DecisionsŸExecutive compensation program objectivesŸCompany financial performance and important achievementsŸAssessment of leaders’ adherence to company values, their leadership traits and achievement of individual objectivesŸRecommendations of the Chief Executive Officer for other named executive officersŸStockholder input through the “say-on-pay” voteŸAdvice of an independent compensation consultant on market and peer group pay practices Role of Compensation CommitteeOur Compensation Committee oversees our executive compensation program and has done so historically. In this role, the Compensation Committeehas reviewed all compensation decisions relating to our named executive officers and has made recommendations to the Board of Directors. OurCompensation Committee has the authority, without approval of the Board of Directors, to retain and terminate an independent compensation consultant toassist in the evaluation of executive officer compensation.Our Board of Directors has determined that each of the members of our Compensation Committee is independent as defined under the rules of the NewYork Stock Exchange. Our Compensation Committee periodically works with an independent compensation consulting firm, Towers Watson, as described in“Role of the Compensation Consultant” below.Role of Chief Executive OfficerOur Chief Executive Officer annually reviews the performance of each of our other executive officers and, based on these reviews, providesrecommendations to the Compensation Committee and the Board of Directors with respect to salary adjustments, annual cash incentive bonus targets andawards, and equity incentive awards.Our Compensation Committee meets with our Chief Executive Officer annually to discuss and review the Chief Executive Officer’s recommendationsregarding executive compensation for our executive officers, excluding the Chief Executive Officer. These recommendations are forwarded to the Board ofDirectors, which typically meets in executive session to discuss those recommendations before the Compensation Committee makes final decisions regardingour executive officers’ compensation. Our Chief Executive Officer is not present for discussions regarding the Chief Executive Officer’s compensation.Our Chief Executive Officer is authorized by the Compensation Committee to grant options to employees who are not directors or executive officers ofour company and determine the number of shares covered by, and the timing of, option grants. The Board of Directors has, and it exercises, either directly orthrough its delegation of authority to the Compensation Committee, the ability to materially increase or decrease amounts of compensation payable to ourexecutive officers pursuant to recommendations made by our Chief Executive Officer.Role of the Compensation ConsultantThe Compensation Committee engages an independent compensation consulting firm from time to time to provide advice regarding our executivecompensation program and general information regarding executive compensation practices in our industry. At the Compensation Committee’s request, theindependent compensation consulting firm, Towers Watson, advised the Compensation Committee in 2014 and provided advice on some, but not all,executive compensation actions and decisions. The Compensation Committee and Board of Directors81considered Towers Watson’s advice regarding our executive compensation program and then, ultimately, made their own decisions about these matters.Executive Compensation Peer GroupThe executive compensation peer group is a select group of companies that our Compensation Committee believes are representative of the talentmarket in which we compete. In 2014, the Compensation Committee considered compensation data from this peer group as one of several inputs to helpshape our executive compensation program to make sure we continue to provide total compensation that is competitively positioned in the marketplace. TheCompensation Committee has approved the following set of peer companies, which were selected in 2013 based on the following criteria:•Similar revenues and complexity of business model;•In the technology, business process outsourcing or healthcare services industries; and•Publicly traded in the United States.Our peer group for 2014 consists of the following companies:2014 Executive Compensation Peer GroupAllscripts Healthcare SolutionsathenahealthCatamaranCernerCognizant Technology SolutionsGenpactGlobal PaymentsHuron Consulting GroupMAXIMUSMedAssetsQuality Systemssalesforce.comWNS HoldingsWhile the Board of Directors and Compensation Committee consider peer group data in determining the competitiveness of our executivecompensation, it is only one factor taken into consideration when determining the total compensation for our named executive officers. The Board ofDirectors and Compensation Committee also consider the other factors listed in “Factors Guiding Decisions” above.Risk Considerations in our Executive Compensation ProgramWe provide a mix of executive compensation elements, and design such elements, in order to discourage management from assuming excessive risk.We believe that risks arising from our compensation policies and practices for our employees are not reasonably likely to have a material adverse effect onour business. In addition, the Compensation Committee believes that the mix and design of the components of executive compensation do not encouragemanagement to assume excessive risks.82Elements of the Executive Compensation ProgramThe following table describes how elements of compensation are intended to satisfy our executive compensation objectives. PurposeType of CompensationLink to Program ObjectivesBase SalaryFixed level of cashcompensation toattract and retain keytalent in a competitivemarketplaceCash●Determined based on evaluationof individual’s experience,position, current performance,internal pay equity, peer groupcompensation data and externalmarket competitive dataAnnual CashIncentiveBonusTarget incentiveopportunity (set as apercentage of basesalary) that encouragesexecutives to achieveannual companyoperating plan goalsCashNote: For 2014, the Annual CashIncentive Bonus for our currentnamed executive officers will be paidout in restricted stock that vests 1/12per month over a one-year period,commencing on April 10, 2015, ratherthan in cash.●Provides compensation based onachievement of our operating plangoals, as well as individualperformance against specificcorporate objectives ●No minimum guaranteed payoutLong-TermEquityIncentiveAwardsHelps ensure executivecompensation isdirectly linked to theachievement of ourlong-term objectivesLong-TermEquity●Provides our named executiveofficers with a strong link to ourlong-term performance byenhancing their accountability forlong-term decision makingCreates an ownershipculture by aligning theinterests of our namedexecutive officers withthe creation of valuefor our stockholdersFurthers our goal ofexecutive retention●Delivered through stock optionsand/or restricted stock awards●Time-based awards generally vestratably over a four-year period;Performance-based awards vest atthe end of an applicableperformance period based on theachievement of performance goalsBenefitsImportant element of atotal rewards programand helps attract andretain executive talentBenefit●Same broad-based benefits thatare provided to all employees,including our 401(k) retirementplan, a medical care plan,vacation, short- and long-termdisability coverage and standardcompany holidays●Our named executive officers donot receive a matching 401(k)contribution from AccretiveHealthChange ofControlBenefitsAttracts and retainsemployees in acompetitive marketBenefit●Combination of “single trigger”and “double trigger” vesting,along with severanceEmploymentAgreementsEnsures continueddedication ofemployees in case ofpersonal uncertaintiesor risk of job lossProvidesconfidentiality andnon-competeprotectionsBenefit●Specific for the individual83Analysis of 2014 Compensation DecisionsBase SalaryBase salary represents 25% or less of the target pay opportunity for our Chief Executive Officer’s and other named executive officers. We usecompetitive base salaries to attract and retain qualified talent to help us achieve our growth and performance goals. Base salaries take into account a namedexecutive officer’s experience, knowledge and responsibilities. The independent compensation consultant periodically provides the CompensationCommittee with analyses of competitive salary ranges for the named executive officer positions, based in part on peer group compensation data.Base Salary AdjustmentsFrom time to time, at their discretion, our Compensation Committee and Board evaluate and adjust named executive officers’ base salary levels basedon factors determined to be relevant, including:•Executive officer’s skills and experience•Particular importance of the executive officer’s position to us•Executive officer’s individual performance•Executive officer’s growth in his or her position•Market level increases•Base salaries for comparable positions within our company•Inflation rates2014 Base Salary DecisionsIn February 2014, our Compensation Committee elected not to increase base salaries for any named executive officers.Salaries for the new executive team members, including named executive officers Dr. Rizk and Mr. Csapo, were determined based on competitivemarket data for similar positions and the need to attract leaders with the experience to meet our current business challenges. Individual negotiations duringthe recruiting and hiring process were a substantial factor in determining base salaries, which reflected the significant business challenges facing ourcompany at the time. Base Salary (Annualized) 2013 Salary 2014 Salary Percent ChangeEmad RizkN/A $750,000 N/APeter CsapoN/A $470,000 N/AJoseph Flanagan$595,000 $595,000 0%Stephen Schuckenbrock1$595,000 $595,000 0%Sean Orr2$450,000 $450,000 0%1 Mr. Schuckenbrock resigned as an employee in October 2014 and as a member of ourBoard of Directors in May 2015.2 Mr. Orr resigned as Chief Financial Officer in August 2014 and as an employee in December 2014.84Annual Cash Incentive BonusWe maintain an annual cash incentive bonus program in which each of our named executive officers participates. These annual cash incentive bonusesare intended to compensate our named executive officers for achievement of corporate goals, as well as individual performance in the areas of:•Economic and financial contributions•Operations•Customer satisfaction•Business development•Organizational and leadership developmentDriving PerformanceThe annual cash incentive bonus program rewards our named executive officers for their individual and collective contributions towards our corporateobjectives including:•Building operational excellence across sites•Driving operational efficiencies and reducing cost•Creating a sustainable infrastructure to serve customers•Ensuring 100% of sites have specific action plans to support Net Promoter Score (NPS) improvements•Implementing best practices across multiple hospitals focused on patient satisfaction•Driving significant improvement in shared services capabilitiesAnnual Cash Incentive Bonus Design•Our annual cash incentive bonus awards have varied significantly from year to year, and we expect that they will continue to vary, depending onactual corporate and individual performance results.•At the beginning of each year, our Board of Directors establishes our corporate financial and operational goals and through the CompensationCommittee, individual incentive bonus targets for our executive officers. The goals established by the Board of Directors are based on ourhistorical operating results and growth rates, as well as our expected future results, and are designed to require significant effort and operationalsuccess on the part of our named executive officers and Accretive Health. However, during the course of the year, the Board of Directors and ourCompensation Committee may (based in part on recommendations of our Chief Executive Officer, with respect to our other named executiveofficers) adjust such goals as they deem appropriate.•In addition to corporate goals, each named executive officer is also responsible for setting individual performance goals at the beginning of eachyear. The goals are based on the executive’s role and responsibilities and are designed to help drive our success.•Each named executive officer’s initial target annual bonus is established upon commencement of employment as part of the executive’s overallcompensation package. The target annual bonus amount is then reviewed and may be adjusted in each subsequent year, if appropriate, based onexternal market data to ensure that the values reflect external competitiveness and internal equity. The Compensation Committee’s independentcompensation consultant, using the same approach as described for annual base salary, periodically reviews the competitive range for annual cashincentive pay for our Chief Executive Officer and each other named executive officer (which is set as a percentage of annual base salary) andprovides such data to the Compensation Committee, which determines annual bonus targets.•If growth and performance expectations for corporate and individual performance are exceeded, bonuses above target can be awarded. If they arenot met, then bonuses below target, or no bonuses at all, may be awarded. Prior years’ performance and corresponding bonus award levels areconsidered when setting bonus targets. We believe this helps to calibrate incentive compensation with our performance.85•The Compensation Committee approves actual annual cash incentive bonus payouts, which are based on input from our Chief Executive Officerin the case of named executive officers other than the Chief Executive Officer. There are no minimum or maximum payout levels, and ourCompensation Committee has broad discretion to make adjustments to the awards. Note: For 2014, the Annual Cash Incentive Bonus will be paid out to our current named executive officers in restricted stock that vests 1/12 per month overa one-year period, commencing on April 10, 2015, rather than in cash. The number of shares of restricted stock that will be awarded to each individual willequal the amount of the cash incentive bonus to be paid in restricted stock to such individual, divided by the closing trading price of a share of our commonstock on the date of grant, which we expect to be in mid-year 2015. Additional restricted stock, equal to 20% of the non-cash bonus amount, which will alsovest 1/12 per month over a one-year period, commencing on April 10, 2015, will be awarded to offset the fact that restricted stock will be provided in lieu ofcash, will not be granted until mid-year 2015 and has vesting restrictions as noted above.2014 Annual Cash Incentive Target Bonus DecisionsFor 2014, the Compensation Committee based annual cash incentive bonus decisions on both achievement of individual goals, as well as progresstowards the following corporate goals. These goals were designed to help us build critical infrastructure and consistent operational execution capability tosupport sustainable growth in the future. GoalOperations andTechnologyŸ Build and deliver multi-year profitability roadmapŸ Achieve significant improvement in customer satisfaction as measured by Net Promoter ScoreŸ Launch upgraded claims-denial reduction programŸ Deliver reduction in customers’ operations costs as measured by growth in Net Operating FeesŸ Achieve improvements in shared service center penetration rate and capabilitiesŸ Develop integrated operations and technology scorecard metrics for 2014FinancialŸ Deliver financial commitments as measured by the 2014 budget (using an internal definitionof Adjusted EBITDA that does not reflect changes to our revenue recognition policiesresulting from our restatement)ControlsŸ Achieve key elements of internal control remediation planStrategy/GrowthŸ Integrate physician advisory service into RCM serviceŸ Increase operating focus on value based reimbursementŸ Achieve qualitative and quantitative improvement in salesPeople andCustomersŸ Roll out company-wide talent management process, including specific focus on site talent andsuccessionŸ Continue to build critical skills with focus on customer-facing roles and salesŸ Review organizational structures to help ensure proper alignmentBased on our 2014 performance results, the Compensation Committee approved a company-wide bonus pool equal to 85% of the target amount and, inFebruary 2015, approved bonus awards to our named executive officers that ranged from 0% to 112% of target amounts.Basis for 85% Bonus Pool Funding for 2014Factors Considered by the Compensation Committee in Determining the Bonus Pool•New leadership team established mid-year and made meaningful contributions during such time•Our company was continuing to overcome significant issues from the past•Our company continued to work on, and made progress towards the completion of, our financial restatement86•Sales performance fell below expectations Important Achievements•Completed our financial restatement and made meaningful progress towards remediating our control environment deficiencies•Improved performance for existing customers◦Significant year-over-year improvement in operating performance for our customers◦Simplified the measurement model with which we measure economic value for our customers◦Completed the development of a catalogue of our operational standards, which catalogs how we create value for our customers and definesthe operational standard by which we measure our operational performance◦Successfully launched critical functionality in our technology platforms aimed at improving integration with our customers’ patientaccounting systems◦Double digit improvement in customer satisfaction, as measured by Net Promoter Scores (NPS)•Completed restructuring actions resulting in meaningful cost reduction and improvements in organizational effectiveness•Made significant improvements to shared services capabilities, including in our India operations, and completed the development and approval ofour geographic footprint optimization plan.In determining these award levels for our named executive officers, the Compensation Committee took into account additional factors beyondcompany performance and individual goals, including that, although key members of the leadership team had been in place only for a partial year,achievements had been made in solidifying relationships with our customers, adding experienced healthcare executives to the leadership team, andoverseeing the completion of key operational changes to support our strategic growth.The table below shows the annual target for 2014 and actual bonus payments for 2014 for each named executive officer: 2014 Annual Cash Incentive BonusNote: For 2014, the Annual Cash Incentive Bonus for current named executiveofficers will be paid out in restricted stock that vests 1/12 per month over a one-yearperiod, commencing on April 10, 2015, rather than in cash Target Award OpportunityTarget as a % of Base SalaryActual Bonus AwardedEmad Rizk1$750,000100%$350,000Peter Csapo1$376,00080%$156,670Joseph Flanagan$595,000100%$595,000Stephen Schuckenbrock$595,000100%$0Sean Orr$350,00078%$227,5001 2014 target bonus was prorated based on the number of months of employment during the calendar year.Our Board of Directors uses our unaudited financial results to make initial performance determinations under our annual cash incentive bonus program,and those results may be adjusted in connection with the preparation of our audited consolidated financial statements. The purpose of the goals listed abovewas to establish a method for determining the payment of cash incentive bonuses. These performance goals are not intended as a prediction of our futureperformance.87Equity Incentive AwardsOur equity incentive award program is the primary vehicle for offering long-term incentives to our named executive officers. Equity incentive awardsto our named executive officers may be made in the form of restricted stock and/or stock options. Although we do not have any equity ownership guidelinesor requirements for our named executive officers, we believe that equity incentive awards:◦Provide our named executive officers with a strong link to our long-term performance by enhancing their accountability for long-term decisionmaking;◦Help balance the short-term orientation of our annual cash incentive bonus program;◦Create an ownership culture by aligning the interests of our named executive officers with the creation of value for our stockholders; and◦Further our goal of executive retention.In determining the size of equity incentive awards to named executive officers, our Compensation Committee generally considers the executive’sexperience, skills, level and scope of responsibilities, competitive practices for similar positions, and internal comparisons to other comparable positions inour company.Focus on Stockholder ValueLong-term incentive grants are intended to balance Accretive Health’s short-term operating focus and align the long-term financial interests of seniormanagement with those of our stockholders.Stock OptionsStock options are a performance-based compensation component that only provides value when the market price exceeds the exercise price, tyingexecutive compensation to stock price value and stockholder appreciation. Stock option grant date value is estimated using the Black-Scholes method ofstock option valuation. Information about Accretive Health’s Black-Sholes valuation is presented as part of the summary compensation tables. Stock optionsare generally granted with a four-year vesting period, vesting ratably on each of the first four anniversaries of the applicable grant date.Restricted Stock Awards Restricted stock awards are time-based or performance-based. Time-based restricted stock awards generally vest ratably over four years. Time-basedrestricted stock awards are valued on an actual basis and their valuation is presented as part of the summary compensation tables.Performance-based restricted stock awards vest at the end of the applicable performance period, subject to the achievement of specified stock pricegoals. Performance-based restricted stock awards are valued on an actual basis (assuming that the applicable performance target has been fully achieved).2014 Equity Incentive DecisionsIn connection with their offers of employment, Dr. Rizk and Mr. Csapo each received long-term incentive grants in the form of stock options andrestricted stock in 2014, as specified below. These initial grants were determined as the result of a negotiating process, the need for highly skilled andexperienced executives to address significant organizational and performance challenges and to provide a substantial incentive to significantly increase thevalue of the organization, and advice from our independent compensation consultant. These grants were awarded outside the 2010 Plan as employmentinducement grants.As a result of Mr. Flanagan’s revised employment terms, the Board granted him a one-time long-term incentive grant of stock options and restrictedstock in April 2014, which was contingent upon the approval by our stockholders of an amendment to the 2010 Plan increasing the number of sharesauthorized for issuance under our882010 Plan to an amount sufficient to cover these grants. Since this contingency was not realized, this stock grant was terminated and, in lieu thereof, pursuantto the terms of Mr. Flanagan’s amended employment agreement, Mr. Flanagan became entitled to receive cash payments based on the value that the stockgrants would have had on each intended vesting date. The material terms of this agreement are described under "Employment Agreements - Agreement withMr. Joseph Flanagan" in this Compensation Discussion and Analysis.No other long-term incentives were granted to named executive officers in 2014. 2014 Long-Term Incentive Awards Number ofStockOptionsExercise PriceValue ofStockOptionsNumber ofRestricted StockAwardsValue ofRestricted StockAwardsEmad Rizk Performance-Based¹———500,000$3,620,000Emad Rizk Time-Based¹2,700,000$8.98$12,150,000500,000$4,490,000Peter Csapo²300,000$8.15$1,221,000200,000$1,630,000Joseph Flanagan³500,000$8.05$2,025,000300,000$2,415,000Stephen Schuckenbrock4——$15,000——Sean Orr—————1Dr. Rizk’s stock options vest in equal annual installments over four years. Half of his restricted stock vests in equal annual installments over four years andthe remaining half vests based on a stock price performance goal achievement of $17.96 (which represents two times the closing price of a share ofAccretive Health’s common stock on the grant date), which must be equaled or exceeded for at least 20 consecutive trading days.2Mr. Csapo’s stock options and restricted shares vest in equal annual installments over four years.3Mr. Flanagan’s stock options and restricted shares were intended to vest in equal monthly installments over two years, however this equity grant wasterminated by its terms on December 31, 2014 as a result of a condition to the grant not being satisfied and, in lieu thereof, pursuant to the terms of Mr.Flanagan’s amended employment agreement, Mr. Flanagan became entitled to certain cash payments based on the value that the stock grants would havehad on each intended vesting date.4 Mr. Schuckenbrock received a stock option grant as a member of the Board of Directors, consistent with our Board of Directors compensation policy.Other Employee BenefitsWe maintain broad-based benefits that are provided to all employees, including our 401(k) retirement plan, flexible spending accounts, a medical careplan, vacation, short- and long-term disability insurance and standard company holidays. Our named executive officers are eligible to participate in each ofthese programs on the same terms as non-executive employees; however, we do not provide a matching 401(k) contribution for any of our named executiveofficers.Employment AgreementsAgreement with Dr. Emad RizkIn connection with his appointment to Chief Executive Officer, in July 2014, we entered into an offer letter agreement with Dr. Rizk that provides himthe following:•Annual base salary of $750,000;•Annual target bonus opportunity of at least 100% of base salary;•Eligibility to participate in the employee benefit programs generally available to senior executives of our company; and•A non-statutory stock option to purchase up to 2,700,000 shares of our common stock at a per share exercise price equal to the closing price of our commonstock on the grant date, and a restricted stock award for 1,000,000 shares of our common stock.89◦The stock option generally will vest in equal annual installments over four years following the grant date, subject to continued service with ourcompany.◦One-half of the restricted stock award generally will vest in equal annual installments over four years following the grant date, subject to continuedservice with our company. The remaining one-half of the restricted stock award generally will vest based on a stock price performance goal of twotimes the closing price of a share of our common stock on the grant date, which must be equaled or exceeded for at least 20 consecutive trading daysbased on the average closing price for such 20-consecutive trading day period.In the event that Dr. Rizk’s employment is terminated by us without “cause” or by Dr. Rizk for “good reason” (as defined in the offer letter agreement),in addition to any earned but unpaid salary and his accrued and vested benefits under our employee benefit programs, which are payable upon anytermination of employment, Dr. Rizk also will be entitled to receive the following payments and benefits:•A cash amount equal to two times Dr. Rizk’s base salary plus two times his target bonus, paid monthly for a period of 24 months following suchtermination, subject to Dr. Rizk’s timely execution of a general release of claims in favor of us and our affiliates;•Continued company-subsidized health benefits for a period of 24 months following the date of such termination, subject to Dr. Rizk’s timely execution ofa general release of claims in favor of us and our affiliates;•A pro-rata portion of an annual bonus for the calendar year in which such termination occurs based on actual results for such year;•A pro-rata portion of the time-based vesting equity awards will become vested and exercisable (as applicable) on such termination determined bymultiplying the number of shares of common stock underlying such time-based vesting equity awards that would have become vested and exercisable (asapplicable) on the anniversary of the grant date immediately following the date of such termination had such termination not occurred, by a fraction, thenumerator of which is the number of days during which Dr. Rizk was employed by us for the period beginning on the anniversary of the grant dateimmediately preceding the date of such termination (or the grant date, if such termination occurs prior to the first anniversary of the grant date) and endingon the date of such termination, and the denominator of which is 365;•An additional portion of the time-based vesting equity awards will become vested and exercisable (as applicable) with respect to 25% of the shares ofcommon stock underlying such time-based vesting equity awards;•The performance vesting restricted stock will vest or be forfeited on such termination based on achievement of the stock price goal, except that if suchtermination occurs prior to the second anniversary of the grant date, the two times stock price goal multiple will be replaced with a 1.5 times multiple, ifsuch termination occurs prior to the first anniversary of the grant date, or a 1.75 times multiple, if such termination occurs on or following the firstanniversary of the grant date but prior to the second anniversary of the grant date; and•In the case of such termination upon or within two years following the occurrence of a “change in control” (as defined in the offer letter agreement) of ourcompany, full accelerated vesting of the outstanding, unvested portion of the time-based vesting equity awards.In addition, with regard to the performance vesting restricted stock, upon the occurrence of the first change in control to occur following the date ofgrant and while Dr. Rizk remains in our continued employment, to the extent that the stock price goal has not previously been achieved, the performancevesting restricted stock will vest or be forfeited upon the occurrence of such change in control based on the achievement of the stock price goal in relation tothe highest per share price for our common stock in the change of control, except that if such change in control occurs prior to the second anniversary of thegrant date, the two times stock price goal multiple will be replaced with a 1.5 times multiple, if such change in control occurs prior to the first anniversary ofthe grant date, or a 1.75 times multiple, if such change in control occurs on or following the first anniversary of the grant date but prior to the secondanniversary of the grant date.90Agreement with Mr. Peter CsapoIn connection with his appointment to Chief Financial Officer and Treasurer, in August 2014, we and Mr. Csapo entered into an offer letter agreementthat provides him the following:•Annual base salary of $470,000;•Annual target bonus opportunity of at least 80% of base salary;•Eligibility to participate in the employee benefit programs generally available to senior executives of our company; and• A non-statutory stock option to purchase up to 300,000 shares of our common stock at a per share exercise price equal to the closing price of our commonstock on the grant date, and a restricted stock award for 200,000 shares of our common stock, both of which will vest in equal annual installments over fouryears following the grant date, subject to continued service with us. These incentive equity grants were issued outside of our 2010 Plan as employmentinducement grants in accordance with the rules of the New York Stock Exchange.In the event that Mr. Csapo’s employment is terminated by us without “cause” or by Mr. Csapo for “good reason” (as defined in the offer letter agreement), inaddition to any earned but unpaid salary and his accrued and vested benefits under the employee benefit programs of our company, which are payable uponany termination of employment, Mr. Csapo also is entitled to receive the following payments and benefits:•A cash amount equal Mr. Csapo’s base salary rate, paid monthly for a period of 12 months following the date of such termination, subject to Mr. Csapo’stimely execution of a general release of claims in favor of us and our affiliates;•Continued company-subsidized health benefits for a period of 12 months following the date of such termination, subject to Mr. Csapo’s timely executionof a general release of claims in favor of us and our affiliates;•If Mr. Csapo’s annual bonus for the fiscal year preceding the date of termination has not been paid prior to such termination, an annual bonus for suchfiscal year equal to the amount of Mr. Csapo’s target bonus opportunity multiplied by the payout percentage that is approved by our Board of Directors forcompany-wide bonus payouts with respect to such fiscal year;•A pro-rata portion (based on the number of days that Mr. Csapo was employed by us during the fiscal year in which such termination occurred) of an annualbonus for the fiscal year in which such termination occurs based on actual results for such year, payable at the same time as it would have otherwise beenpaid had such termination not occurred;•A pro-rata portion (based on the number of days that Mr. Csapo was employed by us following the anniversary of the grant date immediately preceding thedate of such termination, or following the grant date if such termination occurs prior to the first anniversary of the grant date, divided by 365) of theunvested portion of his incentive equity awards outstanding at the time of termination that would have become vested and exercisable (as applicable) onthe anniversary of the grant date immediately following the date of such termination had such termination not occurred will become vested and exercisable(as applicable) as of the date of such termination;•In the case of such termination upon or within the 90 days immediately preceding, or within one year following, the occurrence of a “change in control” (asdefined in the offer letter agreement) of our company, full accelerated vesting of the outstanding, unvested portion of his incentive equity awards. 91Agreement with Mr. Joseph FlanaganIn connection with his appointment to Chief Operating Officer, in April 2013, we and Mr. Flanagan entered into an offer letter agreement that provideshim the following:•Annual base salary of $595,000;•Annual target bonus opportunity of at least 100% of base salary;•A $400,000 sign-on bonus;•A one-time payment of $30,000 (less required deductions) for relocation expenses in addition to relocation expense benefits commensurate with hisposition in accordance with our relocation program (the additional relocation expense benefits amounted to $266,680 and included reimbursement forexpenses and losses incurred in connection with the move from Singapore);•Eligibility to participate in the employee benefit programs generally available to our senior executives; and•A non-statutory stock option to purchase up to 800,000 shares of our common stock at a per share exercise price equal to the closing price of the commonstock on the grant date, and a restricted stock award for 400,000 shares of our common stock, both of which generally vest in equal monthly installmentsover 48 months, subject to continued service with us. These incentive equity awards were issued outside of our 2010 Plan as employment inducementgrants in accordance with the rules of the New York Stock Exchange. One-half of the unvested portion of these incentive equity awards will be subject toaccelerated vesting upon the occurrence of a “change in control” (as defined in the offer letter agreement) of our company while Mr. Flanagan remainsemployed.In the event that Mr. Flanagan’s employment is terminated by us without “cause” or by Mr. Flanagan for “good reason,” in addition to any earnedbut unpaid salary and his accrued and vested benefits under our employee benefit programs, which are payable upon any termination of employment,Mr. Flanagan also will be entitled to receive:•Continued salary and health benefits for a period of 12 months following the date of such termination, subject to Mr. Flanagan’s timely execution of ageneral release of claims in favor of us and our affiliates;•In the case of such termination prior to the first anniversary of the grant date of the equity awards, accelerated vesting of the outstanding, unvested portionof the equity awards that would have become vested on or prior to the first anniversary of the date of such termination; and•In the case of such termination upon or within one year following the occurrence of a “change in control” of our company, full accelerated vesting of theoutstanding, unvested portion of Mr. Flanagan’s incentive equity awards. As an incentive for Mr. Flanagan to remain with Accretive Health during a critical juncture during our Chief Executive Officer transition process in2014, we amended his employment terms in April 2014 to provide him the following additional compensation and benefits:•Monthly supplemental cash retention bonus of $25,000 for the duration of Mr. Flanagan’s employment;•One-time cash retention bonus of $1,700,000, payable on April 29, 2016, which is the second anniversary of the date on which the agreement was signed;•Retention equity awards of a one-time non-statutory stock option to purchase up to 500,000 shares of our common stock at a per share exercise price equalto the closing price of our common stock on the grant date, and 300,000 shares of restricted stock, which incentive equity awards were subject to ratablevesting on a monthly basis over a two-year period, and also subject to the approval by our stockholders, prior to December 31, 2014, of an amendment toour 2010 Plan increasing the number of shares authorized for issuance under our 2010 Plan to an amount sufficient to cover these grants (which approvalwas not received);Since our stockholders did not approve the amendment to our 2010 Plan described above prior to December 31, 2014, Mr. Flanagan’s incentive equityawards described above terminated, and in lieu thereof, Mr. Flanagan became entitled to receive a Replacement Cash Award consisting of cash paymentsfrom us following each date that any portion of such incentive equity grants would have vested (had such grant not terminated) equal to the value of eachoption (based on the difference between the exercise price and the closing price of our common92stock on the applicable vesting date) and each share of restricted stock (based on the closing price of our common stock on the applicable vesting date)that would have otherwise vested on such date.•In the event that Mr. Flanagan’s employment is terminated by us without “cause” or by Mr. Flanagan for “good reason” (each, as defined in Mr. Flanagan’semployment offer letter agreement), 100% of the then unpaid portion of Mr. Flanagan’s Replacement Cash Award will become payable by us within sixty(60) days of such termination (with the value of that payment being determined based on the closing price of our common stock on the date of suchtermination rather than the applicable vesting date);•In the event of a “change in control” (as defined in Mr. Flanagan’s applicable incentive equity award agreements), 50% of the then unpaid portion ofMr. Flanagan’s Replacement Cash Award will be payable by us upon such change in control (with the value of that payment being determined based onthe closing price of our common stock on the date of such change in control rather than the applicable vesting date) and the remaining 50% of theReplacement Cash Award will remain payable by us on the originally contemplated payment schedule (with the accelerated portion of the payment beingapplied pro-rata to each remaining installment);•Relocation expense benefits, including reimbursement for expenses and losses incurred in connection with the sale of Mr. Flanagan’s then-currentresidence in Dallas, Texas (which relocation expense benefits amounted to $372,961), plus a reimbursement of up to $6,000 per month in housingexpenses for a period of two years;•Reimbursement of up to $50,000 for legal fees in connection with the negotiation and documentation of his employment agreement; and•An extension, under specified circumstances, of the period of time during which Mr. Flanagan may exercise the stock option that we awarded to him at thecommencement of his employment in April 2013. This extension would be triggered upon a termination of Mr. Flanagan’s employment by us withoutcause or by Mr. Flanagan for good reason. If the extension is triggered, the then-vested portion of the stock option would remain exercisable for a period oftime equal to sixty days plus the number of days that Mr. Flanagan is employed by us, but not longer than two years or until the stock option otherwiseexpires, if earlier.In addition to the compensation and benefits described above, we also provided Mr. Flanagan with $443,740 of additional relocation expense benefitsbetween November 2013 and May 2014 in connection with our intended move of certain corporate functions from Chicago, Illinois to Plano, Texas (whichmove did not occur), which relocation expense benefits included reimbursement for expenses and losses incurred in connection with the sale of Mr.Flanagan’s then-current residence in Chicago, Illinois.93Agreement with Mr. Stephen SchuckenbrockIn connection with his appointment to Chief Executive Officer, in April 2013, we and Mr. Schuckenbrock entered into an offer letter agreement, asamended in May 2015, that provided him the following:•Annual base salary of $595,000;•Annual target bonus opportunity of at least 100% of base salary;•Eligibility to participate in the employee benefit programs generally available to senior executives of our company; and•A non-statutory stock option to purchase up to 2,903,801 shares of our common stock with an exercise price of $9.56, which was the closing price of ourcommon stock reported on the New York Stock Exchange on the grant date.◦The stock option will vest and become exercisable on a ratable monthly basis over 48 months based on continued service to our company(including service as a member of our Board of Directors), subject to acceleration in specified circumstances, and will expire on the tenth anniversaryof grant. The stock option was issued outside of our 2010 Plan as an employment inducement grant in accordance with the rules of the New YorkStock Exchange.As previously noted, Mr. Schuckenbrock terminated his service as an employee in October 2014 and as a member of our board of directors in May2015. In connection with Mr. Schuckenbrock’s voluntary resignation from the Board, the stock option became subject to the following treatment:•The vested portion of the stock option as of the termination date will remain exercisable for the remaining term of the stock option, and the unvestedportion of the stock option as of the termination date will continue to vest and become exercisable in accordance with the original vesting schedule of thestock option described above. Agreement with Mr. Sean OrrIn connection with his appointment to Chief Financial Officer and Treasurer, in August 2013, Mr. Orr and Accretive Health entered into an offer letteragreement that provided him the following:•Annual base salary of $450,000;•Annual target bonus opportunity of $350,000;•One-time transition bonus of $50,000 and relocation benefits commensurate with his position in accordance with the company relocation program;•Eligibility to participate in the employee benefit programs generally available to senior executives of our company; and•A non-statutory stock option to purchase up to 300,000 shares of our common stock at a per share exercise price equal to the closing price of our commonstock on the grant date.◦The award generally vested 25% each year over four years, subject to continued service with us. Vesting of this award ceased on December 30, 2014.Had Mr. Orr’s employment been terminated by us without cause (as defined in his agreement), in addition to any earned but unpaid salary and hisaccrued and vested benefits under the employee benefit programs which are payable upon any termination of employment, Mr. Orr would have also beenentitled to receive continued salary and health benefits for a period of 12 months following the date of such termination, subject to Mr. Orr’s timelyexecution of a general release of claims in favor of us and our affiliates. In connection with Mr. Orr’s resignation as our Chief Financial Officer andassumption of the role of Senior Vice President, Finance, on August 6, 2014, we agreed that Mr. Orr would be entitled to the same severance benefits in theevent of his voluntary resignation from our company. Mr. Orr resigned from the company effective as of December 30, 2014.94Confidentiality and Non-Disclosure AgreementsAs a condition to employment, each named executive officer entered into a confidentiality and non-disclosure agreement with us. Under theseagreements, each named executive officer has agreed:•not to solicit our employees and customers during his or her employment and for a period of 18 months after the termination of employment;•not to compete with us during his or her employment and for a period of 12 months after the termination of employment;•to protect our confidential and proprietary information; and•to assign to us intellectual property developed during the course of his or her employment.Severance and Change-of-Control ArrangementsChange-of-control incentives can encourage our executives to objectively evaluate potential transactions that may be in stockholders’ best interests,further aligning the interests of our executives with those of our stockholders. We have designed our change-of-control compensation provisions to:•Protect the compensation already earned by executives and help ensure they will be treated fairly in the event of a change of control, and•Help ensure the retention and focus of key executives who are critical to ongoing operations of Accretive Health.We have employment agreements with each of Emad Rizk, our Chief Executive Officer, Peter Csapo, our Chief Financial Officer, and StephenSchuckenbrock, our former Chief Executive Officer and a member of our Board of Directors, that provide for “double trigger” benefits in connection with achange of control of our company together with the termination of employment and an employment agreement with Joseph Flanagan, our Chief OperatingOfficer, that provides for both “single trigger” and “double trigger” benefits in connection with a change in control of our company together (with respect tothe “double trigger” benefits) with the termination of Mr. Flanagan’s employment. Details of these agreements are listed under “Employee Agreements.”Deductibility of Executive CompensationSection 162(m) of the Internal Revenue Code generally disallows a tax deduction for compensation in excess of $1.0 million paid to our ChiefExecutive Officer and our three other officers (other than our Chief Executive Officer and our Chief Financial Officer), whose compensation is required to bereported to our stockholders pursuant to the Exchange Act by reason of being among the three other most highly-paid executive officers. Qualifyingperformance-based compensation is not subject to the deduction limitation if specified requirements are met. Our Board of Directors or CompensationCommittee may, in their judgment, authorize compensation payments that are not exempt under Section 162(m) when they believe that such payments areappropriate to attract and retain executive talent.95Summary Compensation TableThe following table sets forth information regarding compensation earned by our named executive officers. Name and Principal Position Year Salary ($) Bonus ($) Stock Awards (1)($) Option Awards(1) ($) Non-Equity IncentivePlan Compensation(2) ($) All OtherCompensation ($) Total ($)Dr. Emad Rizk (3) 2014 $338,835 — $8,110,000 $12,150,000 — — $20,598,835President and Chief ExecutiveOfficer Peter P. Csapo (4) 2014 $183,590 — $1,630,000 $1,221,000 — $40,726(8) $3,075,316Chief Financial Officer andTreasurer Joseph Flanagan (5) 2014 $595,000 $200,000(9)$2,415,000(11)$2,195,000(11) — $735,777(12)$6,140,777Chief Operating Officer 2013 $345,175 $400,000(10)$4,588,000 $4,392,000 $277,667 $312,935(12)$10,315,777Stephen Schuckenbrock (6) 2014 $450,827 — — — — $54,760(13)$505,587Former President and ChiefExecutive Officer 2013 $422,054 — — $15,941,867 $312,375 $62,961(13)$16,739,257Sean Orr (7) 2014 $452,145 — — $39,000(15)$227,500 $475,896(14)$1,194,541Former Senior Vice President,Finance and Former ChiefFinancial Officer and Treasurer 2013 $158,654 $50,000 — $1,494,000 $81,667 $112,561(14)$1,896,882(1)Valuation of these option and stock awards is based on the dollar amount of share-based compensation expense that we recognized for financial statement reportingpurposes in 2013 and 2014 computed in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, or ASC 718, excluding theimpact of estimated forfeitures related to service-based vesting conditions. These amounts do not represent the actual amounts paid to or realized by the named executiveofficer during 2013 and 2014. The assumptions used by us with respect to the valuation of option awards are the same as those set forth in Note 5, Share-BasedCompensation, to our consolidated financial statements included in this Annual Report on Form 10-K.(2)Represents payments to named executive officers under our annual cash incentive bonus program. The payouts under the annual cash incentive bonus program for 2014 toour current named executive officers will be paid out in restricted stock that vests 1/12 per month over a one-year period, commencing on April 10, 2015, rather than incash. The number of shares of restricted stock that will be awarded to each individual will equal to the amount of the cash incentive bonus to be paid in restricted stock tosuch individual, divided by the closing trading price of a share of our common stock on the date of grant, which we expect to be made in mid-year 2015. Additionalrestricted stock, equal to 20% of the non-cash bonus amount, which will also vest 1/12 per month over a one-year period, commencing on April 10, 2015, will be awardedto offset the fact that restricted stock will be provided in lieu of cash, will not be granted until mid-year 2015 and has vesting restrictions as noted above.(3)Dr. Rizk joined our company on July 21, 2014.(4)Mr. Csapo joined our company on August 12, 2014.(5)Mr. Flanagan joined our company on April 29, 2013.(6)Mr. Schuckenbrock joined our company on April 3, 2013. Mr. Schuckenbrock resigned from his position on July 9, 2014, effective July 21, 2014. Mr. Schuckenbrockcontinued to serve as a director of the company throughout 2014.(7)Mr. Orr joined our company on August 24, 2013. Mr. Orr resigned from his position on August 6, 2014, effective August 12, 2014. Mr. Orr continued to serve as a SeniorVice President of the company until December 30, 2014.(8)This amount for Mr. Csapo is comprised of the following: temporary living expenses:, $12,198; tax gross-up payments, $3,993; and compensatory travel andentertainment expenses and taxes, $24,535.96(9)This amount represents Mr. Flanagan’s monthly supplemental cash retention bonus, as described in the summary of his employment agreement above.(10)This amount represents Mr. Flanagan’s sign-on bonus, as described in the summary of his employment agreement above.(11)Since our stockholders did not approve the amendment to our 2010 Plan described above prior to December 31, 2014, Mr. Flanagan’s incentive equity awards describedabove terminated, and in lieu thereof, Mr. Flanagan became entitled to receive cash payments from the company following each date that any portion of such stock awardand option award that would have otherwise vested equal to the value of each share of restricted stock (based on the closing price of the company's common stock on theapplicable vesting date) and option award (based on the difference between the exercise price and the closing price of the company's common stock on the applicablevesting date). These cash payments will be reported in the Summary Compensation Table in the proxy statement for the 2016 Annual Meeting of Stockholders. Thisamount includes $170,000 in incremental fair value computed in accordance with ASC 718 related to the modification of Mr. Flanagan's vested options to extend theexercise period of such vested options in connection with his amended employment agreement.(12)For 2014, this amount for Mr. Flanagan represents the following: relocation benefits, $503,766; tax gross-up, $76,784; household goods, $56,602; legal expenses,$50,000; temporary living expenses, $48,000; payments for educational consulting services, $625. For 2013, this amount for Mr. Flanagan represents relocation benefits.(13)For 2014, this amount for Mr. Schuckenbrock represents the following: director fees, $15,000; relocation benefits, $14,829; compensatory travel and entertainmentexpenses and taxes, $24,931. For 2013, this amount for Mr. Schuckenbrock represents the aggregate incremental cost to our company for reimbursing Mr. Schuckenbrockfor travel, lodging and related expenses for the commute between his residence and our company’s headquarters in Chicago.(14)For 2014, this amount represents the following: separation payments - 12 months of salary continuation payments in the aggregate amount of $450,000 in connection withMr. Orr’s termination of employment effective as of December 30, 2014; 12 months of benefits continuation in the aggregate amount of $10,209 in connection with Mr.Orr’s termination of employment effective as of December 30, 2014; reimbursement for household goods, $3,420; tax gross-up payments, $5,170; car lease payments -$6,029; temporary living expenses, $806; carry costs on property owned by Mr. Orr, $262. For 2013, this amount for Mr. Orr represents expenses incurred as part ofrelocation benefits paid in 2013.(15)This amount represents $39,000 in incremental fair value for computed in accordance with ASC 718 related to the modification of Mr. Orr's vested options to extend theexercise period of such vested options in connection with his resignation from the company on December 30, 2014.97Grants of Plan-Based Awards in 2014The following table sets forth information regarding grants of compensation in the form of plan-based awards made during 2014 to our namedexecutive officers. Estimated Future Payouts UnderNon-Equity Incentive Plan Awards(1) Estimated Future PayoutsUnder Equity Incentive PlanAwards (2) All OtherStockNumberof Sharesof Stockor Units(#) (3) All OtherOptionAwards:Number ofSecuritiesUnderlyingOptions (#)(4) Exerciseor BasePrice ofOptionAwards($) Grant DateFair Valueof Stock andOptionAwards ($)Name GrantDate Threshold($) Target ($)Maximum($) Threshold(#)Target(#)Maximum(#) Dr. EmadRizk N/A $— $338,835$— 7/21/2014 — 500,000 $3,620,000 7/21/2014 500,000 $4,490,000 7/21/2014 2,700,000 $8.98 $12,150,000Peter P.Csapo N/A $— $146,872$— 8/12/2014 200,000 $1,630,000 8/12/2014 300,000 $8.15 $1,221,000JosephFlanagan N/A $— $595,000$— 4/29/2014 300,000 $2,415,000 4/29/2014 500,000 $8.05 $2,025,000StephenSchuckenbrockN/A $— — — Sean Orr N/A $— $350,000$— (1)Actual annual cash incentive bonuses paid under the annual cash incentive bonus program for 2014 will be paid out inrestricted stock that vests 1/12 per month over a one-year period, commencing on April 10, 2015, rather than in cash. Thenumber of shares of restricted stock that will be awarded to each individual will equal the amount of the cash incentive bonus tobe paid in restricted stock to such individual, divided by the closing trading price of a share of our common stock on the dateof grant. Additional restricted stock, equal to 20% of the non-cash bonus amount, which will also vest 1/12 per month over aone-year period, commencing on April 10, 2015, will be awarded to offset the fact that restricted stock will be provided in lieuof cash, will not be granted until mid-year 2015 and has vesting restrictions as noted above. These grants of restricted stock willbe reflected in the “Summary Compensation Table” in the proxy statement for the 2016 Annual Meeting of Stockholders.There are no minimum or maximum payout levels, and our board of directors has broad discretion to make adjustments to theawards based on the factors discussed under the caption “Annual Cash Incentive Bonus.”(2)For Dr. Rizk, these performance-based restricted shares vest based on a stock price performance goal of two times the closingprice of a share of our common stock on the grant date, which must be equaled or exceeded for at least 20 consecutive tradingdays based on the average closing price for such 20-consecutive trading day period.(3)For Dr. Rizk and Mr. Csapo, these restricted shares vest in equal installments over four years following the respective grantdates, subject to continued service with our company. For Mr. Flanagan, these restricted shares vest on a monthly basis over atwo year period, subject to the approval by our stockholders of an amendment to our 2010 Plan increasing the number ofshares authorized for issuance under our 2010 Plan to an amount sufficient to cover these grants. Since our stockholders did notapprove the amendment to our 2010 Plan described above prior to December 31, 2014, Mr. Flanagan’s incentive equity awardsdescribed above terminated, and in lieu thereof, Mr. Flanagan became entitled to receive cash payments from the companyfollowing each date that any portion of such stock award that would have otherwise vested equal to the value of each share ofrestricted stock (based on the closing price of the company's common stock on the applicable vesting date).(4)For Dr. Rizk and Mr. Csapo, these stock options vest in equal installments over four years following the respective grant dates,subject to continued service with our company. For Mr. Flanagan, these stock options vest on a monthly basis over a two yearperiod, subject to the approval by our stockholders of an amendment to our 2010 Plan increasing the number of sharesauthorized for issuance under our 2010 Plan to an amount sufficient to cover these grants. Since our stockholders did notapprove the amendment to our 2010 Plan described above prior to December 31, 2014, Mr. Flanagan’s incentive equity awardsdescribed above terminated, and in lieu thereof, Mr. Flanagan became entitled to receive cash payments from the companyfollowing each date that any portion of such stock option award that would have otherwise vested equal to the value of eachshare of option award (based on the difference between the exercise price and the closing price of the company's common stockon the applicable vesting date).98Outstanding Equity Awards at December 31, 2014The following table sets forth information regarding stock options and stock awards held by our named executive officers as of December 31, 2014. Option Awards Stock Awards Equity Incentive PlanAwards: Number ofSecuritiesUnderlyingUnexercisedOptions (#)exercisable Number ofSecuritiesUnderlyingUnexercisedOptions (#)Unexercisable OptionExercisePrice ($) OptionExpirationDate Number ofShares orUnits ofStock ThatHave NotVested (#) MarketValue ofShares orUnits ofStock ThatHave NotVested ($) Number ofUnearnedShares, Unitsor OtherRights thatHave NotVested (#) Market orPayoutValue ofUnearnedShares,Units orOther Rightsthat HaveNot Vested($)Dr. Emad Rizk— 2,700,000(1) $8.98 7/21/2024 500,000(2) $3,430,000 500,000(3) $3,430,000Peter P. Csapo— 300,000(4) $8.15 8/12/2024 200,000(5) $1,372,000 JosephFlanagan— 500,000(6) $8.05 4/29/2024 300,000(6) $2,058,000 300,000(7) 500,000(7) $11.47 6/3/2023 250,000(8) $1,715,000 StephenSchuckenbrock1,209,900(9) 1,693,901(9) $9.56 4/2/2023 Sean Orr75,000(10) — $9.94 8/26/2023 (1)These options were granted on July 21, 2014 and vest in equal annual installments over four years, beginning one year fromthe date of grant, based on continued employment.(2)These restricted shares were granted on July 21, 2014 and vest in equal annual installments over four years, beginning oneyear from the date of grant, based on continued employment.(3)These performance-based restricted shares were granted on July 21, 2014 and vest based on a stock price performance goalof two times the closing price of a share of our common stock on the grant date, which must be equaled or exceeded for atleast 20 consecutive trading days based on the average closing price for such 20-consecutive trading day period.(4)These options were granted on August 12, 2014 and vest in equal annual installments over four years, beginning one yearfrom the date of grant, based on continued employment.(5)These restricted shares were granted on August 12, 2014 and vest in equal annual installments over four years, beginningone year from the date of grant, based on continued employment.(6)Since our stockholders did not approve the amendment to our 2010 Plan described above prior to December 31, 2014, Mr.Flanagan’s incentive equity awards described above terminated, and in lieu thereof, Mr. Flanagan became entitled to receivecash payments from the company following each date that any portion of such stock award and option award that wouldhave otherwise vested equal to the value of each share of restricted stock (based on the closing price of the company'scommon stock on the applicable vesting date) and option award (based on the difference between the exercise price and theclosing price of the company's common stock on the applicable vesting date).(7)These options were granted on June 3, 2013 and vest in equal monthly installments over four years, beginning one monthfrom date of grant, based on continued employment.(8)These restricted shares were granted on June 3, 2013 and vest in equal monthly installments over four years, beginning onemonth from date of grant, based on continued employment.(9)These options were granted on April 2, 2013 and vest in equal monthly installments over four years, beginning on the dateof grant notwithstanding Mr. Schuckenbrock's termination of employment and board service.(10)These options were granted on August 26, 2013 and represent the portion of Mr. Orr’s stock option award that was vested asof December 30, 2014, the date of termination of his employment. Pursuant to our agreement with Mr. Orr, the time periodin which Mr. Orr may exercise his stock options has been extended.99Option Exercises and Stock VestedThe following table sets forth information regarding stock acquired upon vesting by our named executive officers during the fiscal year endedDecember 31, 2014. No stock options were exercised during the fiscal year ended December 31, 2014. Stock Awards (1)Name Number of SharesAcquired onVesting (#) Value Realized onVesting ($) (2)Dr. Emad Rizk— —Peter Csapo— —Joseph Flanagan (3)100,008 814,065Stephen Schuckenbrock— —Sean Orr— —(1)Represents shares of restricted stock that vested during the year ended December 31, 2014.(2)Based on the fair market value of our common stock on the date of vesting.(3)Excludes 112,500 shares of restricted stock that were awarded to Mr. Flanagan and vested in 2014 but weresubsequently terminated since our stockholders did not approve the amendment to our 2010 Plan as described in thesummary of his employment agreement above.100Potential Payments Upon Termination or Change of ControlThe table below provides information related to potential payments upon termination by the company without cause or by the NEOs listed in the tablefor good reason, assuming that the terminations were effective on December 31, 2014. No payments were made to Mr. Schuckenbrock, who resigned as ourChief Executive Officer in July 2014, in connection with the termination of his employment. Pursuant to our agreement with Mr. Orr described above, Mr. Orrbecame entitled to receive twelve months of salary continuation payments in the aggregate amount of $450,000 and twelve months of benefits continuationin the aggregate amount of $10,209 following his resignation on December 30, 2014. In addition, pursuant to our agreement with Mr. Orr, the time period inwhich he may exercise his vested options as of December 31, 2014 has been extended.Termination by the Company without Cause or by a NEO for Good ReasonNameSalarySeverance (1)IncentiveSeverance(2)EarnedIncentive(3)AcceleratedOptions (4)AcceleratedRestrictedStock (5)AcceleratedPerformanceStock (6)Benefits(7)TotalDr. EmadRizk$1,500,000$1,500,000$350,000$0$478,673$0$35,832$3,864,505Peter Csapo$470,000$120,888$130,034$0$132,501N/A$17,916$871,339JosephFlanagan$595,000$0$0$0$1,286,250N/A$18,516$1,899,766(1)Salary severance represents a cash payment that the NEO is entitled to receive upon termination. Dr. Rizk’s salary severance represents two times hiscurrent base salary. Messrs. Csapo and Flanagan’s salary severance represent one times their current, respective base salaries.(2)Incentive severance represents a cash payment that the NEO is entitled to receive upon termination. Dr. Rizk’s incentive severance represents twotimes his current target bonus. Mr. Csapo’s incentive severance represents the pro-rata bonus amount adjusted based on the number of daysemployed by the company in 2014 and further adjusted based on actual results of the company for 2014. Mr. Flanagan is not entitled to receive anincentive severance payment.(3)Earned incentive represents a cash payment that the NEO is entitled to receive upon termination for the payout from the 2014 annual incentivebonus award. Dr. Rizk’s earned incentive represents a pro-rata portion of his annual bonus for 2014 based on the company’s actual results for 2014.Mr. Csapo’s earned incentive represents the target bonus adjusted for the bonus pool funding for 2014. Mr. Flanagan is not entitled to receive anearned incentive payment.(4)The vesting of the following number of shares of our common stock underlying unvested options held by the NEOs would be accelerated as a resultof a termination of employment on December 31, 2014: Dr. Rizk, 376,798; Mr. Csapo, 28,973; and Mr. Flanagan, 312,500. The amounts reflect thedifference between the $6.86 closing trading price of our common stock on December 31, 2014 and the exercise price of each option.(5)The vesting of the following total number of unvested shares of restricted stock held by the NEOs would be accelerated as a result of a termination ofemployment on December 31, 2014: Dr. Rizk, 69,777; Mr. Csapo, 19,315; and Mr. Flanagan, 187,500. The amounts reflect the $6.86 closing tradingprice of our common stock on December 31, 2014.(6)Dr. Rizk’s performance-based restricted shares would not accelerate in the event of a termination by the company without cause or by Dr. Rizk forgood reason because the stock price hurdle would not be achieved upon his termination. Messrs. Csapo and Flanagan do not hold performance-based restricted stock.(7)The NEOs are entitled to receive a continuation of benefits for up to one year, except for Dr. Rizk who is entitled to receive a continuation ofbenefits for up to two years. The amounts reflect the annualized current benefit amounts multiplied by the benefit continuation policy for eachexecutive.101The following table provides information related to potential payments upon termination by the company without cause or by the NEOs listed in thetable for good reason following a change of control, assuming that the terminations were effective on December 31, 2014:Termination by the Company without Cause or by Officer for Good Reason following a Change of ControlNameSalarySeverance(1)IncentiveSeverance(2)EarnedIncentive(3)AcceleratedOptions (4)AcceleratedRestrictedStock (5)AcceleratedPerformanceStock (6)Benefits (7)ExciseTaxGrossUp (8)TotalDr. EmadRizk$1,500,000$1,500,000$350,000$0$3,430,000$0$35,832$0$6,815,832PeterCsapo$470,000$120,888$130,034$0$1,372,000N/A$17,916$0$2,110,838JosephFlanagan$595,000$0$0$0$2,358,125N/A$18,516$0$2,971,641(1)Salary severance represents a cash payment that the NEO is entitled to receive upon termination following a change of control. Dr. Rizk’s salaryseverance represents two times his current base salary. Messrs. Csapo and Flanagan’s salary severance represent one times their current, respectivebase salaries.(2)Incentive severance represents a cash payment that the NEO is entitled to receive upon termination following a change of control. Dr. Rizk’sincentive severance represents two times his current target bonus. Mr. Csapo’s incentive severance represents the pro-rata bonus adjusted based onthe number of days employed by the company in 2014 and further adjusted based on actual results of the company for 2014. Mr. Flanagan is notentitled to receive an incentive severance payment.(3)Earned incentive represents a cash payment that the NEO is entitled to receive upon termination following a change of control for the payout fromthe 2014 annual incentive bonus award. Dr. Rizk’s earned incentive represents a pro-rata portion of his annual bonus for 2014 based on thecompany’s actual results for 2014. Mr. Csapo’s earned incentive represents the target bonus adjusted for the bonus pool funding for 2014. Mr.Flanagan is not entitled to receive an earned incentive payment.(4)The vesting of the following number of shares underlying unvested options held by the NEOs would be accelerated as a result of a termination ofemployment following a change of control on December 31, 2014: Dr. Rizk, 2,700,000; Mr. Csapo, 300,000; and Mr. Flanagan, 656,250. Theamounts reflect the difference between the $6.86 closing trading price of our common stock on December 31, 2014 and the exercise price of eachoption.(5)The vesting of the following total number of unvested shares of restricted stock held by the NEOs would be accelerated as a result of a termination ofemployment following a change of control on December 31, 2014: Dr. Rizk, 500,000; Mr. Csapo, 200,000; and Mr. Flanagan, 343,750. The amountsreflect the $6.86 closing trading price of our common stock on December 31, 2014.(6)Dr. Rizk’s performance-based restricted shares would not accelerate in the event of a termination following a change of control because the stockprice hurdle would not be achieved upon his termination. Messrs. Csapo and Flanagan do not hold performance-based restricted stock.(7)The NEOs are entitled to a continuation of benefits for up to one year, except for Dr. Rizk who received a continuation of benefits for up to twoyears. The amounts reflect the annualized current benefit amounts multiplied by the benefit continuation policy for each executive.(8)The NEOs are not eligible to receive an excise tax gross up.102Compensation Committee ReportThe compensation committee has reviewed and discussed the Compensation Discussion and Analysis included in this Annual Report on Form 10-K forthe fiscal year ended December 31, 2014 with the company’s management. Based on such review and discussion with management, the compensationcommittee recommended to the board of directors that the Compensation Discussion and Analysis be included in this Annual Report on Form 10-K.By the Compensation Committee of the Board of Directors of Accretive Health, Inc.Steven N. Kaplan (chair)Edgar Bronfman, Jr.Denis J. NaydenCompensation Committee Interlocks and Insider ParticipationThe members of the Compensation Committee throughout the fiscal year ended December 31, 2014 were Messrs. Kaplan (chair), Bronfman, Cline,Nayden and Spiegel. None of Messrs. Kaplan, Bronfman, Cline, Nayden and Spiegel has ever been an officer or employee of Accretive Health. No member ofthe compensation committee had any relationship with us during fiscal 2014 requiring disclosure under Item 404 of Regulation S-K under the Exchange Act.None of our executive officers serves as a member of the board of directors or compensation committee, or other committee serving an equivalentfunction, of any entity that has one or more executive officers who serve as members of our board of directors or our compensation committee.103DIRECTOR COMPENSATIONWe pay each non-employee director a $60,000 annual retainer. The chairs of the board of directors and the audit committee receive an additionalannual retainer of $20,000, and the chairs of the compensation committee and the nominating and corporate governance committee receive an additionalannual retainer of $10,000. There are no additional fees for attending board or board committee meetings. Cash fees are paid quarterly in arrears to the non-employee directors who were serving as directors at the end of a quarter.In lieu of cash fees, non-employee directors may elect to receive fully-vested options to purchase shares of our common stock. Elections must bereceived by the 75th day of a quarter and apply to all subsequent quarterly cash fees until a new election is received. Such options are granted on the firsttrading day of each quarter with respect to the fees payable for the preceding quarter, and the exercise price equals the fair market value of the common stockon the date of grant. The number of shares subject to such options is calculated by dividing the dollar amount of the cash fees for the quarter by the Black-Scholes option value we used for purposes of determining the share-based compensation expense that we recognized for financial statement reportingpurposes in that quarter.Unless a different arrangement is specifically agreed to, any non-employee director who joins our board in the future will be granted a stock option onthe date of such director’s first board meeting. The option will have a total Black-Scholes value of $520,000 (based on the target value of $130,000 per year),and the exercise price will equal the fair market value of the common stock on the date of grant. Each such option will vest in four equal annual installments,based on continued service as a director.In addition, under the Chairman’s Agreement between us and Ms. Mary Tolan, Ms. Tolan was entitled to additional compensation and benefits for herservices as Chairman of our board of directors from April 2013 through April 2014, as described under “Agreements with Ms. Mary Tolan” in the“Agreements with Directors” section below. Also, under the Chairman Services Agreement between us and Mr. Steven Shulman, Mr. Shulman is entitled toadditional compensation and benefits for his services as Chairman of our board of directors as described under “Agreement with Mr. Steven Shulman” in the“Agreements with Directors” section below.We reimburse each non-employee director for ordinary and reasonable expenses incurred in attending board and board committee meetings.1042014 Director Compensation. The following table sets forth, for each of our non-employee directors, information concerning compensation earned orpaid for services in all capacities during the fiscal year ended December 31, 2014. Fees Earned or Paidin Cash ($) Option Awards($)(1) Name Total ($)Edgar Bronfman, Jr. $— $70,000 $70,000J. Michael Cline $ 60,000 $— $60,000Steven N. Kaplan $— $70,000 $70,000Stanley N. Logan $80,000 $— $80,000Alex J. Mandl $— $60,000 $60,000Denis J. Nayden $50,000 $60,000 $110,000Steven Shulman $425,000(2)$— $425,000Arthur H. Spiegel, III $ 15,000 $45,000 $60,000Robert V. Stanek $60,000 $— $60,000Mary A. Tolan $166,833(3)$— $166,833Mark A. Wolfson $— $60,000 $60,000(1) Valuation of these options awards is based on the dollar amount of share-based compensation expense that we recognized for financial statementreporting purposes in 2014 computed in accordance with ASC 718, excluding the impact of estimated forfeitures related to service-based vesting conditions.These amounts do not represent the actual amounts paid to or realized by the director during 2014. The assumptions used by us with respect to the valuationof option awards are the same as those set forth in Note 5, Share-Based Compensation, to our consolidated financial statements included in this AnnualReport on Form 10-K.(2) This amount includes $350,000 of fees paid to Mr. Shulman as Chairman of our board of directors pursuant to the Chairman Services Agreement betweenus and Mr. Shulman. Mr. Shulman was appointed Chairman effective April 2, 2014. See "Agreement with Mr. Steven Shulman" in this section for moreinformation.(3) This amount includes $121,833 of fees paid to Ms. Tolan as non-executive Chairman of our board of directors pursuant to the Chairman's Agreementbetween us and Ms. Tolan. Ms. Tolan’s engagement as our non-executive Chairman ended effective as of April 2, 2014. See "Agreements with Ms. MaryTolan" in this section for more information.As of December 31, 2014, our non-employee directors held the following options to acquire shares of our common stock: Name Aggregate OptionAwards Outstanding asof December 31, 2014Edgar Bronfman, Jr. 103,246J. Michael Cline 90,883Steven N. Kaplan 105,886Stanley N. Logan 43,283Alex J. Mandl 120,568Denis J. Nayden 98,413Steven J. Shulman 103,174Arthur J. Spiegel, III 97,094Robert V. Stanek 109,473Mary A. Tolan 1,176,000Mark Wolfson 97,094105Agreements with DirectorsAgreement with Mr. Steven ShulmanAs part of our strategy to navigate significant business challenges in March 2014, including the initiation of NYSE delisting proceedings and thecontinuing effects of both the negative publicity in connection with the lawsuit filed against us in January 2012 by the Minnesota Attorney General and ourfinancial restatement, our Board of Directors appointed Steven Shulman as our Chairman on April 2, 2014 and negotiated a compensation package forMr. Shulman’s services as our Chairman. Since being appointed as our Chairman, Mr. Shulman has played a pivotal role in assisting us in navigating thischallenging business environment, including by leading and successfully concluding the search for our new Chief Executive Officer, Dr. Rizk, as well asassisting us to strengthen our relationships with certain of our key customers and helping to provide strategic direction for our company.Our Chairman Services Agreement with Mr. Shulman, which reflects terms that were agreed upon in principle during late March and April 2014, butwhich was not executed until November 2014, provides for the following benefits to Mr. Shulman:•Annual cash fee of $500,000;•A one-time payment of $291,667 in respect of services provided by Mr. Shulman between April 2, 2014 (the date of Mr. Shulman’s appointment asChairman of our Board of Directors) and the date of execution of the Chairman Services Agreement;•A restricted stock award of 2,250,000 shares of our common stock, subject to approval by our stockholders at the Annual Meeting of an amendmentto our 2010 Plan increasing the number of shares authorized for issuance under our 2010 Plan to an amount sufficient to cover the grant of theseshares of restricted stock to Mr. Shulman.•Of these 2,250,000 shares, 1,750,000 generally will vest in equal annual installments on each of the first three anniversaries of the dateMr. Shulman was appointed as our Chairman, subject to Mr. Shulman’s continued service as Chairman. These shares will also vest upon atermination of Mr. Shulman’s Chairman Services Agreement by us without cause, as defined in the Chairman Services Agreement.•The remaining 500,000 shares will vest on the third anniversary of the date Mr. Shulman was appointed as our Chairman (or upon a change incontrol transaction or our termination of the Chairman Services Agreement without cause, as defined in the Chairman Services Agreement),subject to (i) Mr. Shulman’s continued service as Chairman and (ii) the average closing price of our common stock as reported on the New YorkStock Exchange (or if not then traded on NYSE, the principal national securities exchange in the United States on which our common stock isthen traded), measured over ninety days exceeding 200% of the closing price of a share of our common stock on April 2, 2014 (or, if the averagetrading price of our common stock measured over a ninety day period exceeds the closing price of our common stock on April 2, 2014 by lessthan 200%, a pro-rata portion of these 500,000 shares of restricted common stock will vest based on the percentage of the closing price of ourcommon stock on April 2, 2014 represented by such average trading price, using a linear interpolation between 100% and 200%).•In the event that (i) our stockholders do not approve the amendment to our 2010 Plan increasing the number of shares authorized for issuanceunder our 2010 Plan at the Annual Meeting in an amount sufficient to allow for the restricted stock award described above, (ii) either partyterminates the Chairman Services Agreement on or before June 1, 2015, or (iii) as of the first business day following the Annual Meeting thecompany is subject to an agreement which provides for a change in control and such agreement is terminated prior to its consummation, thenMr. Shulman would be entitled to receive a one-time payment of approximately $5.9 million (which amount is equal to $400,000 for eachmonth then-elapsed between April 2, 2014 and the first business day following the Annual106Meeting (pro-rated for partial months), less the portion of any annual fees he received during such time payable within 30 days of the AnnualMeeting.If, as of the first business day following the Annual Meeting, we have either consummated a change in control transaction or are subject to anagreement providing for a change in control transaction which is consummated after that date, then Mr. Shulman is entitled to receive a cash payment equalto the value of the shares of common stock which would have vested on or prior to the time of such change of control under his restricted stock awarddescribed above, had the restricted stock award been made on April 2, 2014, together with the value of any dividends that would have been paid on suchshares prior to the change of control transaction.Agreements with Ms. Mary TolanIn connection with the transition of the role of Chief Executive Officer from Mary Tolan to her successor, Stephen F. Schuckenbrock, we entered into aChairman’s Agreement and a related Mutual General Release Agreement, each dated April 24, 2013, with Ms. Tolan.In connection with her service as non-executive Chairman, Ms. Tolan was entitled to the following compensation and benefits:•An annual retainer of $731,000, for the duration of Ms. Tolan’s engagement as our non-executive Chairman;•Continued health benefits entirely subsidized by Accretive Health, pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985, for aperiod of up to 18 months following April 3, 2013; and•Continued vesting and exercisability of the outstanding stock options held by Ms. Tolan as of April 3, 2013, in accordance with the terms andconditions of the applicable equity award documentation, for the duration of her continued service to Accretive Health. Following termination of hercontinued service with us, the vested stock options held by Ms. Tolan remained exercisable for the remainder of the maximum stated term of the stockoptions.Ms. Tolan’s engagement as our non-executive Chairman ended effective as of April 2, 2014.107Item 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder MattersThe information required by this item with regard to securities authorized for issuance under equity incentive plans as of December 31, 2014 iscontained in Item 5 of this Annual Report on Form 10-K.The following table contains information as of June 1, 2015 about the beneficial ownership of shares of our common stock by:•each person, or group of affiliated persons, who is known by us to beneficially own more than 5% of our common stock;•each of our directors and nominees for director;•each of our named executive officers; and•all of our directors and executive officers as a group.For purposes of the table below, and in accordance with SEC rules, we deem shares of common stock subject to options that are currently exercisable orexercisable within 60 days of June 1, 2015 to be outstanding and beneficially owned by the person holding the options for the purpose of computing thepercentage ownership of that person, but we do not treat them as outstanding for the purpose of computing the percentage ownership of any other person. Asof June 1, 2015, there were 97,948,301 shares of our common stock outstanding. Except as otherwise noted, the persons or entities in this table have solevoting and investment power with respect to all of the shares of common stock beneficially owned by them, subject to community property laws, whereapplicable. Except as otherwise set forth below, the street address of the beneficial owner is c/o Accretive Health, Inc., 401 North Michigan Avenue, Suite2700, Chicago, Illinois 60611. Common StockBeneficially OwnedNameShares%5% Stockholders FMR, LLC (1)14,590,02514.9%Mary A. Tolan (2)11,161,12811.4%Jasper Ridge Partners, L.P. (3)8,101,7748.3%J. Michael Cline (4)7,386,0227.5%Directors and Named Executive Officers Emad Rizk (5)1,675,0001.7%Peter Csapo (6)200,000*Stephen F. Schuckenbrock (7)1,643,2871.7%Joseph G. Flanagan (8)816,675*Sean Orr (9)75,000*Edgar Bronfman, Jr. (10)3,270,9153.3%Charles J. Ditkoff—*Michael B. Hammond—*Steven N. Kaplan (11)506,104*Arthur A. Klein—*Lawrence B. Leisure—*Stanley N. Logan (12)45,344*Alex J. Mandl (13)48,386*Denis J. Nayden (14)1,422,5321.5%Amir Dan Rubin—*Steven J. Shulman (15)51,588*Mark A. Wolfson (16)806,297*Robert V. Stanek (17)27,369*All current executive officers and directors as a group (16 persons)8,870,2109.1% *Less than 1%108(1)Consists of 14,590,025 shares of common stock as reported as beneficially owned by FMR LLC, of which FMR LLC reports sole voting power over164 shares and sole dispositive power over 14,590,025 shares. Fidelity OTC Portfolio reports sole voting power over 9,842,302 shares. Edward C.Johnson, III is a Director and the Chairman of FMR LLC and Abigail P. Johnson is a Director, the Vice Chairman, the Chief Executive Officer and thePresident of FMR LLC. Members of the family of Edward C. Johnson, III, including Abigail P. Johnson, are the predominant owners, directly orthrough trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and allother FMR LLC Series B stockholders have entered into a stockholders’ voting agreement under which all Series B voting shares will be voted inaccordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and theexecution of the shareholders’ voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to forma controlling group with respect to FMR LLC. Neither FMR LLC nor Edward C. Johnson, III or Abigail P. Johnson has the sole power to vote or directthe voting of the shares owned directly by the various investment companies registered under the Investment Company Act of 1940 (the “FidelityFunds”), which powers reside with the Fidelity Funds’ board of trustees. Fidelity Management & Research Company carries out the voting of theshares under written guidelines established by the Fidelity Funds’ boards of trustees. The address of FMR LLC is 245 Summer Street, Boston,Massachusetts 02210. We obtained information regarding beneficial ownership of these shares solely from Amendment No. 4 to Schedule 13G thatwas filed with the SEC on February 13, 2015.(2)Includes 2,587,200 shares held by Tolan Family Trust U/A/D 6/29/03, the beneficiaries of which are Ms. Tolan’s children who share voting andinvestment power with respect to the shares held by this trust. Also includes 1,176,000 shares subject to options exercisable within 60 days of June 1,2015.(3)Includes the shares beneficially owned by Jasper Ridge Partners, L.P. (formerly known as Oak Hill Investment Management, L.P.), or Jasper Ridge, thatare managed by Jasper Ridge on behalf of various advisory clients pursuant to Investment Advisory Agreements. Pursuant to such agreements, JasperRidge has sole voting and investment power over the shares. Mark Wolfson is a managing partner of Jasper Ridge and may be deemed to share votingand investment power with respect to all shares held by Jasper Ridge. Mark Wolfson disclaims beneficial ownership of the securities listed aboveexcept to the extent of any pecuniary interest therein. Does not include 332,835 shares owned by JRP GP Holding, L.P. (formerly known as OHIM GPHoldings, L.P.), or JP Holdings, an entity affiliated with Jasper Ridge. The address of Jasper Ridge is 201 Main Street, Suite 1000, Fort Worth, Texas76102.(4)Consists of (i) 7,216,016 shares beneficially owned by JMC Holdings, L.P. JMC Holdings is a Delaware limited partnership of which the Trust datedDecember 30, 2005, or the Trust, is the general partner and Mr. Cline is the trustee and beneficiary of the Trust through which Mr. Cline isdeemed have beneficial ownership by reason of his sole voting and investment power with respect to the 7,216,016 shares. Mr. Cline disclaimsbeneficial ownership of such shares, except to the extent of his pecuniary interest therein. The address of JMC Holdings, L.P. is c/o Accretive,LLC, 51 Madison Avenue, 31st Floor, New York, New York 10010; (ii) 19,045 shares of Common Stock held directly by Accretive AssociatesSBIC, LLC, of which Mr. Cline is the managing member, (iii) 60,078 shares held directly by Mr. Cline; and (iv) 90,883 shares subject to optionsexercisable within 60 days of June 1, 2015.(5)Includes (i) 675,000 shares subject to options exercisable within 60 days of June 1, 2015, and (ii) 1,000,000 shares of restricted stock, none of whichwere vested as of June 1, 2015.(6)Includes 200,000 shares of restricted stock, none of which were vested as of June 1, 2015.(7)Includes 1,643,287 shares subject to options exercisable within 60 days of June 1, 2015.(8)Includes (i) 416,675 shares subject to options exercisable within 60 days of June 1, 2015, and (ii) 400,000 shares of restricted stock, of which 191,667shares were vested as of June 1, 2015.(9)Includes 75,000 shares subject to options exercisable within 60 days of June 1, 2015.(10)Includes 114,823 shares subject to options exercisable within 60 days of June 1, 2015.(11)Includes 117,463 shares subject to options exercisable within 60 days of June 1, 2015.(12)Consists of (i) 2,000 shares held in an investment retirement account for the benefit of Mr. Logan and his spouse, over which Mr. Logan has sharedvoting and investment power; (ii) 41 shares held jointly by Mr. Logan and his spouse, over which Mr. Logan has shared voting and investment power;(iii) 20 shares held by Mr. Logan as custodian for Mr. Logan’s minor grandchild, over which Mr. Logan has voting and investment power; and (iv)43,283 shares subject to options exercisable within 60 days of June 1, 2015.(13)Includes 48,386 shares subject to options exercisable within 60 days of June 1, 2015.(14)Includes (i) 505,630 shares held in a grantor retained annuity trust, or GRAT, established for estate planning purposes, and (ii) 108,335 shares subjectto options exercisable within 60 days of June 1, 2015. Mr. Nayden is the sole trustee and sole annuitant of the GRAT. Also includes 249,999 sharesheld by Britta & Denis Nayden109Charitable Foundation Ltd., or the Foundation, of which Mr. Nayden is president and a director. Mr. Nayden does not have any pecuniary interest inthe shares held by the Foundation.(15)Includes 51,588 shares subject to options exercisable within 60 days of June 1, 2015.(16)Includes of 107,016 shares subject to options exercisable within 60 days of June 1, 2015. Mr. Wolfson is a managing partner of Jasper Ridge Partners,but disclaims beneficial ownership of any shares held by Jasper Ridge Partners or Jasper Ridge Partners Holdings.(17)Includes 27,369 shares subject to options exercisable within 60 days of June 1, 2015.110Item 13.Certain Relationships and Related Transactions, and Director IndependencePolicies and Procedures for Related Person TransactionsOur board of directors has adopted a written related person transaction policy to set forth policies and procedures for the review and approval orratification of related person transactions. This policy covers any transaction, arrangement or relationship, or any series of similar transactions, arrangementsor relationships, in which we were or are to be a participant, the amount involved exceeds $120,000, and a related person had or will have a direct or indirectmaterial interest, including, without limitation, purchases of goods or services by or from the related person or entities in which the related person has amaterial interest, indebtedness, guarantees of indebtedness, and employment by us of a related person. Our related person transaction policy containsexceptions for any transaction or interest that is not considered a related person transaction under SEC rules as in effect from time to time.Any related person transaction proposed to be entered into by us must be reported to our general counsel and will be reviewed and approved by theaudit committee in accordance with the terms of the policy, prior to effectiveness or consummation of the transaction whenever practicable. If our generalcounsel determines that advance approval of a related person transaction is not practicable under the circumstances, the audit committee will review and, inits discretion, may ratify the related person transaction at the next meeting of the audit committee.Alternatively, our general counsel may present a related person transaction arising in the time period between meetings of the audit committee to thechair of the audit committee, who will review and may approve the related person transaction, subject to ratification by the audit committee at the nextmeeting of the audit committee.In addition, any related person transaction previously approved by the audit committee or otherwise already existing that is ongoing in nature will bereviewed by the audit committee annually to ensure that such related person transaction has been conducted in accordance with the previous approvalgranted by the audit committee, if any, and that all required disclosures regarding the related person transaction are made.Transactions involving compensation of executive officers will be reviewed and approved by the compensation committee in the manner specified inthe charter of the compensation committee.A related person transaction reviewed under this policy will be considered approved or ratified if it is authorized by the audit committee in accordancewith the standards set forth in the policy after full disclosure of the related person’s interests in the transaction. As appropriate for the circumstances, the auditcommittee will review and consider:•the related person’s interest in the related person transaction;•the approximate dollar value of the amount involved in the related person transaction;•the approximate dollar value of the amount of the related person’s interest in the transaction without regard to the amount of any profit or loss;•whether the transaction was undertaken in the ordinary course of business of our company;•whether the transaction with the related person is proposed to be, or was, entered into on terms no less favorable to us than the terms that could havebeen reached with an unrelated third party;•the purpose of, and the potential benefits to us of, the transaction; and•any other information regarding the related person transaction or the related person in the context of the proposed transaction that would be materialto investors in light of the circumstances of the particular transaction.The audit committee will review all relevant information available to it about the related person transaction. The audit committee may approve or ratifythe related person transaction only if the audit committee determines111that, under all of the circumstances, the transaction is in, or is not inconsistent with, our best interests. The audit committee may, in its sole discretion, imposesuch conditions as it deems appropriate on us or the related person in connection with approval of the related person transaction.Since January 1, 2014, we have engaged in the following transactions with our directors, executive officers and holders of more than 5% of our votingsecurities, and affiliates or immediate family members of our directors, executive officers and 5% stockholders, in which such person had or will have a director indirect material interest:Certain Employment ArrangementsWe employed Theresa Coughlin as an employee benefits manager through January 2013, and then as an employee benefits senior manager fromJanuary 2013 through January 2014. Ms. Coughlin is the sister of Mary Tolan, who served as our Chief Executive Officer through April 2013 and as amember of our board of directors until May 15, 2015. Ms. Coughlin’s employment with our company ended on January 31, 2014. In 2012 and 2013,Ms. Coughlin’s total compensation, including salary, bonus and the amount of share-based compensation expense that we recognized for financial statementreporting purposes for stock options previously granted to her, was $135,104, and $148,323, respectively.Registration RightsWe are a party to a stockholders’ agreement with certain of our stockholders, including the following current and former directors, former executiveofficers and holders of more than 5% of our voting securities and their affiliates and immediate family members: Mary A. Tolan, Etienne H. Deffarges,Gregory N. Kazarian, Irrevocable 2009 Kazarian Children’s Trust, Irrevocable 2009 Gregory N. Kazarian Trust, John T. Staton Declaration of Trust, Steven N.Kaplan, Kazarian Family, LLC, and Spiegel Family LLC. Pursuant to the stockholders’ agreement, we are required to pay all registration fees and expenses,including the reasonable fees and disbursements of one counsel for the participating stockholders, and indemnify each participating stockholder with respectto each registration of registrable shares that is affected.IndemnificationOur restated certificate of incorporation provides that we will indemnify our directors and officers to the fullest extent permitted by Delaware law. Inaddition, we have entered into indemnification agreements with each of our directors and executive officers that are broader in scope than the specificindemnification provisions contained in the Delaware General Corporation Law.Board Determination of IndependenceOur securities are traded through the facilities of the OTC Markets Group, Inc., which does not have requirements that a majority of the board ofdirectors be independent, so we have elected to apply the requirements for independence under the listing standards of the NYSE, where our common stockwas traded until March 2014. Pursuant to the corporate governance listing standards of the NYSE, a director currently or recently employed by us or notsatisfying other bright-line independence standards under NYSE rules cannot be deemed to be an “independent director”. In addition, in accordance with theNYSE corporate governance listing standards, each other director will qualify as “independent” only if our board of directors affirmatively determines that heor she has no material relationship with us, either directly or as a partner, stockholder or officer of an organization that has a relationship with us. Ownershipof a significant amount of our stock, by itself, does not constitute a material relationship.Our board of directors has affirmatively determined that each of Messrs. Bronfman, Ditkoff, Hammond, Kaplan, Klein, Logan, Mandl, Nayden, Rubin,Shulman, Stanek and Wolfson is “independent” in accordance with Section 303A.02 of the NYSE Listed Company Manual, and that Messrs. Cline andSpiegel, former directors, were independent prior to their resignations from our board of directors on May 15, 2015 and May 18, 2015, respectively. Indetermining that Mr. Ditkoff is independent, our board of directors considered payments that we made to Alvarez112& Marsal, where Mr. Ditkoff serves as a Senior Advisor and as an employee, for facilities and transformation services. The payments that we made to Alvarez& Marsal in any of the last three fiscal years did not exceed the greater of (i) $ 1 million or (ii) 2% of Alvarez & Marsal’s consolidated gross revenues for theyear in which such payments were received.Our board of directors has established an audit committee, a compensation committee and a nominating and corporate governance committee. Ourboard of directors has affirmatively determined that all of the members of each of the board’s three standing committees are independent as defined under therules of the NYSE, including, in the case of all members of the audit committee, the independence requirements contemplated by Rule 10A-3 under theExchange Act, and in the case of all members of the compensation committee, the independence requirements contemplated by Rule 10C-1 under theExchange Act.113Item 14.Principal Accountant Fees and ServicesWe incurred the following fees from our independent registered public accounting firm, Ernst & Young LLP for the years ended December 31, 2014 andDecember 31, 2013 (in thousands): For the years ended 2014 2013Fee category Audit and restatement fees $2,500 $37,449Audit-related fees 25 34Tax fees — 9All other fees 2 2Total fees $2,527 $37,494Audit Fees. Audit fees consist of fees for the audit of our annual consolidated financial statements, the review of the interim consolidated financialstatements, subsidiary audits and other professional services provided in connection with our filings with the SEC for each respective year. The amountspresented for Audit and Restatement Fees for 2014 represent estimated final fees in connection with the ongoing audit of our 2014 consolidated financialstatements, as well as the ongoing review of our unaudited condensed consolidated financial statements for the quarterly periods in 2014. The amountspresented for 2013 consisted of fees associated with the audit of our 2013 and 2012 consolidated financial statements, as well as the restatement of ouraudited results for the year ended December 31, 2011 and the restatement of our unaudited condensed consolidated financial statements for the quarterlyperiods in 2012 and 2011, which we refer to as the Restatement.Audit-Related Fees. Audit-related fees for 2014 and 2013 consisted of fees for audits of employee benefit plans.Tax Fees. Tax fees for 2013 consisted of fees for tax compliance and related regulatory filings.All Other Fees. All other fees for 2014 and 2013 consisted of a subscription for access to an accounting research tool.The audit committee of our board of directors believes that the non-audit services described above did not compromise Ernst & Young LLP’sindependence. The audit committee’s charter, which you can find in the “Corporate Governance” section of the “Investor Relations” page of our website,www.accretivehealth.com, requires that all proposals to engage Ernst & Young LLP for services, and all proposed fees for these services, be submitted to theaudit committee for approval before Ernst & Young LLP may provide the services. None of the above fees were approved using the “de minimis exception”under SEC rules.Pre-Approval of Audit and Non-Audit ServicesOur audit committee has adopted policies and procedures relating to the approval of all audit and non-audit services that are to be performed by ourregistered public accounting firm. This policy generally provides that we will not engage our registered public accounting firm to render audit or non-auditservices unless the service is specifically approved in advance by our audit committee.From time to time, our audit committee may pre-approve specified types of services that are expected to be provided to us by our registered publicaccounting firm during the next 12 months. Any such pre-approval is detailed as to the particular service or type of services to be provided and is alsogenerally subject to a maximum dollar amount. Our audit committee pre-approved all of the services described under the headings “Audit and RestatementFees,” “Audit-Related Fees,” “Tax Fees” and “All Other Fees” above.114PART IVItem 15.Exhibits and Financial Statement Schedulesa) The following documents are filed as a part of this report:(1) Financial Statements: The financial statements and notes thereto annexed to this report beginning on page F-1.(2) Financial Statement Schedules: Schedule II- Valuation and Qualifying Accounts Disclosure schedules have been omitted because they are notrequired or because the required information is in the Consolidated Financial Statements and notes thereto.(3) Exhibits: The list of Exhibits filed as part of this Annual Report on Form 10-K is set forth on the Exhibit Index immediately preceding suchExhibits and is incorporated herein by this reference.115SIGNATURESPursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on itsbehalf by the undersigned, thereunto duly authorized. ACCRETIVE HEALTH, INC. By:/s/ Emad Rizk Emad Rizk President and Chief Executive Officer By:/s/ Peter P. Csapo Peter P. Csapo Chief Financial Officer and TreasurerDate: June 23, 2015Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant inthe capacities and on the dates indicated.Signature Title Date /s/ Emad RizkEmad Rizk Director, President and Chief Executive Officer(Principal Executive Officer) June 23, 2015 /s/ Peter P. CsapoPeter P. Csapo Chief Financial Officer and Treasurer(Principal Financial Officer) June 23, 2015 /s/ Richard EvansRichard Evans Principal Accounting Officer June 23, 2015 /s/ Steven J. ShulmanSteven J. Shulman Chairman of the Board June 23, 2015 /s/ Edgar M. Bronfman, Jr.Edgar M. Bronfman, Jr. Director June 23, 2015 /s/ Steven N. KaplanSteven N. Kaplan Director June 23, 2015 /s/ Stanley N. LoganStanley N. Logan Director June 23, 2015 /s/ Alex J. MandlAlex J. Mandl Director June 23, 2015 /s/ Denis J. NaydenDenis J. Nayden Director June 23, 2015 /s/ Robert V. StanekRobert V. Stanek Director June 23, 2015 /s/ Mark A. WolfsonMark A. Wolfson Director June 23, 2015116 Signature Title Date /s/ Charles J. DitkoffCharles J. Ditkoff Director June 23, 2015 /s/ Michael B. HammondMichael B. Hammond Director June 23, 2015 /s/ Arthur A. KleinArthur A. Klein Director June 23, 2015 /s/ Lawrence B. LeisureLawrence B. Leisure Director June 23, 2015 /s/ Amir Dan RubinAmir Dan Rubin Director June 23, 2015117Accretive Health, Inc.Index to Consolidated Financial Statements PageAudited Consolidated Financial Statements Report of Independent Registered Public Accounting Firm F-2Consolidated Balance Sheets F-3Consolidated Statements of Operations and Comprehensive Income (Loss) F-4Consolidated Statements of Stockholders’ Equity (Deficit) F-5Consolidated Statements of Cash Flows F-6Notes to Consolidated Financial Statements F-7F-1Report of Independent Registered Public Accounting FirmTo the Board of Directors and Stockholdersof Accretive Health, Inc.We have audited the accompanying consolidated balance sheets of Accretive Health, Inc. as of December 31, 2014 and 2013, and the relatedconsolidated statements of operations and comprehensive income (loss), stockholders’ equity (deficit), and cash flows for each of the three years in the periodended December 31, 2014. These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express anopinion on these financial statements based on our audits.We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standardsrequire that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An auditincludes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing theaccounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe thatour audits provide a reasonable basis for our opinion.In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Accretive Health,Inc. at December 31, 2014 and 2013, and the consolidated results of its operations and its cash flows for each of the three years in the period endedDecember 31, 2014, in conformity with U.S. generally accepted accounting principles.We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), Accretive Health, Inc.’sinternal control over financial reporting as of December 31, 2014, based on criteria established in Internal Control-Integrated Framework issued by theCommittee of Sponsoring Organizations of the Treadway Commission (1992 framework) and our report dated June 23, 2015, expressed an adverse opinionthereon. Chicago, IllinoisJune 23, 2015F-2Accretive Health, Inc.Consolidated Balance Sheets(In thousands, except per share data) December 31, 2014 2013Assets Current assets: Cash and cash equivalents $145,167 $228,891Restricted cash 5,000 —Accounts receivable, net 4,438 24,557Prepaid income taxes 6,138 9,738Current deferred tax assets 62,322 105,015Other current assets 7,389 6,943Total current assets 230,454 375,144Property, equipment and software, net 14,594 16,275Non-current deferred tax asset 201,163 112,993Restricted cash — 5,000Goodwill and other assets, net 162 579Total assets 446,373 509,991Liabilities and stockholders’ equity (deficit) Current liabilities: Accounts payable 12,488 4,254Current portion of customer liabilities 219,998 356,694Accrued compensation and benefits 14,983 11,810Other accrued expenses 15,680 20,046Total current liabilities 263,149 392,804Non-current portion of customer liabilities 317,065 195,392Other non-current liabilities 8,405 7,407Total liabilities 588,619 595,603Stockholders’ equity (deficit): Common stock, $0.01 par value, 500,000,000 shares authorized, 102,890,241 shares issued and 98,112,019shares outstanding at December 31, 2014; 100,525,241 shares issued and 96,010,911 shares outstanding atDecember 31, 2013 1,029 1,005Additional paid-in capital 307,075 283,439Accumulated deficit (397,517) (317,897)Accumulated other comprehensive loss (1,763) (1,459)Treasury stock (51,070) (50,700)Total stockholders’ equity (deficit) (142,246) (85,612)Total liabilities and stockholders’ equity (deficit) 446,373 509,991See accompanying notes to consolidated financial statements.F-3Accretive Health, Inc.Consolidated Statements of Operations and Comprehensive Income (Loss)(In thousands, except per share data) Year Ended December 31, 2014 2013 2012Net services revenue $210,140 $504,768 $72,254Operating expenses: Cost of services 182,144 186,752 188,666Selling, general and administrative 69,883 79,951 67,750Restatement and other 86,766 33,963 3,714Total operating expenses 338,793 300,666 260,130Income (loss) from operations (128,653) 204,102 (187,876)Net interest income 302 330 141Income (loss) before income tax provision (128,351) 204,432 (187,735)Income tax provision (benefit) (48,731) 74,349 (67,995)Net income (loss) $(79,620) $130,083 $(119,740)Net income (loss) per common share: Basic $(0.83) $1.36 $(1.21)Diluted $(0.83) $1.34 $(1.21)Weighted average shares used in calculating net income (loss) per common share: Basic 95,760,762 95,687,940 98,602,099Diluted 95,760,762 96,845,664 98,602,099Consolidated statements of comprehensive income (loss) Net income (loss) (79,620) 130,083 (119,740)Other comprehensive loss: Foreign currency translation adjustments (304) (703) (46)Comprehensive income (loss) $(79,924) $129,380 $(119,786)See accompanying notes to consolidated financial statements.F-4Accretive Health, Inc.Consolidated Statements of Stockholders’ Equity (Deficit)(In thousands, except per share data) Common Stock Treasury Stock AdditionalPaid-InCapital AccumulatedDeficit Accumulatedothercomprehensive(loss) Total Shares Amount Shares Amount Balance at January 1, 2012 98,701,161 $987 (14,804) $(379) $226,911 $(328,240) $(710) $(101,431)Share-based compensation expense — — — — 25,298 — — 25,298Issuance of common stock related toshare-based compensation plans 1,306,377 13 — — 7,383 — — 7,396Excess tax benefit from share basedcompensation plans net of deferred taxasset write off of $1,920 — — — — 2,483 — — 2,483Treasury stock purchases — — (4,322,683) (50,160) — — — (50,160)Foreign currency translationadjustments — — — — — — (46) (46)Net loss — — — — — (119,740) — (119,740)Balance at December 31, 2012 100,007,538 $1,000 (4,337,487) $(50,539) $262,075 $(447,980) $(756) $(236,200)Share-based compensation expense — — — — 25,025 — — 25,025Deferred tax asset write off net ofexcess tax benefit of $15 — — — — (3,702) — — (3,702)Issuance of common stock related toshare-based compensation plans 517,703 5 — — 41 — — 46Treasury stock purchases — — (176,843) (161) — — — (161)Foreign currency translationadjustments — — — — — — (703) (703)Net income — — — — — 130,083 — 130,083Balance at December 31, 2013 100,525,241 $1,005 (4,514,330) $(50,700) $283,439 $(317,897) $(1,459) $(85,612)Share-based compensation expense — — — — 27,181 — — 27,181Deferred tax asset write off includingshortfall of $176 — — — — (3,521) — — (3,521)Issuance of common stock related toshare-based compensation plans 2,365,000 24 — — (24) — — —Treasury stock purchases — — (263,892) (370) — — — (370)Foreign currency translationadjustments — — — — — — (304) (304)Net income — — — — — (79,620) — (79,620)Balance at December 31, 2014 102,890,241 $1,029 (4,778,222) $(51,070) $307,075 $(397,517) $(1,763) $(142,246)See accompanying notes to consolidated financial statements.F-5Accretive Health, Inc.Consolidated Statements of Cash Flows(In thousands) Year Ended December 31, 2014 2013 2012Operating activities Net income (loss) $(79,620) $130,083 $(119,740)Adjustments to reconcile net income (loss) to net cash provided by (used in) operations: Depreciation and amortization 6,047 6,823 6,355Share-based compensation 27,181 25,025 25,298Loss on disposal 1,604 — —Provision (recovery) for doubtful receivables (430) 634 183Deferred income taxes (49,227) 79,356 (76,887)Excess tax benefit from share-based awards (176) (15) (4,403)Changes in operating assets and liabilities: Accounts receivable 20,548 658 (8,926)Prepaid income taxes 3,794 (4,836) 6,980Other assets (47) 14,434 (1,571)Accounts payable 8,251 3,378 (358)Accrued compensation and benefits 3,174 3,813 (7,581)Other liabilities (3,312) (2,955) 2,166Customer liabilities (15,023) (201,975) 207,650Net cash provided by (used in) operating activities (77,236) 54,423 29,166Investing activities Purchases of property, equipment, and software (6,034) (1,877) (10,544)Net cash used in investing activities (6,034) (1,877) (10,544)Financing activities Excess tax benefit from share-based awards 176 15 4,403Exercise of vested stock options — 46 7,396Purchase of treasury stock (370) (161) (50,160)Collection of non-executive employee loans — — —Net cash used in financing activities (194) (100) (38,361)Effect of exchange rate changes in cash (260) (511) (30)Net increase (decrease) in cash and cash equivalents (83,724) 51,935 (19,769)Cash and cash equivalents, at beginning of year 228,891 176,956 196,725Cash and cash equivalents, at end of year $145,167 $228,891 $176,956Supplemental disclosures of cash flow information Income taxes paid $(801) $(1,742) $(1,531)Income taxes refunded $3,014 $754 $87Supplemental disclosure of non-cash operating activities Non-cash increase in litigation liability and related insurance receivable included in other liabilitiesand other assets, respectively $— $— $14,000See accompanying notes to consolidated financial statements.F-6Accretive Health, Inc.Notes to Consolidated Financial StatementsNote 1. Description of BusinessAccretive Health, Inc. (the "Company") is a leading provider of services that help healthcare providers generate sustainable improvements in theiroperating margins and cash flows while also improving patient, physician and staff satisfaction for its customers. The Company achieves these results for itscustomers through an integrated approach encompassing its end-to-end revenue cycle management service and physician advisory service offerings. TheCompany does so by deploying a unique operating model that leverages its extensive healthcare site experience, innovative technology and processexcellence. The Company also offer modular services, allowing clients to engage the Company for only specific components of its end-to-end revenue cyclemanagement service offering.The Company’s primary service offering consists of revenue cycle management ("RCM"), which helps healthcare providers to more efficiently managetheir revenue cycles. This encompasses patient registration, insurance and benefit verification, medical treatment documentation and coding, bill preparationand collections from patients and third-party payers. The Company’s physician advisory services offering assists hospitals in complying with third-partypayers’ requirements regarding whether to classify a hospital visit as an in-patient or an out-patient observation case for billing purposes and consists of bothconcurrent review and retrospective chart audits. The Company also provides customers with retrospective appeal management service support for bothgovernmental and commercial payers.Note 2. Summary of Significant Accounting PoliciesBasis of PresentationThe consolidated financial statements include the assets, liabilities and results of operations of the Company and its wholly owned subsidiaries. Allmaterial intercompany transactions and balances have been eliminated in consolidation. The preparation of financial statements in conformity with theUnited States generally accepted accounting principles ("GAAP") requires management to make estimates and assumptions that affect the amounts reportedin these consolidated financial statements and accompanying notes. Actual results can differ from those estimates.SegmentsReporting segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by thechief operating decision maker, or decision-making group, in making decisions on how to allocate resources and assess performance. All of the Company’soperations are organized around the single business of providing end-to-end management services of revenue cycle operations for U.S-based hospitals andother medical providers. The Company views its operations and manages its business as one operating and reporting segment.Revenue RecognitionRevenue is generally recognized when all of the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) services have beenrendered, (iii) the fee is fixed or determinable and (iv) collectability is reasonably assured.F-7Accretive Health, Inc.Notes to Consolidated Financial StatementsNote 2. Summary of Significant Accounting Policies (continued)Net service fees, as reported in the consolidated statement of operations and comprehensive income (loss), consist of: (a) RCM service fees and(b) professional service fees earned on a fixed fee, transactional fee, or time and materials basis. The Company’s primary source of revenue is RCM servicefees. RCM service fees are primarily contingent, but along with fixed fees are generally viewed as one deliverable. To the extent that certain RCM servicefees are fixed and not subject to refund, adjustment or concession, these fees are recognized into revenue on a straight-line basis over the term of the contract.RCM service fees that are contingent in nature are recognized as revenue once all the criteria for revenue recognition are met, which is generally at theend of a contract or other contractual agreement events. Revenue is recognized for RCM service fees upon the contract reaching the end of its stated term(such that the contractual relationship will not continue in its current form) to the extent that: (i) cash has been received for invoiced fees; and (ii) there are nodisputes at the conclusion of the term of the contract.If fees or services are disputed by a customer at the end of a contract, a settlement agreement entered into with the customer triggers revenuerecognition. An “other contractual agreement event” occurs when a renewal or amendment to an existing contract is executed in which the parties reachagreement on prior fees. Revenue is recognized up to the amount covered by such agreements.RCM service fees consist of the following contingent fees: (i) Net Operating Fees and (ii) Incentive Fees.Net Operating FeesThe Company generates net operating fees to the extent the Company is able to assist customers in reducing the cost of their revenue cycle operations.The Company's delivery model leverages the customers' RCM personnel. The Company’s net operating fees consist of:i) gross base fees invoiced to customers; lessii) corresponding costs of customers’ revenue cycle operations which the Company pays pursuant to its RCM agreements, including salaries andbenefits for the customers' RCM personnel, and related third-party vendor costs; lessiii) any cost savings the Company shares with customers.Net operating fees are reported as deferred customer billings until the Company recognizes revenue for a customer contract at the end of a contract orreaches an "other contractual agreement event". The amount of unpaid costs of customers’ revenue cycle operations and shared cost savings are reported asaccrued service costs within customer liabilities in the consolidated balance sheets.Incentive FeesThe Company generates revenue in the form of performance-based fees when the Company improves the customers’ revenue yield. These performancemetrics vary by customer contract. However, certain contracts contain a contract-to-date performance metric that is not resolved until the end of the term ofthe contract. Incentive fees are reported as deferred customer billings only upon cash receipt and until the Company recognizes revenue for a customer at theend of a contract or other contractual agreement event. In some cases, when a customer agreement is extended under an evergreen provision or otheramendment, fees may not be considered finalized until the end of the customer relationship. Incentive fees associated with performance metrics which are notresolved until the end of the term of the contract or an “other contractual agreement event” are recorded in deferred customer billings until we recognizerevenue. Incentive fees are considered contingent fees.F-8Accretive Health, Inc.Notes to Consolidated Financial StatementsNote 2. Summary of Significant Accounting Policies (continued)Customer LiabilitiesBase fees and fixed fees are billed on a monthly or quarterly basis and incentive fees are billed to customers on a quarterly basis. Generally, base fees arebilled in advance of each service period. Customer liabilities include: (i) accrued service costs (amounts due and accrued for cost reimbursements net ofamounts receivable for base fees from the corresponding customer), (ii) deferred customer billings (net operating fees invoiced or accrued and incentive feescollected that have not met all revenue recognition criteria), (iii) customer deposits (consisting of net operating fees under the Company’s RCM contractsthat are paid prior to the service period and amounts due as a refund to our customers on incentive fees) and, (iv) deferred revenue (fixed fees amortized torevenue over the service period or fixed or determinable fees that have not met all other revenue recognition criteria). Deferred customer billings are classifiedas current based on the customer contract end dates or other termination events that fall within twelve months of the balance sheet dates. Accrued servicecost, customer deposits, and deferred revenue are classified as current or non-current based on the anticipated period in which the liabilities are expected tobe settled or the revenue is expected to be recognized. December 31, 2014 2013Deferred customer billings, current $132,063 $232,876Accrued service costs, current 68,077 100,833Customer deposits, current 19,675 22,817Deferred revenue, current 183 168Current portion of customer liabilities 219,998 356,694Deferred customer billings, non-current 317,065 192,826Customer deposits, non-current — 2,566Non current portion of customer liabilities 317,065 195,392Total customer liabilities $537,063 $552,086Consulting Fees, Transaction Fees and Contingent Service FeesThe Company also generates revenue from fixed-fee arrangements, transactional service contracts and contingency-fee service contracts. Provided allother criteria of revenue recognition are met under Accounting Standards Codification ("ASC") 605, Revenue Recognition, revenue under these arrangementsis recognized as services are performed, deliverables are provided and related contingencies are removed. All related direct costs are recorded as period costswhen incurred. These consulting fees, transactional fees and contingent service fees are generated from services such as physician advisory services,population health solutions, and other related consulting services.Cost of ServicesCosts associated with generating the Company’s net services revenue, including the cost of operating its shared services centers, are expensed asincurred. Cost of services consist of (i) infused management and technology costs, (ii) shared services costs and (iii) other costs to perform physician advisoryservices and population health solutions. Infused management and technology costs consist primarily of wages, bonuses, benefits, share-based compensation,travel and other costs associated with deploying the Company’s employees at customer sites to help manage the Company’s customers’ revenue cycleoperations. The other significant portion of these expenses is anF-9Accretive Health, Inc.Notes to Consolidated Financial StatementsNote 2. Summary of Significant Accounting Policies (continued)allocation of the costs associated with maintaining, improving, and deploying our integrated proprietary technology suite. Shared services costs relate to theCompany’s shared services centers in the U.S. and India that perform patient scheduling and pre-registration, medical transcription, cash posting,reconciliation of payments to billing records, patient follow-up, and Medicaid eligibility determination for our customers. The Company incurs expensesrelated to salaries and benefits for employees in its shared services centers and non-payroll costs associated with operating its shared services centers. Otherexpenses consist of costs related to managing physician advisory services, population health solutions, and other services. These expenses consist primarilyof wages, bonuses, benefits, share-based compensation, and facilities costs.Comprehensive Income (Loss)Comprehensive income (loss) is the net income (loss) of the Company combined with other changes in stockholders’ equity (deficit) not involvingownership interest changes. For the Company, such changes are foreign currency translation adjustments.Cash and Cash EquivalentsThe Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The followingtable summarizes assets that are measured at fair value and are categorized using the fair value hierarchy (in thousands). December 31, 2014 2013Level 1 assets – Money market funds with maturities of less than 90 days $137,802 $217,065Accounts Receivable and Allowance for Doubtful AccountsAccounts receivable is comprised of unpaid balances pertaining to non-RCM service fees and net receivable balances for RCM customers afterconsidering cost reimbursements owed to such customers, including related accrued balances.The Company maintains an estimated allowance for doubtful accounts to reduce its accounts receivable to the amount that it believes will be collected.This allowance is based on the Company’s historical experience, its assessment of each customer’s ability to pay, the length of time a balance has beenoutstanding, input from key customer resources assigned to each customer, and the status of any ongoing operations with each applicable customer.Movements in the allowance for doubtful accounts are as follows (in thousands): December 31, 2014 2013 2012Beginning balance $740 $183 $95Provision (recovery) (430) 634 183Write-offs 4 (77) (95)Ending balance $314 $740 $183F-10Accretive Health, Inc.Notes to Consolidated Financial StatementsNote 2. Summary of Significant Accounting Policies (continued)Property, Equipment and SoftwareProperty and equipment are stated at cost, and related depreciation and amortization are calculated on the straight-line method over the estimateduseful lives of the assets.For many internally developed software projects, the Company adheres to a development methodology where the process moves quickly betweenplanning, design, development, testing, and then moves back to planning before the testing is complete. As such, there are short development cycles andrapid production changes for these software projects. As a result, the qualifying activities to capitalize development costs have a short timeframe andtherefore, the Company expenses its internal development labor costs as incurred for these projects. For projects that do not meet the criteria described above,the Company capitalizes qualifying internal costs in accordance with GAAP. The Company capitalizes qualifying third-party costs and hardware andsoftware costs related to the Company’s software development activities in accordance with GAAP. The Company amortizes the capitalized softwaredevelopment costs over their estimated life on a straight-line basis.The major classifications of property, equipment and software and their expected useful lives are as follows: Computers and other equipment 3 yearsLeasehold improvements Shorter of 10 years or lease termOffice furniture 5 yearsSoftware 3 to 5 yearsGoodwillGoodwill represents the excess purchase price over the net assets of a business the Company acquired in May 2006. Goodwill is not subject toamortization but is subject to impairment testing at least annually. The Company’s annual impairment assessment date is October 1. The Company has $0.2million and $0.5 million of goodwill that is included in “Goodwill and other assets, net” in the accompanying consolidated balance sheets at 2014 and 2013,respectively.The Company has the option to assess goodwill impairment by first performing a qualitative assessment to determine whether it is more likely than notthat the fair value of a reporting unit is less than its carrying amount. If the Company determines that it is more likely than not that the fair value of areporting unit is less than its carrying amount, the Company is required to perform a two-step goodwill impairment test. In the first step, the fair value of thereporting unit is compared to its book value including goodwill. If the fair value of the reporting unit is in excess of its book value, the related goodwill isnot impaired and no further analysis is necessary. If the fair value of the reporting unit is less than its book value, there is an indication of potentialimpairment and a second step is performed. When required, the second step of testing involves calculating the implied fair value of goodwill for the reportingunit. The implied fair value of goodwill is determined in the same manner as goodwill recognized in a business combination, which is the excess of the fairvalue of the reporting unit determined in step one over the fair value of its net assets and identifiable intangible assets. If the carrying value of the reportingunit’s goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to that excess. There was no impairmentof goodwill during the years ended December 31, 2014, 2013 and 2012.Impairment of Long-Lived AssetsProperty, equipment, software and other acquired intangible assets are reviewed for impairment whenever events or changes in circumstances indicatethat the carrying amount of the asset may not be recoverable. If circumstances require a long-lived asset or asset group be reviewed for possible impairment,the Company first compares undiscounted cash flows expected to be generated by each asset or asset group to its carrying value. If theF-11Accretive Health, Inc.Notes to Consolidated Financial StatementsNote 2. Summary of Significant Accounting Policies (continued)carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment charge is recognized to the extentthat the carrying value exceeds the fair value. There was no impairment of property, equipment, software or other acquired intangible assets for the yearsended December 31, 2014, 2013 and 2012.Income TaxesIncome taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequencesattributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating lossand tax credit carry forwards. Deferred tax assets and liabilities are measured using current tax laws and enacted tax rates in effect for the years in which thosetemporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in incomein the period that includes the enactment date. The Company records a valuation allowance for deferred tax assets if, based upon the weight of all availableevidence, both positive and negative, it is more likely than not that some or all of the deferred tax assets will not be realized.The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained uponexamination by the tax authorities, based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements fromsuch a position are measured based on the largest amount of benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement.Interest and penalties relating to income taxes are recognized in our income tax provision in the statements of consolidated operations.Fair Value of Financial InstrumentsThe Company records its financial assets and liabilities at fair value. The accounting standard for fair value (i) defines fair value as the price that wouldbe received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date,(ii) establishes a framework for measuring fair value, (iii) establishes a hierarchy of fair value measurements based upon the ability to observe inputs used tovalue assets and liabilities, (iv) requires consideration of nonperformance risk, and (v) expands disclosures about the methods used to measure fair value. Theaccounting standard establishes a three-level hierarchy of measurements based upon the reliability of observable and unobservable inputs used to arrive atfair value. Observable inputs are independent market data, while unobservable inputs reflect the Company’s assumptions about valuation. The three levels ofthe hierarchy are defined as follows:•Level 1: Observable inputs such as quoted prices in active markets for identical assets and liabilities;•Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices forsimilar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active, and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and;•Level 3: Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.The carrying amounts of the Company’s financial instruments, which include financial assets such as cash and cash equivalents, restricted cash,accounts receivable, amounts due from related party and certain other current assets, as well as financial liabilities such as accounts payable, accrued servicecosts, accrued compensation and benefits and certain other accrued expenses, approximate their fair values, due to the short-term nature of theseF-12Accretive Health, Inc.Notes to Consolidated Financial StatementsNote 2. Summary of Significant Accounting Policies (continued)instruments. The Company’s financial assets which are required to be measured at fair value on a recurring basis consist of cash equivalents, which are highlyliquid money market funds and accordingly are classified as Level 1 assets in the fair value hierarchy. The Company does not have any financial liabilitiesthat are required to be measured at fair value on a recurring basis.Legal and Other ContingenciesIn the normal course of business, the Company is subject to regulatory investigations or legal proceedings, as well as demands, claims and threatenedlitigation. The Company records an estimated loss for any claim, lawsuit, investigation or proceeding when it is probable that a liability has been incurredand the amount of the loss can be reasonably estimated. Significant judgment is required in both the determination of the probability and whether the losscan be reasonably estimated. Actual expenses could differ from these estimates.Foreign Currency Translation and Transaction Gains/(Losses)Assets and liabilities of non-U.S. subsidiaries that operate in a local currency environment, where that local currency is the functional currency, aretranslated to U.S. dollars at exchange rates in effect at the balance sheet date. Income and expense accounts are translated at average exchange rates duringthe year which approximate the rates in effect at the transaction dates. The resulting translation adjustments are recorded as a separate component ofaccumulated other comprehensive income (loss).The Company’s foreign currency transaction gains and losses are included in selling, general and administrative in the accompanying consolidatedstatements of operations and comprehensive income (loss).Share-Based Compensation ExpenseThe Company determines the expense for all employee share-based compensation awards by estimating their fair value and recognizing that value asan expense, on a ratable basis, in the consolidated financial statements over the requisite service period in which the employees earn the awards. The fairvalue of performance and service condition stock options is calculated using the Black Scholes option pricing model and, for market condition stockoptions, the fair value is estimated using Monte Carlo simulations.To determine the fair value of a share-based award using the Black-Scholes option pricing model, the Company makes assumptions regarding the risk-free interest rate, expected future volatility, expected life of the award, and expected forfeitures of the awards. These inputs are subjective and generallyrequire significant analysis and judgment to develop. The Company aggregates all employees into one pool based on the grant date for valuation purposes.The risk-free rate is based on the U.S. treasury yield curve in effect at the time of grant. The Company estimates the expected volatility of the share price byreviewing the historical volatility levels of its common stock in conjunction with that of public companies that operate in similar industries or are similar interms of stage of development or size and then projecting this information toward its future expected volatility. The Company exercises judgment inselecting these companies, as well as in evaluating the available historical and implied volatility for these companies. The Company calculates the expectedterm in years for each stock option using a simplified method based on the average of each option’s vesting term and original contractual term. The Companyapplies an estimated forfeiture rate derived from its historical data and estimates of the likely future actions of option holders when recognizing the share-based compensation expense of the options.To determine the fair value of a share-based award using Monte Carlo simulations, the Company makes assumptions regarding the risk-free interest rate,expected future volatility, expected dividend yield and performance period. The risk-free rate is based on the U.S. treasury yield curve in effect at the time ofgrant. The Company estimates the expected volatility of the share price by reviewing the historical volatility levels of its common stock in conjunction withthat of public companies that operate in similar industries or are similar in terms of stage ofF-13Accretive Health, Inc.Notes to Consolidated Financial StatementsNote 2. Summary of Significant Accounting Policies (continued)development or size and then projecting this information toward its future expected volatility. Dividend yield is determined based on the Company’s futureplans to pay dividends. The Company had no plans to do so at December 31, 2014. The Company calculates the performance period based on the specificmarket condition to be achieved and derived from historical data and estimates of future performance.The Company recognizes compensation expense, net of forfeitures, using a straight-line method over the applicable service or performance period.During each quarter, the share-based compensation expense is adjusted to reflect all expense for options that vested during the period; however,compensation expense already recognized is not adjusted if market conditions are not met.The Company accounts for stock options issued to non-employees based on their estimated fair value determined using the Black-Scholes optionpricing model. The stock options issued to non-employees vest over the arrangement period. The fair value of the equity awards granted to non-employees isremeasured on each balance sheet date until the awards vest, and the related expense is adjusted based on the resulting changes in fair value, if any. The non-employee share-based compensation expense is recognized over the performance period which is the vesting period. Upon vesting, the performance of thenon-employee is deemed complete and the vested awards are not remeasured subsequently.The fair value of modifications to share-based awards is generally estimated using the Black-Scholes option pricing model. If a share-basedcompensation award is modified after the grant date, incremental compensation expense is recognized in an amount equal to the excess of the fair value ofthe modified award over the fair value of the original award immediately before the modification. Incremental compensation expense for vested awards isrecognized immediately. For unvested awards, the sum of the incremental compensation expense and the remaining unrecognized compensation expense forthe original award on the modification date is recognized over the modified service period.Treasury StockThe Company records treasury stock at the cost to acquire such shares and includes treasury stock as a component of stockholders’ equity (deficit).Earnings (Loss) Per ShareBasic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares outstandingduring the period. The diluted net income (loss) per common share computation includes the effect, if any, of common shares that would be issuable upon theexercise of outstanding stock options, unvested restricted stock, reduced by the number of common shares which are assumed to be purchased by theCompany with the resulting proceeds from the exercise of stock options, at the average market price during the year, when such amounts are dilutive to thenet income (loss) per share calculation.Recently Adopted Accounting Standards and DisclosuresFrom time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other standard setting bodies.Unless otherwise discussed, the Company’s management believes that the impact of recently issued accounting pronouncements that are not yet effectivewill not have a material impact on the Company’s consolidated financial position or results of operations upon adoption.In February 2013, the FASB issued Accounting Standards Update ("ASU") 2013-02, Comprehensive Income (Topic 220): Reporting of AmountsReclassified Out of Accumulated Other Comprehensive Income. ASU 2013-02 requires reporting entities to provide information about the amountsreclassified from accumulated other comprehensive income by component. In addition, reporting entities are required to present, either on the face of theF-14Accretive Health, Inc.Notes to Consolidated Financial StatementsNote 2. Summary of Significant Accounting Policies (continued)statement of income and comprehensive income or in the footnotes to the financial statements, significant amounts reclassified from accumulated othercomprehensive income by statements of income and comprehensive income line item. This ASC does not change current requirements for reporting netincome or other comprehensive income in financial statements. ASU 2013-02 is effective for fiscal years, and interim periods within those years, beginningon or after December 15, 2012. The Company adopted the provisions of the ASU in 2013. The adoption of the ASU did not have an impact on the Company’sconsolidated financial statements.In July 2013, the FASB issued ASU 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar TaxLoss, or a Tax Credit Carryforward Exists. ASU 2013-11 provides guidance for presentation of an unrecognized tax benefit, or a portion of an unrecognizedtax benefit. ASU 2013-11 provides that a benefit should be presented in the financial statements as a reduction to a deferred tax asset for a net operating losscarryforward, a similar tax loss, or a tax credit carryforward, except as follows. To the extent a net operating loss carryforward, a similar tax loss, or a tax creditcarryforward is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result fromthe disallowance of a tax position or the tax law of the applicable jurisdiction does not require the entity to use, and the entity does not intend to use, thedeferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combinedwith deferred tax assets. ASU 2013-11 is effective for fiscal years and interim periods within those years, beginning on or after December 15, 2013, and willbe effective for the Company’s fiscal year beginning January 1, 2014. The adoption of the ASU did not have an impact on the Company’s consolidatedfinancial statements.Newly Issued Accounting Standards and DisclosuresIn May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognitionrequirements in ASC 605, Revenue Recognition. This ASU is based on the principle that revenue is recognized to depict the transfer of goods or services tocustomers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The ASU alsorequires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, includingsignificant judgments and changes in judgments. This pronouncement is effective for annual reporting periods beginning after December 15, 2016, includinginterim periods within that reporting period and is to be applied using one of two retrospective application methods, with early application not permitted. InApril 2015, the FASB proposed deferring the standard effective date by one year. The Company has not yet determined the potential effects of the newstandard on the consolidated financial statements, if any.F-15Accretive Health, Inc.Notes to Consolidated Financial StatementsNote 3. Property, Equipment, and SoftwareProperty, equipment, and software consist of the following (in thousands): December 31, 2014 2013Computer and other equipment $17,701 $16,630Leasehold improvements 12,491 13,346Software 12,398 9,589Office furniture 3,152 3,258Property and equipment and software, gross 45,742 42,823Less accumulated depreciation and amortization (31,148) (26,548)Property and equipment and software, net $14,594 $16,275The following table summarizes the allocation of depreciation and amortization expense between cost of services and selling, general andadministrative expenses (in thousands): For the Year Ended December 31, 2014 2013 2012Cost of services $4,603 $4,697 $3,957Selling, general and administrative 1,444 2,126 2,398Total depreciation and amortization $6,047 $6,823 $6,355Note 4. Stockholders’ Equity (Deficit)Preferred StockThe Company has 5,000,000 shares of authorized preferred stock with a par value of $0.01 each. The preferred stock may be issued from time to time inone or more series. The board of directors is authorized to determine the rights, preferences, privileges and restrictions of the Company’s authorized butunissued shares of preferred stock. As of December 31, 2014, 2013, and 2012, the Company does not have any shares of preferred stock outstanding.Common StockEach outstanding share of common stock is entitled to one vote per share on all matters submitted to a vote by shareholders. Subject to the rights of anypreferred stock which may from time to time be outstanding, the holders of outstanding shares of common stock are entitled to receive dividends and, uponliquidation or dissolution, are entitled to receive pro rata all assets legally available for distribution to stockholders. No dividends were declared or paid onthe common stock during 2014, 2013, and 2012.Treasury StockIn September 2012, the board of directors authorized a share repurchase plan allowing the Company to repurchase up to $50.0 million of itsoutstanding shares of common stock. For the year ended December 31, 2012, the Company repurchased 4,307,362 shares of its common stock under thisshare repurchase plan at an average price of $11.61 per share for a total of $50.0 million; this amount was recorded as a reduction of stockholders’ equity(deficit). As of December 31, 2012, the share repurchase plan was concluded.F-16Accretive Health, Inc.Notes to Consolidated Financial StatementsNote 4. Stockholders’ Equity (Deficit) (continued)On November 13, 2013, the Company’s board of directors authorized another repurchase of up to $50.0 million of the Company’s common stock in theopen market or in privately negotiated transactions following the Restatement, as defined in Note 7, Restatement and Other Costs. The timing and amount ofany shares repurchased will be determined by the Company based on its evaluation of market conditions and other factors. The repurchase program may besuspended or discontinued at any time at the sole discretion of the board of directors. Any repurchased shares will be available for use in connection with theCompany’s stock plans and for other corporate purposes. The Company currently intends to fund the repurchases from cash on hand. No shares of commonstock had been repurchased under this plan as of the date at which these consolidated financial statements were issued.Treasury stock also includes repurchases of Company stock related to employees’ tax withholding upon vesting of restricted shares. See Note 5, Share-Based Compensation.Note 5. Share-Based CompensationThe Company maintains two stock incentive plans: the 2006 Amended and Restated Stock Option Plan (the “2006 Plan”) and the 2010 StockIncentive Plan (the “2010 Plan” and, together with the 2006 Plan, the “Plans”). Under the 2010 Plan the Company could issue (up to a maximum of24,374,756 shares) any shares that remained available for issuance under the 2006 Plan as of the date of the IPO and any shares subject to awards that wereoutstanding under the 2006 Plan as of the date of the IPO that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased by theCompany without the issuance of shares thereunder. The Company will not make any further grants under the 2006 Plan. The 2010 Plan provides for thegrant of incentive stock options, non-statutory stock options, Restricted Stock Awards, (“RSAs”) and other share-based awards. As of December 31, 2014, anaggregate of 13,548,081 shares were outstanding as either options or RSAs under the Plans, and 5,262,904 shares were available for future grants of awardsunder the 2010 Plan. To the extent that previously granted awards under the 2006 Plan or 2010 Plan expire, terminate or are otherwise surrendered, canceled,forfeited or repurchased by the Company, the number of shares available for future awards under the 2010 Plan will increase.Under the terms of both plans, all awards will expire if they are not exercised within ten years of their grant date. Substantially all employee options andRSAs vest over four years at a rate of 25% per year on each grant date anniversary. Substantially all non-employee options vest over either one year or fouryears (at a rate of 25% per year). Options granted under the 2006 Plan could be exercised immediately upon grant, but upon exercise the shares issued weresubject to the same vesting and repurchase provisions that applied before the exercise. There were no such exercises during the years ended December 31,2014, 2013, and 2012. Options granted under the 2010 Plan cannot be exercised prior to vesting.In 2014 and 2013, the Company granted service-based, non-qualified options to purchase 3,400,000 and 4,703,801 shares of common stock andawarded 1,000,000 and 400,000 shares of restricted stock, respectively, to key employees pursuant to NYSE inducement grant rules, of which 7,103,801 and4,703,801of the stock options and 1,749,988 and 349,996 of the shares of restricted stock were outstanding as of December 31, 2014 and 2013, respectively.Also in 2014, pursuant to NYSE inducement grant rules, the Company granted a market-based award of 500,000 shares of restricted stock to the ChiefExecutive Officer. This RSA vests only when the average closing price of the Company’s stock price equals or exceeds twice the grant date stock price.F-17Accretive Health, Inc.Notes to Consolidated Financial StatementsNote 5. Share-Based Compensation (continued)The Company uses the Black-Scholes option pricing model to estimate the fair value of its service-based options as of its grant date. The followingtable sets forth the significant assumptions used in the Black-Scholes option pricing model and the calculation of share-based compensation cost during2014, 2013, and 2012: Year Ended December 31, 2014 2013 2012Expected dividend yield — — —Risk-free interest rate 1.9% to 2.2% 0.9% to 2.1% 0.8% to 1.4%Expected volatility 50% 50% 50%Expected term (in years) 6.25 5.82-8.82 6.25Forfeitures 5.68% annually 5.68% annually 4.42% annuallyThe Company uses Monte Carlo simulations to estimate the fair value of its market condition RSAs as of its grant date with the following: dividendyield of 0 percent; volatility of 50 percent; risk free interest rate of 2.20 percent and performance period of 7.5 years.Total share-based compensation costs that have been included in the Company’s consolidated statements of operations were as follows (in thousands): Year Ended December 31, 2014 2013 2012 Share-Based Compensation Expense Allocation Details: Cost of services $6,668 $10,740 $11,625Selling, general and administrative 13,503 13,061 13,673Restatement and other costs 8,761 1,224 —Total share-based compensation expense $28,932 $25,025 $25,298There was $42.8 million, $43.3 million, and $53.5 million of total, unrecognized share-based compensation expense related to stock options and RSAsgranted under the plans, which the Company expects to recognize over a weighted-average period of 3.2, 2.8 and 2.7 years as of December 31, 2014, 2013,and 2012, respectively. Refer to the consolidated statements of stockholders’ equity (deficit) for the tax benefits realized for the tax deductions from stockoption exercises.F-18Accretive Health, Inc.Notes to Consolidated Financial StatementsNote 5. Share-Based Compensation (continued)Stock optionsThe following table sets forth a summary of all employee and non-employee option activity under all plans and inducement grants for the years endedDecember 31, 2014, 2013, and 2012: Shares Weighted-AverageExercisePrice Weighted-AverageRemainingContractualTerm(in years) AggregateIntrinsic Value(in thousands)Outstanding at January 1, 2012 15,362,749$14.967.7 $138,632Granted 6,470,94912.49 Exercised (1,256,377)5.89 Canceled (546,100)15.31 Forfeited (2,324,082)21.11 Outstanding at December 31, 2012 17,707,13913.887.6 25,957Granted 8,345,43710.09 Exercised (9,400)4.34 Canceled (1,057,052)17.60 Forfeited (4,445,851)15.64 Outstanding at December 31, 2013 20,540,27311.777.4 15,673Granted 4,406,8568.78 Exercised —— Canceled (1,494,219)13.41 Forfeited (3,528,505)12.14 Outstanding at December 31, 2014 19,924,40510.916.9 9,444Outstanding, vested and exercisable at December 31, 2012 6,915,086$11.476.0 $20,761Outstanding, vested and exercisable at December 31, 2013 9,605,505$11.895.9 $15,096Outstanding, vested and exercisable at December 31, 2014 11,879,209$11.735.6 $9,444The weighted-average grant date fair value of options granted in the years ended December 31, 2014, 2013, and 2012 was $4.40, $5.19 and $6.05 pershare, respectively. The total intrinsic value of the options exercised in the years ended December 31, 2013 and 2012 was $0.1 million and $15.4 million,respectively. No options were exercised in the year ended December 31, 2014. The total fair value of options vested in the years ended December 31, 2014,2013, and 2012 was $22.9 million, $27.1 million and $25.4 million, respectively.Stock option activity for non-employee consultantsIncluded in the table and disclosures above are options to purchase 109,887, 265,517, and 403,712 shares held by non-employees as of December 31,2014, 2013, and 2012, respectively. These options had a weighted average exercise price of $17.12, $20.05, and $21.88 at December 31, 2014, 2013, and2012, respectively.F-19Accretive Health, Inc.Notes to Consolidated Financial StatementsNote 5. Share-Based Compensation (continued)Restricted stock awardsIn the third quarter of 2011, the Company began to grant RSAs to its employees. A summary of the activity during the years ended December 31, 2014,2013, and 2012 is shown below: Shares Weighted-Average GrantDate Fair Value Weighted-AverageRemainingContractualTerm(in years)Outstanding at January 1, 2012 159,080 $25.90 9.7Granted 50,000 11.16 Vested (48,860) 26.14 Forfeited — — Outstanding and Unvested at December 31, 2012 160,220 $21.23 9.0Granted 508,303 11.46 Vested (50,004) 11.47 Forfeited (160,220) 21.23 Outstanding and Unvested at December 31, 2013 458,299 $11.45 9.4Granted 2,365,000 8.39 Vested (127,084) 11.46 Forfeited (218,750) 9.40 Outstanding and Unvested at December 31, 2014 2,477,465 $8.71 9.3The total fair value of RSAs vested in the years ended December 31, 2014, 2013, and 2012 was $1.5 million, $0.6 million and $1.3 million,respectively. The Company’s RSA agreements allow employees to deliver to the Company shares of stock upon vesting of their RSAs in lieu of their paymentof the required personal employment-related taxes. The Company does not withhold taxes in excess of minimum required statutory requirements. During theyears ended December 31, 2014, 2013, and 2012, employees delivered to the Company 45,142, 16,623 and 15,321 shares of stock, respectively, which theCompany recorded at a cost of approximately $0.4 million, $0.2 million and $0.2 million, respectively. As of December 31, 2014, the Company held 91,890shares of surrendered common stock in treasury related to the vesting of RSAs.Forfeited and canceled RSAs are added to treasury stock. For the years ended December 31, 2014 and 2013, 218,750 and 160,220 shares were added totreasury stock due to canceled RSAs. No shares were canceled for the year ended December 31, 2012.Modifications of share-based awardsAs described in Note 7, Restatement and Other, during 2013, the Company failed to timely file its annual report on Form 10-K for the fiscal year endedDecember 31, 2012, and on March 4, 2013, its Registration Statement on Form S-8 was suspended. As a result, individuals have not been permitted toexercise vested options until such time as the S-8 is effective. During the second quarter of 2013, the Company modified the terms of the share-based awardsfor those individuals who were involuntarily terminated in connection with the 2013 restructuring plan as described in Note 8. These modifications allowedfor the extension of the exercise period for vested options from 60 days following each affected employee's respective termination date to the later of 60 daysfollowing the filing of the Company's 2012 consolidated financial statements with the SEC or December 31, 2013. During the quarter ended June 30, 2013,13 employees were terminated under the 2013 restructuring plan, resulting in an increase in share-based compensation expense of $1.1 million for the yearended December 31, 2013.F-20Accretive Health, Inc.Notes to Consolidated Financial StatementsNote 5. Share-Based Compensation (continued)During the second quarter of 2014, the Company modified the terms of awards granted to 39 employees (including the 13 who were affected in 2013)who were terminated under the 2013 restructuring plan to allow for the extension of the exercise period for vested options until such time as the Company'sRegistration Statement on Form S-8 has been effective for 60 consecutive days. These modifications resulted in a net increase in share-based compensationexpense of $2.3 million for the year ended December 31, 2014.During the first quarter of 2014, in connection with the resignation of a senior executive from the Company, the Company modified the terms of awardspreviously granted to such senior executive. This modification extended the term to exercise vested options from 60 days following his effective resignationdate to such time as the Company's Registration Statement on Form S-8 has been effective for 60 consecutive days. This modification resulted in a netincrease of share-based compensation expense for the year ended December 31, 2014 of $5.6 million.During the second quarter of 2013, the Company modified the terms of an award granted to Mary Tolan, the Company's former chief executive officer,in connection with her transition to the role of the Chairman of the Board of Directors of the Company. This modification allowed for the extension of theexercise period for options vested as of the date of the modification from 60 days following the termination of employment to the expiration of the originalaward (ten years from the grant date). This modification resulted in a net increase in share-based compensation expense of $0.1 million and $1.5 million forthe years ended December 31, 2014 and 2013, respectively.During the second quarter of 2014, the Company granted to the Chief Operating Officer (the "COO") retention equity awards subject to the approval ofour stockholders of an amendment to our 2010 Stock Incentive Plan (the "2010 Plan"). In the event that the stockholders did not approve the amendmentprior to December 31, 2014, then in lieu of the incentive equity awards, the COO would be entitled to receive cash payments following each date that anyportion of such equity grant would have otherwise vested equal to: (i) for stock options, the difference between the exercise price and the closing price of thecommon stock on the vesting date and (ii) for restricted stock, the closing price of the common stock on the vesting date. The Company determined thatstockholder approval to amend the 2010 Plan would not occur by December 31, 2014 and accrued for these grants at the value as explained above. For theyear ended, December 31, 2014, the Company incurred $0.9 million of share-based compensation expense related to this grant.Additionally, as part of the COO's retention agreement, the Company modified the terms of a stock option granted to the COO at the commencement ofhis employment. This modification would be triggered upon termination of employment by the Company without cause or by the COO for good reason andif triggered, the vested portion of the stock option would remain exercisable for a period of time equal to 60 days plus the number of days of service with theCompany, but not longer than two years, or until the stock option otherwise expires, if earlier. This modification resulted in a net increase in share-basedcompensation expense of $0.2 million for year ended December 31, 2014.Lastly, as all employees were restricted from exercising vested options during the year ended December 31, 2014, the Company settled share-basedawards in cash with three employees who had options that expired during the year. This modification resulted in an increase in share-based compensation of$0.9 million for the year ended December 31, 2014.F-21Note 6. Retirement PlanThe Company maintains a 401(k) retirement plan that is intended to be a tax-qualified defined contribution plan under Section 401(k) of the InternalRevenue Code. In general, all employees are eligible to participate. The 401(k) plan includes a salary deferral arrangement pursuant to which participantsmay elect to reduce their current compensation by up to the statutorily prescribed limit, equal to $17,500, $17,500 and $17,000 in 2014, 2013, and 2012,respectively, and have the amount of the reduction contributed to the 401(k) plan. The Company currently matches employee contributions up to 50% of thefirst 3% of base compensation that a participant contributes to the 401(k) plan. In 2014, 2013, and 2012, director-level and above employees were excludedfrom the matching contribution feature of the plan. For the years ended December 31, 2014, 2013, and 2012, total Company contributions to the plan were$0.5 million, $0.6 million, and $0.6 million, respectively.Note 7. Restatement and OtherRestatement and OtherIn the first quarter of 2013, the Company determined that it would restate its previously issued consolidated financial statements (the "Restatement").The Restatement corrected accounting errors relating to timing of recognition of net services revenue, as well as the presentation of net services revenue andcost of services, and also certain capitalized costs for internal use software, goodwill, income taxes and other miscellaneous items. The Company completedthe Restatement in December 2014. In 2014 and 2013, the Company incurred $57.3 million and $23.1 million in Restatement costs, respectively. Theselegal, accounting and consulting costs were incurred to complete the Annual Report on Form 10-K for the years ended December 31, 2013, 2012 and 2011. In2013 and 2012, the Company incurred costs for litigation, primarily related to the lawsuit filed against the Company in January 2012 by the MinnesotaAttorney General that is described in Note 10, Commitments and Contingencies, of $3.3 million and $3.7 million, respectively. In 2013, the Companyaccrued $2.3 million for litigation settlement to former shareholders of SDI Acquisition, Inc. (a wholly owned subsidiary of Company). For the year endedDecember 31, 2014, the Company incurred $6.5 million in costs associated with its transformation office, which was created to provide continuity and crossfunctional accountability associated with the continued execution of the Company's turnaround plan during the period subsequent to StephenSchuckenbrock's resignation as our Chief Executive Officer and prior to the appointment of Dr. Emad Rizk as our Chief Executive Officer ("TransformationOffice"). In addition, the Company incurred other non-recurring costs in 2014 of $0.9 million in additional employment tax expense relating to prior years.ReorganizationIn 2013, the Company initiated a restructuring plan consisting of reductions in workforce in order to align its organizational structure and resources tobetter serve its customers. The plan consisted of two separate staff reductions, that occurred in 2013. Pursuant to the plan, the Company incurred $3.9 millionfor severance and other costs during the year ended December 31, 2013. In addition, the Company incurred $1.2 million non-cash expense related to share-based compensation for modification of existing option agreements for affected employees.In January 2014, the Company continued and revised the 2013 plan to include additional reductions to its workforce in certain corporate,administrative and management functions (the "Plan"). The Plan consists of severance payments, medical and dental benefits, outplacement job training forcertain U.S.-based employees and relocation costs. In connection with the Plan, the Company incurred $22.1 million in pretax restructuring charges duringthe year ended December 31, 2014, consisting of $17.1 million in severance and employee benefits, including $7.9 million of non-cash expense related toshare-based compensation for modification of existing options for affected employees and $5.0 million in facilities and other related expenses.The Company has included $3.3 million and $0.2 million in accrued compensation and benefits and other accrued expenses in the accompanyingconsolidated balance sheet at December 31, 2014, respectively, and has included $1.1 million in accrued compensation and benefits at December 31, 2013.F-22Accretive Health, Inc.Notes to Consolidated Financial StatementsNote 7. Restatement and Other (continued)The Company's reorganization activity was as follows (in thousands): Severance andEmployee Benefits Facilities andOther Costs TotalReorganization liability at January 1, 2013$— $— $—Restructuring charges5,173 — 5,173Cash payments(2,806) — (2,806)Non-cash charges(1,224) — (1,224)Reorganization liability at December 31, 2013$1,143 $— $1,143Restructuring charges17,108 5,010 22,118Cash payments(7,050) (3,482) (10,532)Non-cash charges$(7,905) $(1,370) $(9,275)Reorganization liability at December 31, 2014$3,296 $158 $3,454F-23Accretive Health, Inc.Notes to Consolidated Financial StatementsNote 8. Income TaxesThe domestic and foreign components of income (loss) before income taxes consist of the following (in thousands): Year Ended December 31, 2014 2013 2012Domestic $(130,945) $202,222 $(189,791)Foreign 2,594 2,210 2,056Total income (loss) before income taxes $(128,351) $204,432 $(187,735)For the years ended December 31, 2014, 2013, and 2012, the Company’s current and deferred income tax expense (benefit) attributable to income (loss)from operations are as follows (in thousands): Current Deferred TotalYear Ended December 31, 2012 U.S. Federal $6,924 $(72,244) $(65,320)State & Local 1,717 (4,666) (2,949)Foreign 247 27 274 $8,888 $(76,883) $(67,995)Year Ended December 31, 2013 U.S. Federal $(5,060) $75,737 $70,677State & Local (330) 3,635 3,305Foreign 367 — 367 $(5,023) $79,372 74,349Year Ended December 31, 2014 U.S. Federal $(627) $(42,240) $(42,867)State & Local 46 (6,363) (6,317)Foreign 1,025 (572) 453 $444 $(49,175) $(48,731)Reconciliation of the difference between the actual tax rate and the statutory U.S. federal income tax rate is as follows: Year Ended December 31, 2014 2013 2012Federal statutory tax rate 35%35%35%Increase in income tax rate resulting from: State and local income taxes, net of federal tax benefits 3%1%1%Actual tax rate 38%36%36%In the three month period ended March 31, 2014, the Company corrected the statutory rate used in one of its state deferred calculations for the yearended December 31, 2013. The Company discovered this error in the process of preparing its annual and quarterly financial statements for the year endedDecember 31, 2014, and recorded the amount in the first quarter of 2014. The correction of this error increased tax expense for the year ended December 31,2014 by approximately $2.4 million. The Company has determined the amount is immaterial for the quarterly and annual periods in 2013 and the yearended December 31, 2014.F-24Accretive Health, Inc.Notes to Consolidated Financial StatementsNote 8. Income Taxes (continued)The following table sets forth the Company’s net deferred tax assets as of December 31, 2014 and 2013 (in thousands): As of December 31, 2014 2013Deferred Tax assets: Deferred customer billings 181,567 181,932Net operating loss carryforwards 41,654 5,295Share-based compensation 33,895 27,257Accrued bonus 3,791 3,269Other reserves 1,019 —Alternative minimum tax 1,185 —Other 1,235 462R&D credit 711 665Charitable contributions 514 225Stock warrants 127 154Total gross deferred tax assets 265,698 219,259Less valuation allowance (299) (268)Net deferred tax assets 265,399 218,991Deferred tax liabilities: Goodwill and fixed assets (817) (983)Total deferred tax liability (817) (983)Net deferred tax asset $264,582 $218,008At December 31, 2014, the Company has cumulative U.S. federal net operating loss carryforwards of approximately $105.8 million which are availableto offset U.S. federal taxable income in future periods through 2034.At December 31, 2014, the Company has cumulative state net operating carryforwards of approximately $111.6 million which are available to offsetstate taxable income in future periods through 2034. A valuation allowance is required to be established when, based on currently available information, it ismore likely than not that all or a portion of a deferred tax asset will not be realized. The guidance on accounting for income taxes provides important factorsin determining whether a deferred tax asset will be realized, including whether there has been sufficient taxable income in recent years and whether sufficientincome can reasonably be expected in future years in order to utilize the deferred tax asset.Consideration is given to the weight of all available evidence, both positive and negative. Generally, a cumulative loss in recent years is negativeevidence in determining the need for a deferred tax asset valuation allowance. However, the recent cumulative losses in book income are primarily the resultof a delay in revenue recognition on contracts that have been in place for a number of years. Under the Restatement, revenue is being deferred by theCompany until a future event occurs and the revenue becomes fixed, per the terms of each contract. The Company believes that the deferred revenue fromcontracts that the Company has previously entered into will be recognized in the future. The majority of the deferred revenue amounts have already beenreported on income tax returns filed in accordance with a previously established and approved method of accounting for federal and state income taxreporting. The significant positive evidence related to the projected realization of the deferred customer billings from existing contracts and projectedtaxable income outweighs the negative evidence from the cumulativeF-25Accretive Health, Inc.Notes to Consolidated Financial StatementsNote 8. Income Taxes (continued)losses incurred in recent years based on the Restatement. Accordingly, the Company believes that it is more likely than not that the remaining deferred taxassets will be realized.The Company has recorded valuation allowances at December 31, 2014 and 2013 of $0.3 million and $0.3 million, respectively based on ourassessment that it is more likely than not that a portion of the Company’s separate state income tax net operating loss will not be realized.The Company has not recognized a deferred tax liability for the undistributed earnings of its foreign subsidiaries that arose in 2014 or 2013 because theCompany considers these earnings to be indefinitely reinvested outside of the United States. As of December 31, 2014 and 2013, the undistributed earningsof these subsidiaries were $6.8 million and $5.0 million, respectively. It is not practicable to estimate the amount of recognized deferred tax liabilities, if any,for these undistributed foreign earnings.The 2014, 2013 and 2012 current tax provision includes $1.0 million, $0.4 million, and $0.3 million, respectively, for income taxes arising from thepre-tax income of the Company’s India subsidiaries. The tax provisions are net of the impact of a tax holiday in India. The Company’s benefits from this taxholiday was $0.5 million for the year ended December 31, 2014 and $0.4 million for each of the years ended December 31, 2013 and 2012. The majority ofthese benefits are set to expire after the year ending December 31, 2018.The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained onexamination by taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a positionare measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. The Company’sunrecognized tax benefits as of December 31, 2014, 2013, and 2012 totaled $1.1 million, $1.3 million and $2.4 million, respectively. The following tablesummarizes the activity related to the unrecognized tax benefits (in thousands): Tax BenefitUnrecognized tax benefits as ofJanuary 1, 2012$2,313Increases in positions taken in a current period67Increases in positions taken in prior period31Decreases due to lapse of statute of limitations— Unrecognized tax benefits as ofDecember 31, 20122,411Increases in positions taken in a current period67Increases in positions taken in prior period—Decreases due to lapse of statute of limitations(1,176) Unrecognized tax benefits as ofDecember 31, 20131,302Increases in positions taken in a current period66Increases in position taken in prior period94Decreases in positions taken in prior period(51)Decreases due to lapse of statute of limitations(313)Unrecognized tax benefits as ofDecember 31, 2014$1,098 F-26Accretive Health, Inc.Notes to Consolidated Financial StatementsNote 8. Income Taxes (continued)As of December 31, 2014, approximately $1.1 million of the total gross unrecognized tax benefits represented the amount that, if recognized, wouldresult in a reduction of the effective income tax rate in future periods. The Company recognizes interest and penalties related to income tax matters as part ofincome tax expense. The Company recorded adjustments to interest and potential penalties related to these unrecognized tax benefits during 2014, and intotal, as of December 31, 2014, the Company has recorded a liability for interest and potential penalties of $0.8 million. The Company anticipates changes tothe reserves within the next 12 months to be primarily related to interest. The Company believes it has sufficient accruals for contingent tax liabilities.In connection with tax return examinations, contingencies can arise that generally result from different interpretations of tax laws and regulations asthey pertain to the amount, timing or inclusion of revenues and expenses in taxable income, or the ability to utilize tax credits to reduce income taxespayable. While it is probable, based on the potential outcome of the Company’s Federal and State tax examinations or the expiration of the statute oflimitations for specific jurisdictions, that the liability for unrecognized tax benefits may increase or decrease within the next twelve months, the Companydoes not expect any such change would have a material effect on our financial condition, results of operations or cash flow.The Company and its subsidiaries are subject to U.S. federal income tax as well as income tax of multiple state and foreign jurisdictions. U.S. federalincome tax returns for 2013, 2012 and 2011 are currently open for examination. The 2013, 2012 and 2011 U.S. federal income tax returns are currently underexamination. State jurisdictions vary for open tax years. The statute of limitations for most states ranges from 3 to 6 years. Local tax authorities havecompleted their income tax examinations of the Company’s subsidiary in India for fiscal years 2009 and 2010. The proposed adjustments in India have beenappealed, and the Company believes the ultimate outcome of these appeals will not result in a material adjustment to its tax liability.Pursuant to the acquisition of a business in May 2006, the sellers, certain of which are employees of the Company, are obligated to indemnify theCompany for federal and state income taxes, including 50% of any interest and penalties incurred, related to periods up to and including the date of theacquisition. The potential amount due to the Company related to this indemnity was $1.3 million, $1.3 million and $1.2 million as of December 31, 2014,2013, and 2012, respectively. The amount due from related party is secured by the fair value of shares and cost held by the Company in escrow. The cost andfair value of these shares was $0.8 million, $1.0 million and $1.1 million at December 31, 2014, 2013, and 2012, respectively. Given that the fair value of theshares was less than the amount due from related party in 2014 and 2013, the Company recorded a reserve of $0.5 million and $0.3 million, respectively, toreflect the difference between the fair value of the shares and the receivable they securitize. No reserve was required at December 31, 2012. The amounts duefrom related party in the consolidated balance sheets reflect the net realizable value of the receivable. The Company intends to keep these shares in escrowuntil the related tax matters are fully resolved and any indemnification obligations in connection therewith have been satisfied.F-27Accretive Health, Inc.Notes to Consolidated Financial StatementsNote 9. Earnings (Loss) Per ShareBasic and diluted net income (loss) per common share are calculated as follows (in thousands, except share and per share data): Year Ended December 31, 2014 2013 2012Net income (loss) $(79,620) $130,083 $(119,740)Basic weighted-average common shares 95,760,762 95,687,940 98,602,099Add: Effect of dilutive securities — 1,157,724 —Diluted weighted-average common shares 95,760,762 96,845,664 98,602,099Net income (loss) per common share (basic) $(0.83) $1.36 $(1.21)Net income (loss) per common share (diluted) $(0.83) $1.34 $(1.21)Stock options totaling 18,450,699 were not included in the computation of diluted income per share for the year ended December 31, 2013 as theoptions were anti-dilutive. Due to the net loss, stock options and RSAs totaling 22,401,870 and 17,867,359 were not included in the computation of dilutedincome (loss) per share for the years ended December 31, 2014 and 2012, respectively.Note 10. Commitments and ContingenciesOperating LeasesThe Company rents office space and equipment under operating leases, primarily for its Chicago corporate office, U.S. shared services centers and Indiaoperations. Office space lease terms range from 1 to 12 years, whereas equipment lease terms range from 1 to 3 years. The Company’s leases contain variousrent holidays and rent escalation clauses and entitlements for tenant improvement allowances. Lease payments are amortized to expense on a straight-linebasis over the lease term. For a description of the Company’s leased properties refer to “Part I - Item 2 - Properties” of this Annual Report on Form 10-K.Total rent expense under all operating leases was $3.9 million, $3.8 million and $3.6 million for the years ended December 31, 2014, 2013, and 2012,respectively.The aggregate future minimum rental commitments under all noncancelable operating leases having remaining terms in excess of one year as ofDecember 31, 2014 are as follows (in thousands): 2015$6,20820165,06720175,83720185,69720194,965Thereafter13,624 Total$41,398 F-28Accretive Health, Inc.Notes to Consolidated Financial StatementsNote 10. Commitments and Contingencies (continued)Revolving Credit FacilityIn September 2011, the Company reduced its outstanding line of credit with the Bank of Montreal from $15.0 million to $3.0 million. The Company'sline of credit expired on February 15, 2015 and has not been renewed. As such, the Company has reclassified the $5.0 million in restricted cash to currentassets at December 31, 2014. The $3.0 million line of credit could only be utilized by the Company in the form of letters of credit and was secured by a$5.0 million demand deposit with the Bank of Montreal which is presented as restricted cash in the Company’s consolidated balance sheets. Any amountsoutstanding under the line of credit accrued interest at the greater of (i) the bank-established prime commercial rate, (ii) a LIBOR plus 1% rate, (iii) or a ratethat combines the characteristics of both. The line of credit had an initial term of three years and was renewable annually thereafter. As of December 31, 2014and 2013, the Company had outstanding letters of credit of approximately $0.7 million and $0.9 million, respectively.Legal ProceedingsThe Company is subject to various claims, pending and possible legal actions for product liability and other damages, and other matters arising out ofthe conduct of the Company’s business. On a quarterly basis, the Company reviews material legal claims against the Company. The Company accrues for thecosts of such claims as appropriate and in the exercise of its judgment and experience. However, due to a lack of factual information available to theCompany about a claim, or the procedural stage of a claim, it may not be possible for the Company to reasonably assess either the probability of a favorableor unfavorable outcome of the claim or to reasonably estimate the amount of loss should there be an unfavorable outcome. Therefore, for many of the claims,the Company cannot estimate a range of loss. The Company believes, based on current knowledge and after consultation with counsel, that the outcome ofsuch claims and actions will not have a material adverse effect on the Company’s results of operations or financial position. However, in the event ofunexpected future developments, it is possible that the ultimate resolution of such matters, if unfavorable, could have a material adverse effect on theCompany’s results of operations or financial position.Other than as described below, the Company is not presently a party to any material litigation or regulatory proceeding and is not aware of any pendingor threatened litigation or regulatory proceeding against the Company which, individually or in the aggregate, could have a material adverse effect on thebusiness, operating results, financial condition or cash flows.On January 19, 2012, the State of Minnesota, by its Attorney General, filed a complaint against the Company in the United States District Court for theDistrict of Minnesota, alleging violations of federal and Minnesota state health privacy laws and regulations, Minnesota debt collection laws, and Minnesotaconsumer protection laws resulting from, among other things, the theft in Minnesota in July 2011 of an employee’s laptop that contained PHI. On January 25,2012, the Commissioner of the Minnesota Department of Commerce served the Company an administrative subpoena seeking information and documentsabout its debt collection practices and the privacy of personal and health data within its possession or control. On February 3, 2012, the Company enteredinto a Consent Cease and Desist Order with the Commissioner, voluntarily agreeing to cease all debt collection activity in the State of Minnesota. Aspreviously disclosed, on July 30, 2012, without any admission of liability or wrongdoing, the Company entered into a Settlement Agreement, Release andOrder with the Minnesota Attorney General to settle the lawsuit filed by the Minnesota Attorney General and the investigation commenced by the MinnesotaDepartment of Commerce and to resolve fully all disputes which in any way related to, arose out of, emanated from, or otherwise involved such lawsuit orinvestigation and all investigations by the Minnesota Attorney General, the Minnesota Department of Commerce, and the Minnesota Department of HumanServices relating to the Company. As part of the settlement, the Company paid a settlement sum of $2.5 million and voluntarily agreed to cease all remainingoperations in Minnesota.F-29Accretive Health, Inc.Notes to Consolidated Financial StatementsNote 10. Commitments and Contingencies (continued)On April 26, 2012 and May 1, 2012, the Company, along with certain of its former officers, was named as a defendant in two putative securities classaction lawsuits filed in the U.S. District Court for the Northern District of Illinois, which were consolidated as Wong v. Accretive Health et al. The primaryallegations are that the Company’s public statements, including filings with the SEC, were false and/or misleading about its violations of certain federal andMinnesota privacy and debt collection laws. On September 26, 2013, without any admission of liability or wrongdoing, the Company entered into aSettlement Agreement to resolve these suits for $14 million, which has been funded into escrow by its insurance carriers. On April 30, 2014, the U.S. DistrictCourt for the Northern District of Illinois granted final approval of the Settlement Agreement. A single objector to the Settlement Agreement appealed to theU.S. Court of Appeals for the Seventh Circuit, and on December 9, 2014, the court of appeals affirmed the district court’s approval of the settlement. OnDecember 23, 2014, that objector submitted a petition for en banc rehearing, which was denied on January 26, 2015.In addition, the Company, along with certain of its directors and former officers, has been named in several putative shareholder derivative lawsuitsfiled in the U.S. District Court for the Northern District of Illinois on May 3, 2012 and July 31, 2012 (consolidated as Maurras Trust v. Accretive Health etal.), in the Circuit Court of Cook County, Illinois on June 23, 2012 and June 27, 2012 (consolidated as In re Accretive Health, Inc. Derivative Litigation) andin the Court of Chancery of the State of Delaware on November 5, 2012 (Doyle v. Tolan et al.). The primary allegations are that its directors and officersbreached their fiduciary duties in connection with the alleged violations of certain federal and Minnesota privacy and debt collection laws.On July 11, 2013, the Court of Chancery of the State of Delaware granted its motion to stay Doyle v. Tolan et al., in favor of the action pending in theU.S. District Court for the Northern District of Illinois. On September 24, 2013, the U.S. District Court for the Northern District of Illinois granted its motion todismiss without prejudice, giving plaintiffs in that case leave to file an amended consolidated complaint, which plaintiffs filed on October 22, 2013,amending their complaint to also include allegations with respect to the Restatement. On February 25, 2015, the Company entered a settlement agreementwith plaintiffs in all of these suits that would resolve the derivative actions, subject to court approval. On February 26, 2015, plaintiffs in the action pendingin the U.S. District Court for the Northern District of Illinois filed a motion seeking preliminary approval of that settlement, which was granted on March 19,2015. A final fairness hearing is scheduled for July 23, 2015.On May 17, 2013, the Company, along with certain of its directors, former directors and former officers, was named as a defendant in a putativesecurities class action lawsuit filed in the U.S. District Court for the Northern District of Illinois (Hughes v. Accretive Health, Inc. et al.). The primaryallegations, relating to its March 8, 2013 announcement that the Company would be restating its prior period financial statements, are that its publicstatements, including filings with the SEC, were false and/or misleading with respect to its revenue recognition and earnings prospects. On November 27,2013, plaintiffs voluntarily dismissed the Company’s directors and former directors (other than Mary Tolan). On January 31, 2014, the Company filed amotion to dismiss the Complaint. On September 25, 2014, the Court granted the Company motion to dismiss without prejudice, however the plaintiffs filed aSecond Amended Complaint on October 23, 2014. On November 10, 2014, the Company filed a motion to dismiss the Second Amended Complaint. Whilethat motion was still pending, on January 8, 2015, plaintiffs filed a motion to amend the Second Amended Complaint, seeking to add allegations regardingthe recently issued Restatement. On April 22, 2015, the court granted plaintiffs’ motion to amend, and a Third Amended Complaint was filed on May 13,2015. The Company moved to dismiss the Third Amended Complaint on June 3, 2015. The Company continues to believe it has meritorious defenses andintend to vigorously defend itself, Mary Tolan, and its former officers against these claims. The outcome is not presently determinable.The SEC’s Division of Enforcement in the Chicago Regional Office is also conducting an investigation regarding the circumstances surrounding theRestatement. The Company is fully cooperating with the investigation.F-30Accretive Health, Inc.Notes to Consolidated Financial StatementsNote 10. Commitments and Contingencies (continued)On February 11, 2014, the Company was named as a defendant in a putative class action lawsuit filed in the U.S. District Court for the Southern Districtof Alabama (Church v. Accretive Health, Inc.). The primary allegations are that the Company attempted to collect debts without providing the notice requiredby the FDCPA and attempted to collect debts after they were discharged in bankruptcy. The Company believes that it has meritorious defenses and intends tovigorously defend itself against these claims. The outcome is not presently determinable.On July 22, 2014, the Company was named as a defendant in a putative class action lawsuit filed in the U.S. District Court for the Eastern District ofMichigan (Anger v. Accretive Health, Inc.). The primary allegations are that the Company attempted to collect debts without providing the notice required bythe FDCPA. The Company believes that it has meritorious defenses and intends to vigorously defend itself against these claims. The outcome is not presentlydeterminable.On February 6, 2015, the Company was named as a defendant in a putative class action lawsuit filed in the U.S. District Court for the Eastern District ofMichigan (Cassale v. Accretive Health, Inc.). The primary allegations are that the Company attempted to collect debts without complying with the provisionsof the FDCPA. The case was settled in April 2015.On February 24, 2015 (amended Feb. 25, 2015), the Plaintiff in the Church action (above) filed a motion with the Joint Panel for MultidistrictLitigation to transfer and consolidate the Church, Anger and Cassale actions for pretrial purposes in the Southern District of Alabama where the Church caseis currently pending. That motion was withdrawn in May 2015.In April 2015, the Company was named among other defendants in an employment action brought by a former employee before the Maine HumanRights Commission alleging that she was improperly terminated in retaliation for uncovering alleged Medicare fraud. The Company filed its response withthe MHRC on May 19, 2015 seeking that the Company be dismissed entirely from the action. The Plaintiff has filed a parallel qui tam action in the Districtof Maine (Worthy v. Eastern Maine Healthcare Systems) in which she makes the same allegations. The U.S. Department of Justice declined to intervene inthe federal court action, and the case was unsealed in April 2015 but has not been served on any defendant. The Company believes that it has meritoriousdefenses to both the MHRC action and the federal court case, and intends to vigorously defend itself against these claims. The outcomes are not presentlydeterminable.Note 11. Segments and Customer ConcentrationsThe Company has determined that it has a single operating segment in accordance with how its business activities are managed and evaluated. All ofthe Company’s significant operations are organized around the single business of providing end-to-end management services of revenue cycle operations forU.S.-based hospitals and other medical providers. Accordingly, for purposes of segment disclosures, the Company has only one reporting segment. All of theCompany’s net services revenue and trade accounts receivable are derived from healthcare providers domiciled in the United States.While managed independently and governed by separate contracts, several of the Company’s RCM customers are affiliated with a single healthcaresystem. The Company evaluates each separate affiliated contract as a customer. The Company has between 25 and 30 individual customers for RCM Servicesin each of the three years ended December 31, 2014, 2013, and 2012. The Company recognizes revenue on RCM services when there is a contracttermination or other contractual agreement event, as defined in Note 2, Summary of Significant Accounting Policies in accordance with its accountingpolicy. The Company’s revenue is not consistent with its cash flows in that cash may be accumulated over 3 to 5 years prior to a revenue recognition event.Therefore, measuring customers as a percent of total revenue may not be meaningful.F-31Accretive Health, Inc.Notes to Consolidated Financial StatementsNote 11. Segments and Customer Concentrations (continued)Hospital systems affiliated with Ascension Health have accounted for a significant portion of the Company’s net services revenue each year since theCompany’s formation. In 2014, 2013, and 2012, net services revenue from hospitals affiliated with Ascension Health represented 12%, 73% and 5% of theCompany’s total net services revenue, respectively. An affiliate of Ascension Health, individually, accounted for 12%, 28% and 1% of the Company’s totalnet services revenue for 2014, 2013, and 2012, respectively.The Ascension Health system, through its individual customer contracts with the Company, account for more than 76%, 55% and 73% of theCompany’s total deferred customer billings at December 31, 2014, 2013, and 2012, respectively. The loss of the customers within this large health systemwould have a material adverse impact on the Company’s operations.The Company does not have a concentration of credit risk within accounts receivable as reported in the consolidated balance sheets with any one largecustomer at December 31, 2014, 2013, and 2012.Note 12. Subsequent EventsThe Company entered into a settlement agreements with two customers after the year ended December 31, 2014 which will result in revenuerecognition events for the Company under its revenue recognition policy (see Note 2) in the year ended December 31, 2015. These agreements did not have asignificant impact on the Company’s deferred customer billings, assets or liabilities at December 31, 2014.Note 13. Quarterly Financial Information (Unaudited)The following tables provide our Quarterly Condensed Consolidated Statements of Operations (in thousands, except per share data): 1st Quarter Ended March 31, 2nd Quarter Ended June 30, 3rd Quarter EndedSeptember, 30 4th Quarter EndedDecember 31, 20142013 20142013 20142013 20142013Net services revenue $12,964$28,157 $58,975$374,408 $90,745$18,342 $47,456$83,861Total operating expenses 97,59970,621 86,16776,854 76,00179,288 79,02673,903Income (loss) from operations (84,635)(42,464) (27,192)297,554 14,744(60,946) (31,570)9,958Net income (loss) $(54,723)$(26,465) $(16,799)$187,733 $9,553$(37,571) $(17,651)$6,386 Net income (loss) per common share Basic $(0.57)$(0.28) $(0.18)$1.96 $0.10$(0.39) $(0.18)0.07Diluted $(0.57)$(0.28) $(0.18)$1.93 $0.10$(0.39) $(0.18)0.07F-32EXHIBIT INDEX ExhibitNumber Description 3.1 Restated Certificate of Incorporation of the Registrant, as amended (incorporated by reference to Exhibit 3.2 to Amendment No. 4 to theRegistration Statement on Form S-1 (File No. 333-162186) filed on April 26, 2010)3.2 Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.4 to Amendment No. 4 to the RegistrationStatement on Form S-1 (File No. 333-162186) filed on April 26, 2010)4.1 Specimen Certificate evidencing shares of Common Stock (incorporated by reference to Exhibit 4.1 to Amendment No. 4 to theRegistration Statement on Form S-1 (File No. 333-162186) filed on April 26, 2010)10.1* Amended and Restated Stock Option Plan, as amended (incorporated by reference to Exhibit 10.1 to Amendment No. 4 to theRegistration Statement on Form S-1 (File No. 333-162186) filed on April 26, 2010)10.2* Form of Acknowledgment of Grant, used to evidence option grants under the Amended and Restated Stock Option Plan (incorporated byreference to Exhibit 10.2 to the Registration Statement on Form S-1 (File No. 333-162186) filed on September 29, 2009)10.3* Restricted Stock Plan, as amended (incorporated by reference to Exhibit 10.3 to Amendment No. 4 to the Registration Statement onForm S-1 (File No. 333-162186) filed on April 26, 2010)10.4* Form of Restricted Stock Award Agreement under the Restricted Stock Plan, as amended (incorporated by reference to Exhibit 10.4 to theRegistration Statement on Form S-1 (File No. 333-162186) filed on September 29, 2009)10.5 Third Amended and Restated Stockholders’ Agreement, dated as of February 22, 2009, among the Registrant and the parties namedtherein, as amended (incorporated by reference to Exhibit 10.5 to the Registration Statement on Form S-1 (File No. 333-172707) filed onMarch 9, 2011)10.6 Form of Share Exchange Agreement, entered into in February 2009, with each of Etienne H. Deffarges, Steven N. Kaplan, Gregory N.Kazarian, The Shultz 1989 Family Trust, Spiegel Family LLC and John T. Staton Declaration of Trust (incorporated by reference toExhibit 10.6 to the Registration Statement on Form S-1 (File No. 333-162186) filed on September 29, 2009)10.7 Lease Agreement, dated as of May 4, 2005, between the Registrant and Zeller Management Corporation, as amended by First LeaseAmendment, dated as of January 30, 2007, and Second Lease Amendment, dated as of November 26, 2008 (incorporated by reference toExhibit 10.7 to the Registration Statement on Form S-1 (File No. 333-162186) filed on September 29, 2009)10.8* Employment Agreement, dated as of June 17, 2005, between the Registrant and John T. Staton, as amended (incorporated by reference toExhibit 10.19 to the Registration Statement on Form S-1 (File No. 333-162186) filed on September 29, 2009)10.9* Form of Indemnification Agreement, entered into between the Registrant and each director and executive officer (incorporated byreference to Exhibit 10.20 to Amendment No. 1 to the Registration Statement on Form S-1 (File No. 333-162186) filed on November 19,2009)10.10* 2010 Stock Incentive Plan (incorporated by reference to Exhibit 10.23 to Amendment No. 4 to the Registration Statement on Form S-1(File No. 333-162186) filed on April 26, 2010)10.11* Form of Incentive Stock Option Agreement under the 2010 Stock Incentive Plan (incorporated by reference to Exhibit 10.24 toAmendment No. 4 to the Registration Statement on Form S-1 (File No. 333-162186) filed on April 26, 2010)10.12* Form of Nonstatutory Stock Option Agreement under the 2010 Stock Incentive Plan (incorporated by reference to Exhibit 10.25 toAmendment No. 4 to the Registration Statement on Form S-1 (File No. 333-162186) filed on April 26, 2010)10.13+ Master Professional Services Agreement by and between Ascension Health and the Registrant effective as of August 6, 2012 (incorporatedby reference to Exhibit 10.1 to Quarterly Report on Form 10-Q for the quarter ended September 30, 2012 (File No. 001-34746) filed onNovember 8, 2012)ExhibitNumber Description 10.14* Chairman’s Agreement, dated April 24, 2013, between Registrant and Mary A. Tolan (incorporated by reference to Exhibit 10.14 toAnnual Report on Form 10-K for the fiscal year ended December 31, 2013 (File No. 001-34746) filed on December 30, 2014)10.15* Mutual General Release Agreement, dated April 24, 2013, between Registrant and Mary A. Tolan (incorporated by reference to Exhibit10.15 to Annual Report on Form 10-K for the fiscal year ended December 31, 2013 (File No. 001-34746) filed on December 30, 2014)10.16* Employment Agreement, dated April 2, 2013, between Registrant and Stephen F. Schuckenbrock (incorporated by reference to Exhibit10.16 to Annual Report on Form 10-K filed for the fiscal year ended December 31, 2013 (File No. 001-34746) filed on December 30,2014)10.17* Stock Option Agreement, dated April 3, 2013, between Registrant and Stephen F. Schuckenbrock (incorporated by reference to Exhibit10.17 to Annual Report on Form 10-K for the fiscal year ended December 31, 2013 (File No. 001-34746) filed on December 30, 2014)10.18* Offer Letter, dated April 27, 2013, between Registrant and Joseph Flanagan (incorporated by reference to Exhibit 10.18 to AnnualReport on Form 10-K for the fiscal year ended December 31, 2013 (File No. 001-34746) filed on December 30, 2014)10.19* Restricted Stock Award, dated June 3, 2013, between Registrant and Joseph Flanagan (incorporated by reference to Exhibit 10.19 toAnnual Report on Form 10-K for the fiscal year ended December 31, 2013 (File No. 001-34746) filed on December 30, 2014)10.20* Nonstatutory Stock Option Award Agreement, dated June 3, 2013, between Registrant and Joseph Flanagan (incorporated by referenceto Exhibit 10.20 to Annual Report on Form 10-K for the fiscal year ended December 31, 2013 (File No. 001-34746) filed on December30, 2014)10.21* Transition Agreement, dated April 24, 2013, between Registrant and Gregory N. Kazarian (incorporated by reference to Exhibit 10.21 toAnnual Report on Form 10-K for the fiscal year ended December 31, 2013 (File No. 001-34746) filed on December 30, 2014)10.22* Severance Agreement and Release of Claims, dated June 28, 2013, between Registrant and Richard Gillette (incorporated by referenceto Exhibit 10.22 to Annual Report on Form 10-K for the fiscal year ended December 31, 2013 (File No. 001-34746) filed on December30, 2014)10.23* Offer Letter, dated August 24, 2013, between Registrant and Sean D. Orr (incorporated by reference to Exhibit 10.23 to Annual Reporton Form 10-K for the fiscal year ended December 31, 2013 (File No. 001-34746) filed on December 30, 2014)10.24* Resignation Letter, dated March 28, 2014, between Registrant and John T. Staton (incorporated by reference to Exhibit 10.24 to AnnualReport on Form 10-K for the fiscal year ended December 31, 2013 (File No. 001-34746) filed on December 30, 2014)10.25* Amendment to Offer Letter, dated April 29, 2014, between Registrant and Joseph Flanagan (incorporated by reference to Exhibit 10.25to Annual Report on Form 10-K for the fiscal year ended December 31, 2013 (File No. 001-34746) filed on December 30, 2014)10.26* Nonstatutory Stock Option Award Agreement, dated April 29, 2014, between Registrant and Joseph Flanagan (incorporated by referenceto Exhibit 10.26 to Annual Report on Form 10-K for the fiscal year ended December 31, 2013 (File No. 001-34746) filed on December30, 2014)10.27* Restricted Stock Award Agreement, dated April 29, 2014, between Registrant and Joseph Flanagan (incorporated by reference toExhibit 10.27 to Annual Report on Form 10-K for the fiscal year ended December 31, 2013 (File No. 001-34746) filed on December 30,2014)10.28* Offer Letter, dated June 3, 2014, between Registrant and Thomas Gibson (incorporated by reference to Exhibit 10.28 to Annual Reporton Form 10-K for the fiscal year ended December 31, 2013 (File No. 001-34746) filed on December 30, 2014)10.29* Offer Letter, dated July 10, 2014, between Registrant and Emad Rizk (incorporated by reference to Exhibit 10.29 to Annual Report onForm 10-K for the fiscal year ended December 31, 2013 (File No. 001-34746) filed on December 30, 2014)10.30* Nonstatutory Stock Option Award Agreement, dated July 21, 2014, between Registrant and Emad Rizk (incorporated by reference toExhibit 10.30 to Annual Report on Form 10-K for the fiscal year ended December 31, 2013 (File No. 001-34746) filed on December 30,2014)ExhibitNumber Description10.31* Restricted Stock Award Agreement, dated July 21, 2014, between Registrant and Emad Rizk (incorporated by reference to Exhibit 10.31to Annual Report on Form 10-K for the fiscal year ended December 31, 2013 (File No. 001-34746) filed on December 30, 2014)10.32* Resignation Letter Agreement, dated August 6, 2014, between Registrant and Sean Orr (incorporated by reference to Exhibit 10.32 toAnnual Report on Form 10-K for the fiscal year ended December 31, 2013 (File No. 001-34746) filed on December 30, 2014)10.33* Offer Letter, dated August 6, 2014, between Registrant and Peter Csapo (incorporated by reference to Exhibit 10.33 to Annual Report onForm 10-K for the fiscal year ended December 31, 2013 (File No. 001-34746) filed on December 30, 2014)10.34* Nonstatutory Stock Option Award Agreement, dated August 12, 2014, between Registrant and Peter Csapo (incorporated by reference toExhibit 10.34 to Annual Report on Form 10-K for the fiscal year ended December 31, 2013 (File No. 001-34746) filed on December 30,2014)10.35* Restricted Stock Award Agreement, dated August 12, 2014, between Registrant and Peter Csapo (incorporated by reference to Exhibit10.35 to Annual Report on Form 10-K for the fiscal year ended December 31, 2013 (File No. 001-34746) filed on December 30, 2014)10.36* Chairman Services Agreement, dated November 14, 2014, between Registrant and Steve Shulman (incorporated by reference to Exhibit10.36 to Annual Report on Form 10-K for the fiscal year ended December 31, 2013 (File No. 001-34746) filed on December 30, 2014)10.37* Offer Letter, dated January 9, 2015, between Registrant and Richard Evans10.38* Omnibus Amendment, dated May 18, 2015, to Employment Agreement dated April 2, 2013 between Registrant and Stephen F.Schuckenbrock and Stock Option Agreement, dated April 3, 2013, between Registrant and Stephen F. Schuckenbrock21.1 Subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 to Amendment No. 4 to the Registration Statement on Form S-1filed on April 26, 2010)23.1 Consent of Ernst & Young LLP31.1 Certification of Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 200231.2 Certification of Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 200232.1 Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-OxleyAct of 200232.2 Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-OxleyAct of 2002101 The following materials from the Accretive Health, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2014, formattedin eXtensible Business Reporting Language (XBRL): (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements ofOperations and Comprehensive Income (Loss), (iii) the Consolidated Statements of Stockholders’ Equity, (iv) the ConsolidatedStatements of Cash Flows, and (v) related notes. *Management contract or compensatory plan or arrangement required to be filed pursuant to Item 15(b) of Form 10-K.+Confidential treatment requested as to certain portions, which portions have been omitted and filed separately with the Securities and ExchangeCommission.Richard Evans, Jr. January 9, 2015 232 Phillippa Street Hinsdale, IL Dear Rick, We have very much enjoyed getting to know you during the recent weeks, and I am delighted to confirm our offer of employment. You are invited to join Accretive Health as Senior Vice President, Finance-Corporate Controller and Principle Accounting Officer. Your starting salary will be $300,000.00, per year paid semi-monthly. You will be eligible to participate in the Company’s Annual Bonus Program with an annual bonus target equal to 40% of your salary. The bonus is discretionary and will be earned based upon your performance and that of the company. The performance year for the Annual Bonus Program ends December 31st and your first year bonus target will be pro-rated based on number of full months of employment prior to December 31, 2015. Additionally, you are eligible to participate in the Company's Long Term Incentive Program (the LTI Program") with an annual target equal to 30% of your base salary. Both the annual bonus and annual equity grants will be made at the discretion of management and can be changed, amended, or discontinued at any time. You will also be eligible to participate in the Accretive Health's employee health benefit programs beginning on your first date of employment. Finally, we will offer you a significant stake in the success of our companyin the form of an initial option grant for the purchase of 50,000 shares of Accretive Health common stock. This stock option grant will be made after your employment start date, pursuant to the terms and conditions of the Accretive Health 2010 Stock Incentive Plan, (the "Option Plan"). These options shall vest annually over a four year period on the anniversary of the date of grant, (i.e., 25% annual cliff vesting) subject to your continued employment at Accretive Health, in accordance with the terms of the Option Plan. We are extending this offer contingent upon successful completion of routine background and reference checks, including verification of all information reported on your application. In addition, your acceptance of this offer indicates you are willing to participate in, and pass (if applicable), additional screening procedures including immunizations, drug screenings, etc. should they be requested prior to or during your employment with Accretive Health. Your employment with Accretive Health is “at will”, meaning it is terminable at any time by either you or Accretive Health. We will work with you on a mutually agreeable start date, which we anticipate to be on or around January 26, 2015 Richard, we truly believe that we have built the best team in the industry and that you will enjoy working with us. We look forward to receiving your acceptance, and also working with you. If you haveany questions please contact me directly at 678.327.9289. Agreed and Accepted: Jeffrey Koppin ________________________________________________ Talent Acquisition Director Richard Evans Date Exhibit 10.38Omnibus Amendment to Employment Agreement and Stock Option AgreementWHEREAS, Accretive Health, Inc. (the “Company”) and Stephen F. Schuckenbrock (“Schuckenbrock”) entered into that certain EmploymentAgreement, dated as of April 2, 2013, setting forth the terms and conditions of Schuckenbrock’s employment by the Company and certain additional terms inconnection with Schuckenbrock’s membership on the Company’s Board of Directors (the “Board”); andWHEREAS, pursuant to the Employment Agreement, Schuckenbrock and the Company entered into that certain Stock Option Agreement, dated asof April 3, 2013 (the “Option Agreement”), setting forth the terms and conditions of a grant by the Company to Schuckenbrock of a non-qualified stockoption to purchase 2,903,801 shares of the Company’s common stock at a price of $9.56 per share; andWHEREAS, Schuckenbrock voluntarily resigned as an employee of the Company in October 2014; andWHEREAS, Schuckenbrock has delivered to the Company a notice of his resignation from the Board, with such resignation effective as of May 18,2015; andWHEREAS, in connection with Schuckenbrock’s resignation from the Board, Schuckenbrock and the Company desire to modify the EmploymentAgreement and the Option Agreement as set forth herein; andWHEREAS, capitalized terms used herein and not otherwise defined shall have the meanings ascribed to such terms in the Employment Agreement.NOW, THEREFORE, in consideration of the premises and mutual covenants contained herein, and for other good and valuable consideration, thereceipt of which is mutually acknowledged, the Company and Schuckenbrock agree as follows:1.Amendment to Section 9(d) of the Employment Agreement.Section 9(d) of the Employment Agreement is hereby amended and restated in its entirety as follows:(a)Voluntary Termination. In the event that the Executive terminates his employment and/or Board service hereunder prior to thethen-scheduled expiration of the Term of Employment or Term of Board Service (as applicable) on his own initiative, other than by death, forDisability or in a Constructive Termination Without Cause, then the Term of Employment and/or Term of Board Service (as applicable) shallexpire and the Initial Stock Option shall, to the extent (x) exercisable on the applicable Termination Date or (y) exercisable subsequent to theTermination Date pursuant to the last sentence of this Section 9(d), (i) remain exercisable for at least the lesser of 90 days following theTermination Date and the remainder of its maximum stated term, if such voluntary termination is prior to the first anniversary of the Start Date,or (ii) remain exercisable for the remainder of its maximum stated term, if such voluntary termination is on or after the first anniversary of theStart Date. No voluntary termination under this Section 9(d) shall be deemed a breach of this Agreement. Notwithstanding anything to thecontrary set forth herein, in the event Executive terminates his Board Service prior to the then-scheduled expiration of the Term of BoardService, the portion of the Initial Stock Option that is unvested as of the date of such termination shall continue to vest and become exercisablein accordance with the vesting schedule set forth in Section 2(a) of the Option Agreement, and, for the avoidance of doubt, such vesting shallnot be contingent upon any continued employment or Board service by Executive.”2.Amendment to Section 2(f) of the Option Agreement.Section 2(f) of the Option Agreement is hereby amended and restated in its entirety as follows:(a)In the event that the Term of Employment or Term of Board Service terminates under circumstances governed by Section 9(d) ofthe Employment Agreement (relating to voluntary terminations), then this option shall, to the extent (x) that it is exercisable as of theTermination Date or (y) that it becomes exercisable subsequent to the Termination Date pursuant to the last sentence of this Section 2(f), remainexercisable until (i) in the case of such voluntary termination prior to the first anniversary of the Grant Date, the earlier of 11:59 p.m. on the 90thday following such Termination Date and the tenth anniversary of the1Grant Date, at which time it shall expire to the extent that it has not yet been exercised, or (ii) in the case of such voluntary termination on orafter the first anniversary of the Grant Date, 11:59 p.m. on the tenth anniversary of the Grant Date, at which time it shall expire to the extent thatit has not yet been exercised. Notwithstanding anything to the contrary set forth herein, in the event Optionee terminates his Board Service priorto the then-scheduled expiration of the Term of Board Service, the portion of this option that is unvested as of the date of such termination shallcontinue to vest and become exercisable in accordance with the vesting schedule set forth in Section 2(a) above, and, for the avoidance ofdoubt, such vesting shall not be contingent upon any continued employment or Board service by Optionee.3.Amendment to Section 2(j) of the Option Agreement.Section 2(j) of the Option Agreement is hereby amended by adding the following sentence to the end of such Section 2(j):“For the avoidance of doubt, this Section 2(j) shall remain applicable and in full force and effect following any termination by Optionee of his Termof Board Service and/or his Term of Employment.”4.Acknowledgement of Voluntary Resignation. 5.The Parties hereby acknowledge that Schuckenbrock’s resignation from the Board constitutes a voluntary termination of Schuckenbrock’s Boardservice pursuant to Section 9(d) of the Employment Agreement and was completed at Schuckenbrock’s own initiative and that such resignation shallnot be deemed to be a Constructive Termination Without Cause.6.No Further Amendments.Except as otherwise set forth herein, each of the Employment Agreement and the Option Agreement shall remain in full force and effect inaccordance with their terms.IN WITNESS WHEREOF, the undersigned have executed this Agreement as of this 18th day of May, 2015./s/ Stephen F. SchuckenbrockStephen F. SchuckenbrockAccretive Health, Inc.By: /s/ Daniel Zaccardo_____________Name: Daniel A. Zaccardo Title: Senior Vice President, General2Exhibit 23.1Consent of Independent Registered Public Accounting FirmWe consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-170718) pertaining to the Amended and Restated StockOption Plan, as amended and the 2010 Stock Incentive Plan of Accretive Health, Inc. of our reports dated June 23, 2015, with respect to the consolidatedfinancial statements of Accretive Health, Inc., and the effectiveness of internal control over financial reporting of Accretive Health, Inc., included in thisAnnual Report (Form 10-K) for the year ended December 31, 2014./s/ Ernst & Young LLPChicago, IllinoisJune 23, 2015Exhibit 31.1Certification of Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002I, Emad Rizk, certify that:1. I have reviewed this Annual Report on Form 10-K of Accretive Health, Inc.;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make thestatements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financialcondition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in ExchangeAct Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrantand have:(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, toensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within thoseentities, particularly during the period in which this report is being prepared;(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under oursupervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for externalpurposes in accordance with generally accepted accounting principles;(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about theeffectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recentfiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materiallyaffect, the registrant's internal control over financial reporting; and5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to theregistrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonablylikely to adversely affect the registrant's ability to record, process, summarize and report financial information; and(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controlover financial reporting.Date: June 23, 2015/s/ Emad Rizk Emad RizkPresident and Chief Executive Officer(Principal Executive Officer)Exhibit 31.2 Certification of Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002I, Peter Csapo, certify that:1. I have reviewed this Annual Report on Form 10-K of Accretive Health, Inc.;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make thestatements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financialcondition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in ExchangeAct Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrantand have:(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, toensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within thoseentities, particularly during the period in which this report is being prepared;(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under oursupervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for externalpurposes in accordance with generally accepted accounting principles;(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about theeffectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recentfiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materiallyaffect, the registrant's internal control over financial reporting; and5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to theregistrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonablylikely to adversely affect the registrant's ability to record, process, summarize and report financial information; and(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controlover financial reporting.Date: June 23, 2015/s/ Peter Csapo Peter CsapoTreasurer and Chief Financial Officer(Principal Financial Officer)Exhibit 32.1Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adoptedpursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report on Form 10-K of Accretive Health, Inc. (the “Company”) for the period ended December 31, 2014 as filed withthe Securities and Exchange Commission on or about the date hereof (the “Report”), the undersigned, Emad Rizk, President and Chief Executive Officer ofthe Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:1.the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and2.the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of theCompany.Date: June 23, 2015/s/ Emad Rizk Emad RizkPresident and Chief Executive Officer(Principal Executive Officer) Exhibit 32.2Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adoptedpursuant to Section 906 of the Sarbanes-Oxley Act of 2002In connection with the Annual Report on Form 10-K of Accretive Health, Inc. (the “Company”) for the period ended December 31, 2014 as filed withthe Securities and Exchange Commission on or about the date hereof (the “Report”), the undersigned, Peter Csapo, Chief Financial Officer and Treasurer ofthe Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:1.the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and2.the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of theCompany.Date: June 23, 2015/s/ Peter Csapo Peter CsapoTreasurer and Chief Financial Officer(Principal Financial Officer)

Continue reading text version or see original annual report in PDF format above